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ABSTRACT 
The first drug licensed for treatment of HIV- 1, the causative agent of AIDS, was 
Zidovudine (AZT, ZDV). Two years after licensing, patients presented showing 
reduced sensitivity to this monotherapy. Subsequent genotypic and phenotypic 
analyses showed that variation at five codons within the reverse transcriptase region 
of the poi gene where responsible: M41-+L, D67—N, K7O—R, T215—YfF, 
K219-+Q/E. As the use of ZDV in the clinical setting increased, either as a 
monotherapy or in combination with other antiretrovirals, the occurrence of mutations 
increased, and it became apparent that there was an increasing risk of transmission of 
such resistant variants. Transmission of resistant variants was soon documented to 
have occurred through several routes: parenteral, homosexual, heterosexual. The 
initiation of an HTV- 1 infection with already resistant viral strains has serious clinical 
implications in patient management, and treatment. 
To investigate at what frequency transmissions of resistant variants of HTV- 1 are 
occurring a group of ántiretroviral naive HIV- 1 positive individuals where chosen 
from the MRC Molecular Epidemiology Project, Edinburgh. From this collection of 
over 600 individuals, 35 patients that had never received any drug therapy were 
analysed genotypically for the presence of any variation at codon 215 of the RT, the 
position most frequently observed with ZDV use. By direct automated sequence 
analysis of proviral DNA obtained from peripheral blood mononuclear cells, variation 
was detected in two individuals. This variation was an as yet unpublished change, 
never observed at this position (215D, GAQ. Further analysis showed this to be 
linked with a known ZDV resistance-associated mutation M41-+L. 
Drug resistant variants appeared to have survived within the drug free environment 
for a period of 1-3 years, post-seroconversion. Previous data had shown that resistant 
variants would revert back to wild type within a year of cessation of therapy. These 
variants were investigated further to deduce what role this as yet undocumented 
mutation at codon 215 played in resistance to ZDV. Recombinant virus was 
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produced that used a common genetic background of the HXB2-D variant, with the 
RI portion deleted so that it could be replaced by patient derived RI fragments. 
These recombinants were tested in phenotypic assays to determine the sensitivity of 
the .AC mutation at codon 215 (single or linked to 41L)with respect to ZDV. They 
were also used in competition assays to determine the fitness of the virus in 
comparison to wild type variants in the absence of drug. 
It appeared that the presence of the GAC mutation at codon 215 conferred a 2.8 fold 
increase in resistance to ZDV, even when linked to the 41L mutation (which alone 
confers a 4-fold increase in resistance). This variant was also outgrown by the wild 
type RI in assays where the two variants were grown together in one continuous 
culture, indicating some loss of fitness conferred by these changes. The apparent 
transmission of resistant variants of HIV-1 has important implications for the 
management of infection, where ZDV is still used in combination with other 
antiretrovirals. 
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LIST OF ABBREVIATIONS 
SJJNSI Syncytium/Non-syncytium inducing 
PBMC Peripheral blood mononuclear cells 
PCR Polymerase chain reaction 
RT Reverse transcriptase 
ZDV/AZT Zidovudine 
MCS Infectious molecular clone of HE\T-1, 'Multiple cloning site' 
AENV MCS, as above with a region of HEy-i env deleted 
ART Non-infectious molecular clone, with region of RT deleted 
Amino acid codes 
A alanine M methionine 
C cysteine N asparagine 
D aspartate P proline 
E glutamate Q glutamine 
F phenylalanine R arginine 
G glycine S serine 
H histidine T threonine 
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L leucine Y tyrosine. 
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I 	Introduction 
1.1 Discovery of the Human Immunodeficiency Virus 
Acquired Immunodeficiency Syndrome (AIDS) was the title given the new clinical 
syndrome that was first described in 1981 (Gottlieb et a!, 198 1) characterised by 
profound cellular immunological deficiency and severe, irreversible 
immunosuppression that eventually leads to death (Masur etal., 1981; Nelson eta!, 
1990). This immunosuppression leaves the sufferers of AIDS open to many 
opportunistic infections such as persistent cytomegalovirus infection (CMV), 
Pneumocystis carinii pneumonia (PCP), malignant tumours (eg Kaposi's sarcoma), 
and persistent generalised lymphadenopathy (PGL). 
The first indication that a virus was responsible for AIDS was the recovery of a 
reverse transcriptase (RT) containing virus from the lymph node of a man with 
persistent lymphadenopathy syndrome (LAS): hence a retrovirus was the likely 
etiological agent of AIDS (Barre-Sinoussi eta!, 1983; Webster eta!, 1986). It was 
still widely believed, however, that a known human virus such as Epstein Barr (EBV) 
or CMV or a virus closely related to Human T-cell leukaemia virus (HTLV-1), could 
be the cause of the illness. 
HTLV-1 was isolated from a continuous culture line of leukaemia T cells (MT-1). 
This had been established from patients with adult T-cell leukaemia (ATL) in Japan, 
where type C virus particles were observed (Miyoshi eta!, 1981). This type C 
morphology is characteristic of retroviruses which have a central spherical core on 
budding. At around the same time Poiesz et al in the USA also observed type C virus 
particles from a T-cell line derived from a cutaneous T-cell lymphoma (Poiesz et al, 
1980). Thus two independent groups appeared to have identified a similar agent that 
was involved with certain T-cell malignancies.In 1983 Gallo isolated HTLV from 
patients suffering from AIDS (Gallo eta!, 1984). However this, and subsequent 
studies, identified characteristics of this virus that did not correspond to observations 
of the etiological agent of AIDS in-vivo: most notably, HTLV was exclusively 
associated with cells, but haemophiliacs had contracted AIDS from factor VIII i.e. 
from cell-free plasma, and HTLV does not lyse lymphocytes but can immortalise them 
into continuous growth (Miyoshi eta!, 1981), which does not correspond with the 
loss of CD4+ lymphocytes observed in AIDS patients 
Over the next few years several viruses were isolated and identified from different 
research groups: In 1983 (Barre-Sinoussi eta!, 1983) a virus named 
lymphadenopathy-associated virus (LAV) was isolated, and observed to grow to 
substantial titres in CD4+ cells, killing these targets: Gallo et a! (1984) identified 
another virus, HTL V-rn (Shaw et a!, 1984; Fisher eta!, 1985), which had been 
isolated from peripheral blood mononuclear cells (PBMCs) pooled from several AIDS 
patients; Levy (Levy et a!, 1984) isolated an AIDS-associated retrovirus (ARV) from 
different risk groups as well as from some clinically asymptomatic individuals. This 
isolation from apparently healthy patients indicated a carrier state for the AIDS virus. 
All three retroviruses (LAV, HTLV-Ill, ARV) had similar characteristics, 
grew in peripheral blood mononuclear cells 
killed CD4+ immunological cells 
did not immortalise cells. 
It was also noted that infection with these viruses was not limited to AIDS patients, 
but found in individuals with other clinical conditions. 
By 1986 it was clear that all 3 viruses were isolates of the causative agent of AIDS 
and the International Committee on Taxonomy of Viruses recommended the AIDS 
virus be known as the Human Immunodeficiency Virus (HIV)(Coffin eta!, 1986). 
HIV isolates were subsequently recovered from the blood of many patients with 
AIDS, AIDS-related complex and neurologic syndromes, as well as from peripheral 
blood mononuclear cells (PBMCs) from clinically healthy individuals. 
Soon after the identification of HIV (HIV-1) in the US and Europe a separate virus, 
HIV-2 (Clavel et al., 1986) which also causes AIDS, was discovered in Portugal in 
patients from Western Africa. 
1.1.1 Retroviridae 
HTV- 1 is a retrovirus. Retroviruses can be broadly divided into two categories, 
simple and complex, distinguishable by the organization of their genomes. Simple 
retroviruses carry the basic genomic information, wheresas complex retroviruses have 
additional regulatory proteins derived from multiply spliced messages (see section 
1.2). These retroviruses can be further subdivided into seven groups defined by 
evolutionary relatedness: Avian sarcoma and leukosis viral group (Rous sarcoma 
virus (simple)); Mammalian B-type viral group (mouse mammary tumor virus 
(simple)); Murine leukemia-related viral group (Moloney murine leukemia virus 
(simple)); Human T-cell leukemia-bovine leukemia viral group (human T-cell 
leukemia virus (complex)); D-type viral group (Mason-Pfizer monkey virus (simple)); 
Lentiviruses (human immunodefiencey virus (complex)); Spumaviruses (human foamy 
virus (complex)). 
Retroviral particles are spherical with a diameter of 80-1 OOnm, and are 
morphologically diverse. They consist of an envelope provided with glycoprotein 
projections, an icosahedral or spherical shell, and a central nucleoid or core containing 
two single stranded RNA molecules and reverse transcriptase. 
1.1.2 Lentiviruses 
Lentiviruses constitute a separate genus of the Retroviridae, and include HIV, simian 
immunodeficiency virus (Sly, primates), feline immunodeficiency virus (Fly, cats), 
bovine immunodeficiency syndrome (BIV, cattle), equine infectious anaemia virus 
(EIAV, horses), visna virus (sheep), and caprine arthritis encephalitis virus (CAEV, 
goats). 
Characteristics common to lentiviral infections include long incubation periods, 
immune suppression, host species specificity, cytopathic effect in certain infected cell 
types, noncytopathic infection of macrophages and latent or persistent infection in 
some infected cells. Lentiviruses have relatively large genome sizes (9-11 kb), highly 
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glycosylated envelope protein, sequence polymorphism, particularly in the envelope 
region, and presence of additional genes encoding accessory/regulatory genes. 
1.2 Genes of liv-! 
The genome of HI-i contains the three genes, gag, poi and env, encoding the 
proteins common to all replication competent retroviruses. In addition HIV-1 also 
has genes that encode two different proteins required for virion morphogenesis and 
maturation (vf and vpu), a protein which is required for replication in macrophages 
(vpr), and three non-structural, regulatory proteins (tat, rev, and nef) (Cullen et al, 
1989). The genomic size of HIV is about 9.8kb with open reading frames coding for 
several viral proteins (see Figure 1.1). 
The compact structure of the genome forces the virus to rely on post-transcriptional 
mechanisms of gene regulation to allow the production of the proteins listed above 
from one primary transcript that spans the entire genome. This is carried out by 
alternative splicing events to generate many different mRNAs that specify the 
individual proteins. HIV- 1 contains at least four splice donors and six splice 
acceptors, which enable it to produce more than thirty different mIRNAs (Cullen, 
Human Retroviruses, IRL Press, 1993). 
nef 3'LTR 5' LTR 
U3 R 1J5 gag 'if 
vpr 
FIGURE 1.1 
HIV-1 Genomic Organisation 
Structural genes 	 M Regulatory Genes 
0 Viral Enzymes 	 0 Accessory Genes 
1.2.1 Structural genes of HIV-1 
1.2.1.1 gag (group specific antigen) 
The gag gene of HIV-1 encodes the structural components of the virion that form the 
nucleocapsid and matrix (see Figure 1.2). The gag gene products are expressed from 
full length mRNA, resulting in either the Gag (p53gag) or Gag/Pot fusion proteins 
(prl60gag-pol), (see ribosomal frameshifting in section 1.3.2.3), which are then 
cleaved by viral protease into the proteins: p24 (capsid, CA); p17 (matrix, MA); p15 
(nucleocapsid, NC), which is further cleaved to produce p9 and p7. 
1.2.1.2 env (envelope) 
The env gene of HIV-1 encodes for the structural components of the membrane, 
producing the transmembrane and outer membrane proteins. The env gene is 
transcribed as a singly spliced mRNA, which when translated produces a gpl6Oenv 
protein, which is cleaved by cellular protease to produce the glycoproteins gp 120 and 
gp4 1 (external surface glycoprotein (SU) and transmembrane protein (TM) 
respectively). The envelope proteins are then exported to the cell surface where 
gp120 is present as a multimeric unit non-covalently linked to gp4l. 
1.2.2 Viral enzymes of 11W-1 
1.2.2.1 pol (polymerase) 
The pol gene of HIV-1 encodes for the viral enzymes protease (PR), reverse 
transcriptase (RT, with Rnase H) and integrase (IN). The pol gene products are 
translated in -1 frame (see ribosomal frameshifting in section 1.3.2.3), from full length 
genomic mRNA to produce a Gag-Pot polyprotein, pr 160 gag-pot, which is cleaved 
by viral protease to yield the viral enzymes: plO (protease, PR); p32 (integrase, IN); 
p66 and p51 (reverse transcriptase, RT, which is a heterodimer with Rnase H activity 
at the C-terminus of the p66 subunit). 
1.2.2.1.1 Reverse transcriptase 
lILY-i encodes its own polymerase, reverse transcriptase (RT). The RT is a dimeric 
protein composed of two polypeptide subunits, 66k-Da and 5 1-kDa (Veronese et a!, 
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FIGURE 1.2 
Schematic Representation of the HIV-1 Virion 
Q Reverse Transcriptase 
I 	p7 gag 
0 p9 gag 
Integrase and Protease 










1986; Lightfoote et a!, 1986), present in a 1:1 stoichiometry (Jacobo-Molina et a!, 
1993). The function of HIV-1 RT, and of retroviral RT, is to synthesise a DNA 
molecule from its genomic RNA template, followed by generation of double-stranded 
DNA (reviewed in Goff, 1990). The RT also contains RNase H activity (Larder eta!, 
1987), located at the carboxyl terminal of RT, which degrades the RNA template. 
The RT of HIV- 1, and retroviruses in general, lacks proof-reading activity (3'-5' 
DNA exonuclease), which leads to error prone reverse transcription (Preston et a!, 
1988; Roberts et a!, 1988; Williams and Loeb, 1997). 
The crystal structure of the 1-TV-1 RT was reported (Kohlstaedt et a!, 1992; Jacobo-
Molina eta!, 1993, and by Stammers (personal communication)), to a resolution of 
2.2 A when 'complexed' with non-nucleoside reverse transcriptase inhibitors. Four 
individual subdomains of RT make up the polymerase domains of p66 and p51 and 
these are named the 'fingers, palm, thumb, and connection' (see Figure 1.3). 
1.2.2.1.2 Protease 
Protease (PR) is a l5kDa protein encoded on the 5'-terminal region of pol (Borman 
eta!, 1996; Wain-Hobson eta!, 1985; Gelderblom, 1991) and is a dimeric enzyme 
(Borman et al, 1996). The aspartyl protease cleaves the Gag p55 and Gag-Pol p160 
polyproteins to liberate mature structural and enzymatic proteins of the core (Kaplan 
eta!, 1996; Oroszlan and Luftig, 1990), and is essential for production of infectious 
progeny virions. It is active when the polyproteins gather under the surface of the cell 
and in the immature virion. 
1.2.2.1.3 Integrase 
Integrase (IN) is an 11 kDa protein encoded at the 3'-terminal ofpo!, and integrates 
the newly synthesised viral cDNA into the host cell genome. 
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FIGURE 1.3 
Folding Diagram of HIV-1 Reverse Transcriptase 
The diagram shows the two subunits of RT, p66 and p5  1, showing the four 
subdomains, fingers, thumb, palm and connection. The polymerase domain is shown 
in the p66 subunit. 
(Jacobo-Molina et a!, 1993, Boucher and Larder, 1994) 

















1.2.3 Regulatory genes of ll1V-1 
1.2.3.1 tat (trans-activator) 
The tat gene is encoded on two exons, the products of which are translated from 
multiply spliced mRNA early in infection. The tat gene product is localised in the 
nucleus and acts as a transactivator of LTR promoter-driven transcription (Hauber et 
al, 1987; Kao et a!, 1987), by binding to the transactivation response element (TAR) 
located between +1 and +60 in the viral RNA. It is therefore an RNA binding protein 
and functions by mediating binding of cellular proteins. 
-LTR 
Long terminal repeats (LTRs) (see Figure 1. 1), flank the viral genes, and are 
produced upon synthesis of proviral DNA. These are non coding regions whose 
major function is to provide signals for transcription of the proviral genome. 
U3: 3' Untranslated region, forms the 5' portion of the LTR, and contains a number 
of cis-acting signals necessary for viral replication. 
R: Terminally redundant region, containing identical sequences which are important 
in the transfer of nascent DNA during replication and strand 'jumps' and transfers. 
U5: Untranslated region at 3' portion of LTR, containing signals necessary for 
intiation of reverse transcription (primer binding site), and also for integration (att). 
1.2.3.2 rev (regulator of expression of the virion) 
The rev gene product is translated from a multiply spliced nIRNA transcript, to 
produce a 1 9kDa protein, Rev, which is localised in the nucleus, especially the 
nucleolus of infected cells (Cullen et a!, 1988). Rev is an RNA binding protein, and 
post-transcriptional trans-activator (Sodroski et a!, 1986). This viral regulatory 
protein interacts with a cis-acting RNA loop structure called the Rev response 
element (RRE)(Malim et a!, 1989), which is located in the viral envelope mRNA. 
This interaction allows unspliced mRNA to enter the cytoplasm from the nucleus and 
give rise to full-length viral proteins needed for progeny production. 
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1.2.4 Accessory genes of lilY-i 
1.2.4.1 nef (negative factor) 
The nef gene product of HIV-1 is translated from multiply spliced mRNA, to produce 
a 206 amino acid, 27kDa protein which is myristoylated at the N-terminus 
(attachment of a fatty acid chain allowing a water soluble protein to be localised to a 
membrane), and hence is associated with the plasma membrane at the cytoplasmic 
domain (Franchini eta!, 1986; Kaminchik eta!, 1994; Niederman et al, 1993). It is 
expressed during early gene expression and is believed to have a variety of potential 
functions. Early primate studies using the simian immunodeficiency virus-rhesus 
macaque model showed that Nef was essential for high levels of viral replication in 
adult animals as well as disease progression (Kestler eta!, 1991). Tissue culture 
experiments have shown Nef to increase infectivity, although its exact mechanisms 
are unclear. Nef also has been shown to downregulate both surface CD4 expression 
(Garcia eta!, 1991; Guy eta!, 1987), and the major histocompatablility complex class 
I molecules (Schwartz et a!, 1996). It has also been linked with the viral matrix and 
formation of preintegration complexes through its association with cellular protein 
kinases (Swingler eta!, 1997). 
1.2.4.2 vpu (viral protein u) 
The vpu gene product is translated from singly spliced message, to encode a 80-
82kDa protein, whose function has still to be determined, although it has been 
implicated in several activities (reviewed by Subbramanian et a!, 1994). In the 
absence of Vpu there appears to be a decrease of virion release from infected cells 
(Klimkait eta!, 1990), and an accumulation of virus proteins in the cells. The 
infectivity of these viruses trapped in the infected cells however, does not appear to be 
affected. Possible suggestions attribute this to destabilisation of the gpl6O/CD4 
receptor interactions and may induce rapid degradation of the CD4 receptors (Willey 
eta!, 1992a; Willey eta!, 1992b; Willey eta!, 1994; Tiganos eta!, 1997). 
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1.2.4.3 vf (viral infectivity factor) 
The vf gene product is translated from singly spliced message, to produce a 23kDa 
protein. The role of this protein is also largely unknown but may also be involved in 
viral infectivity (reviewed in Subbramanian et a!, 1994). It has been shown that the 
presence of this protein is a requirement for the formation of HIV-1 virions competent 
for both cell-to-cell and cell-free transmission in peripheral blood lymphocytes and 
macrophages. (von Schwedler eta!, 1993). The presence of Vif was studied in a 
range of continuous cell lines, showing that it was required in some CD4+ T-cell lines 
(e.g. H9), but not in others (such as C8166)(Gabuzda eta!, 1992), suggesting that 
this protein may compensate for cellular factors not present in some cell lines, 
required for production of infectious particles. Vif is a cytoplasmic protein that is not 
associated with the virus particle, but has been shown to localise at the cellular 
membranes (Goncalves eta!, 1994), which suggests a role in processing and assembly 
of virion structural proteins. 
1.2.4.4 vpr (viral protein r) 
The vpr gene product is translated from singly spliced message, to produce a 96 
amino acid protein (14kDa). Recent reports show that Vpr expression may have a 
complex effect on the host (reviewed by Emerman, 1996). Expression of wild type 
Vpr prevents infected cells from proliferating, blocking the cell cycle pathway in the 
G2 phase (O'Connell and Nurse, 1994), thus preventing progression to mitosis (Rogel 
et a!, 1995; Jowett et a!, 1995). This stage in the cell cycle is controlled by the cyclin-
dependent kinase complex (Coleman eta!, 1994), through a series of 
phosphorylations, and it is thought that Vpr acts upstream of this G2 checkpoint, 
although its exact site of action is as yet unknown (Murray, 1994). It is not fully 
understood what role this arrest plays in viral pathogenesis. Vpr has also been shown 
in association with the gag matrix protein in transportation of HTV-1 preintegration 
complex (that is RNA-protein complex competent to integrate in host cell genome) 
into the nucleus of nondividing cells and macrophages by an importin-independent 
process (Gallay eta!, 1996; Heinzinger eta!, 1994; Sugasawa eta!, 1990; Ellison et 
a!, 1990; Bukrinsky eta!, 1991). 
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1.3 Life Cycle 
The retrovirus infectious cycle can be separated into two stages, termed early and 
late. The early stage is when the virus attaches to the host cell, the virus core passes 
through the cell membrane into the cytoplasm where DNA synthesis by viral reverse 
transcriptase occurs. The viral DNA is then transported to the nucleus where it is 
integrated into the host cell genome. This stage is dependent upon the pol gene 
products such as the reverse transcriptase (RT) and integrase (IN), which are present 
in the virus core. In the late stage the integrated viral DNA, termed provirus, is 
expressed via transcription and translation, to produce progeny particles. This stage 
is dependent upon host cell functions such as RNA polymerase II, RNA splicing 
events, translation and post-translational modification of proteins. 
1.3.1 Early stage 
1.3.1.1 Entry 
The entry of HIV- 1 into the cell can be divided into three major events: binding, 
activation and fusion (Yashwantrai eta!, 1991). The viral envelope protein consists 
of the surface subunit, gp120 and the transmembrane subunit, gp4l, which form an 
oligomeric complex in the virion membrane. The gpl2O molecule contains the 
specific binding domain for the human CD4 molecule, the cellular receptor for HIV-1 
(Dalgleish et a!, 1984). It is the interaction between these two molecules that 
activates the fusion activity of the envelope oligomer by inducing a conformation shift 
that exposes new functional domains, followed by binding to specific cofactors, 
transmembrane chemokine receptors. Several chemokine receptors have now been 
identified and shown to be required in conjunction with CD4 for fusion of HIV 
envelopes to plasma membranes (Bjorndal eta!, 1997; Cohen, 1996; Lapham eta!, 
1996; Wain-Hobson, 1996; Cocchi eta!, 1996; Trkola eta!, 1996; Wu eta!, 1996; 
Paxton eta!, 1996; Wilkinson, 1996). Isolates that differ in their cellular tropism also 
use different subsets of chemokine receptors, with the envelope glycoproteins from T-
cell-line adapted (TCLA, T-cell-tropic) syncytia inducing viruses (SI) using the 
CXCR4 receptor, and the non-T-cell-line adapted viruses i.e. primary isolates 
(macrophage-tropic), non-syncytia inducing (NSI) using the CCR5 receptor. These 
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NSI viruses have also been shown to utilise the CCR3 receptor (Bjorndal eta!, 1997). 
The fusion between the viral and plasma membranes releases the viral core into the 
cell to initiate replication. 
1.3.1.2 Replication 
HIV-1 contains two identical copies of RNA, the RNA genome, with positive polarity 
with respect to translation. After entry to the cell and uncoating of the virus particle, 
double-stranded DNA is synthesised through a multistep process involving "jumps" or 
strand transfers (Goff, 1990; Wainberg and Gu, 1995; Kupiec and Sonigo, 1996), to 
allow replication of the linear viral RNA into a double stranded DNA provirus with 
LTRs flanking the viral genes: genetic information going from RNA to DNA in a 
reverse or 'retro' direction (Mitsuya et a!, 1987). 
This process is carried out by the viral reverse transcriptase enzyme, first shown to 
exist in RNA tumour viruses in the 1970's (Baltimore, 1970; Temin and Mizutani, 
1970) and common to all retroviruses. Initiation of replication occurs at the primer 
binding site of viral RNA, by attachment of the primer tRNA, which is packaged in 
the virion (Wakefield eta!, 1995). Initially the viral RT produces a DNA strand, with 
the RNA template subsequently hydrolysed by the RT RNase H activity. This minus 
strand DNA is then copied by the RT to produce the second (plus) DNA strand, 
resulting in a double-stranded DNA copy of the viral RNA genome. The linear viral 
DNA, which is now called a provirus, is then transported to the nucleus where it is 
integrated in the host cell chromosome by viral IN. HJV, like other retroviruses, has 
therefore two genome forms: single stranded RNA in the extracellular phase of the 
life cycle called the virion, and a double stranded DNA provirus within the cell. 
1.3.2 Late stage 
The regulation of viral gene expression by lilY-i is more complex than other 
retroviruses, and is actually similar to many DNA viruses, in that they encode 
transcriptional trans-activators of viral gene expression and divide their replication 
cycle into early (regulatory) and late (structural) phases of protein synthesis. Proviral 
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DNA replication is dependent on host cell enzymes and occurs concomitantly with 
host chromosomal DNA replication, with transcription of viral genomic RNA 
catalysed by host cell RNA polymerase H. Some of the genomic RNA produced is 
spliced, translated and modified to produce the proteins that will constitute viral 
particles and encapsidate the two molecules of genomic RNA (Cullen and Greene, 
1989; Rosen, 1991; Parsiow, 1993). 
1.3.2.1 Early gene expression 
The combined action of inducible and constitutive host transcription factors present in 
the activated T cell is sufficient to stimulate a low but significant level of transcription 
of the HIV-1 provirus. This initial population of genomic length viral niRNA 
molecules reaches the cytoplasm as doubly spliced —2kb mIRNA that encodes the 
regulatory gene products Tat, Nef, and Rev (Cullen and Greene, 1989). 
1.3.2.2 Late gene expression 
The Rev protein induces the transition from early to the late phase of viral gene 
expression, characterised by the predominant expression of the viral structural 
proteins, possibly through some critical threshold level of rev expression. Rev, 
particularly localised in the nucleoli, induces the cytoplasmic expression of unspliced 
(gag, and gag-pol) and singly spliced (env, vJ) viral mRNAs, while simultaneously 
reducing the expression of the doubly spliced RNA types that encode the viral 
regulatory proteins. Thus rev down regulates its own production. 
1.3.2.3 poi Gene expression and ribosomal frameshifting 
Ribosomal frameshifting is used to produce two different sets of proteins in a different 
ratio using a single translational initiation site (Wilson et al, 1988; Jacks et al, 1988). 
The primary unspliced transcript of HTV is a full length niRNA and provides the 
template for the synthesis of the Gag and Pol proteins. The virus therefore confronts 
the problem of translating two different proteins from a single mRNA, which is 
additionally complicated by the fact that there is no functional start codon at the 5' 
end of the pol gene, and therefore thepo/ gene of HTV-1 (or any retroviruses), is 
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incapable of being translated independently but must be translated along with gag, to 
produce a single Gag/Pol fusion protein. 
Translation of both proteins starts identically at the 5' end of gag, and most ribosomes 
traverse the entire gag region in frame. The Gag protein translation terminates at an 
in-frame stop codon, however a short distance upstream of the gag termination 
codon, some ribosomes (less than 5%), shift into thepo/ reading frame without 
interrupting the growing polypeptide chain: the shift to the -1 frame upstream from 
this codon allows the synthesis of the fusion protein. This frameshift occurs because 
of features in the local RNA, the sequence of the shift site itself, a heptanucleotide 
sequence, and a distinctive secondary structure of a simple RNA stem-loop, and 
always occurs at precisely the same location in a given mRNA. It is thought that such 
physical features cause the ribosome to linger at the shift site long enough for a slip 
backward by one nucleotide on the ribosome (tRNA attached to the carboxyl 
terminus of the growing polypeptide chain now pairs with a UUU codon instead of 
the UUA codon that had specified its incorporation) (Cullen, Human Retroviruses, 
IRL Press, 1993). 
The unspliced mRNA translated in-frame produces the Gag precursor p53 
(p55),which is proteolytically cleaved to give five smaller proteins: p24 (capsid, CA); 
p17 (matrix, MA); p15, which is further cleaved to produce p9 and p7. In the -1 
frame the Gag-Pol precursor is produced, pr160. This 160kDa protein is processed 
by viral protease to produce the poi proteins: plO (protease, PR); p32 (integrase, 
IN); p66 and pSi (reverse transcriptase, RT, which is a heterodimer with RNase H 
activity at C-terminus of p66 subunit). 
1.3.2.4 Virion assembly and release 
The viral genomic RNA is spliced, translated and modified to produce the viral 
proteins that make up the viral particle. Some RNA is not spliced however and this 
genomic RNA is encapsidated in the production of the new progeny virus which then 
buds from the host cell cytoplasmic membrane. The precise mechanism is unknown, 
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but takes place in close association with the plasma membrane and involves an 
ordered assembly of the myristoylated Gag and Gag-Pol proteins targeted to the host 
cell membrane. The genomic RNA is obtained through an association with the gag 
gene product, p1  7, where a nucleic acid binding motif associates with the packaging 
signal in the leader sequence of the genomic RNA. The assembled virus buds through 
the plasma membrane at regions high in viral envelope glycoproteins. At this stage or 
shortly after, the viral protease cleaves the precursor proteins within the new virion to 
produce mature structural and enzymatic proteins, that make the progeny infectious. 
1.4 HIV Variation 
HIV appears to be able to tolerate a considerable level of variation along the whole 
genome. This variation however varies in different genes with the env, tat, rev, nef, 
v/ and vpr showing the highest rates of nucleotide substitutions. The rate is lower in 
the p01 and gag genes (Li et a!, 1988; Quinones-Mateu eta!, 1996). 
Variation in the env gene, which shows the highest rates of substitution, has been 
studied intensively. It has shown the presence of regions particularly amenable to 
change, termed the hypervariable regions (Vito V5), determined as regions with 
25% or less amino acid conservation (Modrow eta!, 1987). The location of these 
regions was mapped to the surface glycoprotein, gpl2O, of env. Interspersed between 
these regions of variability are areas of relative conservation (Cl to C5). Although 
extensive variation is observed in env out-with the gpl2O region, this does not appear 
in distinct clustered regions. 
1.4.1 Source of variation 
Differences in the rates of evolution between RNA and DNA viruses is due to the 
replication machinery and their inherent inaccuracy. The ultimate source of the 
variation in HIV is due to the error prone nature of the viral reverse transcriptase 
enzyme and of RNA Polymerase II. Both enzymes lack any 3'45' DNA exonuclease 
proof-reading activity (Roberts eta!, 1988). The error rates produced by this process 
have been studied by many investigators to produce an average mutation frequency of 
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10 to 10-5 substitutions per nucleotide per replication (1/2000 to 1/4000 or 5-10 
errors per genome per replication, Preston eta!, 1988; 1/1700, Robertson eta!, 1995; 
1.6 x 102  to 3.4 x 102  for independent samples relative to their consensus, and 3.6 x 
iO to 1.1 x 102  for individual quasispecies distributions, Najera eta!, 1995; 3 x 10 
5Mansky and Temin, 1995; all values represent substitutions per nucleotide). 
1.4.1.1 Hypermutation 
A phenomenon known as hypermutation has also been suggested as a cause of 
variation. This hypermutation, which refers to the occurrence of clusters of A--->G 
transitions (Meyerhans eta!, 1989; Vartanian eta!, 1991; Goodenow, 1989), whose 
cause is unknown but is believed to be due to the error prone RT. It was observed 
that these transitions occurred significantly higher in HIV when compared to other 
viral systems such as AMV RT and M-MuLV RT, even though these viruses share 
similar RT mutation frequencies (Williams and Loeb, 1997). A more recent study 
suggested that it may be due to the mammalian double stranded RNA adenosine 
deaminase (dsRAD) (Kim et a!, 1996). 
1.4.1.2 Recombination 
In addition to the error prone RT and hypermutational events, recombination has also 
been shown to be responsible for distribution mutations within the virus population. 
Recombinational events have been well documented in many biological systems 
producing diversity and removing lethal mutations from the population. Genetic 
recombination in viruses was first described in the early 1970's in RNA tumour 
viruses (Kawai and Hanaflisa, 1972; Vogt, 1971), where multiple crossover events 
were observed. Recombination occurs during replication and is a consequence of 
HIV having two RNA genomes packaged within the virion. Two models of such 
homologous recombination were proposed: the forced copy choice model (Coffin, 
1979), and the strand displacement-assimilation model (Junghans eta!, 1982). Each 
requires the presence of two different RNA genomes, the product of dual infection of 
the cell, and replication to occur (Hu and Temin,, 1990), during which recombination 
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can occur. For HIV-1 recombination between distinct clades of virus has been shown 
through analysis of viral genomic sequences (Robertson eta!, 1995), and has also 
been shown as a result of co-infection (Zhu eta!, 1995). 
HTV-1 has been shown to have a high replication rate (Ho et al, 1995; Wei eta!, 
1995; Coffin, 1995; Perelson eta!, 1996), predicted at 300 replicative cycles a year, 
producing levels of 10 3 to 106  RNA copies per millilitre of plasma (Piatak eta!, 
1993), with a half life of approximately 6 hours (Perelson eta!, 1996). As a 
consequence of these high replication rates and virus turnover, mutation frequencies 
of HIV-1 replication, and recombinational events, HIV-1 undergoes rapid and 
extensive evolution within the infected individual during the course of infection 
(Simmonds et a!, 1990a). 
1.4.2 Three phases of genetic variation 
A general course of disease with HTV- 1 can be separated into three clinical phases: 
the primary infection, an asymptomatic phase where the patient may appear clinically 
healthy, and finally the symptomatic phase when the patient's immune system breaks 
down and he/she suffer from many opportunistic infections. These three phases of 
infection have been linked to three similarly distinct evolutionary stages in the viral 
quasispecies (Leigh Brown, 1991; Wolfs et al, 1992; Zhang eta!, 1993). 
At the time of initial infection the patient has no specific immune response to the virus 
and it can therefore replicate freely to produce an initial peak of viral antigenaemia. 
Many studies have investigated the viral quasispecies at this time-point using the env 
gene (Zhang et a!, 1993). At this pre-seroconversion (seroconversion being the time 
at which the first antibody response to HIV-1 is detected) stage or Phase I, along 
with the expansion of the viral population, a decrease in genetic variability was 
observed, maintained until the time of seroconversion. At the time prior to 
seroconversion the population is essentially homogeneous. At this point a second set 
of selective processes begins to act. 
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In Phase II, the asymptomatic phase, specific immune responses are mounted 
towards the virus. Cells expressing viral antigens will be selectively killed, therefore 
virus that can evade this recognition will be favoured. This response is linked to the 
viral load with the most abundant virus being the main target of the immune system. 
Low frequency variants of the minor population have an advantage at this stage. 
Phase 111 can be characterised by clinical markers such as lymphocyte counts, where 
a decline in CD4 T-cell numbers indicates the break down of the immune responses 
and 'control' of infection. It is at this time, without the selective constraints of the 
immune system, that all variants of HIV- 1 can replicate. At this time the quasispecies 
would be largely heterogeneous. However, virus with a replicative advantage would 
be selected, returning the population to a more homogeneous state. Decreasing CD4 
T-cell numbers at this time constrains the viral population size to a level that should 
theoretically be lower than that of Phase I. However, virus production in other 
biological compartments could maintain this at a significant level. 
1.5 Targets for Retroviral Intervention 
The goal of any antiretroviral therapy is to reduce the number of virus particles in the 
body. As with any virus different stages in the life cycle present possible targets for 
intervention by therapy (reviewed in Mitsuya and Broder, 1987, and De Clercq, 
1991). These include: 
1 	Virus adsorption to the cell membrane 
2 	Fusion between the viral envelope and the cell membrane 
3 	Uncoating of the viral nucleocapsid 
4 	Reverse transcription of the viral RNA to proviral DNA 
5 	Integration of the proviral DNA into the cellular genome 
6 	Transcription of the proviral DNA to RNA, regulated by the TAT protein 
7 	Conversion of the viral precursor mRNA to mature mIRNA, a process 
regulated by post-transcriptional transactivators like REV. 
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8 	Post-translational processing of the viral precursor proteins by proteolysis, 
glycosylation, and myristoylation. 
9 	Virion assembly and release i.e. budding 
Therapies targeted at the earlier stages of infection from attachment of the virus 
through to transcription of proviral DNA, could block acute HIV infection preventing 
infection of new cells. Targeting the later stages, such as transcription of new viral 
mRNA and production of new viral proteins, through to budding of new progeny, 
could be expected to prevent chronic infection and HIV production from persistently 
infected cells (De Clercq, 1991). There have been many different drugs produced that 
act at different stages of the infection, some of which are discussed below. 
Adsorption of virus was shown to be inhibited in-vitro by a series of compounds that 
targeted the CD4 receptor-gp 120 interaction. Soluble CD4 and various derivatives in 
immune complexes, blocked the interaction by binding the gpl2O. Other compounds, 
such as sulphated polysaccharides and its derivatives, PVAS and PAVAS, acted by 
shielding the viral gpl2O (Schols et al, 1990), acting at levels that were not toxic to 
the host cell. These compounds have also been shown to prevent syncytia formation 
and cell killing, a process that also involves the CD4-gp 120 interaction. Polyanions 
have been shown to act directly with the CD4 receptor (Schols et a!, 1989). 
Inhibitors targeted at later stages of infection included oligodeoxynucleotides which 
act against transcription and translation. These compounds, which are complementary 
to certain regions of the genome, may bind with the proviral DNA, or bind with viral 
mRNA preventing translation. A derivative of these oligodeoxynucleotides, adapted 
for more efficient uptake in the cell without subsequent degradation, oligonucleoside 
phosphorothioate, directed against rev, was shown to suppress viral protein 
expression in chronically infected HIV- 1 infected cells (Matsukura et a!, 1989). 
However this was not sequence-specific in effect. 
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Mature viral proteins are highly glycosylated, and this process has also been a target 
for inhibitors, as has the myristoylation of Gag, Gag-Pol precursor proteins. These 
types of inhibitors were found to be poor inhibitors of HIV, probably because they 
were not targeted at HIV specific processes. 
1.5.1 Zidovudine: The first licensed drug against BIV-1 
The most successful inhibitors of HIV are those targeted against the poi gene, the RI 
enzyme (reverse transcription process), and the protease enzyme. In a review of 
agents directed against the RT enzyme, De Clerq (1992) cited no less than 93 
different compounds and the activity of these in cell culture. 
The first drug licensed for treatment against the retrovirus HIV- 1 was Zidovudine, a 
nucleoside analogue, which acts on the production of new virus from infected cells, by 
blocking DNA chain elongation, and will be discussed further in section 1.6. Within 
two years of its initial use, patients with reduced sensitivity to ZDV where discovered 
and this was later found to be linked to the accumulation of point mutations in the 
HTV-1 reverse transcriptase coding region of the poi gene (discussed further in 
section 1.7). These five resistance-associated codons, at positions 41, 67, 70, 215, 
and 219, accumulated in a step-wise pattern as treatment continued, although the 
number of mutations acquired varied in each individual (see section 1.7.3). 
1.5.2 Alternative antiretroviral therapy 
Obviously the appearance of these resistant variants led to the search for other drugs 
targeted at different aspects of the viral life cycle, and other genes of HIV- 1 (see 
section 1.5). These drugs fall in to several classes, the nucleoside analogues, the non-
nucleoside inhibitors, and the protease inhibitors. 
Nucleoside reverse transcriptase inhibitors 
HIV-1 nucleoside RT inhibitors, NRTIs, consist of 3'-azido-2',3'-dideoxynucleoside 
(ZDV, AZT), the 2',3'-dideoxynucleosides (ddC and ddl), 2',3'-didehydro-2',3'-
dideoxynucleo sides (d4T), and the negative enantiomer of 2' ,3 '-dideoxy-3 '- 
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thiacytidine (3TC). The mechanism by which these drugs act is thought to be similar 
to ZDV, the most widely studied (discussed further below), and is by blocking of 
infection through competitive inhibition of RT and chain termination (reviewed in Arts 
and Wainberg, 1996). 
Although ZDV was beneficial, the appearance of resistance under the selective 
pressure of the drug limited its potential, however, it still remains the pivotal drug in 
combination therapy due to its ease of use and also its effectiveness against 
neurological aspects of AIDS, HIV-related dementia (Portegies, 1995). The 
introduction of other NRTIs offered an alternative to those failing ZDV monotherapy, 
and developing resistance, and many studies were undertaken comparing ZDV 
monotherapy with NRTI monotherapy (ddl and ddC), or combinations of both. 
The first trials for an alternative to ZDV were with ddl, ACTG 116 and ACTG 117 
(Dolin et a!, 1995; Kahn eta!, 1992), which compared two arms of ZDV experienced 
groups, long term and short term experience, with ddl. The results showed that 
patients who had beend on ZDV monotherapy for a significant time benefited from this 
switch, as defined by clinical end points (time until AIDS-defining illness, mortality). 
ddl was then recommended as an alternative to those failing ZDV monotherapy. 
The first studies examining combination therapies, looked at combining the use of the 
two drugs, ZDV + ddC, and ZDV + ddl (Delta, ACTG 175)(Hammer et a!, 1996; 
Delta Coordinating Committee, 1996). These studies showed that the combination 
therapies although not as successful as anticipated, did show improvements when 
compared to ZDV monotherapy, on clinical end-points such as survival, measured as 
a reduction in mortality, and risk of disease progression, however, these were again 
short lived. The most exciting combination therapy was the combination of 3TC with 
ZDV, NUCA 3001/3002, NUCB 3001/3002 (Eron eta!, 1995; Bartlett eta!, 1996), 
where increases in CD4+ T-cell numbers (40-100 cells/mm3) and decreases in viral 
load (0.6-1.0 log) were sustained for significant times in both the experienced and 
naive study groups, a success also reflected by the delay in disease progression. 
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Non-nucleoside reverse transcriptase inhibitors 
HIV- 1 specific RT inhibitors, non-nucleoside RT inhibitors, NNRTIs, (nevirapine, and 
delavirdine) are actually a very diverse group of compounds including pyridinone 
derivatives, bis(heteroaryl) piperazines (BHAPs), dipyridodiazepinone nevirapine, 
thymine derivative TSAO and a-anilino phenylacetamide ((x-APA) (Moyle, 1995). 
Unlike NRTIs, compounds such as nevirapine do not require in vivo activation and 
bind directly to the RT, an attachment which alters the position of critical amino acids 
within the catalytic site of the enzyme, inhibiting the polymerase and therefore 
replication (for action of NNRTIs see Spence et al, 1995). 
There was then a move to the use of triple combinations, and the addition of 3TC to 
ZDV + ddllddC proved successful, delaying disease progression and improving 
survival (CAESAR Coordinating Committee, 1997). The introduction of the 
NNRTIs and the proteases has led to many different combination studies. The use of 
the non-nucleoside drug nevirapine showed best results when combined in a triple 
therapy, such as ZDV + ddl + Nevirapine, where viral load reduction was sustained 
for up to 52 weeks (INCAS study, B11046, 32 (Conway et al, 1996). 
Proteases 
The protease inhibitors target the action of the viral protease enzyme which is 
responsible for the proteolysis of the precursor proteins Pr5 5g'  and Pri 6O1)0i, 
required for production of infectious progeny virions. These compounds are largely 
dissimilar is structure and include the drugs ritonavir (ABT-538), indinavir (known 
also as MK-639, L-735,524), and saquinavir (Ro 3 1-8959). 
Saquinavir was the first protease drug licensed, in 1995, and triple therapy studies 
combining this with ZDV + ddC (ACTG 229) showed that the triple therapy was 
more effective than dual therapy, with reductions in plasma HIV significantly greater 
in the triple therapy arm (Collier et al, 1996), although some results indicated that this 
was only transient in heavily drug experienced patients (Walmsley et a!, 1997). 
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Additional studies where saquinavir was added to dual combinations did, however, 
show a delay in disease progression, and fewer AIDS-defining illnesses. 
Three further protease drugs have since been licensed, ritonavir, indinavir and 
nelfinavir, which again appear to assert the best effect when used in combination 
therapies. When ritonavir was used in combination with saquinavir, undetectable 
levels of plasma RNA were obtained in almost all participants, and when combined 
with ZDV and 3TC (Markowitz, M., 1997), plasma viral loads again remained at 
undetectable levels. Indinavir is also under trial in triple combinations, such as ZDV, 
3TC, and indinavir, where 86% of patients showed undetectable levels of plasma 
RNA at 68 weeks (Emini, E.A., 1997). The addition of this drug to dual therapies has 
also been shown to reduce progression to AIDS/death in ZDV experienced 
individuals. 
Resistance to antiretroviral therapy 
With all antiretroviral therapies the central problem is the development of resistance 
(see Table 1.1). The new combination regimes, highly active antiretroviral therapy 
(HAART), with triple or quadruple drugs, although maintaining the HTV-1 at 
undetectable levels, do require significant numbers of drugs, and adherence by the 
patient. Obviously any lapse in treatment maintenance would lead to a window for 
virus to replicate and resistance to develop. In 1994, in the early stages of the study 
detailed in this thesis, 42 mutations were listed with respect to antiretroviral therapy 
against 11V-1. This figure has risen to 143 (1997), a figure which includes resistance 
in the env gene (fusion/binding analogues), as well as resistance observed in Sly 
(ZDV, (-)-FTC, and PMPA) and FlY (d4T, ddC, (-)-FTC, and 3TC) viruses, and also 
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TABLE 1.1 
Mutations in p0! Gene Associated with Drug Resistance 
The following shows the resistance in the HIV-1 poi gene associated with 
antiretroviral therapy. (), Denotes mutations not unique to that class. The numbers in 
brackets at the bottom of table indicates the number of mutations unique to that class. 
(Adapted from the International Antiviral News, Schinazi, Larder and Mellors from 
the International Workshop on HTV Drug Resistance, 25-28 June 1997, St 
Petersburgh, Florida, USA) 
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5 multiple drug resistance mutations, related to combination therapy (Schinazi et al, 
1997). 
The use of the NNRTIs, and the protease drugs, has also been hindered by the 
development of resistance, and the added problem of cross-class resistance. 
However, the combination of NRTIs with protease drugs has given the best results of 
all the treatments developed over the past decade, maintaining plasma HIV-1 RNA 
levels at undetectable levels in the most sensitive diagnostic tests, for significant 
periods of time. 
1.6 Zidovudine 
1.6.1 Zidovudine Action 
Zidovudine, ZDV, (3'-azido-2'-deoxythmidine, AZT, Retrovir ®), is an analogue of 
nucleoside thymidine, and is a nucleoside reverse transcriptase inhibitor (NRTI, see 
Figure 1.4). ZDV is administered as an unphosphoiylated substrate, entering the host 
cells by diffusion, where it is activated to its triphosphate form by cellular enzymes (in 
the same manner as the 2'-deoxynucleoside-5'-triphosphates, the natural substrates 
for cellular DNA polymerases and reverse transcriptase are phosphorylated)(Furman 
et al, 1986). Given in an active triphosphate form, ZDV would not be taken up by the 
cells. This activation is achieved through three phosphorylation steps where ZDV is 
converted to the mono-, di-, and 2',3'-dideoxynucleoside-5'-triphosphate by host cell 
kinases: thymidine kinase catalyses the formation of a monophosphate, which serves 
as a competitive inhibitor of thymidylate kinase, which catalyses the second 
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FIGURE 1.4 
Chemical Structure of Zidovudme 
The diagram shows the nucleoside thymidine and its analogue, 
3'-azido-2'-deoxythymidine (Zidovudine, AZT, Azidothymidine, Azddmd). 
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phosphorylation step to diphosphate, which in turn leads to the formation of the third 
phosphorylation product, triphosphate. 
Such analogues compete in the normal binding of nucleotides to DNA polymerase, 
and can be incorporated into DNA to cause chain termination. This is due to the 
substitution of an azido group at the 3'-carbon in ZDV preventing the normal 5'-3' 
phosphodiester linkages (see Figure 1.5). In normal chain elongation nucleotides are 
incorporated via formation of phosphodiester bonds, in which a phosphate group 
forms a bridge between hydroxyl groups on two adjacent sugar residues. However, 
when ZDV-triphosphate is incorporated (as a monophosphate, as with normal chain 
elongation) instead of dTTP, chain termination occurs, resulting in the formation of a 
dead-end complex. The terminally incorporated ZDV has a 3'-azido group instead of 
a 3'-hydroxyl group, therefore inhibiting further chain elongation. 
1.6.2 Zidovudine Administration 
Zidovudine, AZT was shown to inhibit in vitro infectivity of T-lymphotropic virus 
(HTLV-Ill) and lymphadenopathy-associated virus (LAV)(Mitsuya et a!, 1985; 
Mitsuya and Broder, 1986). Zidovudine was licensed for use by the U.S Food and 
Drug Administration in 1987 based on clinical studies which showed that reverse 
transcriptase was a good target for chemotherapeutic intervention. The early trials 
showed that ZDV was beneficial to those patients with AIDS and AIDS-related 
complex (ARC), with reduced occurrences of opportunistic infections and also 
prolonged survival (Yarchoan eta!, 1986; Fischl et a!, 1987). 
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FIGURE 1.5 
DNA Chain Termination by Zidovudine 
The diagram shows a DNA chain, whose replication has been terminated by the presence of the 3'-azido group, N 3 provided by 
Zidovudine, preventing the formation of the next phosphodiester bond and inhibiting further chain elongation. 
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1.7 Zidovudine Resistance 
One definition of an antiretroviral drug is a compound that confers sufficient selective 
pressure on virus replication to select for drug-resistant mutants, because exerting 
such selective pressure on a virus population replicating to such high levels is likely 
to select for resistance (Richman, 1994). As the use of ZDV only reduced virus 
replication below normal levels and did not completely suppress it, it is not surprising 
that resistance to ZDV was detected as early as 1989, some two years after licensing 
(Larder eta!, 1989a). 
In the first documented report of resistance, Larder eta! showed that AIDS and ARC 
patients on therapy for approximately 6 months exhibited reduced sensitivity to ZDV 
(Larder eta!, 1989a). At this time there was no indication that development of 
resistance correlated with a clinical decline, since there was no increase in plasma 
antigenaemia. It was also a possibility that the absence of any negative clinical factors 
could be due to the levels of resistance observed being due to experimental artefact 
caused by the in-vitro culturing (Fitzgibbon et a!, 1991). 
1.7.1 Resistance to ZDV is associated with the presence of point mutations in 
the reverse transcriptase region of pot gene 
It was known that ZDV inhibited replication of HIV-1 by binding to the HIV-1 
reverse transcriptase and causing chain termination in the growing DNA chain 
(Furman et a!, 1986; St Clair et a!, 1987). It was proposed therefore that resistance 
to the drug could be due to mutations in the reverse transcriptase gene (Larder and 
Kemp, 1989). 
DNA was obtained from AIDS and ARC patients on ZDV therapy for a minimum of 
6 months. The virus, both sensitive and resistant, was cultivated in the MT2 
continuous T-cell line, extraction and polymerase chain amplification of the complete 
reverse transcriptase region was then carried out. The DNA obtained was then 
cloned into the M13-based vector containing the HXB2-D lily background, and the 
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clones producing functional reverse transcriptase enzyme were sequenced and their 
genomes analysed for the presence of mutations. 
A range of mutations was identified but mutations at amino acid positions 67, 70, 215 
and 219 only appeared in the resistant isolates (see Figure 1.6), and these sites were 
highly conserved in published HTV sequences. To confirm whether mutations at these 
positions alone could account for the reduced sensitivity observed, infectious 
molecular clones created by site-directed mutagenesis were prepared carrying the 
mutations at the above mentioned positions, and their sensitivity to ZDV was tested in 
the HeLa-1022 plaque reduction assay (Chesebro and Wehrly, 1988). When the IC 
values (which refer to 50 percent inhibitory concentration of drug) obtained from the 
ZDV sensitivity assay for the molecular clones were compared with those obtained for 
the naturally occurring variants, a similar pattern of values were observed. This 
enhanced the link between mutations identified in the patient variants and confirmed 
that these mutations, at codons 67, 70, 215, and 219, caused resistance to ZDV. 
With the increased incidence of resistance observed in patients undergoing ZDV 
monotherapy, there was a switch to the use of other drugs now appearing on the 
market such as dideoxyinosine (ddl, Yarchoan eta!, 1989). One study (St Clair eta!, 
1991) looking at the effects of this switch on the virus population identified a further 
mutation at amino acid codon 41 (Methionine, (Met) ATG to cTG/ITG, Leucine 
(Leu)), which has subsequently been shown to be one of the important ZDV -
associated mutations, conferring high level resistance in conjunction with the 215 
change (see Figure 1.6 and Table 1 .2)(Kellam eta!, 1992). 
1.7.2 The level of resistance is proportional to the number of mutations in the 
RT-coding region of liv 
Some isolates showed variation in drug sensitivity. With respect to the IC-S O values, 
differences in sensitivity obtained by the HeLa assay were separated into three groups: 
ZDV sensitive with an IC 50 value <0. 1.tM; ZDV partially resistant, IC 50 0.1-1. OgM;  
ZDV highly resistant, IC50 value> 1 .%M. To investigate the variation in resistance 
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FIGURE 1.6 










































Sequence ATG GAC AAA 	 ACC AAA Wild Type 
Change 4, 1, 1, 1' 4' 4, 
TTGICTG AAC AGA 	TAC/TTC CAA/GAA Mutant 
defined by these IC50 figures, clones were constructed containing various 
combinations of mutations. This would identify what part each change played in 
overall resistance (Larder et a!, 1991). It appeared that the most resistant had all the 
mutations with partially resistant isolates containing subsets of these mutations (see 
Table 1.2). 
To understand what effect the single mutations had on sensitivity to ZDV therapy 
site-directed mutagenesis was used to construct clones that were again tested using 
the HeLa plaque reduction assay. The results showed an eightfold reduction in 
susceptibility to ZDV with a K70R change (Larder eta!, 1990); a fourfold increase in 
drug resistance for a change at codon 41 alone (Kellam eta!, 1992); a sixteenfold 
increase in drug resistance for the change at codon 215 from Thr-5Tyr alone (Larder 
eta!, 1990). 
The patients studied by Kellam eta! (1994a) showed mixtures of linked mutants. 
Clones were then constructed with these combinations, and the sensitivity to ZDV 
revealed that combinations acquired a different level of resistance to ZDV than that 
predicted by the cumulative values of single resistance. A 64 fold increase in 
resistance to ZDV for the linked 41/215 mutant; a 6 fold increase in resistance with 
linked 70/215, which actually shows a decrease relative to single 215 mutant; a 9 fold 
increase in resistance for linked 41/70. Interestingly the linked mutant 41/70/215 had 
only a 34 fold increase in resistance to ZDV. The double 41/215 mutant is twice as 
resistant, and this may account for why such a variant has never been detected in vivo. 
The genotype containing mutations at 41/67/70/215 showed a 179 fold increase in 
resistance to ZDV, and upon addition of 219 to this background this increased to only 
180 fold. Interestingly the removal of the 41 from this background leaving 
67/70/215/219 reduced the resistance to 121 fold. When the 215 mutation is the less 
frequently observed codon for phenylalanine then resistance to ZDV with the 
41/67/70/215Phe/219 background was 51 fold as compared to 215Tyr at 180 fold. 
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TABLE 1.2 
Resistance to ZDV from the HeLa Plaque Reduction Assay 
Mutations 	 Fold Increase in 	 ICo .Lmol/l 
Inserted 	 Resistance 
1 	 0.01 
41L 4 0.04 
67N 1 0.01 
70R 8 0.08 
215Y 16 0.16 
219Q 1 0.01 
67N, 70R 17 0.17 
215F, 219Q 22 0.22 
67N,70R,219Q 28 0.28 
67N,70R,215Y 35 0.35 
67N, 70R, 215F, 219Q 160 1.60 
The table shows the IC50 values obtained for HTV-1 clones produced by site-directed 
mutagenesis, containing various mutations associated with ZDV-resistance 
(Larder et al, 1991; Kellam et al, 1992). 
Removal of the 41 mutation from this background actually leads to an increased 
resistance of 147 fold. This shows the complex nature of ZDV resistance. 
1.7.3 Appearance of mutations associated with resistance to ZDV follows a 
temporal pattern of emergence 
The pathogenesis of HIV follows a pattern of rapid evolution of viral sequences as 
detailed by many studies focused on the env gene (Balfe et a!, 1990; Simmonds et a!, 
1991; Zhang eta!, 1993; Ball eta!, 1994). It is not surprising therefore that a similar 
scenario is seen when looking at thepo! gene and in particular the resistance 
mutations in the reverse transcriptase region and the acquisition of these mutations 
over time. Several studies have been carried out (Boucher eta!, 1992b; Kellam et 
al, 1994; Cleland eta!, 1996; Leigh Brown and Cleland, 1996) and show that in 
patients there does appear to be an ordered appearance of the ZDV-associated 
mutations towards a more resistant variant which would, under the selective pressure 
of the drug, be at an advantage and outgrow other less resistant variants present. 
In the first study (Boucher eta!, 1992b; Boucher eta!, 1990) 18 initially 
asymptomatic homosexual patients receiving ZDV therapy were followed over time. 
The proviral DNA (co-cultivated with peripheral blood mononuclear cells) was tested 
using a polymerase chain method (Larder eta!, 199 1) that involved probes that 
identified either wild-type or mutant sequences at each of the four mutation sites: 67, 
70, 215 and 219. ZDV sensitivity assays were also carried out on HeLa cell lines and 
ICo values obtained. Results indicated that a pattern of resistance development 
existed. 
A mutation at codon 70 was always observed first, usually followed by 215. More 
detailed analysis of three patients showed that the appearance of the 70 mutation was 
in fact transient and that it was replaced by a homogenous population carrying the 215 
mutation. Extensive therapy, and possibly disease progression, had to occur before 
70 re-emerged in conjunction with 215, although not in all patients. No mutations at 
219 appeared and only one at 67 occurred in this study. Of the samples that were 
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tested phenotypically, those with the 215 mutation were partially resistant, with none 
highly resistant. As several of the study group developed AIDS it would appear that 
the presence of highly resistant variants of MV- 1 is not a prerequisite for disease 
progression. 
In an extension of the previous study by Boucher, Kellam et a! (1994) showed a 
similar pattern of resistance acquisition in high risk asymptomatic patients. The main 
mutations observed were those at 70 and 215, with the 41 now also being taken into 
account. The mutation at 70 was first to arise in the majority of patients and with 
continued therapy this was replaced by the 215 mutation, and then shortly afterwards 
the 41 mutation in conjunction with 215, although not all patients developed the 
double mutation. Once they arose these variants remained fixed in the population, 
unlike those with the 70 mutation, whose appearance was transient. The time during 
infection at which mutations are acquired varied between individuals although the 
same distinct pattern of acquisition still applied (Kellam et al, 1992; Cleland et al, 
1996). Phenotypic analysis agreed with previous observations that as the level of 
mutations increases so to does the resistance to ZDV. 
1.7.4 Phenotypically and genotypically diverse IIJV populations - coexist in 
patients during therapy with ZDV 
At any one time the virus population in an individual can be termed a 'quasispecies', 
this term relates to a diverse, rapidly evolving and competing RNA population (Eigen 
eta!, 1988). The fact that this may also be true with regard to the existence of 
different competing variants with ZDV-associated mutations in the reverse 
transcriptase was studied. 
Proviral DNA was cloned from serial samples from two patients under ZDV therapy 
and examined by sequence analysis. What this showed was mixed populations of both 
wild-type and mutant variants at different time points in drug therapy. With continued 
therapy there was a shift from single mutants to linked 41 and 215 in one patient (by 
53 weeks until 132 weeks of ZDV therapy), and 41, 67, 70, 215 and 219 in the 
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second patient (by 136 weeks of ZDV therapy). It is interesting that for the first 
patient there was no extension to a highly resistant variant, although this could have 
developed over further ZDV therapy. What is apparent is that there does appear to 
exist directional evolution of HIV during drug therapy with respect topol (Leigh 
Brown and Cleland, 1996). 
1.7.5 Does the presence of ZDV associated mutations impart any 
advantage on the growth kinetics 
The clones produced by Kellam et alto study resistance were used in growth assays 
to compare the different reverse transcriptase backgrounds with reference to growth 
kinetics. As they all shared a common HXB2 genetic background, with the only 
difference being in the reverse transcriptase region, any phenotypic differences 
observed would be the result of the specific mutations within the RT region. The 
results showed that there was no significant difference between the clones, and all 
showed a similar pattern of growth in the continuous T-cell line C8166 in the absence 
of the selective pressure of ZDV. 
In the presence of ZDV, the more resistant variants would be expected to outgrow 
and replace less resistant strains (Boucher et al, 1993). With acquisition of increased 
resistance the variants have a selective advantage in the presence of drug that allows 
their outgrowth over previous less resistant populations. It has also been suggested 
that different populations grow in different reservoirs and when they have the 
advantageous background, become dominant in the general peripheral circulation. 
1.7.6 There is no clear correlation between emergence of resistance to ZDV 
and clinical decline or progression to AIDS 
The variable rate of disease progression in HI-i infected patients and especially with 
ZDV treated patients, may be due to certain viral characteristics (drug resistance, viral 
phenotype, viral load) as well as host characteristics (CD4 T-cell numbers and 
function, activation markers). The use of these features has been extensively 
investigated to find surrogate markers for the identification of different time points in 
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infection. Such markçrs would be useful in monitoring infection and could show the 
efficacy of drug regimes. 
Zidovudine resistance and clinical status 
With the identification of ZDV resistance-associated mutations and isolates with 
reduced susceptibilities to ZDV, there was concern about the clinical significance of 
such variants, and whether the acquisition of resistance would lead to disease 
progression and clinical decline. Studies looking at different stages of disease (Larder 
et a!, 1990) showed a higher rate of ZDV-resistant variants in ARC and AIDS 
patients in comparison to early stage HIV- 1 positive individuals. Although this shows 
that the appearance of resistant variants may be associated with later stages of disease 
(although resistant isolates have been obtained at all stages of infection), it does not 
prove that the acquisition of mutations causes progression. There is a stronger case 
for linkage between resistant variants and disease progression in children however, 
where the relationship has been shown to be statistically significant (Tudor-Williams 
eta!, 1992). 
Although there is no consensus on the relationship between presence of ZDV-
resistant isolates of HIV- 1 and clinical deterioration, the appearance of the associated 
mutations are markers for the reduced efficacy of the ZDV therapy, and the possibility 
of progression could be due to other factors like the appearance of syncytium-
inducing phenotypes (St Clair eta!, 1993). 
Biological phenotype: NSI and SI 
The ability of viral strains of HIV to form syncytia in cell culture, has been used to 
predict disease progression (Tersmette et al, 1988; Koot, 1993; Koot, 1995). These 
syncytia are 'giant' multinucleated cells which appear in cell cultures, and the viral 
strains which produce syncytia in cell culture have a greater tropism for, and are more 
cytopathic in-vitro for transformed T lymphocyte cell lines such as MT-2. 
Appearance of such SI strains in patients has been associated with accelerated CD4+ 
cell decline and disease progression. However, it must be noted that not all HIV- 
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infected patients who have progressed have the SI phenotype or develop the SI 
phenotype, indeed in only 50% of patients was the shift in disease status associated 
with appearance of the SI phenotype (Koot, 1992). Once an SI genotype emerges it 
rarely exceeds 60% of total viral load (Koot, 1995), and often remains a minority. 
In the study by St. Clair eta! (1993) which investigated the relationship between 
ZDV-resistance and syncytium-inducing phenotypes, it was the presence of the SI 
phenotype that was the stronger predictor of disease progression. It is still not clear 
however, whether ZDV-resistance mutations and SI phenotypes are linked (Boucher 
et a!, 1992), or act independently of each other. 
Viral load 
Viral load is an important factor in disease progression. With the initiation of ZDV 
monotherapy there appears to be a decrease in the viral burden, shown by a decrease 
in serum levels of HIV antigen (p24 Ag) after therapy initiation (Fischl et a!, 1990). 
Virus can still be selected for during therapy (Larder et a!, 1989a), therefore ZDV 
therapy does not stop viral replication completely. As monotherapy continues ZDV-
resistant variants arise and the viral burden begins to increase (Mohri eta!, 1993). 
With the recent advances in testing HTV-1 RNA in plasma, which can be quick and 
very reproducible, more accurate changes can be obtained. It was found that the 
changes in plasma load of HIV-1 was much greater than that observed for proviral 
DNA, and that the values together, but independent of CD4+ T-cell counts, were 
predictive of treatment efficacy. 
CD4+ T cells 
The CD4+ T helper cell count has always been a marker in ETV-1 infection. With the 
start of ZDV monotherapy it was used as a marker of drug efficacy and showed a 
steady increase after initiation of therapy, however this benefit is short term, with the 
numbers usually returning to base line values (i.e. the number prior to therapy)(Koot, 
1995). One aspect of CD4+ counts that complicates their use is the different rates of 
decline that can be observed between individuals with similar cell counts. It was 
44 
shown that patients with low CD4+ counts (in advanced disease) were more likely to 
have drug resistant variants, with 89% of patients in advanced disease showing 
reduced susceptibility to ZDV, with highly resistant variants only seen in patients with 
AIDS or advanced ARC, compared to 31% in asymptomatics (Richman eta!, 1990). 
Independent of this cell loss, a change in T-cell function can also be observed, with a 
decrease in function as disease progresses. This reduction can be followed using 
proliferation assays, where the pattern of responses to certain mitogens changes 
(reviewed in Miedema et a!, 1994), and a low T-cell reactivity to CD3 monoclonal 
antibody in vitro was a strong predictor for progression to AIDS. In parallel, strong 
preserved T-cell reactivity in asymptomatics (homosexual men) or at AIDS diagnosis, 
predicted a prolonged asymptomatic phase or survival time respectively. In ZDV 
therapy an improved T-cell function is however only transient (Koot, 1995). 
Activation markers 
During HIV infection immune activation to chronic levels results, as indicated by the 
levels in serum of markers such as 13 2-microglobulin, neopterin, and expression of 
CD38 and MIHC-ll. Antiviral therapy has been shown to reduce levels of plasma 
markers such as 32-1111croglobulin and neopterin (Jacobson eta!, 1995; Jacobson eta!, 
1991). 
1.7.7 Reversion of resistance with cessation of therapy 
It has been shown that with ZDV therapy there is an ordered and temporal 
appearance of mutation acquisition (Boucher eta!, 1992b; Kellam eta!, 1994). 
Several studies have looked at the change in phenotypic and genotypic profiles of 
individuals who have stopped therapy, usually due to toxicity, or because of a 
decrease in sensitivity to the drug. 
In a study examining the changes in the RNA viral populations within the plasma 
(Albert et al, 1992), sequence analysis showed that over a 18 month study period, 
from 4 individuals examined, 2 showed a change in resistance profile. Before 
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cessation of therapy all showed the presence of ZDV resistance-associated mutations 
at codons 67, 70, 215 and 219. In one individual there was a partial change at 18 
months (losing the 215 and 219 mutations from a 67/70/215/219 mutation 
background), whereas in the other there was almost complete reversion by 9 months 
post-treatment. Interestingly, analysis of the proviral DNA population showed 
reversion at a slightly faster rate than that shown by the HJIV-1 RNA plasma 
populations. Reversion was also noted in the proviral DNA before it was detected in 
the RNA, detected at 9-12 months, whereas the RNA still showed all mutations up till 
18 months. 
In a study, following a group of 6 homosexual males who had stopped therapy with 
ZDV due to haematologic toxicity (and who were at different stages of disease), 
Boucher eta! (1993), looked at changes in vivo through phenotypic drug sensitivity 
assays. IC 50 values for such assays can be split into three categories, which are: 
<0. 1LM 	zidovudine-sensitive 
0.1-1 .Op.M 	zidovudine-partially resistant 
>1.Op.M 	zidovudine-highly resistant 
These individuals had undergone ZDV treatment for between 1-2 years, and showed 
partial or high level resistance before cessation of therapy, as defined by the categories 
above. After a follow up time of 69 weeks some, but not all, of the partially resistant 
isolates showed changes in the IC 50 values, falling within the drug sensitive range 
(shown above as <1 .0pM). These changes occurred between 8-32 weeks post-
treatment. Using a selective PCR procedure, that probes for the presence of 
particular point mutations (see Chapter 7), the changes in phenotypic profiles were 
shown to be a result of an increase in the frequency of wild type variants within the 
population, and also elimination of certain ZDV resistance mutations (at codon 41 and 
70 in two individual patients). 
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What these studies show is that a period of up to 1 year without ZDV may be 
required to achieve a change from a mutant or mixed virus population to a wild type 
virus population. The slow reversion of resistance in vivo may be reflective of the 
replicative capacities of such variants, indicating that they may be similar to sensitive 
variants of HIV-1. 
1.7.8 Structural basis of ZDV resistance 
As detailed in section 1.2.2.1.1, RT has four individual subdomains that make up the 
polymerase domains of p66 and p5  1, named the 'fingers, palm, thumb, and 
connection'. Mutations at residues M41L, D67N and K70R are located in the 
"fingers" subdomain with the T215YIF and K219Q mutations lying in the "palm" 
subdomain, with the polymerase active site being located at aspartic residues (position 
110, 185 and 186) in the palm domain of the p66 subunit (Jacobo-Molina eta!, 1993, 
Tantillo el al, 1994), in the highly conserved QYMDD motif found in many 
polymerases including Hepatitis B. 
This analysis gives an insight into the effects of the amino acid substitutions at the five 
residues with respect to how resistance actually occurs at a biochemical level. 
Whereas resistance to 3TC is mediated by an active site mutation (position 184) the 
majority of the zidovudine resistance mutations are not located at the polymerase 
active site, but are mapped to sites where the ZDV-triphosphate binds to the RT, 
where mutations could interfere with the positioning of the template-primer, or could 
change the internal geometry, causing a different recognition at the active site 
(Jacobo-Molina et al, 1993; Tantillo eta!, 1994). 
1.7.9 The molecular basis of ZDV resistance 
As discussed earlier, ZDV is a prodrug that requires intracellular activation by cellular 
kinases. It has been shown that phosphorylation to the monophosphate is relatively 
efficient, however ZDV-MP is not a good substrate for the next kinase, thymidylate 
kinase (Lavie et a!, 1997; Hazuda and Kuo, 1997). Sufficient levels of the active 
ZDV-TP may not be present to suppress viral replication to a level that would 
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prevent emergence of resistance. Recent studies of ZDV-MP complexed with yeast 
thymidylate kinase (which shows considerable homology with the human enzyme) has 
shown that binding of ZDV-MP occurs with the same affinity as dTMP, but with its 
larger azido group in place of the usual hydroxyl, there is a structural shift in the P 
loop, which is involved in catalysis, and hence the reason for reduced phosphoryl 
transfer (Lavie et a!, 1997). Another observation was that ZDV-MP could also bind 
to the ATP site, if concentrations accumulate within the cell. It has been shown that 
ZDV-MP levels of millimolar values can be seen, and that increased doses of ZDV to 
prevent resistance, and decrease viral load, could actually have a detrimental effect by 
inhibiting its own phosphorylation. Current dosage of zidovudine (-300mg/day) is 
considerably lower than early doses (-1000mg/day). 
1.8 Transmission of Resistant Variants of HIV-1 
HTV-1 can be transmitted by several routes: sexual (by both homosexual and 
heterosexual contact), percutaneous (by blood products, transfusions, by intravenous 
drug abuse), and perinatal. More recently it has become clear that transmission of 
HEY-i strains carrying mutations associated with ZDV therapy can also occur. 
Documented accounts have shown sexual transmission of resistant variants through 
both homosexual (Erice et al, 1993; Garcia-Lerma eta!, 1996), and heterosexual 
contact (Conlon et al, 1994; Angarano eta!, 1994; Wahlberg eta!, 1994; Garcia-
Lerma et al, 1996), and parenterally, through a needle-stick accident (Anonymous, 
1993; Pratt eta!, 1995), or through intravenous drug abuse (De Ronde eta!, 1996). 
One documented case showed transmission between two children living in the same 
home, probably through blood contact, although the route was never established 
(Fitzgibbon eta!, 1993). 
When this investigation began, no studies had shown the existence of genotypic ZDV 
resistance without exposure to the drug (Larder et a!, 1989a; Richman et al, 1991; 
Fitzgibbon eta!, 1991; Richman, 1992; Mayers et al, 1992; Land eta!, 1992; Jung et 
a!, 1992; Boucher eta!, 1992a,b; Garcia-Lerma eta!, 1996) or without some form of 
contact with a patient undergoing antiviral therapy. One exception is the existence of 
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mutation at codon 70 which had previously been described as a polymorphism in 
untreated populations (Mohri eta!, 1993; Zhang eta!, 1991; Najera eta!, 1995). 
Mutations at amino acid position 70 however, only accounted for one of the 
transmission events documented (Conlon eta!, 1994). Mohri eta! (1993) also 
cultured virus with moderate resistance to ZDV from asymptomatic patients. 
The first transmission of a ZDV resistant variant of HIV-1 was documented in April 
1993 (Erice eta!), and was through homosexual contact. This showed the presence 
of the mutation at codon 215, Thr—*Tyr, and to a lesser extent Thr—Phe, which was 
identified through PCR amplification, cloning and direct sequencing of patient 
PBMCs. Phenotypic analysis showed that the isolate was resistant to ZDV with an 
IC50 value of 0.86.tmol of ZDV. Wild-type virus, sensitive to ZDV will show an IC50  
of <0.1, with the IC 50 for a variant with amino acid change only at 215 at a median of 
>0.16 (Kellam eta!, 1992); this patient was therefore resistant to ZDV. After 17 
weeks of ZDV therapy, although no accumulation of any other ZDV-associated 
mutations was documented, the IC 50 had jumped to 2.90, showing a highly resistant 
viral strain. This would appear to negate the use of ZDV monotherapy during what 
was clinically established as primary HIV- 1 infection, and in particular when the 
infection was caused by a resistant variant. 
In a heterosexual transmission study by Wahlberg et a! (1994) looking at 5 
heterosexual couples (male intravenous drug users and their partners), ITV- 1 was 
tested by genotypic and phenotypic methods. Results showed 4 'donors' to carry the 
Thr—*Tyr 215 mutation, with two of these 'donors' containing a double mutant, 
with a combination of the 215 Tyr mutation, with a mutation at amino acid codon 41: 
wild type sequence ATG (Methionine, Met) to mutant sequence TTG (Leucine, Leu). 
Transmission occurred in only 1 of the partnerships, transferring a variant carrying the 
codon 215 mutation alone. 
Conlon eta! (1994) showed that transmission of a variant encoding the codon 70 
mutation associated with ZDV therapy had been transmitted from a male AIDS 
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patient who had undergone ZDV therapy for 23 months, to a female recipient through 
heterosexual contact. This mutation was detected in the proviral population, and 
persisted for up to a year in the female, and actually increased from 30% to 47% of 
the population examined. Although it is surprising that the male contact did not have 
more resistance associated mutations, it is clear that each patient develops these at 
variable rates. Also, several studies have postulated that the detection of this 
particular mutation either prior to therapy and usually appearing first during therapy, 
suggests that it actually has a replicative advantage, however small, in the absence of, 
or relatively early in, drug therapy. Its appearance first also is not a surprise because 
it only requires a single A to G nucleotide change to confer an 8-fold reduction in 
sensitivity to ZDV. 
Garcia-Lerma et a! (1996) investigated a group of 17 well defined rapid progressors, 
all of whom had been infected for less that 3 years but had developed AIDS (as 
defined by their consistently low CD4 counts), but at the time of testing had never 
undergone any form of antiretroviral therapy. From this study 2 individuals showed 
the presence of the codon 215 mutation: one female whose suspected source was a 
male AIDS patient who had undergone ZDV therapy for 2 years, and one male 
homosexual who had unprotected sex with multiple partners of unknown serostatus. 
Also observed were 4 patients (including the two above) with the codon 70 change. 
This study also suggests the persistence of resistant variants for 2-3 years in the 
absence of drug. 
De Ronde eta! (1996) retrospectively looked at two cohorts (of intravenous drug 
abusers and homosexuals) that had previously been extensively investigated. They 
looked at the first positive serum sample for the presence of the codon 215 mutation 
in the RNA population using the point mutation assay (Kaye et a!, 1992). The 
seroconversions for the groups occurred between 1992 and 1995. Only one incidence 
of the 215 mutation as detected in one of four seroconvertors in 1993 from the 
IVDU group: a total of 1 from 28 patients over the time period, quite low in 
comparison to other studies, over a 4 year period. There was no documented 
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transmission in the homosexual cohort. This was particularly low when compared to 
the occurrence of primary infections in Switzerland (Perrin eta!, 1994), where an 
estimated 10% of these were due to ZDV resistant variants during the period 1990-
1994. 
Pratt et a! (1995) showed the transmission of a ZDV resistant variant from an AIDS 
patient to a health care worker through an accidental needlestick injury. The 
mutations were analysed using the mismatch primer method developed by Larder et a! 
(1991). The assay was carried out on cDNA produced from RNA extracted from 
PBMCs, and involved the annealing of specific probes to the resistance-associated 
positions of interest. The assay is carried out in duplicate with one probe directed 
against the wild type sequence and one directed against the mutant genotype, the 
results of which can be resolved by gel electrophoresis. 
Interestingly, the first sample from the health care worker, 20 days post exposure, did 
not correspond to the transmitter's genotype which showed the 41 and 215 mutations 
with an SI phenotype. In fact the health care worker had sensitive virus (<0.01 
.tg/ml), with an SI phenotype but only the 70 mutation. By 75 days post exposure a 
mixture of 41 and 215 was observed with a 5-fold (0.2) increase in resistance to ZDV, 
but surprisingly the biological phenotype was NSI. This phenotype remained until the 
end of the study period, 608 days post exposure, with a conversion to wild type 
genotype and sensitivity to ZDV (<0.01). The documented reversion of the SI to NSI 
phenotype is not clear, although evidence does suggest that NSI variants are more 
readily transmitted by the sexual and vertical routes. The fact that in a needle stick 
accident there are no physical barriers to impose selection, may account for its 
presence early in infection, although the authors believe this shows that NSI and ZDV 
sensitive virus were selected for in this particular patient. 
An earlier case of needle stick injury was documented in 1993 (Anonymous), where 
again a health care worker was treated with ZDV within 1 hour of exposure. The 
transmitter in this case also had AIDS and had been taking ZDV for 18 months prior 
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to this incident. Although genotyping was not undertaken in this clinical setting, 
sensitivity assays were performed on virus cultured from the peripheral blood 
mononuclear cell from the health care worker. The results showed resistance to ZDV 
with an IC 50 of 0.865 RmolIL: no information was available from the source of 
infection. Interestingly the transmission through percutaneous injury during 
occupational exposure to HTV was estimated to be only 0.3 8% (Cardo et a!, 1997). 
In 5 out of the 10 studies discussed above, the 'donors' had been diagnosed with 
AIDS with recurrent opportunistic infections and/or low CD4+ T-cell counts (Conlon 
eta!, 1994; Fitzgibbon eta!, 1993; Garcia-Lerma eta!, 1996; Pratt eta!, 1995; 
Anonymous, 1993). Such information is not available on the other studies but therapy 
for at least 6 months in the 'donors' in the years 1993-1994 may be more indicative of 
later stage disease. 
Wahlberg (Wahlberg et a!, 1994), using the observations from the heterosexual study, 
hypothesised that resistant variants of HIV-1 were selected against during 
transmission. This suggested that selection of wild-type virus over mutant virus 
occurs either at/during transmission or just after transmission during the initial 
replication in the new host, thus accounting for the small number of documented 
transmission events involving resistant variants. If selection against mutant variants 
occurs during the transmission event then minor pools of wild-type genotypes would 
have an advantage in establishing a new infection. This assumption also raises other 
questions such as whether there is a decrease in the replicative capacity of resistant 
variants in comparison to wild-type which would allow the latter to outgrow the 
resistant variants in the absence of selective pressure. In vitro studies carried out on 
different ZDV resistant variants showed no dramatic difference between wild type and 
resistant variants (Kellam et a!, 1992). Wahlberg suggests however that even a slight 
advantage may be relevant at this initial period of high replication. 
Angarano eta! (1994) also looked at a small group of heterosexual partners and 
found seven out of eight of the study group transmitted a mutant virus (including 
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double mutants with 4lLeu and 215Tyr) to their partner. This result contradicts 
Wahlberg's theory of reduced transmission of resistant variants, but shows that small 
study groups can be subject to different interpretation. 
In all cases of heterosexual studies, transmission has been documented to occur by the 
male to female route. Studies are small and contradict each other with respect to the 
transmissibility of resistant variants of HIV-1. The studies detailed above show that 
resistant variants of H1lV-1 can be transmitted by sexual contact as well as through 
parenteral routes, and this imparts major problems with respect to treatment regimes. 
Transmission of resistance to other drugs such as didanosine and zalcitabine has also 
been documented (St Clair et al, 1991), and with the increased use of multidrug 
regimes used at present, and administration of drugs earlier in infection, the frequency 
of new infections being established by resistant variants is likely to be on the increase. 
De Jong et a! (1996) studied the presence of ZDV resistance-associated mutations in 
the plasma RNA population in a group of ZDV naive patients over a period of 2 years 
ZDV treatment. They wanted to determine whether the loss of sensitivity to ZDV, 
and loss of inhibition of HIV replication, coincided with the appearance of resistant 
variants. The presence and frequency of mutant variants was determined by direct 
sequence analysis and the use of the point mutation assay (Kaye et al, 1992), and the 
results showed that the resurgence of viral load occurred before the presence of 
mutations in the RI were observed. 
They applied a mathematical model, the 'host-parasite model', to understand the 
complex relationships between resistance, viral load, and CD4 T-lymphocyte counts. 
The basic principle of the model is based on the balance between ever changing 
equilibrium between host cells, and parasite viruses, where treatment with an 
antiretroviral drug allows the host's CD4 cells to increase, with the viral load being 
limited by the number of these cells. They found that the acquisition of mutations to 
produce a highly resistant variant could not be explained by the CD4+ T-cell counts 
or serum RNA levels, or on the presence or absence of syncytia-inducing phenotypes. 
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They did conclude however that the rate of resistance acquisition was influenced by 
the prevalence of resistant variants prior to treatment (although no resistant variants 
where detected at baseline). This is an added complication in the management of 
HIV- 1 in the clinical environment by infection caused by resistant variants. 
1.9 Work Presented in this Thesis 
As the occurrence of transmission events with ZDV resistant variants was increasing 
and the use of ZDV in combination with other new drug regimes was also likely to 
increase it was of interest to investigate what level of resistance existed in a chosen 
HW-1 population. The aim of this work was firstly to examine genotypically an 
antiretroviral naïve population, with respect to ZDV, of ETV-1 positive individuals. 
A group of 35 individuals of known seroconversion date was identified, based on their 
antiretroviral status alone. No other selection, apart from choosing those who 
seroconverted after a time point at which ZDV was in general use in the patient areas, 
was applied. Proviral DNA was examined using nested polymerase chain reaction and 
direct sequencing to examine the nucleotide sequence of the reverse transcriptase 
region of the pol gene, including the amino acid positions 215 and 219; documented 
evidence shows the presence of 215 being the most frequently observed mutation and 
therefore this was used as an indicator. Those patients identified as having mutations 
were then further analysed looking at the nucleotide sequence of RT from amino acid 
41 through to 219, threfore including all the ZDV associated mutations. 
The next stage after identification of patients with interesting mutations, was to carry 
out phenotypic assays to elucidate the status of the mutation with respect to ZDV 
sensitivity. Recombinant viral assays were carried out and recombinant virus carrying 
patient RT fragments were used to carry out ZDV sensitivity assays and competition 
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2 	Materials and Methods 
2.1 	Collection and Processing of Patient Samples 
The MRC Molecular Epidemiology Project (MEP), was a resource of HTV positive 
patient samples and data covering all lilY groups. The Edinburgh branch of the MEP 
(Edinburgh Repository: Dr J. Peutherer and Dr A. Leigh Brown) collected patient 
material (peripheral blood mononuclear cells (PBMC), plasma and serum) from 10 
clinical centres covering Scotland, Eire, Northern Ireland and the North of England. 
All clinical and laboratory data collected were stored on a database constructed using 
Paradox 4.0, supplied on a questionnaire which was completed and returned with the 
patient's sample (sex, age, seroconversion dates (last negative-first positive), 
antiretroviral drug status, HTV status, CD4 T-lymphocyte counts). Samples and data 
collected in the MEP were processed by Mrs S. Rebus and Mr D. Lobidel. Patients 
were selected from the Molecular Epidemiology Project, Edinburgh under the criteria 
that their estimated seroconversion date was post 1990 and that they had never 
undertaken any form of antiretroviral therapy. 
2.1.1 	Processing of blood samples 
Blood samples were collected in EDTA or heparin-containing vacutainers, and the 
plasma and PBMCs were separated on the same day as collection as follows. Blood 
was diluted two fold in phosphate buffered saline (PBS tablets supplied by OXOID, 
pH 7.3, or ten times concentrated pre-prepared PBS from GibcoBRL supplied 
without calcium and magnesium), and lOmi layered over lOml LymphoprepTM 
(Nycomed) or NycoPrep 1.077 (Nycomed) in a 20m1 universal tube, taking care not 
to mix the phases. These were then centrifuged at 2000rpm for 30 minutes (Beckman 
GP centrifuge, ]EC Centra-4R), and the plasma and peripheral blood mononuclear 
cell layers (PBMCs) were removed using fine tipped pastettes. 
2.1.2 	Sample storage 
Plasma was stored in cryotubes (NUNC) at -70°C. PBMCs were washed twice with 
1X concentrated PBS, then resuspended in freezing mix (20% Dimethyl Sulphoxide 
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(DMSO, SIGMA Cell Culture), with 80% sterile heat-inactivated foetal calf serum 
(FCS, Advanced Protein Products Ltd), in cryotubes (NTJNC), and cooled to -70°C 
at a rate of 1°C/minute using freezer containers with propan-2-ol (NALGENE Cryo 
1°C Freezing Containers). Thereafter samples were stored in the gaseous phase above 
liquid nitrogen. 
2.2 	Extraction of HIV-1 from Blood Products 
2.2.1 Extraction of proviral DNA from PBMCs 
Proviral DNA was extracted from cryopreserved PBMCs by direct thawing and 
washing once in RPMT 1640 (HyClone® Europe Ltd) to remove freezing mix. The 
cell pellet (approximately 1 x 106  cells) was then resuspended in 400tl lysis buffer 
(50mM EDTA, pH 8.0; 100mM Tris-HCL, pH 7.5; 50mM NaCl; 0.01% Proteinase 
K (10mg/mi stock; SIGMA Molecular Biology 5mg, 14 units/mg); poly A (2mg/mi)) 
and incubated at 37°C for 1.5-2 hours. To this was added 6001.Ll TE saturated phenol, 
then 600J.fl phenol/chloroform (1:1), the mixture vigorously vortexed and then 
centrifuged at 13,000rpm for 10 minutes (Heraeus SEPATECH Biofuge 15). The 
aqueous phase was removed and added to lml of ice cold 100% ethanol and the DNA 
precipitated at -20°C overnight. After overnight precipitation the DNA was pelleted 
by centrifugation at 15,000 rpm for 20 minutes. The supernatant was discarded and 
the DNA pellet washed x2 with ice cold 80% ethanol, to remove unwanted salt. The 
pellet was dried at 42°C on a hot block for approximately 10 minutes and the DNA 
resuspended in 50p.1 diethyl pyrocarbonate (depc) treated distilled water. DNA was 
stored at -20°C prior to use. 
2.2.2 Extraction of viral RNA from plasma 
Viral RNA was extracted from 1 OOp.l plasma using the above technique described for 
DNA extraction. The RNA pellet was resuspended in 20pi depc, and stored at -60°C 
or below. 
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2.3 	Amplification of HIV-1 
2.3.1 Reverse transcription of viral RNA 
Extracted viral RNA was reverse transcribed into cDNA via specific viral primer 
initiated cDNA synthesis. Extracted RNA (5-10Rl)  was added to a reaction buffer 
(50mM Tris-HC1, pH8.0; 5mM MgC12; 5mM DTT; 50mM KC1; 0.05 p.g/j.il bovine 
serum albumin; 6001.LM each of dATP, dGTP, dCTP, and dTTP; 20% DMSO; 
200ng of outer antisense primer (252); 15 units RNasin ® Ribonuclease (40 units/j.Ll, 
PROMEGA) inhibitor; 10 units AMV reverse transcriptase (8,000 units/ml, 
PROMEGA), in a final volume of 20111 and incubated at 42°C for 1 hour. 
2.3.2 	Polymerase chain reactions 
PCR is an in-vitro technique for the amplification of DNA. The target DNA, or 
cDNA, is amplified through a series of repetitive cycles involving template 
denaturation, primer annealing (short oligonucleotide probes), and extension of 
annealed primers with heat stable DNA polymerase, leading to exponential increase of 
target DNA (Mullis, 1990). 
2.3.3 Nested polymerase chain reactions 
Nested PCR is a more sensitive form of PCR involving two such rounds of 
amplification with two sets of primers: an outer pair for the first round, with a second 
pair nested within the outer pair, for the second round. This double action increases 
the sensitivity and specificity and allows the amplification from a single copy of target 
DNA or cDNA. 
2.3.4 	Limit dilution polymerase chain reaction 
Limit dilution PCR allows the amplification from one single copy of DNA. The limit 
dilution point is defined as the dilution at which approximately 20% or less of the 
PCR reaction yield positive, amplified DNA. By applying the Poisson distribution it 
makes it very likely that only single molecules of target sequence were present at the 
outset of the PCR reaction (Simmonds et al, 1990b). 
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2.3.5 Amplification of reverse transcriptase region of pol by PCR 
First round, primary PCR (201.1.1 total volume): ipi DNA/cDNA was added to PCR 
reaction mix containing 50mM KCI, 10mM Tris-HC1 (pH 8.0), 1.5mM MgCl2, 3.31.LM 
each dNTP and 0.2511M each primer, and 5 units Taq DNA polymerase (5,000 
units/ml, PRO1V[EGA). All PCR reaction tubes were overlayed with paraffin to 
prevent evaporation. This reaction mix was subjected to 30 cycles consisting of 
94°C/25 seconds; 55°C/35 seconds; 72°C/i 50 seconds, followed by a final cycle of 
72°C for 7 minutes (TECHNE Thermal Cycler, GENEE Thermal Cycler). 
Second round, secondary PCR (20iil total volume): ipi of the primary PCR 
product was transferred into 19111 of secondary reaction mix (as for primary but with 
the secondary, nested primers). This was then subjected to 30 cycles as described 
above. After amplification the secondary products were visualised on ethidium 
bromide stained 1.5% agarose gels (see section 2.3.6 below). 
	
2.3.6 	Primers 
All primers were produced by OSWEL DNA Service (Southampton) on an Applied 
Biosystems 394 Synthesiser, and purified by HPLC. See Figure 2.1 for primer 
layout, co-ordinates relate to the subtype B HXB2 sequence. 
2.3.7 	Gel electrophoresis of amplified HIV-1 
PCR Products were visualised on ethidium bromide stained gels of various 
percentages, dependent on the size of product. Gels were prepared by adding an 
appropriate amount of agarose (Electrophoresis Grade Agarose, FLOWGEN) to 30 
mis lOx TBE buffer (0.89M Tris-borate, 0.89M Boric acid, 0.1M EDTA, pH 8.5) and 
270 mIs distilled water. The mixture was brought to boiling point under constant 
agitation and allowed to cool to 60°C before the addition of 0.5p.g/ml ethidium 
bromide (10mg/mi). The gel was then poured onto an electrophoresis plate and 
allowed to set. 
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FIGURE 2.1 
HIV-1 p0! Primers 
- 	The table lists the primers used for amplification of the reverse transcriptase region of the poi gene. Figures in brackets relate to primer 
co-ordinates for the MV- 1 HXB2-D clone (Myers et al, 1995, Los Alamos), where '+' refers to sense strand, and '-' the antisense strand 
co-ordinates. On the right hand side of the primer sequence are the primer locations for PCR analysis in this thesis (Figure 2.2). 
B - Denotes a biotinylated primer 
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 251(+2480) GTA GQA-CCT ACA CCT GTC AAC SENSE(OUTER) 
 252(-3868) TTA GCT GCC CCA TCT ACA TAG ANTISENSE(OUTER) 
 155 (+2602) CCC AAA AGT TAA ACA ATG GCC SENSE(INNER) 
 153(+2963) GAC ACC AGG GAT TAG ATA TC SENSE(INNER) 
 150(-3281) GCT GTC TTT TTC TGG CAG CAC ANTISENSE(INNER) 
 154 (-3281) CCA TTT ATC AGG ATG GAG TTC ANTISENSE(INNER) 
 152(-2965) GTC TCA TTG TTT ATA CTA GG ANTISENSE(INNER) 
 B155 (+2602) CCC AAA AGT TAA ACA ATG GCC SENSE(INNER) 
 B154 (-3281) CCA TTT ATC AGG ATG GAG TTC ANTISENSE(ThNER) 
Routinely, 20tl of secondary product was subjected to electrophoresis at 150 volts 
for approximately 15-20 minutes. DNA was then visualised by placing the gel on an 
ultra-violet transiluminator, and photographed using a Polaroid camera and polaroid 
667 film. 
2.4 	Sequencing of HIV-1 
PCR amplified DNA or cDNA was sequenced using a solid matrix to isolate the DNA 
template generated using biotinylated primers and fluorescently labelled deoxy 
terminators on an automated sequencer. Sequencing was carried on directly on PCR 
amplified patient material (which I will term 'bulk') or on single molecules of DNA 
obtained by limit dilution PCR (see section 2.3.4). 
2.4.1 PCR for automated sequencing 
First round IPCR (201.11 volume)as described in section 2.3.5. 
Second round, biotinylated PCR (1201.11 volume): The secondary PCR for 
sequencing reactions was carried out using one biotinylated primer, which leads to the 
end labelling of the PCR product allowing subsequent immobilisation of the DNA 
template on a solid matrix such as Dynabeads (see section 2.4.3). Specific molar 
ratios of both primers were used for these reactions with the biotinylated primer being 
the limiting factor. This adaption aids the Dynabeads immobilisation step, where excess 
free biotinylated primer would adhere to and fill the streptavidin sites on the beads easier 
and quicker than the larger DNA template. 1001.11 of this PCR is used for sequencing, the 
increased volume allowing sufficient template for the direct sequencing chemistry, with the 
remaining 201.11 being resolved on an agarose gel (see section 2.3.6) to check that the 
second round PCR was successful. 
2.4.2 	Primers 
Outer primers 251/252 are used in first round amplifications of PCP,, and 155/154-150 for 
second round, as detailed in section 2.3.6; one biotinylated primer of the primer pair is 
used in the secondary reaction, i.e. biotinylated 155 with 154 or 150 for sequencing of the 
sense strand, or 155 with biotinylated 154 for sequencing of the antisense strand of DNA 
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(lOpmol biotinylated primer with 30pmol of nonbiotinylated primer in a 120pi 
reaction)(see Figure 2.2). 
2.4.3 Immobilisation of fflV-1 PCR product for sequencing 
M-280 Dynabeads Biomagnetic separation system (DYNAL) uses streptavidin coated 
magnetic beads for the capture and purification of biotin labelled PCR products. The 
secondary PCR product contains template tagged on either sense or antisense strand 
with biotin, which binds to the streptavidin of Dynabeads under specific conditions, 
and then allows the manipulation of this template. 
Dynabeads M-280 Streptavidin are supplied as a suspension containing 6-7 x 108 
dynabeads/ml (10mg/mi), suspended in phosphate buffered saline, pH 7.4, containing 
0.1% bovine serum albumin and 0.02% NaN3. The dynabeads were washed xl in an 
equal volume of binding and washing buffer (B&W, 10mM Tris-HC1, pH 7.5, 1 m 
EDTA, 2.OM NaCl), to remove the preservative (NaN 3), using a magnetic particle 
concentrator. After this wash the Dynabeads were resuspended in twice the volume 
of B&W buffer to give a working concentration of 5.Op.g/p.l. 40p.l of washed 
Dynabeads are mixed with 1 OOp.l of secondary PCR product, and incubated at 48°C 
for 30 minutes to separate the DNA strands and leave the biotinylated template 
attached to the beads. The Dynabeads:DNA complex was washed once more with 
B&W buffer before being incubated with 0. 1M NaOH (freshly prepared). The non-
biotinylated strand was discarded in the supernatant (this strand can also if desired be 
recovered and sequenced via neutralisation and ethanol precipitation). The 
immobilised single stranded template is then washed with 50j.tl 0. 1M NaOH, 401.Ll 
B&W buffer, then finally with 50R1  TE (10mM Tris-HC1, pH 7.5, 1 m EDTA), 
before being resuspended in 14pi depc distilled H 20. 
2.4.4 Applied Biosystems dye terminator sequencing 
Sequencing of single stranded DNA template was carried out on PCR product 
purified using Dynabeads and the Applied Biosystems fluorescent terminator DNA 
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FIGURE 2.2 
Diagrammatic Representation of Primers for Amplification of Reverse Transcriptase 
Figure 2.2 shows the primers layout for amplification of the reverse transcriptase region of the pol gene by nested PCR. Arrows pointing to 
the right represent sense primers, and those pointing to the left, antisense primers. 
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sequencing system (PRISM Sequenase Terminator Single Stranded DNA Sequencing 
Kit), with Sequenase Version 2.0 T7 DNA polymerase as follows: 
- Annealing Reaction 
1il (0.8RM) non-biotinylated primer was annealed to the immobilised DNA template 
(14pl) by incubation at 65°C for 2 minutes with 5p.l of 5X SS MOPS buffer (400mM 
MOPS Buffer pH 7.5, 500mM NaCl, 100mM M902, 50mM MnC12, and 150mM 
isocitrate, with 25% glycerol). The DNA:primer mix was allowed to cool slowly until 
it was below 30°C. Samples were pulse centrifuged to collect condensation, and held 
at room temperature. 
- Termination Reaction 
4jfl sequenase dye terminator mix (ABI) was added to the above and incubated at 
37°C for 2 minutes to equilibrate the samples. Dye terminator mix must be 
maintained in the dark and therefore all steps were carried out in subdued lighting and 
incubations covered with aluminium foil. 191 of Sequenase T7 (ABI) was added to 
each tube, mixed by pipetting, and incubated at 37°C for 10 minutes, prior to 
immediate transfer onto ice to stop the enzyme reaction. 
- Isolation and concentration of extension fragments 
The Dynabeads:DNA complex was placed in the MPC, the supernatant was discarded 
and the excess reactants removed by washing twice with 40tl of0.O1M Tris/0. 1% 
TWEEN 20, pH 8.0, and once with 40jil TE. The extended material was eluted from 
the beads by resuspending in SRl  formamidefEDTA (FE, Formamide, spectral grade, 
Eastman Kodak Company) and incubating at 90°C for 2 minutes. Immediately after 
incubation tubes were placed on ice and loaded onto the sequencing gel. 
- PolyAcrylamide sequencing gel 
Gel plates had to be exceptionally clean to prevent defects within the gel due to dust 
particles or bubbles which would interfere with sample running. This was achieved by 
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removing gel residues with non-fluorescent detergent (ALCANOX') followed by 
rinsing with distilled water. KimWipes (Kimberley-Clarke) were used since they do 
not produce fluorescent dust particles. Gel plates were assembled with bare hands 
washed to remove glove powder. 
The 6% sequencing gel was prepared by combining the following: 30g Urea, 0.5g 
Amber light resin, 20ml distilled 1120 and 9ml of 40% T Bis/Acrylamide stock solution 
(30g of 19:1, dissolved in 48ml of H20, BIORAD). Once dissolved the gel solution 
was degassed by vacuum filtration through a 0.2j.IM cellulose acetate filter which had 
been previously wetted with 6m1 of TBE. To this solution was added 300Jfl of freshly 
prepared 10% Ammonium persulphate, and 33 ILl of TEMIED (N,N,N' ,N' - 
Tetramethylethylenedianiine, Eastman Kodak Company), prior to gentle mixing and 
pouring into gel plates. These were then laid flat, and the gel allowed to polymerise 
for 2 hours. 
The gel was run on the ABI 373A automated machine on the sequence run settings 
specified in the sample sheet and settings of the data collection programme (see 
below). The 373A machine operates a five-filter wheel system, with two settings: 
using filter wheel B (531, 560, 580, 610nm) for T7 sequenase sequencing chemistry, 
and filter wheel A (531, 545, 560, 580nm) for Taq based sequencing strategies. Four 
filters are used for each sequence run, one for each dye labelled nucleotide, and the 
filter must be specified on the ABI 373A machine before beginning the data collection 
program on the adjoining Macintosh computer (see below). The run is carried out at 
2500 volts, 40mA, 30 Watts at 40 °C for 12 hours with pre-filtered 1X TBE buffer in 
the upper and lower chambers. 
- Data collection and analysis 
The Applied Biosystems 373A automated sequencer relays the information produced 
by the sequence run to an Apple Macintosh ilci computer with System Software 
7.0.1. The 373A software has two parts, one for data collection and one for 
subsequent data analysis, which are run concurrently upon initiation of the Data 
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Collection Programme, which is opened before beginning a sequence run. The data 
collection programme creates a gel file that contains the original data points from all 
the channels in the gel. The analysis programme extracts individual sample 
information from the gel file to create sample files which contain the data for each 
single sample. This incorporates the information entered in the sample sheet as well 
as the raw data from the instrument detailing the start/stop times, voltage, 
temperature, and power values for that specific run. The sample sheet is similar to a 
spreadsheet, and contains information such as the sample names for each gel lane used 
and sequencing chemistry being used. The settings allow you to choose the 
sequencing strategy used, as well as how many lanes (24 or 36) are being run, and 
which matrix to use. The matrix is a mathematical tool correcting for the overlapping 
emission patterns from the fluorescent dyes, and is created by running standards 
through a sequence run. Specific matrices can be created to suit specific sequences 
which may be difficult to acquire. The system software therefore collects raw data, 
whose collection can be monitored visually on the computer screen during the run, 
and also displays the raw and analysed data after the run is completed, in 4 colour 
plots (see electropherogram in Figure 2.3). 
Because of the limited disk space on the Macintosh computer due to the size of the 
gel file, sequence files produced were transferred to a Sun Sparc computer station 
using the Columbia Apple Talk Package (CAP). After transferring, the sequence files 
were preliminarily edited using TED (part of the Staden Computer Package, SCP), 
and implemented using the Seqprocess script (written by Dr. C. Wade, Centre for 
HIV Research, University of Edinburgh). TED allows low quality sequence at either 
end of the fragment to be excised. The data were then entered into an XBap data 
base, SCP, where, using the Seqedit Script (Dr. C. Wade, as above), the nucleotide 
sequence is checked. At this stage both the sense and antisense fragments were 
brought together to produce the complete nucleotide sequence, therefore allowing 
any anomalies on one fragment to be clarified. The nucleotide sequences produced 
could then be stored for future analysis and subsequently aligned and translated to 
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FIGURE 2.3 
ABI 373A Automated Sequencing Trace Data 
The figure shows trace data for ABI T7 Sequenase automated sequencing of the reverse transcriptase region of the poi gene. The fragment 
shown is the 3' portion of the reverse transcriptase in the antisense orientation, sequenced with the primer 154 (see Figure 2.2). 
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amino acids within the version 2.2 of the Genetic Data Environment Package (GDE, 
provided by the Harvard Genome Laboratory). Nucleotide and amino acid alignments 
were compared to HIV- 1HXB2-D and HIV-1iuj reverse transcriptase sequences. 
2.5 	Point Mutation Assay 
This is a method for the assay of point mutations in the reverse transcriptase gene of 
HIV-1 associated with Zidovudine therapy, developed by Dr. S. Kaye et al (1992), 
who was kind enough to allow me to visit his laboratory to learn the assay. 
The assay involves the capture of biotin-tagged PCR products on streptavidin-coated 
microtitre plates, and, after elution of the non-biotinylated strand and primer 
annealing, the primer is extended using 35 S-radiolabelled dNTPs. The radiolabelled 
extension fragment is eluted and transferred to a further microtitre plate 
(CANBERRA PACKARD) containing Microscint 40, and counted on a Topcount 
microtitre scintillation counter. 
The assay is carried out in quadruple with each of the four radiolabelled dNTPs. By 
analysing the counts obtained the point mutations can be identified by which 35 S-
dNTPs are incorporated. By calculating the percentages of incorporation of each 
35 S-dNTP, the frequencies of various point mutations in the population can be 
deduced. This assay is a fast and efficient way of identifying mixed populations of 
resistance mutations in patient samples. 
2.5.1 Dynabeads point mutation assay 
This is an adaptation of the point mutation assay where instead of using streptavidin 
coated 96 well plates as the solid state, Dynall Dynabeads are used to immobilise the 
proviral DNA template in a similar manner as used for solid state automated 
sequencing. 
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2.5.2 Assay Controls 
2.5.2.1 	Wild type control 
pFlXB2-MCS-ENV (prepared by Dr. S Ashelford, Centre for 111EV Research, 
University of Edinburgh, to facilitate cloning of patient fragments), contains a 
complete genome of FIIV-1 HXB2-D with a portion of the env gene deleted rendering 
it non-infectious, but with a complete poi gene, which contains multiple restriction 
enzyme sites to facilitate cloning. This was used as my wild type control (from now 
on this clone will be referred to as AENV, see Figure 4. 1, or MCS, referring to the 
infectious clone before deletion of env). 
- Restriction digestion of AENV control 
To linearise the molecule, and thus facilitate the annealing of the primers for nested 
PCR, digestion of the supercoiled L\ENV was necessary. Digestion was carried out 
using the restriction enzyme Xba I (source Xanthomonas badrii, PROMEGA) as 
follows: 10.11 of AENV was incubated at 37°C for 1 hour in 20.tl of reaction buffer 
20R1  of DTT, 1451.11 depc distilled water, and 5p.l Xba I. The success of 
digestion was checked by ethidium bromide gel electrophoresis. 
2.5.2.2 Mutant controls 
Patient 1037 was chosen from the MEP repository, Edinburgh, as a patient who had 
undergone Zidovudine monotherapy, and whose virus had been examined 
genotypically via single molecule sequencing. Patient p74 was a haemophiliac who 
received Zidovudine therapy, whose virus had also been examined genotypically over 
several years, and whose ZDV-mutation status was clearly documented. 
2.5.3 PCR conditions 
Primary PCR: 2 . 5Rl of patient proviral DNA was added to 22.591 of 1X PCR 
reaction buffer (5mM KC1, 1mM Tris-HC1 (pH 8.0), 0.15mM MgC1 2), 0.2mM 
dNTPs, 0.2p.M each primer (251 and 252), 1 unit of Taq DNA polymerase and 
subjected to 30 cycles of 94°C for 25 seconds, 55°C for 35 seconds, then 68°C for 
2.5minutes, and a single cycle of 68°C for 7 minutes. 
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Secondary PCR: 1j.il of the primary PCR was added to 49R1  of of the PCR mix but 
with 0. lp.M of biotinylated sense primer (b155), and 0.3pM of antisense primer (154) 
and subjected to the same PCR conditions. The use of excess non-biotinylated primer 
in this reaction is again similar to that carried out for direct automated sequencing 
(see section 2.4), where the limiting of the biotinylated primer ensures that only 
labelled template will bind to the streptavidin sites of the Dynabeads. 5p.l of this 
secondary PCR was run on an ethidium bromide stained gel to ensure successful 
amplification. 
2.5.4 Assay conditions 
The secondary biotinylated PCR (45tl) was incubated at 48°C for 30 minutes with 
40p.l of 5.tg/.tl washed Dynabeads (DYNALL). After this incubation the antisense 
strand was eluted at room temperature for 10 minutes with 0. 1M NaOH), and the 
1pM 215 probe (5' CTG ATG TTT TTT GTC TGG TGT G 3') annealed to the 
immobilised sense template in a mixture containing 40mM Tris HCl (pH 7.6), 20 MM 
M902, and 50 mM NaCl by incubation at 65°C for 2 minutes and cooling to below 
30°C. The annealed probe was elongated by a single 35  radiolabelled dNTP, by 
incubation with labelling mix containing 0. 1M DTT (DL-Dithiothreitol, SIGMA 
Molecular Biology), 35 S- dNTPs from stock of 1:10 dilution in water of NEN Dupont 
1000-1500 Cilmmol (-20°C), Klenow Polymerase (5,000 units/ml, DNA polymerase I 
Klenow (Large) Fragment, PROMEGA), and depc distilled H 20. The reaction was 
terminated by washing with Tris/TWEEN 20 and the beads were resuspended in 40j.il 
of Tris TWEEN 20 prior to addition of Smls of Ecoscint A Scintillint. The samples 
were counted for 1 minute, reading on C14 on a Canberra Packard Tn Carb 
Scintillation counter. Each sample was tested with each of the four 31S  dNTPs. 
2.6 	Recombinant Viral Assay 
The recombinant viral assay was developed by Drs Kellam and Larder (1994) to allow 
phenotyping of patient reverse transcriptase genes in a less intrinsically-variable 
system than a PBMC culture. It was achieved by transfecting a continuous T-cell line 
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with a reverse transcriptase-deleted clone and patient-derived reverse transcriptase 
PCR fragments. The result was production of viable virus by homologous 
recombination within the cell system. The recombinant virus strains share a common 
genetic background, only differing in their reverse transcriptase regions. Differences 
in phenotypes obtained by in-vitro assays carried out with the recombinant virus 
would therefore be the result of the patient derived reverse transcriptase region. 
2.6.1 Amplification of patient IIIV-1 for RVA 
Primary PCR reactions amplified a 1.7Kb DNA fragment and 1.4Kb of which was 
amplified during the secondary process. Changes to the previously detailed process 
(section 2.3.5) are detailed below. Primers are listed in Figure 2.4. 
Primary PCR (lOOp.l total volume): 5111  DNA was added to a reaction buffer 
containing 2.5mM MgCl2, 25mM KC1, 50mM Tris-HC1 (pH8.0), 0.25pg of each 
primer, 10% v/v glycerol, 20011M each dNTP, and 5 units Taq DNA polymerase. 
This was subjected to 30 cycles as described previously. 
Secondary PCR (100111 total volume): 5111  of the primary reaction product was 
transferred into 95jil of secondary reaction mix (as for primary but with second round 
primers), and subjected to 30 cycles as above. After amplification, 10-20111 of 
product was separated on a 1% ethidium bromide-containing agarose gel and viewed 
under UV light. 
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FIGURE 2.4 
Primers for Amplification of RT for Recombinant Viral Assay 
Figure 2.4 shows the primer layout for amplification of the reverse transcriptase region of the poi gene for the recombinant viral assay, using 
the primers whose sequence is shown below. The 'OUT' and 'IN' refers to outer and inner primers respectively, for the primary and 
secondary PCR reactions. 
OUT5 	 5' GQT ACA GTA TTA GTA GGA CCT ACA CCT GTC AAC AT 3' 
OUT3 	 5' CAT TGC TCT CCA ATT ACT GTG ATA TTT CTC ATG 3' 
1N5 	 5' AAT TTT CCC ATT AGT CCT ATT GAA ACT GTA CCA G 3' 
1N3 	 5' TC TAT TCC ATC TAA AAA TAG TAC ITT CCT GAT TCC 3' 




251 	 155 	153 
Protease 	I Reverse Transcnptase 	 Integrase 
4 4 4 4 
152 	 154 150 252 250 
1N3 OUT3 
2.6.2 Purification of PCR products for RVA 
PCR products amplified for RVA require an additional clean up step to remove 
nucleoside triphosphates and primers that will interfere with subsequent transfections. 
Geneclean IT®  Kit (BlO 101 Inc.) was chosen because it does not require the use of 
organic solvents which may be carried over and interfere with further use of the DNA. 
The procedure uses a silica matrix called Glassmilk®  that binds single/double stranded 
DNA without binding DNA contaminants. 
Before using the Geneclean kit the paraffin overlay used in PCR reactions was 
removed by addition of 1001.11 of chloroform to the secondary PCR product. This was 
vortexed vigorously and then centrifuged at 13,000 rpm for 3 minutes. The top 
aqueous layer containing the DNA was removed and transferred to a fresh tube 
containing 3 volumes of 6M sodium iodide and mixed with Glassmilk ® (5tII_<5p.g 
DNA, then an additional lp.l for each 0.5Lg DNA above 5p.g). The DNA was 
allowed to bind to the silica matrix on ice for 15 minutes. After this incubation the 
DNA/silica matrix was pelleted by centrifugation for 2 minutes at 15,000 rpm. The 
supernatant was discarded (although Nal supernatant can be kept and re-bound with 
Glassmilk® in the future, if all the DNA did not bind in the initial incubation), and the 
pellet washed three times with ice cold NEW wash (NaCl, Tris, EDTA, and ethanol). 
After the third and final wash all residual NEW wash was removed. The DNA was 
eluted from the silica matrix by incubation at 55°C for 5 minutes in treated distilled 
water. The volume of water used must be equal to or greater than the volume of 
Glassmilk®. Afier this incubation the silica was pelleted by centrifugation for 3 
minutes and the DNA-containing supernatant was carefully removed. 
2.6.3 Quantitation of 'Genecleaned' DNA 
- Gel electrophoresis 
DNA yields from this procedure were estimated on ethidium bromide-stained agarose 
gels by comparison to Lambda DNA/Hind ifi Markers (PROMIEGA). These markers 
were prepared by digesting lambda DNA to completion with Hind II, followed by heat 
inactivation of the enzyme. The eight resultant DNA fragments ranged from 125 to 
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23,130 base pairs in size. A portion of the markers were diluted to provided DNA 
quantity markers in addition to size markers. 
- Spectrophotomehy 
DNA concentrations were calculated by optical density spectrophotometry. A 5p.l 
sample was diluted in 700 p.1 of depc distilled H 20 and absorbance read at 260 
(DNA) as well as 280,(protein). DNA concentration was calculated by multiplying 
the dilution by a common factor of 50p.g/ml for double stranded DNA (40p.g/ml for 
RNA). Highly pure DNA has an A 0 to Am ratio greater than 1.8. 
2.6.4 	Transformation of bacterial cell lines with ART 
2.6.4.1 piLlVARTBstEII 
This non-infectious clone, which from this point on will be referred to as ART 
(obtained from MIRC AIDS Directed Programme Reagent Project 231, produced by 
Dr. B. Larder and Dr. P. Kellam) contains the complete provirus of HXB2-D (Fisher 
et a!, 1985) except for a 1.4 Kb deletion in the reverse transcriptase coding region. 
ART also has a unique BstEII restriction enzyme site at the deletion junction. ART 
contains the cloning vector pIBI20, a 4.5 Kb vector, with T7 RNA polymerase 
promoter, ampicillin resistance, and 3-galactosidase markers. 
2.6.4.2 Epicurian Coil® JM109 competent cells 
E.coli JM1O9 competent cells (Epicurian Coli ® JM1O9 Competent Cells, 
STRATAGENE catalogue number 200235) supplied as 5 x 0.2m1 aliquots should be 
maintained at -80°C. The efficiency under specific conditions should be 1.0 x 10 8 
colony forming units/p.g of pUC 18 DNA. 
2.6.4.3 Transformation of JM109 
ART DNA was prepared from the transformed JM1O9 cells using the Holmes and 
Quigley method (1981). One EppendorfofiMl09 cells was thawed on ice and 
aliquoted in 50p.l volumes into pre-cooled Falcon 2054 polypropylene tubes, and 
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maintained on ice. 2tl of chilled ART was added and the incubation on ice continued 
for 30 minutes. After this incubation a heat shock of 42°C for 45 seconds was 
followed by returning the cells immediately to ice for 2 minutes. 0.5m1 of LB media 
(Tryptone, NaCl, Yeast extract, and 100.tg/m1 ampicillin) was added to the JM109 + 
ART and placed in a shaker with vigorous aeration, to incubate at 37°C at 150rpm for 
45 minutes. 50 microlitres and 1001.11 of the above mixture were streaked (storing 
remaining culture at 4°C) onto an LB agar plate (LB mixture as above with agar), and 
incubated overnight at 37'C. From the stored LB/ART culture at 4°C 2001.11 was 
removed and used to inoculate 1 litre of LB with ampicillin. This culture was 
incubated in a 37°C shaker, at 150rpm, for >16 hours. After incubation the culture 
was centrifuged in a Sorvall Ultra centrifuge at 15,000rpm for 10 minutes in 250m1 
aliquots. After centrifugation the supernatant was discarded and the pellets stored at - 
20°C until required for DNA extractions. 
2.6.4.4 Extraction of ART from bacteria 
- Small scale preparation of DNA 
To check that the transformation was successful and the colonies on the plate 
contained the DNA required, a quick DNA extraction was carried out and the DNA 
obtained resolved on an agarose gel. A single bacterial colony was used to inoculate 
2m1 of LB media with ampicillan. This culture was incubated, with shaking, at 37°C 
overnight (>14 hours). After this incubation 1.5mls of the culture was used for 
extraction. The culture was centrifuged at 6K for 2 minutes, and the supernatant 
discarded. The pellet was resuspended in 1001.11 of Solution I (50mM Tris-HC1, pH 
7.5, 10mM EDTA, 10% glucose, with 1I.g of fresh RNAse per sample (1t.tl  of 
1mg/mi, -20°C)), and the mixture vortexed vigorously until the pellet was 
resuspended. The mixture was then left to stand at room temperature for 5 minutes, 
after which time 200 j.i.1 of Solution II (0.2M NaOH, 1% SDS), was added. The 
solution was mixed by inverting the tube approximately 25 times, or until the mixture 
was clear. 15041 of Solution ifi (3M KOAc, pH 4.9) was then added and mixed 
gently followed by centrifugation at 12K for 5 minutes. The DNA-containing 
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supernatant was transferred to a clean Eppendorf, discarding the pellet which 
contained the bacterial debris and chromosomal DNA. The DNA was precipitated 
with imi ice cold 100% ethanol by inverting the tube 5-6 times, followed by 
centrifuging at 12K for 2 minutes. The supernatant was discarded and the DNA pellet 
washed with 0.5ml of 75% ethanol, and centrifuged again at 12K for 2 minutes. The 
ethanol supernatant was aspirated, and the pellet dried at 65°C for 10 minutes. The 
pellet was then resuspended in 30111 DEPC treated distilled water. This DNA was 
then checked on an 1% agarose gel by electrophoresis and ethidium bromide staining, 
and also subjected to restriction digestion to check it was the correct clone. 
- Restriction digestion of ART 
ART was linearised by restriction digestion. This was carried out with the enzyme 
BstEll (source Bacillus stearothermophilus, PROMEGA), which cuts at one site in 
the ART clone. 2j.il  of ART was added 1 g of reaction buffer D (1X 6mM Tris-HC1, 
6mM MgC12, 150mM NaCl, 1mM DTT, PROMIEGA), 6p1 distilled DEPC H 20. lp.l 
of BstEII was added and the mixture was incubated at 60°C for 1 hour. The product 
of digestion was visualised on an ethidium bromide-stained gel. 
- Large scale preparation of DNA 
The Qiagen mega kit plasmid purification protocol (Qiagen) was used to extract 
ART DNA from transformed JM1O9 E.coli bulk culture that was stored as 250m1 
bacterial cell pellets (obtained from a 1 litre culture), at -20°C. A total of 500m1 of 
culture or two stored pellets were extracted during each procedure. 
The pellets were resuspended in a combined volume of 50ml of buffer P1(50mM 
Tris-HC1, pH 8.0, 10mM EDTA, lOOp.g/ml RNAse A, 4 0C). This was well 
resuspended to eliminate all cell clumps. To this 50m1 of buffer P2 (200mM NaOH, 
1% SDS) was added and mixed by inverting the tube 4-6 times, incubating at room 
temperature for 5 minutes. To this was added 50 ml of 4°C buffer P3 (neutralising 
buffer, 3.OM potassium acetate, pH 5.5), and the solution was gently mixed by 
inverting the tube 6 times. Incubation was continued on ice for 30 minutes, mixing 
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during this time to prevent local potassium dodecyl sulphate precipitation. After this 
time centrifugation was carried out for 30 minutes at 4°C at 11,000 rpm in Sorvall 
GSA rotor (20,000g). After centrifugation the supernatant was immediately 
transferred to a clean tube and centrifuged at 20,000g. 4°C, for 15 minutes. 
The Qiagen tip-2500 was equilibrated with 35m1 of buffer QBTT (750mM NaCl, 
50mM MOPS, pH 7.0, 15% ethanol, 0.15% Triton X-100), and allowed to drain by 
gravity. After the centrifugation was completed the supernatant was added to the tip-
2500, and allowed to drain by gravity: if the supernatant became cloudy before 
adding to the tip-2500, due to protein precipitation, it was filtered with a 0.45p.M 
pore size MTNTSART to remove clumps which would clog the filter column. The 
DNA remained on the filter. The DNA was washed four times with 50mls of buffer 
QC (I. OM NaCl, 50 mM Tris-HC1, pH 8.5), 15% ethanol). The DNA was then 
precipitated by adding 0.7 volumes of isopropanol maintained at room temperature to 
relieve salt precipitation, and centrifuged immediately at 15,000g (11,000 rpm) in a 
Sorvall SS-34 rotor at 4°C for 30 minutes. The DNA pellet was washed twice with 
7m1 of 70% ethanol. After the second wash all the ethanol supernatant was removed 
and the pellet air dried for approximately 10 minutes. The pellet was resuspended in 
TE (10mM Tris-HC1, pH 8. 0, 1 m EDTA). DNA concentrations were calculated by 
spectrophotometry and gel electrophoresis (see sections 2.3.7 and 2.6.3). DNA was 
then lineansed by restriction digestion and cleaned for the RVA, as detailed below. 
- Clean up of Linearised ART 
After restriction digest linearisation of ART, the ART had to be cleaned to remove 
remaining enzymes and to obtain clean DNA for subsequent transfection reactions. An 
equal volume of TE-saturated phenol was added to the digestion mix, vortexed then 
centrifuged. The top aqueous layer was transferred to a fresh tube and an equal 
volume of chloroform added, the mixture was vortexed and centrifuged. The aqueous 
top layer was transferred to a fresh tube containing ice cold 100% ethanol. The 
DNA was then precipitated at -70°C for approximately 2 hours, and the DNA pelleted 
by centrifugation at 13,000 rpm for 5 minutes. The pellet was washed twice with 
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75% ethanol, and after the second wash all ethanol was removed by drying the pellet 
at 65°C for 10 minutes. The DNA pellet was resuspended in depc treated distilled 
water. DNA concentrations were calculated by spectrophotometry as well as by gel 
electrophoresis. 
2.6.5 	Transfection of T-Cell Lines 
2.6.5.1 Continuous cell lines 
- Non-adherent 
Human T-lymphoblastoid cell line, C8166 (donated to MRC AIDS Directed 
Programme Reagent Project by Dr G. Farrar, ADPO13), was transformed with the 
human T-cell leukemia-lymphoma virus (HTLV-1). It is a nonproducer cell line in 
that it does not express gag antigens, has no reverse transcriptase activity, and no 
viral particles are observed in the culture medium (Salahuddin et a!, 1983). It 
expresses a tat sequence. The C8166 cell line was cultured in RPMI 1640 medium, 
supplemented with 10% foetal calf serum (Advanced Protein Products Ltd, sterile 
heat inactivated), L-Glutamine (Hyclone ® Europe Ltd., HyQ Cell Culture Reagents, 
200mMI100ml) and Penicillin/Streptomycin (GibcoBRL, 5000.1g/ml), and from now 
on this medium will be referred to as CM, for complete medium. The C8166 cell line 
was sub-cultured every 2-4 days. 
Adherent 
COS-1 is an established cell line transformed with simian virus SV40 (Gluzman, 
1981). This cell line has a single integrated copy of complete early regions of SV40 
DNA and expresses the SV40 transforming T-Ag. This cell line was a gift from Dr. 
Myra McClure, London. This cell line was a host for propagation of recombinant 
virus. COS-1 cell line was cultured in Dulbecco's Modified Eagle's Medium 
(DMEM, SIGMA), supplemented with 10% FCS, penicillin/streptomycin, and L-
Glutamine (as detailed above), in a 5% CO2 incubator at 37'C. Cultures were split 
when semi-confluent by cell scraping (Greiner disposable cell scraper, sterile), or 
using trypsin. 
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2.6.5.2 DOSPER Liposomal transfection protocol 
DOSPER Liposomal Transfection Reagent (Boehringer Mannheim, Cat. No. 1781 
995) is a polycationic liposomal reagent: the cationic liposomes, due to its positively 
charged spermine, spontaneously interact with the DNA, to produce 
liposome/polynucleotide complexes. These complexes are non-specifically adsorbed 
to the surface of cells and subsequently taken up by these cells. 
- Transfection of non-adherent cells 
24 hours before the transfection was to be carried out, the non-adherent cells, C8166, 
were split. A mix was prepared containing HEPES (pH7.4), Dosper (3:1, Dosper to 
DNA in .tg's), DNA (ART + patient RT-PCR), in a 200111 volume in Falcon tubes 
(2054 Falcon polypropylene tubes). They were mixed gently and incubated at room 
temperature for 15 minutes to allow complex to form. C8166 cells were washed and 
re-suspended in HEPES at a concentration of 2.5 x 106 cells/ml, and 0.8ml of cells 
were added to each well of a 6 well plate. 200 microlitres of the above DNA/Do sper 
solution was then added over the surface of each well, and incubated at 37°C for 6 
hours. After this period two strategies were undertaken. Either 1 ml of complete 
medium was added/well and the incubation continued, or the culture was removed, 
centrifuged and re-suspended in 2m1 fresh complete medium and incubation 
continued. 
2.6.5.3 LIPOFECTIN® Reagent transfection protocol 
LIPOFECTIN®  Reagent (GIBCOBL, Life Technologies, Cat. No. 18292-011), is a 
1:1 lipo some formulation of cationic lipid DOTMA and DOPE (dioleoyl 
phophotidylethanolamine), which interacts spontaneously with DNA to produce 
lipid/DNA complexes that fuse with tissue culture cells resulting in efficient uptake. 
- Transfection of adherent cells 
In a six well NUCLONE plate, 1-2 x 10 5 COS-1 cells in a 2ml volume of complete 
medium were seeded. The plate was then incubated in a CO2 incubator at 37°C until 
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the cells were 40-60% confluent: approximately 24 hours. After this incubation the 
following two solutions were prepared: 
Solution A, LIPOFECTIN-OPTIMEM 
The LIPOFECTIN®  Reagent was used at a 3:1 ratio against final .ig DNA input 
value. Therefore for each transfection 45pd LIPOFECTIN® (45pg) was diluted in 
lOOp! total OPTIMEM® 1 Reduced Serum Medium. This solution was left at room 
temperature for 45-60 minutes. 
Solution B, DNA-OPTIMEM® 
This solution was prepared by mixing 5pg RT-PCR DNA and lOpg ART clone in a 
total volume of 1 OOpl OPTI-MEM. 
100 microlitres of solution A was combined with solution B in falcon tubes, gently 
mixed and incubated at room temperature for 15-45 minutes. The supernatant was 
removed (discarded) from the COS-1 adherent cells, and the cells were washed twice 
with 2ml OPTIIvIEM®, and after removal of the final wash, 0.8m1 of OPTIMIEM® was 
added to each well. 200 microlitres of the DNA-L1POFECTIN-OpT1jJvffiM ® 
complex was added to each well, and the plate was swirled gently to mix, and the cells 
were then incubate for 6 hours in a CO2 incubator at 37 0 C. After this initial 
incubation, the supernatant, containing unincorporated DNA, was removed 
(discarded), and the cells were washed twice with complete medium. The incubation 
was continued by addition of 1 ml of complete medium, and transferring the plates 
back to the CO2 incubator, at 37°C, for an additional 24 hours. 
1 x 106  C8166 cells were overlayed in imi volume of complete medium in each well, 
and the incubation continued for a further 2449 hours. The supernatant containing 
the C8166 cells (continuous T-cell line) was transferred to a fresh 25cm 3 flask, and 
incubated until peak cytopathic effect was observed. The COS-1 cells were removed 
from the culture wells and stained for the presence of p24Ag and stored in freezing 
mix in liquid nitrogen. 
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- Transfection of non-adherent cells 
24 hours before the transfection was to be carried out, the non-adherent cells, C8166, 
were split. A mix was prepared containing OPTIMEM® 1 Reduced Serum Medium, 
LIPOFECTIN® Reagent (in a ratio of 3:1, against final input p.g' s), DNA (ART + 
patient RT-PCR), in Falcon tubes with a final volume of 200111. This was mixed 
gently and incubated at room temperature for 15 minutes to allow the complex to 
form. C8166 cells were washed and re-suspended in OPTIMEM®  at a concentration 
of 2.5 x 106  cells/ml, and 0.8m] of cells were added to each well of a 6 well plate. 
200 microlitres of the above DNA! LIPOFECTIN ® solution, was then added over the 
surface of each well, and incubated at 37°C for 6 hours. After this period two 
strategies were undertaken. Either 1 ml of complete media was added to each well 
and the incubation continued, or the culture was removed, centrifuged and re-
suspended in 2m1 fresh complete media and incubation continued. 
2.6.5.4 Maintenance of transfection cultures 
Cultures were maintained in 25cm2 flasks in a 5m1 total volume for 1 week, and 
checked visually daily until syncytia developed, at which point cultures were 
transferred to 75cm2 flasks and bulked up to a total culture volume of 20ml. Cells 
were washed by centrifugation and fresh complete media added until cytopathic effect 
was observed, at which time fresh C8166 cells would be added to the culture. Flasks 
were changed weekly, with approximately two cell culture splits per week. 
2.6.5.5 Syncytia formation 
Syncytia, or mutinucleated giant cell formation, formed by fusion between infected 
cells (Lifson et a!, 1986) can be used as an indicator of infection. HXB2-D is known 
to form syncytia in tissue culture, therefore if viable virus is present, syncytia should 
be visible by examination of tissue cultures microscopically, over 3-4 days. 
2.6.5.6 KC57 fluorescence staining 
COULTER CLONE® KC57-FITC (Fluorescein isothiocyanate) is a monoclonal 
antibody against 55, 39, 33 (precursors) and 24kD core proteins of HTV-1. The 
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KC57-FITC antibody binds to core antigens present within the HIV-1 infected cells. 
Specific cell staining was achieved by taking imi of tissue culture and washing twice 
with PBS by centrifugation. The plasma cell membranes were then permeabilized by 
hyperbolic shock by resuspending the cell pellet in 500p1 H20/PBS (40:60 ratio). 15 
microlitres of this was then dotted on to slides (Hendley-Essex Multispot microscope 
slides, PTFE and specialised coatings, PH-001) and air dried for approximately 1 
hour, then fixed by immersion in methanol: acetone solution (1:1) for 10 minutes, after 
which time the slides were non-infectious. 
The KC57-FITC antibody (or control, MsIgGl isotypic control, that assesses non-
specific fluorescence background) was then applied to the slides (1:150 dilution of 
stock KC57-FITC in 1X PBS with 1% bovine serum albumin (SIGMA Molecular 
Biology, 5g B-4287)), covered (tin foil) and incubated at room temperature for 1 
hour, after which time the slides were washed three times with 1X PBS. Oil was 
added to each well (CITIFLUOR, Glycerol/PBS solution, AF-1) along with a 
coverslip (22x64mm borosilicate cover glass, thickness no. 1, BDH), in preparation 
for microscopy (and were maintained at 4°C). Samples were examined by 
fluorescence microscopy (NIKON OPTIPHOT microscope) with water lens 
immersion, where positive cells appear green. 
2.6.5.7 p24  Antibody ELISA 
An in-house p24 antibody ELISA had been developed by Dr. R. Walker (Centre for 
HIV Research, Edinlurgh University). Materials for the assay are listed below: 
1 	Empigen detergent, 30% solution (Calbiochem, Cat. No. 324690) 
2 	Capture antibody, affinity purified sheep anti-HIV p24 which is a mix of 3 
antibodies recognising the amino acid regions 283-297, 173-188, 226-237 of HIV-1 
3B BH 10 strain (Aalto BioReagents Ltd. Cat. No. D7320). The lyophilised product 
was reconstituted in 2ml of distilled water. The plates were coated immediately with 
the capture antibody, and stored at -20°C (20 x 96 well plates). 
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3 	coating buffer, 15OmMNaHCO3 (pH9.0), lox TBS, 1.44MNaC1, 250mM 
Tris (pH7.5), HC1, distilled water. This solution was autoclaved and subsequently 
stored at 4°C. 
4 	Milk solution, 2% Marvel solution in 1X TBS. Make up fresh each time 
1 OmI). 
5 	p24  Standards, Baculovirus-derived p24 was obtained from the MIRC AIDS 
Directed Programme Reagent Project (l0OJ.g/m1, Cat. No. ARP620), and diluted to 
1 pg/mi in CM with 0.1% empigen or PBS with 10% foetal calf serum and 0.1% 
empigen (which form now on will be referred to as CMIE and PBS/FCS/E, 
respectively) and stored in lml aliquots at -70°C. Half log serial dilutions were 
prepared for each ELISA by 46.25p.l transfer volumes in 1001.11 diluent (CMIE or 
PBSIFCSIE). Eight standards were usually prepared, from 103  to l0 ° ng/ml. 
6 	Detection antibody, was a biotinylated monoclonal mouse anti-p24 gag 
obtained from the MRC AIDS Directed Programme Reagent Project (Cat. No. 
A1RP454), and stored in l0l aliquots at -70°C. For one 96 well ELISA 10pl of 
biotinylated p24 antibody was diluted in 1. imi lox TBS, 55p1 10% Tween 20, 2.2m1 
foetal calf serum (filtered through 0.451.tm pore), and 7.7m1 distilled water. 
7 Enzyme, extravidin-peroxidase (SIGMA, Cat. No. E-2886), was stored at 
4°C. For one 96 well ELISA 2.5i1 of enzyme was diluted (1:4000), by adding lOmi 
of PBS with 0.05% Tween 20 (PBS/T20). 
8 	The substrate, TUB, peroxidase substrate (DAKO, Cat. No. S 1600), was 
stored as ready to use solutions at 4°C. 
9 	Stop solution, was IN H2SO4 . 
The protocol below is based on one 96 well plate 
- Preparing ELISA plates 
100 microlitres of capture antibody was added to 9.9m1 of coating buffer, and 100pl 
of this solution was added to each well of the ELISA plate. The plates were then 
covered with a plate sealer and incubated at room temperature overnight. Using an 
ELISA plate washer, each well of the plate was washed six times with 200pL/well 1X 
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TBS. 200microlitres/well of a 2% milk solution was then added to each well, the 
plate was sealed, and incubated at room temperature for 30 minutes. The milk 
solution was then removed and the plates were dried in 37°C oven, and then heat 
sealed in plastic bags containing silica gel sachets, and stored at -20°C until required. 
Plates were allowed to equilibrate to room temperature before use. 
- Test sample preparation 
Samples to be tested by ELISA were treated with detergent to produce a viral lysate 
that was heat inactivated for safety, and therefore non-infectious. The culture 
supernatants (obtained by centrifugation of tissue culture) in CM with empigen were 
diluted so that the final concentration of empigen was 0.1%. These were heat 
inactivated by placing in a 56°C water bath for 30-45 minutes. 
- p24 antigen capture 
Each well of a plate was washed six times with 200pilwell of 1X TBS, after which 
time the plate was inverted and tapped on absorbent paper to remove excess liquid 
(this was carried out after every wash step from this point forward). 100 microlitres 
of p24 standards were added to the appropriate wells, with 1 substrate blank (CM!E) 
and 1 negative supernatant control (uninfected cell culture supernatant). 100 
microlitres of viral lysate dilutions were added to the wells. The plate was sealed and 
incubated at room temperature overnight. 
- Antigen detection 
After p24 antigen capture was completed (detailed above), each well was washed six 
times with 1X TBS with 0.05% Tween 20 (TBS/T20). Antigen detection was 
achieved by adding lOOp i/well of diluted biotinylated antibody solution, sealing the 
plates and incubating at room temperature for 2 hours. Only diluent without antibody 
was added to the substrate blank well. Each well was then washed six times with 
TBS/T20, as described above. 100 microlitres of diluted enzyme solution was then 
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added to each well, the plates were sealed and incubated at room temperature for a 
further 1 hour; again only diluent without enzyme was added to the substrate well. 
After this incubation was completed the plates were again washed as described above. 
100 microlitres of TMI3 substrate was then added to all the wells, including the 
substrate blank, and the plates incubated at room temperature for 15-30 minutes. The 
reaction was stopped by adding lOOp.1/well of IN H 2SO4. Plates were then read on an 
ELISA plate reader using the 450nm filter and GENESIS computer program 
(GENESIS II, WindowsTm Based Microplate Software, Labsystems). 
2.6.5.8 Harvesting recombinant virus 
2.6.5.8.1 Sample collection/storage 
After approximately 30 days of culture, or until the peak cytopathic effect was 
observed (optimum syncytia formation, cytopathic effect, CPE) the whole of the 
tissue culture was centrifuged at 2000rpm for 30 minutes. The culture supernatant 
was filtered through a 0.2pm pore cellulose acetate filter (Minisart) to remove 
cellular debris, using lOml syringe, and stored in lml aliquots in cryovials at -70°C. 
The cell pellet was washed twice with 1X PBS (or 1640 RPMT), and resuspended in 
freezing media, stored first at -70°C, then transferred to liquid nitrogen storage. 
2.6.5.8.2 Quantification of recombinant virus 
- Quantitative infectivity assay: TCIDs 
This assay allowed the virus in the culture supernatant to be titrated to determine the 
50%-tissue culture infective dose (TCID 50)(Current Protocols in Immunology, ed. 
Coligan et at, Volume 3). The assay allowed the input multiplicity of infection to be 
calculated, which wa&useful for future phenotypic assays using the above 
recombinant viral supernatant. The assay involved carrying out serial dilutions of viral 
supernatant in a 96 well plate, and monitoring the migration of cytopathic effect over 
time over the plate. Using the statistical method of Reed and Muench the value of 
TCID50 would be calculated. 
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- Virus assay plate 
133 microlitres of CM was added to all wells in lane 1 of a 96 well flat-bottom plate, 
and 150pi CM to remaining wells (all outside wells of the plate contained 200111 of 
PBS to counteract evaporation, lane 1 of test plates was therefore the second lane 
from left). Undiluted viral supernatant, 67p.ls, was then added to all six wells in lane 
one (vertical), and subsequent dilutions were carried out by transferring 50tl from 
lane 1 to lane 2, repeating along the plate. Serial four-fold dilutions were therefore 
achieved, changing tips at each transfer, until lane 10, and discarding the final 50111s, 
or transferring this on to a second plate if such dilutions were required: each sample 
was carried out in sextuple. 50 microlitres of C8166 cells were then added to each 
well, in a concentration of 4 x 10 5/ml, and the plates incubated at 37°C in a 5% CO2 
incubator. 
- Reading infectivity assay plate 
The plates were inspected daily for the evidence of virus-induced cytopathic effect 
(CPE). As the infection proceeded there was a spread of CPE across the plate from 
left to right, that is from the most concentrated to the most dilute. On day 4 the 
culture was fed by mixing each well, starting from the most dilute, working from right 
to left discarding lOOf.tl of culture, and replacing this with lOOp.l of fresh CM. This 
process was continued twice weekly until the peak CPE was observed, that is there 
was no further migration of CPE beyond the most dilute well in each of the 6 replicate 
wells. Each well was scored as either '+', syncytia present (not determined by 
number of syncytia, one is a + score), or '-', no syncytia. 
- Calculating TCID 50  
TCIDso was calculated by following the method compiled by Reed and Muench. The 
vertical lanes which contained both infected (+) and uninfected (-) wells, and the lanes 
that contained either all infected or all negative wells (the dilution that contained the 
50% endpoint is between these two dilutions), and by application of the statistical 
equation the TCIDso per millilitre could be obtained. 
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2.6.6 Direct sequencing of viral RNA 
To check that the recombinant virus produced was indeed produced from the patient 
RT-PCR, viral RT regions were sequenced using the ABI protocol as detailed 
previously (see section 2.4). 
2.6.6.1 Extraction of viral RNA using Micro RNA Isolation Kit 
Viral RNA was obtained from cell culture supernatant using an adaptation to the 
Micro RNA Isolation Kit STRATAGENE). This technique utilises guanidinium 
isothiocyanate-phenol chloroform extraction, which retains the RNA in the aqueous 
phase while retaining the proteins and DNA in the organic layer. The whole 
procedure was carried out on ice. First 1 OOjil of cell culture supernatant was mixed 
with 1501.11 Solution D (3-mercapthoethanol, 4M guanidinium isothiocyanate (GIT), 
0.02M sodium citrate, 0.5% sarcosyl). To this was added 10.il 2M sodium acetate, 
and 1001.11 water-saturated phenol, 20Rl  chloroform:isoamy lalcohol. The tube was 
capped and vortexed vigorously and centrifuged at 15,000 rpm for 5 minutes. The 
top aqueous layer was then transferred to a fresh tube to which lOOj.1l of isopropanol 
was then added. The tubes were mixed and centrifuged at 15,000rpm for 30 minutes. 
The supernatant was discarded and the RNA pellet was washed with 75% ethanol, 
and centrifuged at 15,000 rpm for 5 minutes. The ethanol-containing supernatant was 
discarded and the pellet was air dried for approximately 10 minutes. Once all residual 
ethanol was removed the pellet was resuspended in 1 Opi of depc treated distilled 
water. 
2.6.6.2 cDNA synthesis 
Extracted viral RNA was reverse transcribed into cDNA via specific viral primer-
initiated eDNA synthesis. Extracted RNA (5i)  was then added to ijil of antisense 
outer primer 250, and incubated at 65°C for 10 minutes and then immediately placed 
on ice. Maintaining on ice, 4Rl  of SX expand RT buffer, 21.Ll  100mM DTT, 6p1 
dNTPS, ipi RNasin® Ribonuclease (PROMEGA) inhibitor and finally ipi of 
ExpandTM Reverse Trascriptase (50 units/pA) were added and incubated at 42°C for 
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I hour. After 1 hour the mixture was heated to 95°C for 2minutes to inactivate the 
enzyme. 
2.6.6.3 Sequence analysis 
PCR was carried out on cDNA (section 2.3.) and the product was sequenced using 
the T7/Dye Terminator sequencing protocol (section 2.4). Sequences obtained were 
compared with parental RT-PCR sequences. 
2.7 	Zidovudine Sensitivity Assays 
The ZDV sensitivity assay was used to determine the phenotype of particular viral 
isolates with respect to resistance to ZDV. This was carried out by infecting a T-cell 
line with a known amount of virus, then incubating with varying concentrations of 
ZDV, in a 96 well microtitre plate. 
2.7.1 	Virus Controls 
- Wild type control 
This control, with no ZDV resistance-associated mutations, was the in-house MCS 
virus (see section 2.5.2.1). DNA from this, prepared by Dr. R. Walker and E. Harvey 
(Centre for HIV Research) was used to transfect COS-1 cell lines (see section 
2.6.5.3) and processed in a similar fashion to the recombinant virus. Virus was 
titrated in the C8166 T-cell line to obtain the TCID 50 value (see section 2.6.5.8.2), 
and stored as cell culture supernatant at -70°C. 
- ZDVresistant virus control 
Virus strains of known ZDV resistance status were obtained from the MRC AIDS 
Reagent Program (Dr H. C. Holmes, Project Leader, EC Programme EVA, donated 
by Drs B. Larder, S. Kemp, and P. Kellam of Glaxo-Wellcome) and supplied as cell 
culture supernatants produced in the MT-2 T-cell line (Miyoshi eta!, 1981). These 
strains were produced by co-transfecting in C8166 cells the M13 RT clone with 
specific ZDV-associated mutations produced by mutagenesis, with the ART proviral 
clone. 
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The cell supernatants provided were used to infect cultures of the T-cell lines C8166 
and MT-2. The infection was initiated in 25cm 2 tissue culture flasks (Costar) with 
complete medium (CM)(section 2.6.5.1) in a concentrated volume of 5rnl to aid cell 
infection. After 24 hours the Sml of additional CM was added to the culture and 
monitored visually for the production of syncytia every 2 days: these virus strains 
have the wild type parental virus H1XB2, as for MCS, and therefore are known to 
produce syncytia in continuous culture. Culture supernatant was removed and 
replaced with fresh CM until there were signs of syncytia, after which time the culture 
was transferred to 75 cm2  flasks and the culture maintained and fed with cells and CM 
for up to 30 days, or until peak cytopathic effect observed. The culture was then 
titrated in the C8166 T-cell line (see section 2.6.5.8.2), and stored as cell culture 
supernatant at -70°C. 
Shown in Table 2.1 are the three resistant viral strains with their associated resistance 
mutations and the characteristics of each one when assayed for ZDV sensitivity in the 
HeLa CD4+ cell assay (Chesebro et a!, 1988). The IC 50 value represents the number 
of fold increase when compared against the HXB2 wild type parental virus (RTMC, 
Larder and Kemp, 1989; RTMF, Larder and Kemp, 1991; RTMN, Larder and 
Kellam, 1992). 
2.7.2 Viral inoculum 
Virus was used at a concentration of 50 tissue culture infectious doses per well 
(TCID50 , previously determined by titration of virus in C8166, scoring cytopathic 
effect and statistically calculating TCID 50 (see section 2.6.5.8.2). 
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TABLE 2.1 
HIV-1 Control Isolates with Known ZDV Resistance 
Isolate 	 Mutations 	 Fold increase in resistance 
(from wild type 1050) 
HXB2* 	41M, 67K, 70K, 215T, 219K 
RTMC 	67N, 70R, 21517, 219Q 	 100 
RTMF 	 215Y 	 15-20 
RTh4N 	 41L, 215Y 	 60-70 
*}T)(B2 represents the wild type 
2.7.3 	Cell line 
5 x 104 C8166 cells per well were infected with 50 TCID50 of virus, and incubated at 
37°C for 1 hour. This step was carried out in bulk, that is, in a volume sufficient for 
all three wells of each sample at each ZDV drug concentration: therefore requiring 27 
wells of C8166 for each test sample, with 50 TCID 50 per well, or 1350 TCID 50 in 1.3 
X 106 C8166 cells in bulk. After the incubation was completed the cells were washed 
to remove unincorporated virus. 
2.7.4 ZDV concentrations 
Zidovudine was provided by the MIRC AIDS Reagent Project (Dr H. C. Holmes, 
Project Leader, EC Programme EVA, donated by Welcome Research Laboratories, 
GLAXO Wellcome). ZDV was maintained as 1mM stock in PBS at -20°C. ZDV 
was added to give the final concentrations per well of 0.001, 0.01, 0. 1, 1, 5, 10, 50, 
1 00IJ.M ZDV. This final concentration was achieved by adding 2X concentrated 
ZDV: 0.002, 0.02, 0.2, 2, 10, 20, 100, 200p.M ZDV diluted incomplete medium. 
2.7.5 	ZDV sensitivity assay in non-adherent T-cell line 
On Day 1 cultures of C8166 cells were split. On Day 2 a cell count was carried out 
to obtain appropriate concentrations of C8166 cells i.e. 5.4 x 106  in total. Cells were 
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centrifuged, the supernatant was discarded and the cell pellet resuspended in freshly 
prepared virus dilutions. The virus dilutions were carried out in complete medium 
(CM) to obtain the appropriate virus concentration in a 'concentrated' volume of 
approximately 500p.1 (prepared using the TCID 50 values). The cell pellet was 
resuspended in the 500111 virus dilution, and was incubated at 37°C for 1 hour to 
allow virus uptake by cells. A two times concentrated ZDV solution was prepared by 
diluting the ZDV in complete medium, to allow for 10041/well, as detailed above. 
Once prepared these dilutions were maintained at -20°C until required. 
The cell/virus mixture was then centrifuged and the supernatant and unincorporated 
virus discarded. The pellet was washed once with complete medium. After this wash 
step the cell pellet was resuspended in an appropriate volume of complete medium to 
allow for 100 p.1 per well of cell/virus mixture: for 27 wells, 2.7m1, and aliquotted into 
wells. 1001.11 of ZDV dilutions were aliquotted into the appropriate wells: adding 
1 OOj.tl complete medium to [0] ZDV control well, and also including a control lane 
of C8166 alone (no virus), and C8166 with ZDV (no virus). Plates were incubated at 
37°C for 3-4 days. 
On Day 4 the plates were observed visually for syncytia formation and a positive 
score was obtained if syncytia were present, regardless of amount. Using a multi-
pipetter each lane was mixed, and 100111 of this was transferred to a fresh 96 well U-
bottom plate for future analysis, see below. To the original plate 1001.11 of appropriate 
2X freshly prepared ZDV dilutions were added to all the appropriate wells and the 
incubation continued at 37'C. 
The 100p.l removed from the test plates was centrifuged. After centrifugation the 
supernatant was removed to a fresh flat bottomed 96 well plate and stored at -20°C 
until required for in-house p24 Ag testing at a later date. The remaining cells were 
washed t'vice with 1X PBS. After the washing the cells were resuspended in 100111 
PBS:H20, for subsequent KC57 staining (see section 2.6.5.6). 
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After Day 7, the plates were again checked visually for the presence of syncytia. 
Plates could now be discarded, or used for KC57 staining and p24Ag testing (see 
section 2.6.5.7). 
2.7.6 HeLa plaque reduction assay 
This was performed by Sara Albanil in the laboratory of Dr. D. Richman, (Department 
of Medicine, University of California, San Diego, USA). A brief summary of the 
assay performed will be detailed below. 
Cell culture supernatant for the four recombinant viruses, and the four controls, 
obtained by culture in the C8166 cell line were used to infect the MT-2 T-cell line. 
Virus isolated from the culture supernatant was titrated in the HeLa HT4-6C 
(Chesbero and Wehrly, 1988) adherent cell line to obtain TCID 50 values. 
On day 0 the HeLa cells were seeded at a concentration of 2.5 x 10 4 to 3 x 104 cells 
per well, and allowed to incubate overnight in a CO2 incubator at 37°C. On day 1 the 
culture medium was aspirated and immediately replaced with 100-200 TCD j of virus 
solution, in a 2001.1.1/well volume and allowed to incubate at 37°C for 2 hours. After 
this period ZDV was added (in this experiment the ZDV final concentrations were 10, 
3.16, 1.0, 0.316, 0.1, 0.03 161.LM per well), in a 0.8m1 volume and the incubation 
continued for 3 days. 
On day 4 the medium was removed and the plates were fixed with 100% MeOH for 
10-15 minutes, and then rinsed with water. The cells were stained with 0.25m1 of a 
0.5% solution of crystal violet for 5 minutes, then rinsed with water and air dried. 
The plate was then scored by counting the large multinucleated cells, or syncytia, in 
each well. 
The % reduction in plaque numbers was obtained by using the number of plaques 
present within the no drug control well, and this was plotted on a logarithmic scale 
against the ZDV concentration. 
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2.8 	Viral Growth Competition Assays 
This is a phenotypic assay in which two viral types, with known genotypic differences, 
were grown together in a continuous cell line and the progress monitored both 
phenotypically and genotypically to establish which virus had the growth advantage 
and was therefore the fittest in that particular environment. 
The continuous T-cell line C8166 was used at a concentration of 0.5 x 106  cells/well 
of a 6 well plate and seeded in a 0.8m1 volume. Virus was prepared in four ratio 
mixtures; 90:10, 70:30, 30:70, and 10:90, with a total combined TCI1D 50 value of 
500/well, in a imi final volume of complete medium. The viral dilutions were then 
added to the cells, gently mixed by swirling the plate, and incubated at 37°C for 24 
hours. After this incubation a further lml of complete medium was added per well 
and the incubation continued. 
Every 4-5 days the culture was scored visually for the presence of syncytia and half 
the culture was removed and replaced by complete medium and fresh C8166 cells, 
when required. The removed culture was centrifuged and the supernatant stored at - 
70°C, and the cells resuspended in 0.5m1 freezing mix and frozen to -70°C before 
being transferred to liquid nitrogen for long term storage. 
2.8.1 	Genotypic analysis of competition assay 
To determine which virus types were present at each time point 100tl of cell culture 
supernatant was used to obtain viral RNA, which was then subjected to cDNA 
synthesis, nested polymerase chain, and direct sequencing using the T7/Dye 
Terminator chemistry (as detailed in section 2.4.4); an additional sequencing strategy 
was also performed, see below. 
2.8.1.1 ABI PRISM dye primer cycle sequencing 
- PCR Amplification for cycle sequencing 
This dye primer sequencing strategy uses the AmpliTaq® DNA Polymerase, FS 
enzyme (Perkin Elmer, ABI, 402111), a variant of the traditional Taq DNA 
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polymerase, leading to a more even peak height and pattern than previously available 
with this sequencing technique. In addition the improved enzyme is able to read 
through areas of repetitive nucleotides, and this is an advantage for the sequencing of 
the RT region ofpol. This sequencing was carried out as a comparison to the T7 
sequencing previously discussed, as a comparison to detection of mixed populations 
within a sample, as it had been used by B. Larder et al (1993) for detection of 
heterozygotes. 
In this sequencing strategy the secondary PCR is carried out using a chimaeric primer 
containing the M13 forward primer sequence at the 5' end of the usual primer 
oligonucleotide. Incorporation of this makes it possible for the cycle sequencing of 
the PCR product using the fluorescently labelled M13 primer (-21M13). This tail 
sequence is added to the 5' end of the normal secondary primers (Oswell). 
The DNA was produced using the same cDNA strategy, and the same primary PCR 
primers and reaction mix detailed in sections 2.3.1, 2.3.5, and 2.3.6, except for an 
increase in volume of the reaction mixture from 20p.1 to lOOp.l. The secondary PCR 
reaction, also carried out in a 1OOil volume with a 1.tl transfer volume from the 
primary PCR, was carried out with one primer containing the tailed sequence, either 
the sense primer or the antisense primer depending on whether sequencing of the 
sense or antisense fragment was required. A concentration of 20pmol of each primer 
was used in this PCR reaction. For cycle sequencing it is important to remove excess 
nucleotides but especially excess tailed primer that could bind the dye labelled primers 
in the subsequent sequencing reaction. The same cycling temperatures previously 
detailed in section 2.3.5 were used for this secondary reaction. After the secondary 
reaction was completed 5t.Ll  was resolved on a standard 1.5% ethidium bromide 
stained agarose gel. 
- PCR Clean-up 
The remaining PCR mix was subjected to a QlAquick PCR purification kit protocol 
(QIAGEN) to remove the unwanted primers, nucleotides, polymerases, and salts. 
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This procedure uses spin-columns with a silica-gel membrane that binds the DNA in 
the presence of a high salt concentration, allowing contaminants to flow through. The 
spin-column enables efficient removal of contaminants in the wash step, followed by 
elution of the DNA from the membrane with Iris buffer. 
To the remaining secondary PCR mix 5 volumes of buffer PB (which contains 
chaotropic salts) was added, and mixed by pipetting (the PCR mix was transferred to 
a clean 1 .5ml Eppendorf, removal of the paraffin is not essential). This mixture was 
then applied to the QlAquick column, held in a 1 .5ml Eppendorf, and centrifuged for 
60 seconds at 13,000rpm in a Microcentaur MSE (SANYO) centrifuge. After 
centrifugation the flow-through was discarded and the DNA/column washed with 
0.75m1 room temperature buffer PE (prepared by addition of 24m1 absolute alcohol to 
6m1 of PE), followed by centrifugation at 13,000rpm for 60 seconds. After discarding 
the flow-through the column was centrifuged again for 1 minute to completely 
eliminate any residual ethanol which might interfere with subsequent procedures. The 
DNA was eluted by applying 501A of buffer EB (10mM Tris-Cl, pH 8.5), left at room 
temperature for 60 seconds followed by centrifugation at 13,000rpm for 60 seconds. 
After the clean-up was completed 51.11  of the DNA was used to calculate the DNA 
concentration by spectrophotometry (see section 2.6.3), and 2.25p.l was resolved on a 
gel. The DNA concentration was adjusted by addition of DEPC distilled water. 
- Cycle sequencing Ready Reaction Kit with AmpliTaq®, FS 
The cycle sequencing ready reaction kit contains a premix of A, C, G and T cocktails 
which contain all the necessary nucleotides, buffers and enzymes. The reaction was 
performed by aliquotting each mixture, A (41.11), G (4p.l), C (8j.xl) and T (8J.1l), into 
individual tubes. To this was added 1J.1l of diluted PCR to A and G, and 21.1.1  to C and 
T. This procedure was carried out on ice. The reactions were overlaid with 201.1.1 of 
mineral oil and placed directly onto a 95°C preheated PCR machine (TECHNE, 
GENEL) with the following cycling temperatures and times: 15 cycles at 95 0C/30 
seconds, 55°C/30 seconds, and 70°C for 60 seconds, followed by a further 15 cycles 
at 95°C/30 seconds, and 70°C/60 seconds, after which the samples were cooled to a 
holding temperature of 4°C. 
After the cycle sequencing was completed all four reactions, A, G, C and T were 
transferred into one tube containing 80il of chilled 95% ethanol, and invert mixed. 
The tubes were maintained on wet ice for 15 minutes, after which time they were 
centrifuged at 13,000rpm for 30minutes. After the centrifugation, the supernatant 
was discarded and the pellet washed once with 250j.il of 70% ethanol at room 
temperature, by centrifugation for 5 minutes at 13,000rpm. The ethanol was removed 
and the pellet air dried. The pellet was then resuspended in Formamide/EDTA (3-
4.Ll), vortexed, pulse centrifuged and placed on a 90°C hot block for 2 minutes after 
which time the samples were transferred to ice until ready to load on the sequencing 
gel. For details of the FE and sequencing gel, which are the same as for the T7 
sequencing strategy see section 2.4.4. 
The sequencing was performed using filter wheel A on the ABI 373A automated 
machine with the 'mqdyeprimer' matrix, and the -21M13 dye primer settings. All 
procedures for loading, running and analysis of data were as previously detailed (see 
section 2.4.4). 
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2.9 	General Materials 
Tissue culture plastics, unless otherwise stated, were supplied by Costar®,  and 
included 25cm2, 75cm2  tissue culture treated, canted neck cell culture flasks (#3055 
and #3375 respectively); Costar 24 (#3524) and 96 well U-bottom or flat-bottom 
culture cluster plates (#3799 and #3595 respectively). 
General plastics, universals (20ml) and bijoux (7m1), supplied by Sterilin. 
Gilson tips, and pastettes (I ml graduated, fine tip), supplied by Alpha. 
Sterile syringes, PLASTIPAK®, by Becton Dickinson. 
Eppendorf tubes, 0.5m1 and 1.5m1 flip tops, Sarstedt. 
30ml Containers supplied by MEDIA. 
Combi tips supplied by Eppendorf(1.25m1, 2.5m1, and 5m1). 
CryoTube 1 .8m1 internal screw, supplied by NUNC. 
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3 	Sequence Analysis of the Reverse Transcriptase Region of poi 
3.1 Introduction 
Transmission of resistant variants of HIV-1 with ZDV-associated mutations had been 
documented before this work commenced through sequence analysis of patient 
derived material and analysis of the reverse transcriptase region of the pol gene. 
However, these studies looked at specific risk groups, and only examined very small 
numbers of individuals (Chapter 1, section 1.8) which could bias the estimates of the 
numbers of transmissions occurring with such variants. 
Examination of antiretroviral naïve populations, in comparison to treatment groups, 
would give an insight into the levels of variation within the pol gene, By examining 
the genotype of a large group of patients in the pol region the incidence of mutations 
can be seen and the mutation frequencies obtained. 
In this chapter I will discuss the results of the sequence studies carried out on the RT 
region ofpoi, consider the possibility that ZDV-resistant variants pre-exist as minor 
undetectable variants, and discuss how this relates to documented transmission 
events. 
3.1.1 Analysis of pol sequence variation and evolution 
Many studies have been carried out on the env gene and the patterns of variation and 
selective processes involved in the presence of particular genotypes within and 
between patients (Simmonds et a!, 1991; Zhang et al, 1993; Leigh Brown, 1991; 
Holmes eta!, 1992; Simmonds et al, 1990a). It is known that distribution of variation 
over the HIV-1 genome is not equal with most concentrated on the env gene (Li eta!, 
1988). 
One study, however, has shown that the level of variation obtained through point 
mutations in the pol gene may actually be only 2-3 fold lower than in the env region. 
Quinones-Mateu eta! (1996) used 81 HIV-1 samples from both antiretroviral treated 
and untreated patients to sequence poi, and 28 samples were used to sequence the 
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C2V3 domains ofgp 120 region within the env gene. The nucleotide and amino acid 
sequences obtained indicated that point mutation frequencies within the regions 
encoding nonstructural proteins were at most two to three-fold lower than for the 
gpl20 region. The majority of mutations did not result in amino acid changes and 
were therefore synonymous, however these changes still lead to substantial variation 
within the pol gene. In a similar study on the foot-and-mouth disease virus (Villaverde 
et a!, 1988), mutations accumulated at a greater rate in the capsid protein VP 1 when 
compared to the polymerase 3D coding region; however they found that the genetic 
heterogeneity between the structural and non-structural protein-coding regions among 
co-circulating viruses were indistinguishable. 
It has been shown that the gp120 region of env readily accepts amino acid 
substitutions as well as short deletions and insertions, whereas within the RT region of 
poi a single or double amino acid substitution can mediate phenotypic changes 
(Mellors et a!, 1995). These studies show that non-structural, specifically enzymatic 
regions, such as the RT region ofpoi may have limitations to variation with respect to 
large deletions or insertions. This does not however preclude tolerance to extensive 
amino acid substitutions along the genome which can result in changes to the overall 
viral phenotype without loss of gene function. 
In a study by Najera eta! (1995) a sequencing strategy was undertaken to answer two 
questions. The first was to discover what the natural frequency of variation in the pol 
gene was, and secondly to attempt to establish if the mutations that arise during 
antiretroviral therapy are a direct result of therapy or whether these mutant variants 
already pre-exist at low frequencies in the viral population. The results of that study 
will be briefly summarised. 
Direct sequence analysis was carried out on PCR amplified proviral genomes from Un-
cultured primary lymphocytes from 60 lilY-i positive individuals; 35 of these were 
receiving some form of antiretroviral therapy, and 25 were antiretroviral naïve. Two 
nucleotide regions within the reverse transcriptase region, from amino acid codons 41 
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to 108, and from codons 181 to 219, were obtained. The results from this showed a 
spread of variation along the entire regions analysed. 
As expected, in the treatment group several mutations related to drug therapy were 
observed. With respect to ZDV, there was a mutation from AAA—AA, that 
corresponds to the K70R mutation shown to occur when patients are treated with this 
drug. This mutation was observed in 7/25 (28%) of naïve and 13/3 5 (37%) treated 
patients. No mutations were observed at the other ZDV-associated sites (codons 41, 
67, 215), although a silent mutation at codon 219, nucleotide sequence AAA—AA, 
was observed in 5/25 (20%) of the naïve group. The presence of the 70 mutation 
was not a surprise as it has been documented in several situations and is likely to be a 
natural polymorphism (Zhang eta!, 1991; Mohri eta!, 1993). 
Clonal analysis of the naïve group showed the presence of this K70R change within 
the viral quasispecies. There were also indications of mutations that are related to 
reduced susceptibility to the non-nucleoside inhibitor 3TC (Ml 84-91 subpopulation 
identified within the quasispecies of a paediatric sample obtained when use of the drug 
was limited), and the nucleoside inhibitor ddC (T69-->D in a patient undergoing ZDV 
and thymic humoral factor therapy). 
Analysis revealed that mutation frequencies both in the individual genome and within 
the quasispecies were high and the presence of mutations, including mutations at 
critical drug resistance associated codons, could therefore be an expected 
consequence of this high mutation frequency within pol. This observation was 
surprising in a gene encoding an essential enzyme such as reverse transcriptase, and 
shows that it is tolerant to amino acid change. Mutation frequencies at some codons 
related to drug resistance were comparable to the average mutation frequencies 
observed as a whole, and from this it can be concluded that it is statistically possible 
that mutations will occur at these positions. However, no variation at the ZDV 
resistance associated mutation positions 41, 67, and 215 had been documented from 
untreated patient samples at the time the current study was conducted. 
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3.1.2 Frequency and turnover of pol variants in peripheral and plasma 
populations 
It is of obvious importance when examining the viral quasispecies to choose the 
material that would best reflect the situation in vivo. The pattern of genetic variation 
observed in both the proviral populations and the circulating viral RNA has been 
extensively investigated (Kaye eta!, 1995; Cleland eta!, 1996; Sinimonds eta!, 1991; 
Zhang et a!, 1993), with conflicting results. It is clear that whatever genotype is 
present in the circulating viral RNA, this will show up in the provirus population in 
the PBMCs. The point at issue is how long this process takes, and whether this 
prejudices studies using PBMCs. 
It is a general consensus that a variant is usually observed first in the plasma RNA, or 
simultaneously in both (Kaye eta!, 1995; Zhang eta!, 1993; Leigh Brown, 1991; 
Simmonds et a!, 1991). In a haemophiliac patient whose infection has been 
extensively characterised, the presence of particular variants in the env gene of a 
plasma RNA sample were observed in the proviral population 3 years later, and were 
still detectable at 5 years (Leigh Brown, 1991). However in a study looking at the 
presence of ZDV associated mutations, an average time of 25 days for the detection 
of a circulating mutation in cell-free viral RNA to be observed in the proviral DNA 
was noted (Kaye eta!, 1995). The presence of the codon 215 mutation in another 
study was observed in the proviral population 34 weeks after it was first observed in 
the plasma RNA (although no interim sampling was carried out between these two 
time-points)(Cleland et a!, 1996). 
If sampled early in the asymptomatic phase the proviral sequences may be more 
representative of the seroconversion type, with later samples corresponding to the 
circulating plasma virus, as has been shown in the env gene (Simmonds eta!, 1991). 
To define the difference between these two compartments, sampling from the same 
time-point can be carried out. Examination of both sequences will determine the 
relatedness of the two distinct compartments, but in general, proviral DNA can be 
thought of as a historical reference of the variants that have existed in the patient. It 
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is proposed that all sequences will be detectable in this population at one time, and it 
is therefore a good source for investigating the possibility of transmission events. 
3.2 Results 
3.2.1 Study group 
3.2.1.1 MIRC Molecular Epidemiology Project 
The MRC Molecular Epidemiology Project (MEP) was a resource of patient samples 
and data covering all HIV risk groups. The Edinburgh branch of the MEP (Edinburgh 
Repository: Dr J. Peutherer and Dr A. Leigh Brown), collected patient material from 
10 clinical centres in 6 major cities within the United Kingdom and Eire: Belfast, 
Dublin, Dundee, Edinburgh, Glasgow and Newcastle. 
Blood was separated on the day that it was collected (or as soon as possible), at the 
Centre for HIV Research, Edinburgh University, by Mrs S. Rebus or D. Lobidel. 
After density gradient separation of the blood (see Chapter 2, section 2.1) serum and 
plasma were maintained at -70°C, and the PBMCs in the gaseous phase of liquid 
nitrogen. At the time that this study was undertaken 602 patients had been recruited 
(1995). All blood was accompanied by a questionnaire (see Appendix I) which was 
completed by the clinician, containing the patient's identification (date of birth, sex, 
race etc.), serostatus (seroconversion dates, including CD4 lymphocyte counts, AIDS 
defining illnesses etc.), and antiretroviral therapy undertaken. This information, along 
with all subsequent procedures performed on the samples, from the numbers of blood 
fractions stored to sequence analysis, were entered into a Paradox 4.0 Database. 
3.2.1.2 Paradox 4.0 database 
The paradox database contains all information on patients within the MEP and was 
developed by Ms Anne Leigh Brown. Any work carried out on the stored samples, 
i.e. culturing, DNA extraction, or acquisition of repeat samples, change in HLV status, 
in addition to the questionnaire information, is added to the database. 
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The Paradox 4.0 database consists of seven permanent related tables. The Patient 
table contains the data from the accompanying questionnaire (see Appendix I). The 
Data table contains information such as the AIDS status, antiretroviral therapy, CD4 
lymphocyte counts, information also supplied on the questionnaire, but which can also 
include follow up information (see Appendix I). The Source table details the hospital 
and clinician information. The Culture table contains the processing data of samples 
by the Edinburgh MEP laboratory, with the Store 1 and Store 2 tables containing the 
Edinburgh MEP laboratory location information of the blood fractions and products 
(such as DNA and RNA). The final table, Destlab, contains the information of those 
laboratories that requested samples from the repository. 
The information from these tables can be linked to one another through patient 
identification either by the repository given number or hospital given codes. This 
allows a search of the database and identification of particular patients who share 
certain common factors of interest which may be specified on two or more different 
tables. 
3.2.1.3 Antiretroviral naïve patient group 
By combining the Patient and Data table information the paradox database was 
searched to identify patients with the specific criteria specified. The study group in 
this thesis was chosen on the basis of two criteria: 
they had never undergone any form of antiretroviral therapy. 
2 	their seroconversion dates were post-1990. 
Seroconversion is defined as the time when an antibody response develops. This 
requires a prior negative test, although some specific infection dates from other 
evidence, were available. The majority of seroconversion dates were estimated as the 
mid-point from the last negative, and the first positive HIV-1 test. Patients who had 
estimated seroconversion dates prior to 1990 were excluded on the basis that in this 
population the drug ZDV had not been used at a significant level. 
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A search of the paradox database under the above criteria identified 35 patients. 
Within this group of 35 patients, the largest represented mode of transmission (that is, 
proposed route of infection), is that of sex between men (44% of the total study 
group so far, see Table 3.1). This is followed by heterosexual transmission, 
intravenous drug users (IDU) then others (either heterosexual or MU). The ratio of 
male to female in this study group is 3:1 respectively. 
TABLE 3.1 
Break Down of Study Group by Clinic and Route of Infection 
Homosexual WD Abuse Heterosexual NG TOTAL 
Belfast 1 - 2 - 3 
Glasgow 3 1 1 - 5 
Edinburgh 2 1 3 1 7 
Newcastle 3 - 1 - 4 
Dublin 7 5 - - 12 
Dundee 1 1 2 - 4 
TOTAL 17 8 9 1 35 
NG = Information on route of infection not given 
Although the study group was chosen solely on the seroconversion dates, in addition 
to never having undertaken any antiretroviral therapy, certain biases do occur. The 
study group is composed of more males (28, 78%) than females (8, 22%). As a 
consequence of this the study group is more biased towards homosexual contact as 
route of infection. The patient characteristics are detailed in Table 3.2. The table lists 
patients by their MEP identification number, and details sex, transmission route and 
the date the sample was taken, as well as the estimated seroconversion date. 
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TABLE 3.2 
Antiretroviral Naive Study Group 
The table illustrates the patients from the MEP repository, listed by MEP 
identification number, who had never undergone any form of antiretroviral therapy, 
and had seroconversion dates post-1990 (see section 3.2.1.3). 
* Denotes the sex of the patient 
# Denotes the proposed route of infection 
t Denotes the date of sample collection 
NG Route of transmission not given 
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SAMPLE MJF* TRANSROUTE# SAMPLE SEROCON VERSION 
DATE .................................... DATE 
1009 M Heterosexual 19.01.93 1990 
1051 M Homosexual 26.04.93 05.01.92 
1072 M Heterosexual 08.06.93 1992 
1083 F Heterosexual 08.07.93 01.11.92 
1087 M IVD Abuse 05.08.93 01.06.93 
1105 M Homosexual 29.09.93 1990 
1111 F IVD Abuse 14.10.93 1990 
1146 F Heterosexual 11.01.94 25.11.91 
1147 M Homosexual 12.01.94 1990 
1154 M Homosexual 19.01.94 1990 
1219 M Homosexual 23.02.94 1993 
1249 M Homosexual 09.03.94 1992 
1294 M Homosexual 06.04.94 1992 
1301 F Heterosexual 12.04.94 01.10.91 
1313 M Homosexual 20.04.94 1992 
1317 M Homosexual 24.04.94 01.01.94 
1334 M Homosexual 09.05.94 1993 
1367 M Heterosexual 27.05.94 1990 
1390 M Homosexual 15.06.94 01.08.92 
1407 M IVD Abuse 29.06.94 1990 
1433 M Homosexual 21.07.94 17.03.93 
1438 M NG 21.07.94 17.03.93 
1441 M IVD Abuse 27.07.94 1990 
1442 M IVD Abuse 27.07.94 1992 
1444 M Homosexual 27.07.94 01.07.91 
1446 M Homosexual 27.07.94 01.12.92 
1449 M IVD Abuse 03.08.94 1990 
1488 M Heterosexual 04.10.94 1992 
1504 M Homosexual 24.10.94 89-92 
1514 M Homosexual 25.10.94 01.08.93 
1525 F Heterosexual 27.10.94 01.02.94 
1531 F IVD Abuse 02.11.94 90-94 
1542 F IVD Abuse 04.11.94 1992 
1544 F Heterosexual 03.11.94 1994 
1568 M Homosexual 22.11.94 01.06.92 
For reasons detailed above proviral DNA was chosen as the main source of viral 
genetic material for the study. DNA was obtained from cryopreserved PBMCs and 
subjected to nested PCR and automated sequence analysis (as detailed in Chapter 2, 
sections 2.3 and 2.4). In addition some PCR and sequencing was carried out on 
plasma derived viral RNA. 
3.2.1.4 ZDV resistant patient control 
A control was selected from the database on the basis that they had undergone ZDV 
therapy. This patient, patient 1037 (MEP identification number), had undergone ZDV 
monotherapy for two years; sample was collected on March 1993, and ZDV therapy 
had been initiated on February of 1991. Resistance can occur within six months of 
therapy, therefore mutations should have been detectable within the proviral DNA of 
this patient. The proviral DNA was extracted from the PBMCs and subjected to limit 
dilution nested PCR, and automated sequencing to produce a nucleotide sequence 
which included the amino acid codons 41 through to 219 which are associated with 
ZDV resistance. 
The results of this sequence analysis can be seen in Table 3.3 (see also Appendix II-
1). From 7 single molecules of proviral DNA sequenced, 5 contained the ZDV-
associated mutation M41--->L at codon 41. Four of this group had this mutation 
linked with the mutations D67—N, and K70—*R (single molecules 4, 5, 6, and 7). 
Four single molecules showed the presence of the 215T-4Y mutation (single 
molecules 3, 4, 6, and 7), with only one sample showing the presence of the K219-3E 
mutation (single molecule number 6). 
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TABLE 3.3 
Amino Acid Changes at ZDV Resistance-Associated Positions in RT 
1037 Single Molecule 	 RT Codon Number 
Number 
41 	67 	70 	215 	219 
1 	 M D K T K 
2 	 M D K T K 
3 	 L D K Y K 
4 	 L N R Y K 
5 	 L N R T K 
6 	 L N R Y E 
7 	 L N R Y K 
The table shows the amino acid changes caused by point mutations at resistance.. 
associated positions 41, 67, 70, 215 and219. The mutant changes are highlighted in 
bold type (see Figure 1.6) 
3.2.1.5 Interval between seroconversion to sampling times 
Samples were obtained between 1993 and 1995. Sample dates along with 
seroconversion dates for all patients are shown in Figure 3.1. The time between 
estimated seroconversion dates and sampling varied within the group, from 0-4 years, 
with the majority being sampled within two years of seroconversion (64%). The 
greatest number of seroconversions within the study group occurred in 1992 (12 
patients), followed by 1990 (9 patients), 1993 (6 patients), 1994 and 1991 (3 
patients), with no seroconversions in 1995 (three patients seroconversion dates could 
only be predicted within a couple of years and hence are not included in above 
figures). The interval between seroconversion date and sample time is likely to have 




Sample and Seroconversion Dates 
Diagrammatic representation of the time from the estimated date of seroconversion to when the patient sample was collected. 
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3.2.2 Direct sequence analysis of reverse transcriptase 
From the 35 patients in the study group, 36 sequences were obtained from the 
uncultured proviral DNA by nested PCR, and direct sequencing of the bulk product 
(Chapter 2, section 2.3). The region initially sequenced was from 2693 to 3281 
(IH\T1 i j clone HXB2 co-ordinates, Myers et al, 1995, Los Alamos) which included 
the amino acid positions 215 and 219, associated with ZDV resistance. The presence 
of the double point mutation at codon T215—YfF, is exclusively associated with 
ZDV treatment and associated with substantial loss of ZDV sensitivity (Larder et a!, 
1989). Once it appears in the population the 215Y mutation (with the F mutation 
occurring at a lower frequency), usually becomes fixed, unlike virus that carry the 
codon K70-4R mutation, which are transient. Resistance associated mutations at the 
215 codon arise by nucleotide substitutions at both the first and second positions, 
from ACC (T) wild-type to TAC (Y) mutant genotype (with a less frequent variant 
TIC (F)). 
The strategy adopted in this study was to look for any changes at codons 215 and 
219, and if variation was observed, those samples would be subjected to further 
sequence analysis of the first half of reverse transcriptase, to include the other three 
positions 41, 67,. and 70 to give a complete picture with regard to ZDV mutational 
pattern (see Appendix 11-2,3, and 4 for sequences). 
When the sequences obtained from this naive study group are aligned against the 
subtype Dpol sequence from the strain HT\T11 (Myers eta!, 1995, as above), a 
range of both synonymous and non-synonymous variation was observed. These 
sequences were compared with a consensus of the variation observed within the 
antiretroviral naïve patients from the Najera eta! (1995) study group. This study was 
chosen as a comparison to the one detailed in this thesis because it was also carried 
out directly on lymphocytes from FIIV-1 infected individuals, and not from samples 
adapted by some form of in vitro culture, which could alter the quasispecies. 
Comparison with the Najera study group can be seen in Figures 3.2 and 3.3. The 
spread of mutations seen in this study group is comparable to that observed in the 
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FIGURE 3.2 
Sequence Variation in The 5' Portion of The RT Region From Amino Acid 41 to 109. 
The figure shows the consensus of variation observed in the Najera study group (1995), and in the antiretroviral naive study group detailed 
in this thesis. Sequences are aligned against the }IIV- 1 HXB2 variant, where A represents the Najera study group, and B, the antiretroviral 
group in this study. The ZDV resistance associated positions are highlighted in bold. The table below shows the wild type and known 
resistance-associated variation observed at these positions, and the International Unioun of Biochemistry codes (TUB), indicating ambiguity 
at a particular nucleotide position. 
Wild... pceotide .çodon Mutant 	 1eot4e 
ATG 41 TTGICTG 
GAC 67 AAC 
AAA 70 AGA 
LUB CODES 
R A or G (puRine) 
Y C or T (pYriniidine) 
M AorC(aMino) 
. 4) 
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NUCLEOTIDE CONSENSUS 
4]. 
HXB2 	 ATGGAAAAGGAAGGGAAAATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGTA 
A A. .A ..... A ... T ...... GGG.A. .A. .A. . .TTC. .T. .TT.C. . . .T.A.. 
BT .... G..A ................ G ............... C ..... T ............ 
B C ........................................................... 
67 	70 
HXB2 	 TTTGCCATAAGAAAAGACAGTACTAATGGAGAATTAGTAGATTTCAGAGCTT 
A G. .G ...... GGC.GGG ....... G ..... C. .CA. .. .G. .G... 
B ................. G ................. G ........... C ..... G ...... 
HXB2 	 AATAAGAGAACTCAAGACTTCTGGGAAGTTCAATTAGGAATACCACATCCCGCAGGGTTA 
A A ...... G. .T ........ GAA ... CC. . .GG... .G ..... T .GA.A. .G 
A ........................................................ T..T 
B 	 A.A. .C... .T. .T ...... A .... G ..... GT.C. .G ..... G. .T .A. .G 
B .................................................. A ..... C... 
B ..................................................y 
B .................................................. T ......... 
108 
HXB2 	 AAAAAGAAAAAATCAGTAACAGTACTG 
AG ........ G ......... 
B 	 .GG ........ G ... A.G ..... TT.A 
B G.. .  
FIGURE 3.3 
Sequence Variation in The 3' Portion of The RT Region From Amino Acid 181 to 219. 
The figure shows the consensus of variation observed in the Najera study group (1995), and in the antiretroviral naive study group detailed 
in this thesis. Sequences are aligned against the HIV- 1 HXB2 variant, where A represents the Najera study group, and B, the antiretroviral 
group in this study. The ZDV resistance associated positions are highlighted in bold. The table below shows the wild type and known 
resistance-associated variation observed at these positions, and the International Unioun of Biochemistry codes (1TJB), indicating ambiguity 
at a particular nucleotide position. 
Wild type nucleotide 	 Codon 	Mutant nucleotide 
AAC 	 215 TAC/TTC 
AAA 219 	 CAA 
rUB CODES 
R 	 A or G (puRine) 
V C or I (pYrimidine) 
M 	 AorC(aMino) 




A ............... A .......... G. .G. .C. . .0 ...... C ... A. .A. .C. . .GT. 
A ............................. T ................. T ..... GG ..... 
B 	 . .C. . .G.T ........ CC.A ........... GA.T ...... C. .AAA. .A. .C. . .GT. 
B ............................................... R ............ 
215 	 219 
HXB2 	 AAAATAGAGGAGCTGAGACAACATCTGTTGAGGTGGGGACTTACCACACCAGACAAA 
A .. .GG.. .C. .A. .A. .GA.G.GCT.AC. . .AA ..... GT.G ..... C ........ C 
AA. .0 ...... G.0 .................... C ............... 
T ........... T .................................... 
B 	 S.A. .MT.A. .RGRT. . .T.AA.ARAR. .R. .GT.AGAT. .G ........ G 
B A ........ G ........M.R ....... Y.G .............. R 
B c............... 
Najera study, showing that within the RT enzyme a certain number of changes appear 
to be well tolerated. 
3.2.2.1 Sequence analysis of the 3' portion of RT 
In three patients point mutations were observed at codon 215. These did not 
correspond to previously published variants observed at this position. At the time of 
this study no variation had been documented at this position other than those known 
to confer a substantial reduction in susceptibility to ZDV (tyrosine, TAC and 
phenylalanine, TIC). 
- Codon 215 
Patient 1514 had the nucleotide sequence GAT instead of an ACC (T215—*D) change 
at codon 215 (Figure 3.4). Patient 1390 also had a T215—D but with ajAC 
sequence (Figure 3.5). Patient 1111 (who had two time-points sampled, 1111.1 and 
1111.2 (sample dates 14/10/93 and 26/05/94 respectively)), also had variation at 
codon 215, with an ACT instead of ACC, but this did not lead to an amino acid 
change. 
-Codon 219 
Patient 1154 showed variation at codon 219, AAA to AA, a change frequently 
observed at this position (Najera et al, 1995). Double peaks present on the 
electropherograms at the third nucleotide position of codon 219 (A and G) for patient 
1111 in the second timepoint sample, indicate the presence of a mixed population. 
3.2.2.2 Sequence analysis of the 5' portion of RT 
Further sequencing of these samples to include the 5' portion of the RI region with 
the resistance-associated codons 41, 67 and 70 was carried out. This identified 
known ZDV-associated mutations at codon 41 in two patients, 1390 and 1514. No 
variation was observed at positions 67 or 70 in this study group. 
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- Codon 41 
Patient 1514 had the nucleotide sequence 2TTG instead of the wild type ATG at codon 
41 (M41—L). Patient 1390 had the nucleotide sequence çTG instead of ATG 
(M41L) at codon 41. Both therefore possessed a documented ZDV resistance 
associated mutation (see Figures 3.4 and 3.5). 
3.2.2.3 Sample Heterogeneity 
The electropherograms (trace data) produced by automated sequencing showed the 
presence of mixed peaks at several positions, as indicated by patient 1111 discussed 
above. This suggests possible heterogeneity within the sample, which was amplified 
and directly sequenced without any cloning step. In patient 1390 mixed peaks were 
observed at the first nucleotide position of codon 215 (see Figure 3.5), this 
corresponds to the known TAC (215Y) ZDV resistance mutation, typically only 
detected after ZDV therapy, as well as AAC (215N), a previously unpublished change 
at this codon. 
The frequency at which this TAC ZDV resistance-associated mutation occurs can be 
estimated within the data analysis program on the Apple Macintosh Ilci computer (see 
Chapter 2, section 2.4.4). Within this program the sequence is represented by the 4 
colour trace data, with both x and  co-ordinates (with respect to peak height and 
location in sequence read). Using the cross hair cursor, and placing it at the tips of 
the peaks, y-co-ordinate readings are obtained. The two figures, one for each of the 
two peaks observed at one nucleotide position, can then be used to obtain a frequency 
value. 
Using this method an arbitrary figure of approximately 20% is obtained. This shows 
that a minor population, representing 20% of the overall viral population in the 
patient, carries a known documented ZDV-resistance associated mutation. These 
variants appear to have persisted in a drug free environment for one year (since the 
seroconversion date, see Figure 3.1 and Table 3.2), in a patient who has never 
undergone any ZDV therapy. 
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FIGURE 3.4 
Trace Data from ABI 373A Automated Sequencing For Patient 1514 
The figure shows trace data obtained from ABI T7 Sequenase automated sequencing 
of the reverse transcriptase region ofpoi from patient 1514, timepoint one. The 
sequence was from bulk PCR amplified proviral DNA (see section 3.2.2). 
A Represents ZDV resistance associated codon 41 (underlined), with the mutant 
genotype TTG 
B Represents ZDV resistance associated codon 215 (underlined), with the mutant 
genotype GAT 
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3.2.3 Single molecule direct sequence analysis of RT 
3.2.3.1 Analysis of individual quasispecies 
To give a clearer picture of the population within these patients, and whether the 
presence of this variant was due to experimental sampling, limit dilution nested PCR 
was undertaken (Simmonds et al, 1990). This technique is a very specific method for 
the amplification from a single molecule of DNA. The proviral DNA from peripheral 
blood cells is diluted and distributed into a number of tubes (30-50 tubes), and 
subjected to PCR. At the end-point dilution only a small number of reactions should 
be positive, 20% or less. By applying the Poisson assumption, the probability that 
each of the PCR-positives originated from a single molecule of DNA can be 
calculated. Using the 20% positives as a cut-off value it is assumed that there is a 
90% probability that each reaction was from a single molecule. 
Such amplifications from single molecules can be detected accurately due to the 
nested PCR reaction, which uses two successive rounds of amplification with two sets 
of primers, both increasing the yield and the specificity of the product. Once the end-
point dilution is determined, this dilution can be reproducibly used in all subsequent 
reactions. 
Using this technique a 622 base pair fragment of reverse transcriptase region was 
successfully amplified, detectable by gel electrophoresis. By direct sequencing of a 
range of such single molecules, and reference to the population as a whole, 
assumptions can be drawn as to the major dominant variant, and/or the presence of a 
heterogeneous population. All sequences obtained can be seen in Appendix 11-2. 
3.2.3.2 Variation observed in RT for first timepoint sampled 
Patient 1390 
- Proviral DNA 
The aspartic acid (C) mutation at position 215 predominated in patient 1390. 
From 13 single molecules sequenced, 11 represented this genotype. The TAC codon, 
indicated by the presence of the mixed peaks within the bulk sequence, were not 
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detected within the quasispecies sampled. However the unusual amino acid asparagine 
(AAC), which was also indicated by mixed peaks was detected in 1 of the 13 single 
molecules from patient 1390 proviral DNA. Another unusual amino acid, cysteine, 
represented by the nucleotide sequence TC, was also detected in 1 of the 13 single 
molecules sequenced (see Table 3.4). 
- Plasma RNA 
An asparagine was the codon observed from the bulk plasma sample at the same time-
point as patient 1390, although single molecule sequence analysis of the RNA failed 
to detect it. From the two single molecules obtained from the plasma RNA one 
corresponded to the GAC genotype, the other was another as yet unpublished variant 
at this position, CAC, coding for histidine (see Table 3.4). 
Patient 1514 
- Proviral DNA 
A smaller number of single molecules were sequenced for patient 1514, but the results 
showed a different spread of variants. From 7 single molecules sequenced, 5 
represented the amino acid tyrosine (Y), a known ZDV associated mutation, with the 
nucleotide sequence TAT. The remaining 2 single molecules corresponded to the 
amino acid GAT (D), aspartic acid as observed in the bulk sequence (see Table 3.5). 
- Plasma RNA 
The bulk sequence analysis of the RNA from patient 1514 showed the GAT (D), 
aspartic acid amino acid in a similar fashion to that observed in the bulk proviral 
DNA. Only 2 single molecules were obtained, one of which corresponded to the 
GAT (D) variant, the other was asparagine (N, MC) at codon 215 (see Table 3.5). 
3.2.3.3 Variation observed in RT for subsequent timepoints sampled 
Two additional samples were obtained from patient 1390 (09.05.96 and 04.12.96), 
and one additional sample from patient 1514 (22.05.96)(see Appendix ifi). Neither 
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patient had undergone any antiretroviral therapy at the time these subsequent samples 
were obtained. 
Patient 1390 
- Codon 41 
Analysis of the proviral DNA at codon 41 showed the presence of the nucleotide 
sequence CTG, similar to that detected in the first timepoint sampled. There was the 
presence of a smaller 'A' sub-peak at the first nucleotide position of this codon which 
corresponds to the wild type ATG sequence. Single molecule analysis of proviral 
DNA showed that this ATG wild type sequence predominated in the population 
(66%), with the CTG only detected once. Also observed was a cTA at this position 
which also codes for the mutant amino acid leucine (see Table 3.4). 
- Codon 215 
The aspartic acid, GAC, mutation at codon 215 still predominated in the second 
timepoint sample for patient 1390. Analysis of 8 single molecules all had the GAC at 
this position (see Table 3.4). 
Patient 1514 
- Codon 41 
Analysis of this second timepoint proviral DNA sample showed that the ITG 
sequence at codon 41 had still persisted in this patient. Only 3 single molecules were 
analysed for this timepoint, but all had the mutant ITG identified by the direct 
sequencing (see Table 3.5). 
- Codon 215 
Bulk sequence analysis of this timepoint proviral DNA sample showed that the GAl, 
aspartic acid had also persisted in this patient. Single molecule analysis showed this 
to predominate in the population, although one sequence showed the sequence AAT, 
which had been seen in the clonal analysis of the plasma RNA from the first timepoint 
for this patient (see Table 3.5). 
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TABLE 3.4 
Direct and Single Molecule Sequence Analysis of Patient 1390 at ZDV Resistance-Associated Codons 41 and 215 
The table shows the results of sequencing of proviral DNA and plasma RNA for all timepoints sampled for patient 1390. Numbers shown in 
subscript represent the numbers of sequences obtained. 
(see Appendix 11-3) 
(0) 	Represents the presence of a minor population (as seen in Figure 3.6) 
ND Sequence not determined 
Opposite page number 127 
Sample 	 Date 	 Source 	 Codon 41 	 Codon 215 
PBMC 	Plasma 	Codon 	Amino Acid Codon 	Amino Acid 
1390.1 	 15.06.94 	Direct CTG L GAC D 
((AAC)) N 
((TAC)) Y 
Clonal ND ND GAC11 D 
AAC 1 N 
TGC 1 C 
Direct 	ND ND AAC N 
Clonal 	ND ND GAC1 D 
CAC 1 H 
1390.2 	 09.05.96 	Direct CTG L GAC D 
((ATG)) M 




Direct and Single Molecule Sequence Analysis of Patient 1514 at ZDV Resistance-Associated Codons 41 and 215 
The table shows the results of sequencing of proviral DNA and plasma RNA for all timepoints sampled for patient 1514. Numbers shown in 
subscript represent the numbers of sequences obtained. 
(see Appendix 11-4) 
(0) 	Represents the presence of a minor population 
ND Sequence not determined 
Opposite page number 128 
Sample 	 Date 	 Source Codon 41 Codon 215 
PBMC 	Plasma Codon Amino Acid Codon 	Amino Acid 
1514.1 	 25.10.94 	Direct TTG L OAT 	D 
Clonal ND ND GAl2 	D 
TAT5 	Y 
Direct ND ND GAT 	D 
Clonal ND ND GAT, 	D 
AAT 1 	N 
1514.2 	 22.05.96 	Direct TTG L GAT 	D 
Clonal TTG3 L GAT4 	D 
AAT1 	N 
3.2.3.4 Resistance to other antiretroviral therapies 
In the study by Najera eta! discussed earlier (1995), existence of mutations related to 
drugs, other than ZDV, was shown to be present even when such drugs were not 
available or in general circulation (see section 3. 1.1 of this Chapter). Any variation 
observed in the sequences from this study group were compared to the resistance 
table contained in the International Antiviral News bulletin (Schinazi et a!, 1997). 
This table lists 143 distinct mutations arising due to therapy by all the known 
antiretroviral therapies against THY, as well as those mutations effecting STY and 
Fly. Comparison with this showed that no mutations at any other sites associated 
with antiretrovirals of any kind were observed in this study group. 
3.2.4.1 Presence and relevance of mutation artefacts due to PCR 
In this study the heat stable DNA polymerase, Taq polymerase, from Therm ophilus 
aquaticus, was used. This is the most common polymerase enzyme used for 
techniques such as PCR, and was used for all amplifications in this study. This 
polymerase however, does not contain a 3'-5' exonuclease, proof-reading ability. 
Due to the lack of this proof-reading activity, reactions can be subject to 
misincorporation which is detected on sequencing of cloned PCR products. The 
levels of such have been shown to range from 1 in 400 nucleotides (Saiki eta!, 1988) 
to 1 in 1800 (Ennis et a!, 1990). Earlier studies from this group have shown however 
that the sequencing of Taq induced PCR errors using the particular method adopted in 
this study is very low and not likely to affect mutation frequency levels (Simmonds et 
a!, 1990a). 
3.2.4.1 Misincorporation 
From a total of 10,927 nucleotides sequenced from single molecules obtained through 
different amplification by limit dilution nested PCR from the same source, a total of 
16 nucleotide substitutions was observed: this excludes the resistance-associated 
positions 41, 67, 70, 215 and 219. This gives a frequency of 1.4 x 10 substitutions 
per nucleotide. An estimate of 1.2 x 10 for the upper limit of Taq induced errors 
was found in a study of the foot-and-mouth disease virus (Najera eta!, 1995). 
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Using the method adopted here, proviral genomes are isolated by molecular limit 
dilution. They are PCR-amplified and the bulk PCR product sequenced directly. 
Only errors occurring in the first round of amplification would be detectable, and then 
only as 25% of the product. 
3.2.4.2 Recombination 
Recombination during PCR, mimicking that occurring in-vitro, can also be 
responsible for variation. Such recombination has been shown to occur when two 
different RNA genomes are packaged in the virion (Robertson et a!, 1995; Zhu et al, 
1995). It has also been shown to occur in-vitro during PCR (Meyerhans eta!, 1990). 
This process is thought to be a consequence of premature termination of Taq during 
one cycle, with a switch to another heterologous template on initiation of a 
subsequent cycle. The rate of recombinants has been shown to be as high as 1 in 5 
after 25 cycles of a 300 base pair fragment of the tat gene of HIV-1 (Meyerhans, as 
above). This problem can also be overcome by applying the limit dilution nested PCR 
method. As amplification is performed on one single proviral copy of DNA, the 
production of false recombinants is minimised. While such strand transfers and 
recombinations may still take place, with a homogeneous sequence population, this 
will have no effect on the end sequence obtained. 
In 36 samples sequenced only 1 inactivating mutation was found. The frameshift 
observed in this patient was caused by a single nucleotide deletion leading to a 
defective sequence, and for reasons given above, was probably a reflection of a 
defective proviral sequence rather than an experimental artefact. As can be seen in 
this study, single molecule analysis produced almost indistinguishable sequences, so 
although it cannot be excluded that Taq may have produced some errors, it does not 
seem likely that it biased the results of this study. 
3.2.5 p0! Gene mutation frequencies 
The fact that HIV- 1 exists as a quasispecies illustrates the ability of this virus for rapid 
genetic and antigenic diversification, indicated by the levels of heterogeneity observed 
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within the individual. This is an obvious concern and obstacle for treatment, as has 
been shown by the selection of resistant variants of HIV-1 to antiretroviral agents 
such as ZDV. The frequency at which RT resistant variants arise is a consequence of 
several factors, including the error prone RT enzyme, the viral load, and also the 
mutation frequencies in the poi gene. 
Several studies have shown that this mutation frequency for pol is relatively high, and 
as such this explains the presence of mutations related to antiretroviral drugs, without 
the selective pressure that would increase the mutation frequency, of the drug. 
3.2.5.1 Antiretroviral Naive Population 
The mutation frequency was calculated for each sequence obtained for the patients 
detailed in Table 3.2, relative to FHV-I1A1 clone HXB2. Any common variant shared 
by the majority of sequences that differs from the consensus was eliminated from the 
calculation. A total of 36 sequences from amino acid codon 137 through to 229 were 
obtained, with a total of 9765 nucleotides analysed. The results showed a range of 
mutation frequencies from 3.5 x 10 to 3.9 x 102  substitutions per nucleotide. The 
average value was 2.2 x 102,  which was very similar to the Naj era study (1995) 
where a value of 2.5 x 102  was obtained: the Najera study looked at a smaller region, 
from codon 181 to 219. 
When looking specifically at the codons related to drug resistance a mutation 
frequency of similar value was obtained. Including the codons 151, 181, 184, 188, 
215, and 219, a frequency of 2.0 x 102  substitutions per nucleotide was obtained. 
Najera (1995), who included all the codons above except the 151 codon, found a 
frequency of 1.1 x 102. 
When looking at the quasispecies through analysis of single molecules obtained by 
limit dilution PCR a mutation frequency of 1.4 x 10.2  substitutions per nucleotide was 
obtained: from patient 1390 time point 1 using the time point 1 direct sequence as the 
consensus for comparison with a total of 10,927 nucleotides sequenced between 
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codon 27and 240. Codons 41, 67, 70, 215 and 219 were omitted from the analysis as 
the majority had mutations at codons 41 and 215. 
3.2.5.2 Antiretroviral Experienced 
A group of 11 patients were chosen (see Table 3.6) and sequenced from codon 35 to 
codon 199 of the reverse transcriptase region (see Appendix 11-5). Treatment times 
range from 14 days to 1 year. No ZDV associated mutations were observed in this 
study group within the region defined. 
TABLE 3.6 
Zidovudine Experienced Study Group 
SAMPLE SEROCON VERSION SAMPLE DRUG THERAPY 
DATE 	 DATE 	 START 
DATE 
1064 1990 20.05.93 ZDV 23.04.93 
1086 1990 03.08.93 ZDV 15.10.91 
1118 1991 03.11.93 ZDV 01.07.93 
1121 1990 08.11.93 ZDV 11.03.93 
1153 1985 19.01.94 ZDV 
1271 1990 23.02.94 ZDV 09.02.94 
1364 NEG. 29.04.94 
1371 1992 01.06.94 ZDV 09.12.93 
1447 1989? 02.08.94 
1523 1990 27.10.94 ZDV 
1538 1993 ZDV 07.93 
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A total of 3340 nucleotides from 11 sequences were analysed. Mutation frequencies 
ranged from 1.3 x 102  to 4.6 x 102,  with an average of 2.6 x 102,  very similar to that 
observed in the untreated group. Interestingly the mutation frequency at codons 
related to resistance was lower than that of the untreated group, with a value of 
1.4 x 102,  although this was not the same region. In the Najera study (1995) values 
of 2.9 and 0.8 x 102  were obtained for the regions 41 to 108 and 181 to 219 
respectively. Again the region analysed in this study group was much larger, the 
analysis also included a much larger set of resistance associated positions (41, 60, 62, 
65, 67, 69, 70, 74, 75, 77, 89, 98, 103, 106, 108, 1116, 151, 181, 184). Using the 
same group of codons as the Najera study a value of 1.9 x 102  was obtained (41, 60, 
65, 67, 70, 75, 89, 98, 103, 108). 
Looking within the quasispecies of an experienced patient, 1037 (see section 3.2.1.4), 
a similar value to that of the untreated group was seen with a frequency of 1.9 x 10 -2  
substitutions per nucleotide: a total of 4239 nucleotides from codons 26 to 228 was 
looked at, similar to the range looked at in the untreated group. 
3.3 Summary of Results 
3.3.1 Sequence analysis 
From the 35 antiretroviral naive HIV-1 patients sequenced, two individuals showed 
the presence of variation at codons in the RT associated with resistance to ZDV. The 
variation at codon 41, methionine-leucine (ATG-)-CTG/ITG), is a documented 
mutation associated with the use of ZDV. Both patients, however, had a previously 
undocumented change at codon 215, threonine-aspartic acid (ACC-+C), a 
change that has neither been associated with ZDV use or observed in naive patients. 
Further analysis of the proviral DNA population through direct sequencing of single 
molecules identified other isolates with variation at codon 215: patient 1390 also had 
an asparagine (AAC), and cysteine (IC). In patient 1514 this analysis showed the 
presence of a documented ZDV associated mutation, tyrosine, at codon 215. 
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3.3.2 Sampling time 
These samples were obtained up to 2 years after the estimated seroconversion dates: 
1390 seroconversion date 08.92, sample date 06.94, 1514 seroconversion date 08.93, 
sample date 10.94 (these seroconversion dates were estimated using the last 
negative/first positive HIV-1 dates and clinical information, seroconversion illness and 
patient-volunteered information respectively). Further samples obtained in 1996 for 
both patients showed similar results, and indicated that these variants containing the 
variation at codon 215 (and codon 41), had persisted in the drug free environment of 
these individuals for up to 4 years post-seroconversion. Follow up information from 
clinicians confirmed that neither had been prescribed any antiretroviral therapy. 
3.3.3 Mutation frequencies in reverse transcriptase 
Najera eta! (1995) proposed from their studies that if the mutation frequencies 
calculated for resistance-associated codons are comparable to the overall frequency, 
then it is statistically likely that a mutation will occur at this position, just as easily as 
it would occur at any other non-resistance associated site. They justify this statement 
from the data that showed similar numbers of substitutions occurred at positions not 
related to resistance, when compared to those positions linked to drug resistance, 
therefore supporting the theory that resistance is a result of random substitutions in 
the absence of any selective pressure from the drug. And unless these changes lead to 
a profound fitness loss, resistant variants of HIV-1 will arise at a high probability, 
given the high mutation frequency and the levels of virus (population numbers) during 
disease progression. 
The average mutation frequency obtained from the antiretroviral naive study group 
from the Naj era study was 2.5 x 102,  based on 60 sequences. From the study group 
detailed in this chapter (35 sequences), a similar value of 2.2 x 102  was obtained. 
When looking at 6 resistance-associated positions (151, 181, 184, 188, 215, and 219), 
then a similar value of 2.0 x 102  was observed, suggesting a comparable chance of 
acquiring mutations to that of non-resistance associated positions. A similar mutation 
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frequency was also obtained when looking at a group of antiretroviral experienced 
patients, although sequencing did not identify mutations in this study group. 
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4 	Production of Recombinant Infectious Virus 
4.1 Introduction 
The development of drugs for use against human pathogens such as viruses involved 
testing in in-vitro assays that best mimic the natural environment. With the appearance 
of drug resistance in F1TV-1 , and its decreased sensitivity to ZDV, susceptibility 
assays that were quick and efficient at showing the sensitivity patterns of patient viral 
isolates against these drugs were required. Assays had been developed for the rapid 
determination of patient genotypes with respect to the presence of mutations. 
However, the viral sensitivity phenotypes of these viral genotypes had to be 
determined, particularly with respect to the use of a drug such as ZDV where 
combinations of mutations may be present. 
The focal immunoassay (Chesebro and Wehrly, 1988) was developed to quantitate 
HIV-1 using the adherent human HeLa cell line expressing the HIV receptor molecule 
CD4. The assay involved titration of virus in the cell line, with subsequent cellular 
staining carried out with antibodies directed against HIV-1, which allowed the foci of 
virus infection to be visualised (see Chapter 5). The virus could be quantitated by this 
technique by applying an end point dilution method. By adapting this method to 
incorporate the drug ZDV in a range of dilutions the sensitivities of viral strains could 
be reproducibly determined (Larder et al, 1989b). The problem of such assay systems 
was the culture selection placed on viral isolates during the procedure, especially in 
the case of ZDV resistance, which has been shown to be affected by culture condition. 
In addition to these in-vitro selection problems certain primary isolates, especially 
those showing the non-syncytia inducing, (NSI) phenotype, were not readily cultured. 
Other assays were also developed such as the peripheral blood lymphocyte virus yield 
reduction assay (Japour et al, 1993), but this is subject to many of the sample 
problems with selection of particular viral subgroups in the course of the experiment 
which have been shown to affect the sensitivity patterns. 
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4.1.1 Recombinant viral assay 
The recombinant viral assay (RVA) was developed therefore to try overcome these 
selective pressures produced by culturing required for previous assay systems, by 
producing a recombinant viral clone where the only variation is in the reverse 
transcriptase region of the poi gene (Kellam and Larder, 1994). The selective effect 
from different HIV- 1 gene products is therefore eliminated. These recombinants are 
produced by a process of homologous recombination within a cell system between a 
non-infectious clone bearing a deletion in the reverse transcriptase and a reverse 
transcriptase coding sequence obtained from proviral DNA by PCR from patient 
peripheral blood lymphocytes. The sensitivity of these recombinants to drugs and 
other phenotypic assays, could then be reproducibly performed. 
4.1.2 Homologous recombination 
The recombining of two DNA forms has been shown in many biological systems. 
Homologous recombination,, recombination between two regions of similarity, can be 
routinely induced between cellular DNAs and exogenous DNA sequences (De Saint 
Vincent eta!, 1983; Pomerantz eta!, 1983; Bandyopadhyay eta!, 1984; Lopez eta!, 
1992). de Saint Vincent eta! (1983) studied Chinese hamster cells with deletions in 
the CAD gene (multifunctional enzyme that catalyses the first 3 steps of uridine 
biosynthesis, containing arbamoyl-phosphate synthetase, aspartate 
carbamoyltransferase, and ihydro-orotase activities), therefore requiring exogenous 
uridine for normal growth. By transfecting plasmid DNA containing wild-type CAD 
genes, recombination occurred to rescue the wild-type genotype of the cells. These 
and other experiments showed that no other substrates were required to be added and 
hence the cell contained all the machinery required for recombination to occur 
successfully. 
Pomerantz eta! (1983) showed that this recombination could also occur between two 
DNA molecules introduced into the cell, by introducing two recombinant 
polyomavirus (a small double stranded tumour virus) plasmids, each with a different 
deletion within the T antigen protein gene responsible for transformation of the cell. 
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Transformation of the cell could be achieved, but only when the two plasmids were 
introduced together. Transfection of one or other was unsuccessful, as the presence 
of the two were required for recombination to take place, and rescue of the wild type 
genotype. 
The efficiencies of these recombinations were linked to the homologous regions 
(Lopez et al, 1992) between the two DNA species, where length of the insert DNA 
has also been shown to be an associated factor. The efficiency of recombination is 
increased when the areas flanking the break have increased lengths of homology 
(Bandyopadhyay et al, 1984), and as the insert size increases, the efficiency of 
recombination increases in a linear manner with the increased size of homologous 
regions. The quantity of DNA has also been shown to be important and it has been 
discussed that a threshold of input exogenous DNA could render it more attractive for 
recombination events than host cell DNA. Recombination may also favour the 
staggered ends of input DNA, such as those produced by restriction endonucleases, 
which may be sites that initiate recombination. 
4.2 Results 
4.2.1 Production of recombinant virus 
In this chapter the production of recombinant virus containing patient reverse 
transcriptase coding regions is described (RVA). The aim of the experiment was to 
take RI coding sequence from patients that had mutations at codon 215, 
GAT/C/AAC, and attempt to produce infectious virus through recombination in a 
continuous I-cell line with the non-infectious RT-deleted clone, as detailed by Kellam 
and Larder (1994). The recombinant clones produced would then be used in 
phenotypic assays, to determine the importance of the aspartic acid residue at codon 
215 with regard to ZDV therapy. 
From the sequence data obtained, discussed in Chapter 3, several samples were 
chosen to use in the RVA. The nucleotide sequences at codon 215 were GAC (D), 
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MAC (Y), and AAC (N). Single molecules of DNA containing these genotypes were 
obtained by limit dilution PCR reactions carried out on proviral DNA (see sections 
2.6.1). 
4.2.1.1 Control Isolate 
The non-infectious isolate of lilY-i pHXB2-MCS-&ENV (prepared by Dr S. 
Ashelford, Centre for HIV Research, Edinburgh), contains proviral HXB2 sequences 
with a portion of the env gene deleted (from now on this clone will be referred to as 
ENV, see Figure 4. 1, or MCS, referring to the infectious clone before deletion of 
env). DNA was used as the pol wild type positive control throughout the transfection 
experiments. LENV DNA was obtained from Dr R. Walker and E. Harvey, Centre for 
HIV Research (Edinburgh), and was used to obtain RT fragments through PCR, to 
test the RVA procedure. 
4.2.1.2 Optimising PCR conditions 
- The PCR reagents 
The PCR reagents, primers and cycle temperatures used were as developed by Kellam 
and Larder (1994). Routine PCR analysis of the RT region in this laboratory 
amplified a fragment of 1.4kb and a secondary fragment of 622 base pairs in length 
from the nested PCR amplification, using primers of approximately 21 bases in length. 
The RVA PCR amplified a region larger than standard PCR described, with a length 
of 1.7kb for the primary reaction and 1.6kb fragment for the secondary using primers 
that are approximately 33 bases long. Although both reactions used essentially the 
same basic reactants (MgC1 2, KC1, Tris-HC1 (pH8.0), dNTP, and Taq DNA 
polymerase), the RVA protocol suggested the addition of glycerol, bovine serum 
albumin, and Herring sperm DNA, to aid in the extension of the larger fragments. By 
carrying out several experimental runs (data not shown), the inclusion of BSA, and or 
Herring sperm DNA did not increase the efficiency or quality of the DNA obtained, 
although glycerol was used in all subsequent reactions. 
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FIGURE 4.1 
Proviral Clone pIIXB2-MCSAenv 
Diagrammatic representation of the non-infectious clone pHXB2-MCS1env, constructed by Dr. S. Ashelford (Centre for HIV 
Research),which has a 428 base pair deletion in the env gene. Co-ordinates given for the deletion (5952, and 6380) correspond to nucleotide 
positions in HXB2R 
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- Cycling temperatures 
Cycling temperatures for the RVA were slightly different from those used for routine 
PCR. The reaction conditions investigated initially were as follows: a hot start at 
95°C for 3 minutes before addition of Taq DNA polymerase was implemented, with 
30 cycles at 90°C/i minute, 55°C/30 seconds, and 72°C for 2 minutes, followed by a 
final extension step at 72°C for 7 minutes. However, results obtained following this 
reaction protocol produced poor DNA with smears on ethidium bromide stained 
agarose gels, and omitting the hot start did not alter these findings. By carrying out a 
series of reactions changing various parameters of the reaction buffer and cycling 
temperatures/times (data not shown), optimum results were obtained using the same 
RVA reaction mixture (section 2.6.1), but with the routine cycling temperatures: 
95°C/25 seconds, 55°C/35 seconds, 68°C/ 180 seconds, for 30 cycles followed by a 
final extension at 68°C for 7 minutes. No hot starts were used. These tests were 
carried out on patient 1037 DNA (see section 3.2.1.4), and another patient 1364 (who 
had also undergone ZDV therapy), chosen from the MEP Repository, Edinburgh (see 
section 3.2.1.1), both had been successfully amplified in previous reactions. The RVA 
reaction mix with 'standard' PCR reaction temperatures was then used for all 
subsequent preparation of control and patient RT-PCR fragments. 
- DNA clean-up 
Full length RT-PCR products were extracted with chloroform to remove overlay 
paraffin and purified with the Geneclean II Kit (BlO 101) using Glassmilk. The DNA 
quantity obtained was calculated by gel electrophoresis against AHindIll markers of 
known quantity and/or using UV spectrophotometty. DNA values of approximately 
3tg, estimated by UV spectrophotometiy, could be obtained after nested PCR. DNA 
was stored in DEPC distilled water at -20°C for subsequent transfection reactions. 
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4.2.2 Reverse transcriptase deleted clone 
4.2.2.1 Construction of the ART clone pfflViRTBstEll 
This non-infectious clone was constructed by site-directed mutagenesis, where 1446 
nucleotides of the reverse transcriptase coding region from the HXB2-D proviral 
sequence were deleted from the pIBI20HIV parental clone (Larder et al. 1989b; 
Kellam and Larder, 1994)(see Figure 4.2). A unique restriction enzyme site was also 
introduced, BstEll, at the deletion junction by mutating codon 41 from ATG to GTG, 
and mutating codon 483 from GAG to GAç (see Figure 4.3, the mutated nucleotides 
are highlighted in blue type). Any recombinant virus produced must reconstitute 
codon 41, and therefore maintain any resistance genotype (Kellam and Larder, 1994). 
4.2.2.2 Preparation of ART 
This non-infectious RT deleted clone, pHIVRTBstEll (ART) was obtained from the 
MRC AIDS Directed Programme Reagent Project 231, and produced by Dr. B. 
Larder and Dr. P. Kellam. Large scale preparations of the clone were carried out by 
transformation in the E.coli JM109 cells and extraction by the QIAGEN plasmid 
extraction protocol, as discussed below. DNA was linearised by restriction enzyme 
BstEll which cuts in only one position, and then cleaned for use in transfections by 
phenol-chloroform extraction and ethanol precipitation. DNA was stored in DEPC 
distilled water at -20'C. 
- Transformation efficiency 
Transformation of JM109 was carried out by a heat shock method, using 50j.il of cells 
and 21.11  of ART clone. 500111 of Luna Broth (LB) media was added and after 45-60 
minutes 50 and 1001.11  volumes were plated out on LB agar and incubated at 37°C for 
24 hours. No colonies were observed on these plates after 48 hours. The experiment 
was repeated with 3111  of ART with 10111 of JM109 cells, plating out 100 and 200111 
volumes after incubation. Again no colonies appeared. Using test DNA pUC18 and 
an in-house DNA control (pSRH-L) that were known to work in similar 
transformation experiments, the procedure was repeated. This time 100111 of cells 
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FIGURE 4.2 
pHIVEiRTBsIEII Non-infectious Clone 
The diagram shows the parental clone (A), and the ART clone (B), produced after 
deletion of 1446 nucleotides from the reverse transcriptase region ofpol. 
(Kellam et al, 1994) 
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Construction of pHI VARTBsIEII Clone 
A diagrammatic representation of the construction of the ART clone, in which the nucleotide sequence at the deletion junction of RT is 
shown and the mutated bases are highlighted in blue 
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treated with 13-mercaptoethanol, and incubated on ice for 10 minutes prior to adding 
the DNA. 1-21.11 of test DNA was used. Both 50 and 1001.tl volumes were plated out 
and incubated overnight. As can be seen in the table below, the efficiency of this 
system was poor. 
TABLE 4.1 
Transformation Efficiencies in E.coli JM109 Cells 
DNA 	Plated volume 	Colony No. 	Expected 	Efficiency 
(ILl) colony No. cfu/p.g pUC18 
DNA 
pUC18 	50 52 833 6x106 
100 79 1660 4.7x 106 
pSRH-L 	50 >100 N/A N/A 
100 >100 
A repeat transformation was attempted with 50p1 JM109 cells with 0.4I11 of 13-
mercaptoethanol, with 11.11  pUC18,  11.11  ART, and 5 1.11  ART (0.44ng/pi). Two 
volumes, 50 and 1001.11 were plated out overnight. From this transformation there 
were 14 colonies for the control DNA, but only 1 colony for ART. This shows an 
efficiency of 1 x 10 5, which could be accounted for by the size of the ART when 
compared to pUC18, at 14kb and 3 k respectively, although the efficiency with the 
control DNA was still lower than expected. 
The colony was picked and used to infect a small volume of LB which was incubated 
overnight in a shaking 37°C incubator. DNA was extracted from a fraction of the 
culture and checked on an ethidium bromide stained gel. When cut with the BsEII 
restriction enzyme the linear ART represents a 14kb fragment. A bulk culture was 
then prepared by inoculating 1 litre of LB for 24 hours. DNA was then extracted 
from 500m1 of this culture using the QIAGEN mega plasmid purification protocol. 
The DNA produced from this extraction was quantified using UV spectrophotometry 
(approximately 300 j.tg of ART DNA was obtained). 
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4.2.3 Transfection of continuous T-cell lines 
4.2.3.1 Comparison between Lipofectin and Dosper transfection protocols 
The first transfection protocols to be undertaken were using the non-adherent C8166 
cell line. Two protocols were compared, the Dosper protocol that uses a polycationic 
liposomal reagent, and the Lipofectin protocol that uses a formulation of the cationic 
lipid DOTMA with DOPE (see sections 2.6.5.2 and 2.6.5.3 respectively). 1041 of 
MCS DNA was used in all transfection reactions as a positive control. ART was used 
as the negative control. The transfection reactions were monitored visually for the 
appearance of syncytia and also by KC57 staining and p24Ag ELISA (see sections 
2.6.5.6 and 2.6.5.7 respectively), every two to three days. 
The first transfection reaction was carried out using the control samples only, i.e. 
MCS and ART, and was performed with both the Dosper and Lipofectin transfection 
protocols in parallel. In these reactions the buffer solution Optimem®  1 reduced 
serum medium, was used in both protocols; HEPES is the buffer normally used with 
the Dosper reactions. 
Syncytia appeared first within the MCS Lipofectin samples, by day 10. KC57 
staining, which detects the presence of the gag proteins, showed that the proportion 
of infected cells was 9.5% with Lipofectin, with 4.2% cells infected within the Dosper 
sample on day 10, rising to 51% and 10.3% respectively, by day 16 of the transfection 
(this value is calculated by dividing the number of positive cells by the total number of 
cells counted). These values were comparable with the p24Ag ELISA results 
showing Sng/ml in the Lipofectin sample, and lng/ml in the Dosper sample, rising to 
125ng/ml and 71ng/ml respectively, by day 16 of the transfection. 
A transfection reaction was then carried out with the deleted clone, ART together 
with AENY PCR amplified RT fragments: for this experiment a ratio lOp.g of ART 
with 5ig of AENV RT-PCR fragment was used. 
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There were no positive cells by day two, by either KC57 staining or visually by the 
appearance of syncytia. By day 4 syncytia were present in the Lipofectin reactions 
with the ART + AENV RT-PCR and in the MCS positive control. On day 7, 
supernatant was removed for testing in the p24 Ag ELISA (see Table 4.2), which 
confirmed that indeed there was viable I{IV-1 within the Lipofectin samples. There 
also appeared to be viable virus within the Dosper sample at a comparable level, but 
nothing within the MCS positive control sample. 
TABLE 4.2 
Transfection of Non-adherent T-cell Line C8166 
Sample 	Transfection 	Syncytia 	p24 Ag (nglml) 
Protocol 	 Day 4 Day 7 
ART + RT-PCR DOSPER 	 - 0.892 
MCS DOSPER 	 - - 
ART DOSPER 	 - - 
ART + RT-PCR LIPOFECT1N 	 + 0.831 
MCS LIPOFECTIN 	 + 1.285 
C8166 LIPOFECT1N 	 - - 
The KC57 staining also showed the presence of p24Ag, indicative of viable 
recombinant virus, although there was only one positive cell within the Lipofectin 
ART + AENV RT-PCR, and five within the MCS Lipofectin sample by day 7. No 
other cells stained positive, even when the Dosper produced a positive p24Ag result. 
Although the results above were from a timepoint early in infection, these 
observations, along with the previous experiments led to the decision to use the 
Lipofectin protocol for all subsequent transfection procedures. 
4.2.3.2 Comparison between transfection of adherent and non-adherent cell 
lines 
Although possible to produce recombinant virus within non-adherent cells, it was 
thought that the transfection may have greater success using an adherent cell line as 
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the initial route of infection. COS-1 cells were chosen, which, being a monkey cell 
line, do not express the CD4 cell receptor. Once the recombinant virus is produced 
and shed from these cells it will not re-infect adjacent cells, but remain within the 
culture supernatant. These cultures could then be overlaid with a suitable non-
adherent human cell line, such as the C8166, which is amenable to infection by HIV- 1 
and the recombinant virus (as detailed previously). 
The ratio of ART clone and the PCR fragments is also an important factor to the 
success of these transfection reactions. The PCR reaction and clean up steps were the 
limiting factor as to the quantity of the PCR fragments available for use in such 
transfections. In this experiment two ratios of patient derived RT fragments were 
used in the Lipofectin protocol: 1g or 5p.g RT-PCR with lOp.g of ART. 
Transfected COS-1 cells were incubated for approximately 6 hours in a concentrated 
volume of imi (6 well plates), to allow for uptake of the DNA. After 24 hours, 
C8166 cells were added and the incubation continued for 48 hours. After this time 
the C8166 cells were transferred to a fresh flask and the incubation continued and 
monitored. The COS-1 cells would be frozen as a source of recombinant virus, and 
during this process some cells would be used for KC57 staining. This experiment was 
carried out in parallel with C8166 cells alone, that is without the initial COS-1 cell 
step. 
Three patient samples were tested as detailed above, 1390 samples 1 and 2 
(corresponding to sampling timepoints 1 and 2 respectively), and 1514 sample 1 
(corresponding to the first timepoint sampled). The results of this experiment 
followed by p24Ag ELISA showed that transfection of COS-1 cells followed by co-
infection with the T-cell line C8166 gave positive results within 24 hours of infection 
with the MCS positive control, and within 48 hours of co-infection with C8166 cells 
in the ART + RT-PCR samples (see Figure 4.4). 
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Figure 4.4 
Production of Infectious HIV-1 Recombinant Virus Monitored by 
p24Ag Production 
The tables show the production of p24Ag after transfection of either the non-adherent 
(A) or adherent (B) cell lines with the ART-deleted clone and patient RT-PCR 
fragments. MCS is the positive control, and ART, the non-infectious clone, is the 
negative control. 
Sample Name, 
1 	1390, timepoint 1 
2 	1390, timepoint 2 
3 	1514, timepoint 1 
Ratio, #: 
1:10 A ratio of 1tg RT-PCR to l0jtg of ART DNA 
5:10 A ratio of 5 j.tg RT-PCR to 1 0jtg of ART DNA 
Opposite page numbers 151 and 152 
Transfection of C8166 Non-adherent T-cell Line 
SAMPLE p24Ag(nm1)  
Name* 	Ratio # 	DAY 1 DAY 3 	DAY 6 	DAY 10 
1 (1:10) - - - - 
1 	(5:10) 	- - 	 - 	 - 
2 (1:10) - - - - 
2 	(5:10) 	- - 	 1.8 	 17 
3 (1:10) - - - - 
3 	(5:10) 	- - 	 - 	 - 
ART / - - - - 
MCS 	/ 	 - 1.2 	 25 	 80 










Day 1 Day 	 Day  






Day 10 	RT 
----MCS 
W 
Transfection of Adherent COS-1 Cells Followed by Co-infection with C8166 
SAMPLE _p24Ag(ng/ml)_______________ 
Name* Ratio # 	DAY 1 DAY 3 	DAY 6 DAY 10 
1 (1:10) - 0.8 5 14 
1 (5:10) 	- 1.3 	 12 29 
2 (1:10) - 2.2 14 48 
2 (5:10) 	- 2.1 	 48 189 
3 (1:10) - 0.9 1.8 ND 
3 (5:10) 	- - 	 2.5 5 
ART / - - 1.1 1.4 
MCS / 	 1.2 286 	242 363 

















Days Post Transfection 
—i---- MCS 
The ratio of input RT-PCR DNA also appeared to be significant. In the transfection 
of non-adherent cells, the only positive result, disregarding the positive control, was in 
the 51g: 10Lg mix (RT-PCR:6RT). In the co-infection procedure all the 5p.g: 1O.tg 
DNA ratio mixes always produced greater quantities of p24Ag when compared to the 
1g: 10j.Lg mixes. 
From these results it was therefore concluded that the initial transfection step should 
be performed using the adherent COS-1 cell line followed by the addition of C8166 
cells. KC57 staining performed on COS-1 cells after 24 hours of infection showed 
approximately 45% of cells with positive staining when the MCS positive control was 
used, but only 5% when the ART clone was transfected with RT-PCR fragments 
(again calculated using the total number of infected cells and total cell count obtained 
by microscopy). It is clear from these results that the production of viable virus is 
possible through this RVA as indicated by the detection of core antigens in the KC57 
staining procedure and the p24Ag ELISA. 
4.2.4 Recovery and analysis of recombinant virus 
4.2.4.1 Cell culture of recombinant virus 
Eight RT-PCR samples were successfully transfected in the combined COS-1/C8 166 
Lipofectin protocol producing viable virus, as indicated by positive results in both 
p24Ag ELISA and KC57 staining, as well as the presence of syncytia. These 
corresponded to 2 samples from patient 1390, from the first timepoint (15.06.94), and 
3 from the second timepoint (09.05.96). Three samples were also obtained from the 
first timepoint of patient 1514(25.10. 94)(see Table 4.3). 
These recombinant viral isolates were maintained in culture with C8166 cells for 
approximately 30 days, to obtain a sufficiently high titre for subsequent phenotypic 
and genotypic analysis. This procedure was carried out by sub-culturing the ongoing 
viral culture from the transfection reaction in a ratio of 1:4 in complete media (CM, 
see section 2.6.5.1), with C8166 cells, every 3-4 days. After sufficient quantities of 
virus have been produced in the culture, monitored by the p24Ag ELISA, the 
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complete culture (30mls) was centrifuged and stored down in lml aliquots of cell 
culture supernatant, filtered to remove cells and cellular debris, at -70°C. The cells 
were also frozen down, and maintained in the gaseous phase of liquid nitrogen (see 
sections 2.1.2). The cell supernatant was used in titration experiments, also in C8166 
cells, to obtain the TCID 50 value (see section 2.6.5.8.2). The values obtained for the 
recombinant viral isolates are shown in Table 4.3 below. 
TABLE 4.3 
TCID50 Values for Recombinant Viral Isolates 
Viral Stock* 	TCID50Im1 
	
1390.1.1 	 8.0x 104 
1390.1.43 	 1.6x 105 
1390.2.8 	 5.3 x 10 
1390.2.11 	 1.6x 10 
1390.2.21 	 5.2 x 104 
1514.1.55 1.2x 10 
1514.1.57 4.3x104 
1514.1.67 2.8x104 
* The patient samples are labelled as MEP identification number, followed by 
timepoint number, followed by PCR molecule identification number. 
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4.2.4.2 Genotypic analysis of recombinant virus 
DNA for sequence analysis of the reverse transcriptase region of pol from the 
recombinant virus was obtained from the stored cell culture supernatant. After 
extraction of the RNA by a quick extraction protocol and cDNA synthesis (see 
section 2.6.6), the DNA was subjected to PCR for amplification of a 622 base pair 
fragment, tagged with a biotinylated primer, for sequencing using the ABI dye 
terminator Sequenase protocol (see section 2.4.4). 
As can be seen from Table 4.4, in all but one case, recombinant virus has the same 
sequence as the input PCR fragment at codon 215. In one case an unexpected 
genotype was observed. This is representative of the MCS genotype, as shown by the 
presence of the CTT sequence at codon 214 and, as in patient material, this codon is 
TTT. It is likely that the culturing process has selected for the wild type 215 codon, 
from H3B2 contamination of the sample at some point in the experiment. 
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TABLE 4.4 
Comparison of Genotypes with Virus Source 
Patient Sample Source * Genotype at 
codon 215 
1390.1.1 PBMC GAC 
RVA GAC 
13901.43 PBMC TAC 
RVA ACC 
1390.1.4 PBMC AAC 
RVA AAC 
1390.2.8 PBMC GAC 
RVA GAC 
1390.2.11 PBMC GAC 
RVA GAC 
1390.2.67 PBMC GAC 
RVA GAC 
1514.1.55 PBMC AAC 
RVA AAC 
1514.1.57 PBMC TAC 
RVA TAC 
1514.1.67 PBMC GAT 
RVA GAT 
* Denotes the source of genome, where the PBMC was the input DNA in the form of 
RT-PCR fragment, and RVA, the 'output' genome from the recombinant virus. 
4.2.4.3 Comparison of growth kinetics of recombinant virus 
Growth assays were carried out infecting 1 x 106  C8166 T-cell line with 1000 TCID 50 
of virus, obtained as detailed in section 4.2.4.1, carried out with the virus detailed in 
Table 4.5. The growth properties of the recombinant virus produced by the RVA 
were compared to the growth of the cell line adapted wild type HIV-1, MCS (HXB2 
provirus), in addition to the well documented ZDV-resistant viral clones 
(RTMN/CIF), and monitored by the production of p24Ag (as detailed section 
2.6.5.7), for a short period of 18 days. As can be seen from Figure 4.5, viral growth 
curves are similar for all the viral isolates grown. Although the experiment was only 
maintained for a short period of time, it seems that in this particular in vitro 
environment, the addition of the mutations in the RT region of poi does not have a 
detrimental effect on the kinetics of virus production. 
Patient 1514.55 (asparagine at codon 215 (AAC)), was of particular interest because 
of the difficulties observed when trying to culture the isolate in this laboratory 
(Edinburgh). After a prolonged time in culture a TCID 50 was obtained using the 
p24Ag ELISA to score positive and negative wells, as normal syncytia were not 
observed, either during the initial culturing or during the titration. Some ballooning of 
the cells was apparent, but syncytia typically observed in infected cultures were never 
seen. The presence of HIV-1 in this culture was confirmed by both KC57 gag staining 
and p24Ag ELISA. Interestingly, culture of this isolate in the MT2 T-cell line was 
unsuccessful (Sara Albanil (IJCSD, USA), see section 5.2.2.2). 
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TABLE 4.5 
Nomenclature of Viral Isolates Grown in C8166 Cell Line And the Amino Acid 
Present at ZDV-Resistance Associated Codons 
Viral Isolate Amino Acid 
41 	215 
MCS* M 	T 
RTMC* L 	F 
RTMF* M 	Y 
RTMN* L 	Y 
LD 1390.1.1 L 	D 
LY 1390.1.43 L 	Y 
MD 1390.2 M 	D 
IN 1514.1 L 	N 
57.LY 1514.1.57 L 	Y 
21.LD 1390.2.21 L 	D 
11.MD 1390.2.11 M 	D 
67.LD 1514.1.67 L 	D 
*For  full listing of sequences at the five ZDV resistance-associated positions for the 




















Days post infection 
The recombinant virus produced by the RVA where grown in the T-cell line C8166 
and there growth monitored by the production of p24Ag via ELISA. In parallel, 
cultures of the wild type HIV-1 (MCS), and ZDV-resistant virus 
(HIVRTMC/MF/MN) where also followed. See Table 4.5 for legend. 
4.3 Summary of Results 
4.3.1 Production of recombinant virus 
Using the amplified RT fragments from the control AENV, several different 
approaches were tested to produce recombinant virus by transfection of this DNA 
with the ART deleted clone, pHIViRTBstEll. Using several methods for monitoring 
infection of continuous cell lines for HIV-1 infection (visually through syncytia 
production, p24Ag ELISA, and KC57 gag cellular staining), the most successful 
transfection method was obtained using the Lipofectin reagent with an initial 
transfection step in a CD4- cell line (COS-1), followed by addition of a CD4+ cell line 
(C8166). Viable 1-HV-1 virus produced within the COS-1 cells would be shed into the 
surrounding media, and because of the lack of the CD4 receptors, these cell lines 
could not be re-infected: the C8166 cells could readily be infected by progeny virions. 
Using the method detailed above, 8 recombinant viral isolates were obtained. These 
isolates contained the aspartic acid mutation at codon 215, either alone or linked with 
the leucine mutation at codon 41. Recombinants containing the threonine ZDV 
resistance-associated mutation, and the unusual asparagine, at codon 215 were also 
successfully produced. 
4.3.2 Sequence analysis of recombinant virus 
As can be seen from Table 4.4, in all but one case, recombinant virus has the same 
sequence as the input PCR fragment at codon 215. In one case an unexpected 
genotype was observed. This is representative of the wild type genotype (MCS), 
indicated by the presence of the CTT sequence at codon 214. In patient isolates this 
codon has the sequence TTT. It is likely that the culturing process has selected for 
the wild type 215 codon, from MCS (HXB2) contamination of the sample at some 
point in the experiment. 
This technique was successful in producing ITV-1 virus that behaves in a similar 
manner to the wild type viral isolates, and grows in continuous culture to titres 
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ranging from 10 to 10. Recombinant virus did not acquire substantial variation 
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5 	Zidovudine Sensitivity Assays 
5.1 Introduction 
5.1.1 Viral phenotypic assays 
With the increase in resistance to ZDV in clinical isolates of HIV- 1 it was necessary 
to develop rapid in vitro phenotypic assays to detect and monitor this reduced 
susceptibility. These assays were required because with the drug ZDV the resistance 
was caused by a complex combination of five distinct mutations, each exhibiting 
differing effects (Larder et a!, 1989b; Kellam et a!, 1992; Kellam et al, 1994). Such 
assay systems had been developed to identify the numerous compounds (Dc Clerq, 
1992) inhibiting the replication of HIV-1. 
The ability to detect virus was initially dependent upon visual effects on the host cells, 
such as syncytia (Rowe et al, 1970). Early assays carried out with the mouse 
leukaemia virus depended on such cytopathic effects, but not all viruses would 
produce this visible effect in monolayers of cells (Rowe eta!, 1970; Rapp eta!, 1975; 
Hopkins eta!, 1975). Immunological assays were then developed exploiting the viral 
antigens produced, and using detection systems such as peroxidase-coupled antibodies 
that would stain infected cells (Nexo, 1977). These plaque assays (where a plaque is 
defined as a focal point of infection) allowed infected cells to be detected visually by 
eye, or by low magnification microscopy. It was hoped that such assays would be 
adapted for use with any virus that was capable of culture in cell monolayers, and that 
had antibody available. 
Early culture and quantitation of primary isolates of HIV-1 were performed in 
phytohemagglutinin (PHA) or allogeneically stimulated human lymphocyte blast cell 
cultures (Barre-Sinoussi et a!, 1983), incorporating an endpoint dilution method to 
obtain ID50 values (infectious dose 50%). The use of immunologically-based plaque 
assays was not possible for HIV- 1 due the lack of a suitable adherent target cell line. 
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5.1.2 Focal immunoassay for detection and quantitation of IIIV-1 
Chesebro et a! (1988) developed a focal immunoassay (FIA) for detection and 
quantitation of HIV-1 isolates obtained from infected cells and cell-free HIV-1. The 
basis of the assay was the production of the adherent human HeLa cell line that 
expressed the CD4 receptor, required for HIV-1 infection of cells. This was achieved 
by infection of the cell line with a retrovirus vector that expressed CD4, and a clone, 
HT4-6C was found to produce the greatest amount of T4. These cells were now 
susceptible to HIV- 1 infection, and infected cells were detected by the use of HII\T- 1 
specific antibodies conjugated with either fluorescein or peroxidase, in a similar 
manner as to that used in the earliest plaque assays (Nexo, 1977). This FIA was 
highly reproducible and quantitative, detecting low frequencies of HIV-1 in 
lymphocytes, 1 infected cell in 106,  and was also efficient at detection of culture 
adapted laboratory strains. 
Larder et a! (1 989b) used the FIA to titrate clinical isolates of HIV- 1 that were 
obtained by cocultivation of patient peripheral blood lymphocytes with the continuous 
cell line, MT-2. By addition of known viral quantities, the TCID 50 could be obtained 
by titration, in the presence of various concentrations of ZDV, and the sensitivity of 
these isolates could be determined by the reduction in plaque numbers, where ID50 
values were obtained by plotting the percentage plaque reduction against the ZDV 
concentration. Visualisation of the plaques was obtained by fixing the cells with 
formaldehyde solutions followed by staining with crystal violet, showing the presence 
of the multinucleated giant cells (syncytia). 
5.1.3 Detection of ZDV resistance 
By comparing the IlI) o values obtained from antiretroviral naive and experienced 
patients, it was clear that those patients who had undergone therapy with ZDV for 6 
months had some reduction in sensitivity to the drug: mean ID 50 for a naive patient 
was 0.03 p.M ZDV, and for a patient on therapy for 6-11 months, 1p.M. 
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The above assay used HIV- 1 obtained by cocultivation in the MT-2 cell line. Virus 
was only isolated from approximately 30% of patients, and it was thought that this 
may not be representative of the whole population but instead be selecting for a 
smaller group of isolates suitable for growth in such MT-2 T-cell lines. Peripheral 
blood lymphocyte (PBL) assays were then developed in the hope that more clinical 
isolates would be obtained. Burke et al (1989, 1990) increased this isolation rate to 
85-90% using donor uninfected PBMCs. These new form assays would therefore 
allow isolation, cultivation, titration and susceptibility assays all to be carried out in 
the one cell type. 
In a study looking at patients (late stage) who had been on ZDV therapy for more 
than one year (Mayers eta!, 1992), this new PBL assay approach was used, with an 
isolation rate close to 100%. The susceptibility assays were performed in ninety six 
well microtitre plates in which mixtures of PHA stimulated donor PBMCs were mixed 
with either fresh patient PBMCs or 200 TCID 50 cell-free virus. Upon addition of 
ZDV, in a range of concentrations, the incubation was allowed to continue to an end 
point of approximately 10 days, when the assay read out was obtained by p24Ag 
ELISA on the culture supernatant. Comparable 1050 values were obtained when using 
either cell-free or cell-associated virus, and they were comparable to the values 
observed in the HeLa plaque reduction assay: 0.02p.M ZDV for naive and 1 .7p.M to 
6.6p.M after therapy with ZDV. 
Further adaptations to these PBL based culture assay were carried out, with each 
research group applying their own conditions and end point determinations (McLeod 
et a!, 1992). To standardise the results from different groups performing differing 
susceptibility assays, one particular protocol was established and tested by several 
laboratories within the USA (Japour et a!, 1993). The first step in this PBL assay was 
titration of virus, again with donor PBMCs, using an end point dilution method. The 
TCID50 was performed in sextuplet by serial four fold dilutions, again in a ninety six 
well microtitre plate, which were tested on day 7 by p24Ag ELISA. A scoring system 
was applied whereby a positive result was above a given threshold value of p24 
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antigen, and the TCID50 defined as the amount of virus stock at which 50% of the 
inoculated wells were positive, determined by the Spearman-Karber equation. 
The second stage, or the drug susceptibility assay, was performed by incubation of 
donor PHA-stimulated PBMCs with a given TCID 50 input viral inoculum in a conical 
tube. After the 1 hour incubation the cells were washed and resuspended in fresh 
media and seeded into a ninety six well plate. The ZDV was then added to the wells 
and the incubation continued until day 7, at which time a p24Ag ELISA was 
performed and the IC 50 values calculated using the median effect equation. In this 
assay the IC 50 values for ZDV-susceptible isolates (no therapy) was 0.002 to 0.113 
.tM and 0.15 to >5.Op.M for ZDV-resistant isolates. 
The disadvantages shared by such assays as those detailed is the in vitro culturing of 
cells to obtain HIV-1 isolates and material for testing. It has been shown that this 
passaging selects for subpopulations of variants in vitro from the heterogeneous 
population that exists in vivo (Meyerhans et a!, 1989; Richman et a!, 1991; Vartanian 
et a!, 1991; Kusumi eta!, 1992). It has also been shown that these PBL assays may 
not be able to distinguish subtler changes within the complex resistance patterns 
observed with ZDV (Mayers et a!, 1992) such as distinguishing between partially and 
highly resistant variants. 
Several assays are dependent on the ability of the isolate to exhibit the syncytium-
inducing phenotype (Larder et a!, 1989b), and this again limits testing to a smaller 
subset of variants. It has been shown that both SI and nonsyncytium-inducing (NSI) 
phenotypes exist together in vivo, therefore such in vitro culturing would eliminate 
these NSI variants, as SI variants outgrow them. Therefore these techniques only 
give a partial insight into the resistance pattern exhibited by a patient's viral 
quasispecies. Several assays were subsequently developed that eliminated the need 
for extensive cocultivation in donor PBMCs (Eron eta!, 1992; Mohri eta!, 1993). 
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To eliminate problems of selection in culturing experiments Kellam and Larder (1994) 
created a recombinant virus, by combining a common backbone from the proviral 
clone I-IX32 with patient reverse transcriptase (RT) coding regions obtained by PCR 
(see Chapter 4). This infectious virus would only differ in its RT region, and could 
therefore be tested in standard sensitivity assays without the selective effect imposed 
by other HIV-1 genes, particularly env. Using recombinant virus in the HeLa plaque 
assays gave comparable IC50 values to those obtained with clinical isolates, with 
<0.05RM ZDV for sensitive virus, and 0.05-1.ORM for partially resistant, and 
>1.OpM for highly resistant virus. 
Subtle differences in sensitivity values with recombinant virus were observed, which 
may be due to the chimeric nature of the recombinant virus. When the five resistance 
associated codons were present in the recombinant virus a level of resistance two fold 
lower than that observed in clinical isolates carrying the same mutations, and with the 
same genotype, was noted. 
The obvious advantage of this technique is the sensitivity testing of all HIV-1 isolates 
including those with the NSI phenotype, because no prior culturing is required, as the 
patient material is extracted as DNA directly from the PBMCs or plasma (as RNA). 
5.2 Results 
5.2.1 ZDV sensitivity assay in the C8166 T-cell line 
Recombinant virus was successfully produced from 2 patients, obtained from single 
molecules of DNA, as discussed in Chapters 3 and 4. The phenotype of these 
patients' RT regions was of particular interest due to the nature of the nucleotide 
sequence at resistance associated codon 215. The wild type genotype is ACC, with 
documented point mutations occurring at the second and third nucleotide positions to 
produce TAC, and TIC mutants. Sequence analysis of patients 1390 and 1514 
showed the codons 1A,C and GAT, respectively, at codon 215, coding for aspartic 
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acid. The phenotype of such a variant had not been documented at the time this study 
was undertaken. 
As the virus had been produced and maintained in the continuous T-cell line C8166 it 
was decided that the ZDV sensitivity assay would be carried out within this cell line. 
The assay is detailed in Chapter 2, section 2.7.5. In summary the assay was based on 
an end point dilution technique (Japour eta!, 1993; McLeod eta!, 1992; and Current 
Protocols in Immunology (In Vitro Evaluation of Experimental Agents for Anti-HIV 
Activity)). A known input of virus (TCID50) was incubated with cells, which where 
then washed and seeded into a microtitre plate, which was then overlaid with 
solutions of ZDV. The read out from the assay was by p24Ag ELISA of culture 
supernatants and also by KC57 staining of cells. The median effect equation (Chou 
and Talalay, 1984), and regression analysis within the Excel package, was used to 
obtain IC 50 values. 
5.2.1.1 Control samples 
The control samples RTMF, RTMC and RTMN, along with the wild type MCS 
(pHXB2-MCS prepared by Dr. S Ashelford, Centre for HIV Research, University of 
Edinburgh, see section 2.5.2.1), with known resistance levels, were used to establish 
the ZDV sensitivity assay (see Table 5.1). 
5.2.1.2 Zidovudine 
Zidovudine was obtained from the MRC AIDS Reagent Project (Dr H. C. Holmes). 
The lyophilised ZDV was reconstituted in 1X PBS to a 1mM stock stored at -20°C. 
5.2.1.3 Viral TCID50 input value 
The input viral quantity was decided by carrying out a series of experiments with the 
wild type isolate MCS, in a range of values from 50 to 500 TCID50s (tissue culture 
infectious dose 50%). The experiment was carried out in the presence of ZDV in the 
JIM amounts 0.001 to 5. The experiment was carried out as detailed in materials and 
methods (Chapter 2). Briefly the virus was incubated with C8166 cells in a 
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TABLE 5.1 
Summary of Data on ZDV Resistant Controls 
* Denotes the wild type control HXB2 and the wild type codons at the 5 ZDV resistance associated positions 
# Denotes the tissue culture infectious dose 50% from titration in the C8166 cell line. 
(Larder and Kemp, 1989; St. Clair eta!, 199 1) 
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Isolate 	 Mutations 	 Fold increase in resistance 	 TCID50/ml# 
(from wild type 1050) 
HXB2* 41M,67K,70K,215T,219K N/A 3.4x104 
RTMC 67N, 70R, 215F, 219Q 100 6.5 x 104 
RTMF 215Y 15-20 3.3x105 
RTMIN 41L, 215Y 60-70 5.0x 10 
concentrated volume for 1 hour, with subsequent washing and then seeding the cells 
in a ninety six well plate, followed by addition of the ZDV solution to give the final 
concentrations of 0, 0.001, 0.01, 0.1, 1, 5LM. On day 3-4, each well was mixed and 
half the culture was removed, and replaced with fresh ZDV containing media, and the 
incubation continued until day 7. At both timepoints the plate was scored visually for 
syncytia, and p24Ag ELISA was performed on the culture supernatant. From the 
results of these experiments it was decided that an input of 50 viral TCID 50s would be 
used. To test whether the assay would be able to distinguish between the wild type 
and resistant virus, experiments were carried out with the MCS wild type control and 
the resistant control RTMC: this control has a predicted resistance of 100-fold over 
the IC50 value for the HXB2 isolate as tested in the HeLa plaque reduction assay. By 
visual analysis of the two virus types, scoring the presence or absence of syncytia, it 
was clear that the resistant variant was able to grow in elevated concentrations of 
ZDV, whereas the wild type only grew on concentrations lower than 1l.LM  (see Table 
5.2 below, and Figure 5.1). 
TABLE 5.2 
Growth of HIV-1 Virus Isolates in the Presence of ZDV 
ZDV Concentration (pM) 
o 	0.001 0.01 	0.1 	1 	5 	10 	50 	100 
MCS 	+ 	+ 	+ 	+ 	- 	- 	- 	- 	- 
RTMC 	+ 	+ 	+ 	+ + + + + 	- 
+ 	+ 	+ 	+ 	+ + + 	+ 
+ 	+ 	+ 	+ + + + 	+ 
+, Syncytia present 
-, No syncytia observed 
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FIGURE 5.1 
Growth of HIV-1 Viral Isolates in the Presence of ZDV 
Shows the growth of the wild type control, MCS, and the recombinant viral isolates, 
LY, LD, and MD, in the presence of increasing concentrations of ZDV, where the '+' 
indicates the presence of syncytia, and '-' , no syncytia observed. 
LY, mutant L, leucine at codon 41, with the tyrosine mutant, Y at codon 215 
LD, mutant L, leucine at codon 41, and aspartic acid, D, at codon 215 
MD, wild type at codon 41, with the aspartic acid D, at codon 215 
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MCS ZI) V Con centration (pM) 
Day 	0 0.001 0.01 0.1 1 	5 	10 	50 	100 
4 + + + + - - - 
7 	+ + + + + 	+ 	- 
LY 	 ZDV Concentration (pM) 
Day 	0 0.001 0.01 0.1 	1 	5 	10 	50 	100 
4 + + + + - - - - 
7 	+ + + + 
LD ZD V Con centration (pM) 
Day 	0 	0.001 	0.01 	0.1 	1 	5 	10 	50 	100 
4 - - + + - - - 
- 	- 	+ 	- 	- 	- 	- 
7 	+ + + +  
MD 	 ZDV Concentration (ELM) 
Day 	0 	0.001 	0.01 	0.1 	1 	5 	10 	50 	100 
4 + + + - - - - - 
7 	+ 	+ 	+ 	+  
5.2.1.4 Inhibition of KC57 cellular staining of gag proteins 
The cells removed from the culture were centrifuged and the supernatant was 
transferred to a fresh microtitre plate for p24Ag ELISA. The cells were washed twice 
with 1X PBS, then stained for the presence of the gag proteins (see Figure 5.2). The 
cells were then observed by UV microscopy and counted. The numbers of positive 
cells was given as a percentage of the total numbers of cells counted: an average of 
500-800 cells was counted in total (see Table 5.3). 
Table 5.3 shows a decrease in the number of positive cells as the concentration of 
ZDV is increased, in all viral isolates tested. To obtain the actual IC 50 value using this 
data the median effect equation (Chou and Talalay, 1984) was applied (see below). 
Log (fa/fu) = mLog (Drug concentration) - mLog (1050) 
fa, Is the fraction affected, and fu, the fraction unaffected by drug. By calculating the 
Log (fa/fu), and Log (Drug concentration), linear regression can be used to solve y 
and x, where y = Log (fa/fu), and x = Log (Drug concentration). From the 
regression analysis (Microsoft Excel), the values for the intercept, -mLog (IC), and 
the x variable, -m, can be obtained, and inserted into the equation below, to obtain the 
infectious concentration 50%. 
Log (1050) = intercept 
-m 
Using this analysis on the KC57 cell staining results gave IC 50 values of 1.63 for 
MCS, 4.3 for RTMC, 1.918 for RTh4F, and 0.37 for RTMN. Similar experiments 
(data not shown) gave results of 4.6 for MCS, 1.072 for RTMC, 4.7 for RTMF, and 
0.6 for RTMN. These results are not comparable with any other IC50 values obtained 




KC57 gag Cellular Staining of a T-cell Line 
The photographs show the cellular staining of the C8166 cell line with fluorescent 
conjugated antibody KC57-FITC, directed against HIV-1 gag 55, 39, 33 (precursors) 
and 24kD core proteins. 
A KC57 gag staining of uninfected C8166 cells 
B KC57 gag staining of recombinant HIV-1 infected C8166 cells 
Opposite page number 175 
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TABLE 5.3 
Percentage HIV-1 Positive Cells by gag Staining In The Presence of 
Increasing Concentrations of ZDV 
Virus ZDV concentration (IIM) % Positive cells 
























5.2.1.5 Inhibition of viral p24 gag protein production 
A p24Ag ELISA was carried out on the cell culture supernatants from the ZDV 
sensitivity assay, as detailed earlier in the chapter. On days 3-4 of the assay each well 
was mixed by pipetting, and half the culture removed (see section 2.7 and 5.2.1.3). 
This removed culture was subjected to centrifugation, after which time the 
supernatant was transferred to a fresh 96 well plate (the cells were used for KC57 gag 
staining as detailed in section 2.6.5.6). This procedure was repeated on day 7. 10-
fold serial dilutions in empigen detergent were then performed on these supernatants 
to inactivate the virus (as detailed in section 2.6.5.7). If p24Ag ELISA was not 
performed immediately, then the samples were frozen at -20'C, and tested within 14 
days of freezing. 
From several experiments carried out on the control isolates (HXB2, RTMNIF/C, see 
Table 5. 1), it became clear that the results obtained did not show the expected trends 
of a decrease in p24Ag production with increasing ZDV concentration in the wild 
type isolate, or indeed higher p24Ag production in the ZDV-resistant control isolates, 
such as RTMC, which should show a 100-fold increase in resistance above the wild 
type (see Table 5.1). 
The viral input, which gave the best test results when following syncytia formation 
(50 TCI1)50), may not have been sufficient in this assay format to produce enough 
p24Ag to show the differences between ZDV concentrations within the time scale 
followed. Increasing the viral input TCID 50 value was carried out to test if the 
sensitivity of the assay could be increased, but this was difficult in the 96 well plate 
format, where increasing the input virus quantity leads to rapid destruction of the 
cells. Attempts to lower the standard curve for detection of subtler differences 
between wells, and therefore ZDV concentrations, still did not enable reproducible 
results with expected differences, such as those predicted through other drug 
sensitivity assays discussed in the introduction of this chapter (i.e. HeLa plaque 
reduction assay, PBL assay). 
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It was felt that for a more accurate comparison of the codon 215 changes in relation 
to codon 41, and the general RT background, and its effect of sensitivity, an assay 
comparable with those in the literature would have to be performed, such as the HeLa 
plaque assay, and it was therefore decided to test the isolates discussed in this thesis in 
an established laboratory, which routinely performed such a test (discussed in next 
section, 5.2.2). 
5.2.2 HeLa plaque reduction assay 
Samples were also tested in the HeLa plaque reduction assay. This was performed by 
Sara Albanil, in the laboratory of Dr. D. Richman, San Diego, USA (see section 
2.7.6). A brief summary of the assay performed will be detailed below. 
The HeLa plaque assay, as discussed in the introduction, is a reproducible drug 
sensitivity assay carried out in the adherent CD4 expressing cell line HeLa HT4-6C. 
For this assay, recombinant virus produced in the C8166 T-cell line was supplied as 
cell culture supernatant and was titrated in the MT-2 cell line. TCID50 input for this 
experiment was calculated from the MT-2 assay, and was between 100 and 200 per 
welt. The assay was performed by adding the virus directly to HeLa cells in growth 
phase, and then incubating for 3 days. After this incubation the cells were fixed and 
stained to visualise the plaques, which can then be counted, and used to calculate the 
IC50 value. 
5.2.2.1 Control viral isolates 
The viral control isolates of known ZDV-resistance, obtained from the MIRC AIDS 
Reagent Project, that had been cultured and titrated in the C8166 T-cell line (see 
Table 5. 1), as well as the in-house wild type control, MCS (see section 2.5.2.1), were 
sent for testing in the HeLa assay. The laboratory strain, H1V-1j, and in-house 
wild-type control used by Sara Albanil (USA), were also included. 
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5.2.2.2 Patient recombinant viral isolates 
Four patient derived recombinant viral isolates were sent for testing in the HeLa 
assay. These represented the codon 41/215 nucleotide sequence combinations of 
CTG/AC, TG/C, ATG/AC, and ITG/AAC (mutant nucleotides underlined, 
see Table 5.4). The codes shown in the table will be used from this point forward 
when referring to the recombinant virus. 
TABLE 5.4 
Recombinant Viral Isolates 
Viral Isolate Code Name Nucleotide Sequence at 
Codon 
41 	 215 
1390.1.1 LD CTG 	GAC 
1390.1.43 LY CTG TAC 
1390.2 MD ATG 	GAC 
1514.1 LN TTG AAC 
The variant with asparagine (MC) at codon 215 (patient 1514), was of particular 
interest because of the difficulties observed when trying to culture this isolate (see 
section 4.2.4.1). Infectivity of the culture was monitored by both KC57 gag staining 
and p24Ag ELISA, as normal syncytia were never seen. Sara Albanil (USA), was 
unable to culture this isolate within the MT-2 cell line, and therefore this recombinant 
virus was not tested in the HeLa ZDV sensitivity assay. 
5.2.2.3 Plaque Assay 
The results obtained from the plaque assays performed on the control isolate and the 
recombinant viral isolates are detailed in Tables 5.5 and 5.6 (control and recombinant 
viral isolates respectively). The tables show the number of plaques visible at each 
concentration of ZDV used, and the corresponding % reduction, which refers to the 
reduction in infectivity. A decrease is clearly observed in infectivity as the 
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concentration of ZDV is increased, which can be seen in the control and recombinant 
viral assays. 
5.2.2.4 Viral isolates IC 50 values 
The '% reduction' detailed in Tables 5.5 and 5.6 was used to calculate the infectious 
dose 50% (1C50)values for each sample, in a similar manner to that detailed in section 
5.2.1.4. The results of this are shown in Table 5.7. 
Looking at the wild type control isolate MCS, the IC 50 value obtained in the assay 
was similar to the in-house wild-type isolate used: 0.13 and 0. 12iM respectively. 
The mutant controls varied (see Table 5.8). This variation is not that unexpected, as 
the isolates have been cultured and titrated in another cell line, MT-2, and the 
possibility of other mutations arising due to this subsequent culturing cannot be 
excluded. These samples are also subject to experimental variation. 
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TABLE 5.5 
HeLa Plaque Reduction Assay for Control Viral Isolates With Known ZDV 
Resistance 
The table shows the average numbers of plaques obtained when the HeLa cell line 
was infected with the control viral isolates in the presence of decreasing 
concentrations of ZDV, with the percentage reduction of infection caused by the drug 
concentration shown also. 
Opposite page number 181 
TABLE 5.5 
Virus Concentration of Average Plaque % Reduction 
ZDV No. 
MCS 10 5 95 
3.16 4 96 
1.0 9 91 
0.316 12 88.1 
0.1 17 83.1 
0.0316 29 71.2 
0.01 53 47.5 
0.00316 71 29.7 
0.001 89 11.8 
no drug 101 
RTMC 10 24 77.9 
3.16 35 67.8 
1.0 44 59.6 
0.316 46 57.7 
0.1 61 44 
0.0316 99 9.1 
0.01 92 15.5 
0.00316 98 10 
0.001 93 14.6 
no drug 109 
RTMF 10 5 92.5 
3.16 5 92.5 
1.0 12 82 
0.316 16 76.1 
0.1 32 52.2 
0.0316 38 43.2 
0.01 61 8.9 
0.00316 84 0 
0.001 73 0 
no drug 67 
RTMN 10 16 75 
3.16 18 71.8 
1.0 24 62.5 
0.316 40 37.5 
0.1 61 4.6 
0.0316 58 9.3 
0.01 61 4.6 
0.00316 55 14 
0.001 54 15.6 
no drug 64 
TABLE 5.6 
HeLa Plaque Reduction Assay for Recombinant Viral Isolates of HIV-1 
The table shows the average numbers of plaques obtained when the HeLa cell line was infected with the recombinant viral isolates in the 
presence of decreasing concentrations of ZDV, with the percentage reduction of infection caused by the drug concentration shown also. 




Resistance to ZDV from the HeLa Plaque Reduction Assay 
Virus Mutations IC50 
1390.1.1 41L, 215D 0.036 
1390.1.43 41L, 215Y? 0.022 
1390.2 215D 0.036 
RTMC 67N, 70R, 215F, 219Q 0.17 
RTMIF 215Y 0.075 
RT1VEN 41L, 215Y 0.56 
MCS WT* 0.013 
LAIL# WT* 0.012 
* WT, refers to wild type 
LAI#, A wild type laboratory strain 
TABLE 5.8 
Comparison of IC50 Values in ZDV Resistant Viral Isolates 
Isolate 	 Expected 1050 * 	 Actual 1050 
RTMF 	 0.26 	 0.075 
RTMN 	 0.91 	 0.56 
RTMC 	 1.3 	 0.17 
* The expected IC. 0 (p.M) was calculated using the MCS value of 0.013J.LM and 
multplying by the fold increase from wild type (see Table 5.1) 
(Kellam eta!, 1992; Larder and Kemp, 1989) 
The recombinant viral isolates had IC 50 values of 0.036, 0.036, and 0.022pM for 
samples LD, MD, and LY respectively (see Table 5.7). This represents a 2.7 and 1.7 
fold increase in resistance to ZDV when compared to the wild type MCS (0.0 13). 
Also of interest is the observation that the presence of the mutant codon 41L, does 
not appear to alter the resistance of the virus when the 215D mutation is present; both 
MD and LD had an IC 50 value of 0.036. 
HeLa sensitivity assays can be separated into three groups: ZDV sensitive with an 
IC50 value <0. 1I.LM;  ZDV partially resistant, IC50 0.1-1 .Op.M; ZDV highly resistant, 
IC50 value> I. Op.M. Using this classification the asp artic acid mutation (21 5D/AC) 
confers sensitivity to ZDV. 
5.3 Summary of Results 
5.3.1 In-house ZDV sensitivity assay 
It is clear from the data presented that the determination of ZDV resistance using the 
non-adherent cell line C8166 did not produce reproducible results, and therefore no 
conclusion as to the relevance of the GAC mutation towards ZDV resistance could be 
determined. There could be several reasons for the variation in results obtained. The 
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input of virus may have been too low in this cell system, although this value was 
determined by initial experiments in the absence of drug and by comparison with other 
phenotypic assays. Subsequently the p24Ag ELISA was not sensitive enough to 
detect the level of antigen produced in these assays, to show the difference between 
experiment groups (i.e. input ZDV concentrations). The visual detection system, 
using KC57 gag staining was very susceptible to handling error, and interpretation at 
lower, less obvious, positive/negative results. 
5.3.2 HeLa plaque reduction assay 
This assay is a well established assay used regularly by many other laboratories. Of 
particular interest from the HeLa sensitivity assay results obtained by S.Albanil (USA) 
was that both the 1390.1 and 1390.2 samples had an identical IC50 value, 0.036 I.LM. 
This result represents a 2.7 fold increase in resistance to ZDV, when compared to the 
parental, wild type (0.013 ji.M). Although both these samples have the GAC variation 
at codon 215, sample 1390.1 also has the mutation ITG at codon 41. The leucine at 
codon 41 alone confers a 4 fold increase in resistance to ZDV (see section 1.7.2, and 
Table 1.1). It appears that in the presence of the 215D mutation, variants carrying the 
4 1 L change have an increased sensitivity to ZDV. 
The MCS wild type control from this laboratory had an almost identical value with the 
wild type control used in the HeLa assay, with values of 0.013, and 0.012 
respectively. Samples were titrated once to obtain the dilution that is then used in all 
subsequent assays. Repeats of the HeLa assay wild type control gave values that 
range from 0.0 18 RM - 0.025 tM (one assay carried out the control in duplicate and 
gave IC50 values of 0.025 and 0.0078 pM). 
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6 	Viral Growth Competition Assays 
6.1 Introduction 
It has been shown that the presence of certain mutations within the reverse 
transcriptase (RT) region of the poi gene are related to reduced sensitivity to the drug 
ZDV: codons 41, 67, 70, 215, and 219 (Larder and Kemp, 1989; St Clair eta!, 1991; 
Kellam eta!, 1992). The presence of these mutations has been shown to correlate 
with, but is not responsible for, disease status, with higher resistance being shown in 
more advanced stages of infection (Larder eta!, 1990). However, although a pattern 
of acquisition of these mutations has been proposed, and most clinical patterns 
observed within patients have been shown to follow this pattern, the time scale and 
the end point vary with each individual (Kellam et al, 1994). Some patients never 
develop highly resistant viral variants, with the presence of all 5 associated mutations. 
The resistance observed with the nucleoside analogue ZDV is complicated, and in 
vitro assays may only give an indication of either the genotype or the phenotype 
independently of eachother. Assays have been developed to detect both the genotype 
and phenotype of viruses, but these systems often involve some form of in vitro 
selection or alteration to the viral quasispecies. As the occurrence of resistance to 
ZDV increased in the HIV-1 population with monotherapy to this drug, there has 
been a switch in the standard of care to the use of combinations of drugs. Such 
combinations have been extensively researched to check factors such as cross-
resistance, toxicity profiles, as well as in vitro synergy. Another complicating factor 
in the complex resistance patterns within HIV-1 was the identification of mutations 
whose presence can either delay or prevent the phenotypic appearance of resistance to 
other drugs (St. Clair eta!, 1991; Larder, 1992). 
6.1.1 Growth competition assays 
One such combination was the use of ZDV with 3TC (lamivudine)(Larder et a!, 
1995). Both ZDV and 3TC are nucleoside analogues whose resistance is mediated by 
point mutations within the RT enzyme, but whereas resistance to ZDV can take up to 
6 months to develop in more advanced HIV-1 infected individuals (longer in 
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asymptomatics) by the accumulation of mutations at five resistance associated 
positions, high level resistance to 3TC is conferred by a single mutation at codon 184 
of RT: ATG (Met) to either GTG (Val) or ATA (lle)(Gu eta!, 1992; Wainberg et a!, 
1996). 
This combination of ZDV and 3TC was found to be clinically beneficial (Leeuwen et 
a!, 1995) with serum HIV-1 RNA levels decreasing even when the mutation 
M184—V was present. Variants of HIV-1 with genotypic resistance to ZDV at 
position 215 were phenotypically sensitive to the drug, in vitro. Sensitivity was 
conferred by the presence of the mutation at residue 184 (M184V), which still 
produces resistance to 3TC. 
To understand the phenotypic and genotypic relationships between various resistance 
conferring mutations, Larder et a! (1995) carried out growth competition assays 
where two variants of HIV-1 with known genotypes would be grown together in 
continuous cell culture either in the presence of, or absence of antiretroviral drugs. It 
was hoped that such an assay could help understand the complex resistance patterns 
and give a greater understanding of what the situation within the host may be, 
particularly when it had been shown that the presence of one mutation could mask the 
resistance of another. 
In the competition assay, Larder eta! (1995) used mutant variants produced through 
site directed mutagenesis of the HXB2-D clone, to create either the 184V or 1841 
mutation within the RT. Two variants were mixed 50:50 using the TCID 50 values 
obtained through HeLa-CD4+ titration, and used to infect the T-cell line MT-4, in the 
presence of or absence of the drugs 3TC and FTC (5-fluoro-3'-thiacytidine, also a 
nucleoside analogue, resistance to which is conferred by a M184—*V change). Virus 
produced from these infections was then serially passaged in fresh MT-4 cells, and the 
genotype at each passage time point determined by automated sequencing (Larder et 
a!, 1993). 
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When competing 184V with 1841 variants, the assay showed that without the 
selective pressure of any drug, 95% of the population contained the 184V mutation by 
passage 8, whereas in the presence of drug this level was obtained by passage 5 for 
10pM 3TC and passage 3 for lOp.M FTC. Therefore in the presence of drug the 
184V mutation showed a greater fitness than the isoleucine change. When competing 
the mutant 184V against the wild type background in the absence of drug, only 30% 
of the viral variants contained the 184V mutation after 11 passages. This still 
illustrates a growth competence for this variant, as it has survived 11 passages in the 
presence of the wild type parental background. Such a system can demonstrate what 
the situation in vivo may be, by comparing the growth of different variants with 
differing combinations of mutations. 
6.1.2 Detection of heterogeneous populations by sequence analysis 
Obviously the accurate detection of such mixed viral populations is important for 
correct interpretation of such experiments as well as allowing detection of various 
populations in clinical samples. Larder et a! (1993) compared several different 
sequencing strategies for analysis of heterogeneous populations of viruses. By 
comparing manual Sanger sequencing, PRISM Sequenase dye terminator and PRISM 
Sequenase dye primer automated procedures with various mixtures of viral variants, 
the sensitivities of each could be determined. The procedure that would allow 
detection of variants at lower frequencies would be adopted for future analysis. 
To test each sequencing approach, mixtures of HIV-1 RT DNA were cloned into the 
M13 bacteriophage, in defined amounts, containing either wild type or mutant 
residues at codons 181 (TAT—TT, conferring resistance to the non-nucleoside RT 
inhibitor Nevirapine), 215 and 219 (ACC-3YfC and AAA—CAA respectively, 
conferring resistance to ZDV). The mixtures were performed in ratios from 100% 
wild type, 90:10% wild type to mutant, 75:25%, 50:50%, 25:75%, 10:90%, 100% 
mutant, and subjected to PCR, then sequence analysis. 
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The results showed that low frequencies of variants were detectable, down to a level 
of 25% for the manual sequencing and as low as 10% for the automated sequencing 
strategies. The advantages of the automated systems were the additional analysis 
packages such as Factura, which can automatically identify heterogeneous within 
series of sequences. The dye primer sequencing accurately replicated the input ratio 
mixtures, and when looking at the 181 mutation ratio series, the 50:50 mixture was 
represented by two peaks at identical heights at the second nucleotide position of the 
codon, resulting in an arbitrary calling of R due to the presence of both an A and G 
peak. However in the dye terminator sequencing the peak heights were not as 
faithfully representative of the input ratio, where the mutant nucleotide, G, never 
equalled the height of the A peak in the 50:50 mixtures. The peak heights with dye 
terminator sequencing kits are sequence motif dependent, such that although the 
peaks are not the same height throughout the sequence read, repeated sequencing of 
the same region produces the same pattern of peak heights. This dye terminator 
sequencing strategy is therefore a useful technique for the identification of mixed 
populations. 
6.1.3 Calculation of the relative fitness of RNA viral populations 
The ability of the RNA viruses to adapt to changing environments has been well 
documented. This biological adaptability was studied in the vesicular stomatitis virus 
(VSV), by Holland et al who were interested in the diversity of clonal populations to 
adapt (Holland eta!, 1991). They employed assays competing various isolates in cell 
culture to quantitate these changes, where the quantification was based on the relative 
competitive ability or relative fitness of each isolate, which they defined as: 
"the frequency with which the (complex quasispecies) progeny of a 
genetically marked virus clone appear following many replicative 
generations (passages) in a given host environment." 
Monoclonal antibody resistant mutants were competed with wild type isolates, in 
different ratios and in different cell lines. The data were interpreted using fitness 
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vector plots, following the shift in the population by plotting the change in frequency 
of a particular isolate at each passage time point sampled. These experiments showed 
that even small changes in relative fitness of a particular isolate can be determined. 
Variants with a replicative advantage in that particular environment were selected 
over less fit variants, and clearly showed the quasispecies character of RNA 
populations. 
Mathematical models were applied to the above principal, to achieve a more accurate 
quantification of changes in viral populations. These models were applied to the 
study of HIV-1 and the relative fitness of viral populations containing point mutations 
associated with antiretroviral therapy. Goudsmit eta! (1996) looked at the presence 
of the serine, ITC, change at codon 215 of the RT, in ITV- 1 patients infected by 
intravenous drug abuse (de Ronde eta!, 1996). Sequence analysis of proviral DNA 
showed the presence of ZDV resistance associated mutations TAC, along with the 
TIC change and also GAC. The TIC change was known to confer sensitivity to 
ZDV (Lacey and Larder, 1 994)(the iAC at that time was unknown), and by sequence 
analysis it was shown that at 9 months post-seroconversion this variant represented 
13% of the population. This figure increased, in a drug free environment, where it 
represented 49% of the population at 20 months. 
The model assumes that both "wild-type" and mutant populations are present at time 
zero (in this case, seroconversion), and that both replicate with different fitness' and 
are present in different proportions. The equation is shown below: 
s = lit In [q(t)p(0) / p(t) q(0)] 
s, The selection coefficient, fitness difference, determined where I is time, q(1), the 
proportion of the more fit, and p(1), the proportion of the less fit population at time I. 
q(0), Andp(0) represent the proportions of each population at time zero. Applying 
this equation to the data set, Goudsmit et a! (1996), calculated that the TTC at codon 
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215 had a 0.4% fitness gain over other variants, which caused a shift in the population 
through time, to a predominantly ]IC population. 
Sharma and Cmmpacker (1997) also applied this equation to determine the fitness of 
the L74-+V (leucine, TTA to valine, TA) mutation of RT associated with resistance 
to the antiretroviral drug ddl in HIV- 1. They carried out competition assays whereby 
two isolates were coinfected into activated PBMCs in equivalent amounts, and the 
change at codon 74 determined by sequence analysis, the frequency of the less fit 
variant being represented by the decrease in peak height over time. They found that 
the mutant G peak decreased, and by day 12 of culture the GTA codon had a loss of 
fitness equivalent to 12%. An equivalent loss of fitness was observed by day 4 when 
competed against a L70-+T mutation. Growth kinetics experiments also showed that 
this mutant replicated less efficiently than the wild type. They concluded that the 
GTA mutation led to an attenuated virus which would become a minor variant in the 
presence of a wild type isolate. 
The contrast between the two values obtained using this mathematical model (0.4% 
and 12%), is not surprising. Both researchers used the model to understand a 
different growth environment, Goudsmit looked at the situation in vivo, whereas 
Crumpacker and Sharma were examining the growth of viral isolates in an in vitro 
system. 
The advantage of applying mathematical models to investigate resistance to 
antiretrovirals is a better understanding of the complicated resistance patterns and 
how this relates to the clinical environment. In one study (Goudsmit et al, 1996) the 
presence of the ICC mutant was shown to impart an increased fitness to these 
isolates. However, this was not linked with a clinical failure, where the RNA levels 
remained steady. In the L74-+V mutation (Sharma and Crumpacker, 1997), it was 
found that in an antiretroviral naive environment this mutation lead to a variant with 
impaired fitness. The investigators believe that this ddl-selected variant with reduced 
replication ability translates into the benefit seen in patients on this therapy, because of 
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the reduced virion production implicated by this reduced fitness, which in turn would 
allow a better immune response. What these studies show is that this additional 
calculation adds to the understanding of the complicated situation of antiretroviral 
therapy and resistance. 
6.2 Results 
In Chapter 3 the identification of a mutation at codon 215 not previously described, 
was detailed. This was caused by mutation at the first and second nucleotide 
positions of codon 215 of the RT, from the wild type ACC to GAC and GAT 
(aspartic acid, D), identified in patients 1390 and 1514 respectively. By analysis of 
single molecules of proviral DNA it was found that some of these 215 mutations were 
linked to mutations at codon 41, CTG and ITG (1390 and 1514 respectively), a 
known ZDV resistance associated mutation. Both patients had harboured these 
variants for approximately 4 years in the absence of any antiretroviral therapy. 
Drug sensitivity assays on recombinant virus produced with the above nucleotide 
changes were performed in the presence of ZDV (see Chapter 5), and showed an 
intermediate sensitivity phenotype for this aspartic acid residue. With these data, and 
experiments detailed previously by Larder et a! (see Introduction above), growth 
competition assays were developed to help understand what the true fitness of such an 
aspartic acid carrying variant was and to understand how it remained the major 
variant in both patients of interest. 
An experiment was designed with the help of Dr. Robert Walker (Centre for HIIV 
Research, Edinburgh), to compete the 215D mutant with or without the linked 41L 
mutation against a wild type variant, or against another mutant variant. 
6.2.1 Viral Isolates 
Three recombinant mutant variants were used, 41L 215D (LD), 41M 215D (MD), 
and 41L 215Y (LY) (see Table 6.1) along with the wild type variant HXB2, termed 
MCS. The production of these recombinants has been described in Chapter 4. 
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TABLE 6.1 
Recombinant Viral Isolates 
Viral Code Nucleotide Sequence at TCID50Im1 
Isolate Name Codon 
41 215 
MCS MT ATG ACC 3.4 X 104 
1390.1 LD TTG GAC 8.0 X 104 
1390.2 MD ATG GAC 5.3 X 105 
1514.1 LY TTG TAC 1.6X io 
The table shows the recombinant viral isolates used for the competition assay, along 
with the wild type control MCS. The table shows the genotypes at the ZDV- 
resistance associated codons 41 and 215. The TCID50 values were obtained by 
titration of the virus in the T-cell line C8166. 
6.2.2 Viral Mixes 
The viral isolate mixtures at defined ratios were prepared using the TCI[) 50 values 
obtained by titration of the recombinant virus and the MCS control in the C8166 T -
cell line (see Table 6.1). 
A total value of 500 TCID 50 was used in ratios of (where virus 1 and 2 are the two 
viral variants used): 
90% virus 1 (Vi) 	v 	10% virus 2 (V2) 
70% Vi 	 v 	30%V2 
30% Vi 	 v 	70%V2 
10% Vi 	 v 	90%V2 
Dilutions of each virus were prepared in bulk ten times concentrated, in a 1 ml volume 
of complete media (CM, see section 2.6.5.1), containing 4500 TCID50 virus for the 
90% mix, 3500 for the 70%, 1500 for the 30% and 500 for the iO%. For example, 
100tl of ten times concentrated virus 1, 90% mix and 100.tl of virus 2, 10% mix 
were added to 8001.11 CM, therefore providing imi of media containing the two viral 
variants with a combined total of 500 TCID 50 . 
Four competition assays in the T-cell line C8 i 66 were investigated, with each 
combination of viral mix being carried out in triplicate. The following assays were 
undertaken: 
LD 	v 	MCS Wild Type 
Ml) 	v 	MCS Wild Type 
LD 	v LY 
MD 	v LD 
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6.2.3 Syncytia Scores 
The competition assays were followed visually by the production of syncytia, which 
all variants will produce due to the presence of the HXB2 parental env sequence. 
Every 3-4 days the plates were scored for the presence of syncytia. Figure 6.1 shows 
the presence or absence of cytopathic effect in all four assays. Looking at the assays 
competing mutant recombinant virus LD or MD (see Table 6.1) with the wild type 
MCS virus (Figure 6.1 A and B), then syncytia were present at all timepoints 
throughout the assay (with the exception of the two earliest timepoints in the 
LD:MCS assay). 
In the assays competing mutant with mutant, a different pattern of cytopathic effects 
was observed. In the LD:LY assay (Figure 6.1 C), when the LY was at the higher 
input ratio (70-90% of virus) then no syncytia were observed in the majority of wells. 
This was caused by the quantity of virus, as the cells were completely destroyed after 
approximately 3 days of culture. It would appear that what ever virus was growing in 
that environment had overrun the culture. When a greater ratio of the LD was 
present, the culture did show syncytia. These cultures would have to be examined 
genotypically to understand what was happening. 
When looking at the M1):LD assay (Figure 6.1 D) a similar pattern of cytopathic 
effects was observed. In this assay the majority of syncytia were observed in the 90% 
viral input wells, where the 70-30% wells showed the most destruction of cells: the 




Competition Assay Syncytia Scores 
The tables show syncytia scores for the four competition assays at each passage time 
point, where '+' indicates the presence of syncytia, regardless of amount, and '-' , no 





Opposite page numbers 198 and 199 
PASSAGE 
NUMBER 
LD v MCS(HXB2) 
Viral ratio 90:10 70:30 30:70 10:90 
REPLICATE I 	11213 11213 11213 11213 
2 - - + + + + + + + + + + 
3 + + + + + + + + + + + + 
4 + + + + + + + + + + + + 
5 + + + + + + + + + + + + 
6 + + + + + + + + + + + + 
7 + + + + + + + + + + + + 
PASSAGE 
NUMBER 
Ml) v MCS(ILXB2) 
Viral ratio 90:10 70:30 30:70 10:90 
REPLICATE I 	11213 1 	11213 1 	1 1 2 1 3  1 	11213 
2 + + + + + + + + + + + + 
3 + + + + + + + + + + + + 
4 + + + + + + + + + + + + 
5 + + + + + + + + + + + + 
6 + + + + + + + + + + + + 





Viral ratio 90:10 70:30 30:70 10:90 
REPLICATE 11213 11213 11213 11213 
------- - - -- -_ ------------ 





Viral ratio 90:10 70:30 30:70 10:90 
REPLICATE 11213 11213 11213 11213 
-- ------- -- 
-- 
----- 4 ----- -- 
---- --- 
-------
-- ---- -- 
•  ___ - -_ ----- 
Cells were also removed from the uninfected well containing C8166 cells to carry out 
a cell viability test using Trypan blue uptake. Previous experiments had shown that 
even in concentrations of up to 5jiM of ZDV, the cell viability did not significantly 
decrease (data not shown). 
6.2.4 Detection of viral mixtures by sequence analysis 
The detection of mixtures of viral variants was determined by automated sequence 
analysis of PCR amplified cDNA obtained from the viral RNA in the stored cell 
culture supernatants, taken at each passage. The reverse transcriptase region 
containing the resistance associated codons 41 through to 219 was sequenced by T7 
sequenase dye terminator direct sequencing, and also by Taq FS dye primer 
sequencing, both of which have been shown to detect mixed populations. Dye 
terminator sequencing was the strategy routinely undertaken within the department, 
and the dye primer was applied as a comparison, to see which would detect the 
presence of mixtures of variants at a given nucleotide position. 
6.2.4.1 Sample Identification 
Both culture supernatant and cells were removed at each passage, as detailed in 
section 2.6.5.8. There were 7 passage times over a period of 25 days. This was a 
total of 84 culture supernatant samples and 84 cell pellet samples for each of the four 
assays carried out. Each sample is numbered numerically, as detailed in Table 6.2. 
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TABLE 6.2 
Competition Assay Sample Numbering 
The tables show the numbering system employed for both the cell culture supernatant 
and the cells, showing each individual ratio number at each passage number 




LD v MCS(HXB2) 
Viral ratio 90:10 70:30 30:70 10:90 
REPLICATE 11213 11213 11213 11213 
1 1 2 3 4 5 6 7 8 9 10 11 12 
2 51 52 53 54 55 56 57 58 59 60 61 62 
3 101 102 103 104 105 106 107 108 109 110 111 112 
4 151 152 153 154 155 156 157 158 159 160 161 162 
5 201 202 203 204 205 206 207 208 209 210 211 212 
6 251 252 253 254 255 256 257 258 1 259 1 2601 261 1 262 




MD v MCS (HXB2) 
Viral ratio 90:10 70:30 30:70 10:90 
REPLICATE I 	11213 11213 11213 11213 
1 13 14 15 16 17 18 19 20 21 22 23 24 
2 63 64 65 66 67 68 69 70 71 72 73 74 
3 113 114 115 116 117 118 119 120 121 122 123 124 
4 163 164 165 166 167 168 169 170 171 172 173 174 
5 213 214 215 216 217 218 219 1 220 221 222 223 224 
6 263 264 265 266 267 268 269 270 271 272 273 274 





Viral ratio 90:10 70:30 30:70 10:90 
REPLICATE 1 1 2 1 3 11213 1 1 2 1 3 1 1 2 1 3 
1 25 26 27 28 29 30 31 32 33 34 35 36 
2 75 76 77 78 79 80 81 82 83 84 85 86 
3 125 126 127 128 129 130 131 132 133 134 135 136 
4 175 176 177 178 179 180 181 182 183 184 185 186 
5 225 226 227 228 229 230 231 232 233 234 235 236 
6 275 276 277 278 1 279 280 281 282 1 283 284 285 286 





Viral ratio 90:10 70:30 30:70 10:90 
REPLICATE 1 	11213  1 	1 1 2 1 3  1 	11213  1 	1 1 2 13 
1 37 38 39 40 41 42 43 44 45 46 47 48 
2 87 88 89 90 91 92 93 94 95 96 97 98 
3 137 138 139 140 141 142 143 144 145 146 147 148 
4 187 188 189 190 191 192 193 194 195 196 197 198 
5 237 238 2391 240 241 242 243 1 244 245 246 247 248 
6 287 288 289 290 291 292 293 294 295 296 297 298 
7 337 338 339 340 341 342 343 344 345 346 347 348 
MCS POSITIVE CONTROL SAMPLES: 49, 99, 149, 199, 249, 299, 349. 
C8166 NEGATIVE CONTROL SAMPLES: 50, 100, 150, 200, 250, 300, 350. 
6.2.4.2 PCR Amplifications 
Extraction of HIV-1 from tissue culture produces greater quantities of RNA 
compared to that obtained from patient samples. Dilutions of the cDNA were 
performed so as to achieve an optimum signal for sequencing after PCR amplification 
without diluting any minor variants at lower frequencies, within the extracted 
material. Table 6.3 shows the samples extracted from the competition assays in 
numerical order, and the dilutions obtained. For standard analysis the dilution two 
fold higher than the cut-off dilution value was used. This lets us assume that we have 
sufficient starting material, RNA, to allow for detection of minor variants within the 
given population. To test that the PCR concentrations chosen were not diluting out 
the presence of such populations, a more concentrated sample was sequenced for the 
following samples: 
68, 71, 156, 159, 160, 168, 171, 253, 256, 259, 260, 268, 271 
The sequences for these can be seen in Appendix 11-6. This sequence analysis did not 
detect any smaller peaks, representative of minor populations. 
203 
TABLE 6.3 
Competition Assay PCR Dilutions 
The table shows the samples extracted from the four competition assays in numerical 
order, and the dilutions achieved by nested PCR. 
* Samples 49, and 50 were the sample numbers extracted from MCS and C8166 
(virus negative) respectively 
Opposite page number 204 
SAMPLE DILUTION 
10 100 1,000 10,000 100,000 1,000,000 
3 + + 
10 + + + + 
53 ± ± + 
55 + + + 
58 + + + + 
60 + + + + + + 
68 + + + + 
71 + + + 
77 + + + 
78 + + 
83  
84  
89 + + + 
90 + + 
95 + 
96 + 
153 + ± + + + 
156 ± ± + + + 
159 + ± + + + 
160 + + + 
168 + + + + + + 
171 + + + + + + 
227 + + + + 
228 + + + + + 
233  
234  




253 ± ± + + 
256 + + + + + + 
259 + + + + + + 
260 + + + + 
268 + + + + 
271 + + - + + 
MCS* + + + + 
C8166* 
6.2.4.3 Dye terminator sequencing 
44 samples were successfully sequenced using the T7 sequenase dye terminator 
strategy. Sequencing was carried out in two sections of the RT region, with the first 
including the ZDV resistance associated mutations 41, 67, and 70 (sequencing with 
primers 155 sense and 152 antisense), and the second including the 215 and 219 
codons (153 sense and 150 antisense, see Chapter 2, section 2.4.1 and 2.4.2). 
The initial samples chosen for sequence analysis were from passage 1 from the 
LD:MCS assay, in the 70 and 30 ratio mixes. This analysis did not detect the presence 
of any mixtures, showing only the presence of the wild type MCS sequence. 
Samples from subsequent passages and samples from each of the assays were then 
analysed. From the LD:MCS assay samples 3,10, 53, 55, 58, 60, 153, 1156, 159, 
160, 253, 256, 259, and 260 were sequenced. From MD:MCS samples 68, 71, 168, 
171, 268, and 271 were sequenced. From LD:LY samples 77, 78, 227, and 228 were 
sequenced. From MD:LD samples 89, 90, 95, 96, and 239 were sequenced. Table 
6.4 shows the results of that sequencing (sequences can be seen in Appendix 11-7). 
Looking at the electropherograms within the Applied Biosystems data analysis 
package, mixed peaks were identified at the first nucleotide position of codon 215 in 
three samples. These were from the LD:MCS assay, numbers 53, 153 and 253, which 
represent the 90%LD: 10%MCS (passage 2, 4 and 6). The smaller peak corresponded 
to the nucleotide G, which represents the recombinant genotype GAC at codon 215. 
The presence of the recombinant virus at a lower frequency, indicated by this G sub-
peak, is confirmed by the presence of a further sub-peak at the first nucleotide 
position of codon 214. CTT at this codon is representative of the MCS (HXB2), wild 
type sequence, whereas the T sub-peak, coding for TTT, represents the recombinant 
viral genotype expected at this codon in conjunction with a (IAC at codon 215. 
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TABLE 6.4 
Nucleotide Sequence at ZDV Resistance Associated Codons 41 and 215 of the 
Reverse Transcriptase Region of poi, from Competition Assays. 
The tables show the amino acid present at the two ZDV resistance associated 
positions after each passage, and at each ratio mix, in the competition assay, where 
41M is ATG, wild type, 41L is CTG, mutant, 215T is ACC, wild type, and 215D is 
1AC, mutant. ND, refers to samples that were not sequenced successfully. 
(see Appendix 11-7 for sequences). 
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A LDvMCS 
Passage No.  Amino Acid Codon  
Viral ratio 90:10 70:30 30:70 1090 
Amino acid 
codon 41 215 41 215 41 215 41  
215 
1 M T M T M T M T 
2 M T M T M T M T 
4 M I M T M T M T 
6 M T M T M T M T 
B MDvMCS 
Passage No.  Amino Acid Codon  
Viral ratio 90:10 70:30 30:70 10:90 
Amino acid 
codon 41 215 41 215 41 215 41 215 
2 ND ND M I M T ND ND 
4 ND ND M T M T ND ND 
6 ND I ND M T M T ND NI) 
C LDvLY 
Passage No.  Amino Acid Codon  
Viral ratio 90:10 70:30 3070 10:90 
Amino acid 
codon 41 215 41 215 41 215 41 215 
2 L D L D ND ND ND ND 
5 L D L D ND ND ND I ND 
D MDvLD 
Passage No.  Amino Acid Codon  
Viral ratio 90i0 70:30 3070 10:90 
Amino acid 
codon 41 215 41 215 41 215 41 215 
2 M D M D L D L D 
5 M D ND NB7 ND ND ND ND 
The frequency of these sub-peaks was determined using the peak heights from the 
electropherograms within the data analysis package on the Apple Macintosh ilci (see 
Chapter 2, section 2.4.4), and by using the cross-hair tool to take the y-coordinate 
reading for both peak heights. The G sub-peak at codon 215 was present at a 
frequency of 33%. The T sub peak at codon 214 was present at a frequency of 37%, 
similar to that seen at codon 215 (see Figure 6.2). These frequencies show that within 
this sample there exists another, minor population of the recombinant virus, which 
initially consisted of 90% of the quasispecies, but after 2 passages, over a time scale 
of almost 2 weeks, has reduced in this in vitro system, to 35% of the population. 
By timepoint 4, sample 153, the frequency of the sub-peaks at codons 214 and 215 
had decreased to 19 and 14% respectively (see Figure 6.2). The sequence for 
timepoint 6, sample 253, had an increased background level, which made it difficult to 
determine frequencies, although it seemed clear that there were sub peaks 
represented. The appearance of these mixed populations at codon 215, and 214 was 
not mimicked at codon 41, where only wild type sequence was observed in samples 
53, 153 and 253. The presence of these smaller peaks was only identified on the 
sense strands, that is, sequencing from the sense 153 primer. As can be seen from 
Figure 6.3, there are no mixed peaks present in the antisense fragment from the same 
sample (trace data from the Sun Sparc station, within the Seqedit Script, see section 
2.4.4), which could be due to sequence context effects observed with this form of 
sequencing. When looking at an electropherogram of T7 sequenase sequencing, 
different peak heights are observed throughout the read (ABI PRISM Comparative 
PCR Sequencing, A Guide to Sequencing-Based Mutation Detection, Perkin Elmer, 
1995). However, the same pattern is observed when a particular region is sequenced 
repeatedly. Therefore when using this strategy to detect mixed populations both the 




Electropherogram Trace Data for LD:MCS 
Competition Assay 
The trace data, obtained in the Applied Biosystems data analysis package, shows 
codon 215 for the 90%LD: 1 O%MCS competition assay, samples 53, 153, and 253 
(passages 2, 4 and 6). Codons 214 and 215 are underlined. The percentage of sub- 
peaks are indicated by arrows (see section 6.2.4.3). 
Opposite page number 208 
53 
A A ( A (.1 	 (;Ac. G( -cAt 	AC;A.C:(AGA A A A A A A C A CAGAAA 
153 
A 	c 	t , 	(;A(.(..(;L.gA( 	t 	 (.?A 	AAAAAA(A 	&(AI 
253 
t 	 A 	 A 	( A 	A 
FIGURE 6.3 
Trace Data for LD:MCS Competition Assay 
The figures shows the sense (bottom panel, sequenced with primer 153 (see Figure 
2.1 and 2.2)) and antisense (top panel, sequenced with primer 150 (see Figure 2.1 and 
2.2)) sequence data represented as a trace. The trace data is from the seqedit package 
(see section 2.4.4), which aligns both the sense and antisense strands to produce the 
complete sequence fragment. Codon 214 and 215 are underlined. 
Viral Mixture 	Nucleotide  
Sense (214/215) 
100% Mutant 	 TTT GAC 
100%w.ild-13pe .CTTACC 
Opposite page number 209 
Trace Data for Competition Assay Sample 53 
!AI!ILUPI!IUIIIIIIUI 
Trace Data for Competition Assay Sample 153 
ATCTGTTGflGGTG6GGRCTTCC AC ACC AGATAARARACA 
CT 6TTGiGGT GGGGRCT TACCACICCA GAl AAAAAACAT 
.M- - W- 6A 
6.2.4.4 Dye primer sequencing 
Sequencing with fluorescently labelled primers produces a more even peak height 
throughout the read, and is ideally suited to the detection of heterozygotes and mixed 
populations at a given locus (ABI PRISM Comparative PCR Sequencing, A Guide to 
Sequencing-Based Mutation Detection, Perkin Elmer, 1995; Larder et al, 1995), 
although sequence context effects still apply. This sequencing strategy uses the 
AmpliTaq FS enzyme, an enzyme optimised for use in fluorescent sequencing, and a 
mutant of the Taq DNA polymerase enzyme with no 5'-33' nuclease activity. The 
more even peaks heights produced by this new enzyme leads to less of a requirement 
for manual interpretation of the data. As the background noise is essentially 
negligible, the presence of mixed peaks is clearer. 
It was decided to clarify the results obtained with the dye terminator sequencing with 
dye primer analysis. To show that this technique was able to detect the presence of 
mixed populations, mixtures of viral DNA were prepared in various ratios. These 
mixtures were prepared from 1.4kb, -21M13 tailed PCR amplified fragments of RT 
DNA, which were subsequently 'cleaned' using a PCR purification kit (see section 
2.8.1.1), and the concentration of DNA determined by UV spectrophotometry. Using 
the concentration of DNA obtained from this analysis, mixtures of wild type and 
mutant viral sequences were prepared, and then subjected to PCR with dye labelled 
primers as detailed in the dye primer sequencing protocol. 
The wild type sequence was provided by the MCS, HXB2 clone, and the mutant was 
from patient 1390 (1390. 1), with GAC at codon 215. From the sequencing results it 
was clear that this dye primer sequencing was able to detect mixtures of virus. Figure 
6.4 shows a section from the electropherograms for three mixtures of mutant and 
wild-type viral isolates, representing the antisense fragment, where codons 214 and 
215 are indicated by the arrows pointing in the sense direction. 
In the 25:75 mutant: wild-type mixture the trace data show the presence of CTT, wild 
type at codon 214, although the 'A' sub peak, which would represent the TTT mutant 
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sequence, is also present at a lower frequency. Using the cross hair tool to estimate 
the frequency of this peak, indicated a frequency of 41% (see section 2.4.4, Data 
analysis). Codon 215 showed the presence of the wild-type ACC codon, but again 
smaller peaks, representing the mutant GAC, were also present: the frequency of the 
'C' sub-peak at the first nucleotide position was 39%, and the 'T' sub-peak at the 
second position was 15%. These values do not reproduce the 25% mutant, 75% wild 
type, but do show that mixtures containing isolates that only represent 25% of the 
population are detectable by this method of dye primer sequencing. 
This is further illustrated in the 50:50 mixture, where the sequence reads TTT ACC 
(for codons 214 and 215 respectively), representing the wild-type sequence, but the 
presence of other peaks at these codons, approximately equal in size (see Figure 6.4), 
is also clearly demonstrated. The 'G' sub-peak at the first nucleotide position of 
codon 214 is present at a frequency of 87%. Codon 215 has 'T' sub-peaks at both 
the first and second nucleotide positions, this would represent the nucleotide sequence 
AAC, not the input wild-type ACC or mutant GAC, and are present at a frequency of 
approximately 69%. 
These results, the unfaithful reproduction of input ratio, and the unusual codon 215 
detailed above could be due to sequence context effects, as sequencing of the 100% 
wild type and mutant (see Figure 6.4) was successfully performed on the same 
sequencing run. What it probably indicates is that that the input mixtures were not 
accurately amplified during the PCR reactions, with the larger input volumes of the 




Electropherogram Showing Codon 215 ACC:j,C Viral Mixtures 
The electropherograms show the trace for codon 215, in the antisense direction (the 
arrows shown in alignment with codon 214 and 215 in sense direction) obtained by 
dye primer automated sequencing. The table below shows the nucleotide sequences 
for wild type (MCS) and mutant (recombinant virus, with aspartic acid at codon 215). 
Viral Mixture 	 Nucleotide Sequence 
Antisense (215/214) 	Sense (214/215) 
100% Mutant 	 GTC AAA 	 TTT GAC 
100% Wild-Type GGTG CTT ACC 
Opposite page number 212 
25:75 Mutant: Wild Type 
G GGG 
50:50 Mutant:Wild-Type 
G ( 	C; G . \ AA 	C r LAC  
4 
100% Mutant 
G 	G  
The competition assay samples 53, 153, and 253 that showed the presence of smaller 
peaks at both codon 214 and 215 by dye terminator sequencing were tested by the 
dye primer method. Both the sense and antisense fragments were sequenced for the 
portion of the RT that included the codon 215 and 219 ZDV resistance associated 
positions. From this analysis, only pure populations of wild type were observed, with 
no smaller peaks distinguishable from the background noise. This contradicts the 
identification of mutant minor population observed by earlier sequencing. 
6.2.5 Calculation of GAC variant fitness 
Using the sequence data for samples 53 and 153 obtained by dye terminator 
sequencing (section 6.2.4.3), from the competition assay competing the 41L 215D 
mutant variant with the wild type variant, the relative fitness of the GAC isolate can 
be calculated using the equation discussed in the introduction to this chapter (section 
6.1.3), see below. 
s = lit In [q(t)p(0) / p(t) q(0)] 
Applying the equation above, where time, t, is equivalent to the number of days in 
culture, q(t) andp(t) are the proportions of each peak height (obtained as detailed in 
section 3:2.2.3)  at time 1, and q(0) andp(0) are the proportions of virus at time zero 
(the input for this competition assay at time zero was 90% 41L 215D, and 10% 41M 
215T, wild type). 
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TABLE 6.5 
Frequency of Variation at RT Codon 215 
Days In 	Frequency of Nucleotide # 
Culture* 	215D 	215T 
0 0.9 0.1 
9 0.33 0.67 
12 0.19 0.81 
* Day 9 relates to sample 53, and Day 12, to sample 153 
# From the peak heights obtained from sequencing 
Using the above data, the selection coefficient, s, is 0.32 and 0.30 for samples 53 and 
153 respectively. This relates to a 32% and 30% reduction in fitness conferred by the 
presence of the GAC mutation by day 12. This resistant variant would be replaced by 
wild type variants in a drug free environment. 
6.3 Summary of Results 
6.3.1 Competition assay results 
The dye terminator sequencing results show that in most cases the wild type, 
H3B2/MCS, was the dominant viral isolate and it was this variant that was the fittest 
in this particular environment, becoming the major variant in the cell culture as 
quickly as 6 days after initiation of infection. In assays competing two mutant viruses, 
although sequencing results are limited, it appeared that the presence of the as yet 
undefined GAC at codon 215 led to an isolate that outgrew the ZDV resistance-
associated mutant with the IAC 215 codon. In the assay that competed two variants 
who both had the 1AC codon 215, but linked with either wild type or mutant codon 
41 (ATG and ITO respectively), then the outcome was dependent on the input ratio 
of virus. In the assay with a 70-90% input of4lMJ2l5D, then only MD variants were 
detected, and in the assay with 70-90% 41L/21 15D input, then only LD was detected. 
Again limited sequence data were obtained and no conclusions can be drawn from this 
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small data set. This result however, may not be unexpected at this early time in 
infection, but further sequencing at later timepoints would have to be achieved to 
determine what role the presence of the mutant codon 41 plays in conjunction with 
the aspartic acid codon 215. 
6.3.2 Detection of mixed populations by sequence analysis 
The presence of mixed populations of viral isolates in the competition assays was 
detected genotypically using the dye terminator sequencing chemistry. However, 
such mixtures were only identified in one sub-set of samples from the LD:MCS 
competition assay: sample numbers 53, 153 and 253, which represent the 
90%LD: 10%MCS (passage 2, 4 and 6). Using the dye primer chemistry on the same 
samples failed to detect this mixed population. 
The fact that two sequencing chemistries did not detect similar results is not so 
unexpected when you take into account the steps undertaken before and during the 
sequencing strategies used. In dye terminator the amplification and purification of 
product is performed first, whereas in dye primer the amplification and sequencing 
reactions are combined. It is therefore difficult to control the input DNA 
concentrations. To achieve a successful run using the dye primer chemistry, a dilution 
of the input DNA must be carried out, this eliminates excess primers which may act as 
templates during the sequencing reaction. This dilution eliminates the background 
noise and therefore allows the presence of mixed peaks to be seen on the 
electropherogram. 
The main advantage of dye primer sequencing for detection of mixed populations is 
the production of data with very even peak heights. With dye terminator sequencing 
mixed peaks will still be identifiable but, for example, equal mixtures of two isolates 
will not show a 50:50 peak height distribution. This is a consequence of the 
sequencing chemistry and also sequence specific motif effects. Therefore the presence 
of mixed peaks in samples 53 and 153 detected only in this chemistry can be believed, 
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and the fact that other mixtures where not detected could be due to a mixture of the 
processing of the sample and input DNA concentration. 
Dye primer sequencing is carried out using small volumes (maximum total is lOtil), 
whereas in dye terminator the sequencing is performed on larger volumes (1001.11 of 
PCR derived DNA), although primer sequencing is cycle sequencing with 
amplification and sequencing combined. However, small, minor populations may be 
missed, in favour of the major dominant variant during this amplification procedure. 
Although the same problem could be relevant to dye terminator sequencing as well, 
the small volumes used in the primer sequencing exacerbate the problem. 
The presence of the mutant and wild type sequences at codon 215 was not mimicked 
by detection of the mutant codon 41. There was no presence of the smaller sub-peaks 
in samples 53, 153 or 253 by either dye primer or dye terminator sequencing, 
indicating the presence of the mutant 11G. This is more surprising in the 53 sample, 
where the sub-peaks represent approximately 30% of the population. The absence of 
the mutant codon 41 could again be due to sequencing strategy and handling 
variation, but could also be due to recombination between the two input viral isolates, 
although we have no way of confirming this. 
6.3.3 Fitness of II1V-1 recombinant with codon GACI215 
Using the data obtained for the dye terminator sequencing and the mathematical 
model detailed above the fitness of the isolate carrying the GAC change at codon 215 
of the RI was calculated to be 30-32%. This value relates to the reduction in fitness 
conferred by the presence of this mutant when compared to the wild type ACC codon 
215. Because no mixed peaks were detected at codon 41, we must assume that this 
isolate is different from the wild type at codon 215 alone: input virus was 41L/215D, 
whereas the fitness is based on a 41M/215D isolate (no other variation was observed 
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7 	Point Mutation Assay 
7.1 	Introduction 
An increasing number of genetic diseases and phenotypic polymorphisms are being 
identified at the gene level. Understanding the causes of such diseases has lead to the 
need for diagnostic tools to allow detection of such defects. 
7.1.1 Detection of mutations in HIV-1 DNA 
With the increased occurrence of resistance to antiretroviral drugs against HIV-1, 
assays for the quick and accurate detection of the associated mutations in large 
sampling groups are required. Point mutations responsible for ZDV resistance were 
tested in a PCR-based method. In a study of high risk, symptom free HIV-1 
individuals on three various doses of Zidovudine monotherapy (Boucher et al, 1990), 
a double PCR reaction was developed in order to identify the double nucleotide 
substitution at amino acid codon 215 of the reverse transcriptase region of pol 
responsible for reduced sensitivity to the drug ZDV. 
In this nested PCR reaction the second round reaction was a selective amplification, 
performed with primers that annealed to codon 215. Samples were amplified in 
parallel with a primer which annealed specifically to either the wild type sequence or 
the mutant sequence. The results of a successful amplification were dependent upon 
the presence of the primer specific sequence present within the sample, and resulted in 
a 210 base pair fragment, identified through resolution on agarose gels. The samples 
were scored wild type or mutant based on the intensities of the gel bands, with a 
mixture represented by bands of equal intensity in the wild type and mutant lanes. 
Two bands were sometimes observed, which could indicate the presence of both 
mutant and wild type, or the presence of an intermediate, caused by a single base 
change. 
7.1.2 Point Mutation Assay For Detection of Mutations in BIV-1 
An alternative point mutation assay was developed (Kaye et a!, 1992). Using the 
theory behind the previous techniques discussed above, they developed an assay that, 
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in addition to identifying nucleotide variation at a specific point in the DNA, was also 
able to provide quantitative data on proportions of mutant and wild-type sequences. 
This advantage, combined with the ease of handling large numbers of clinical samples 
due to the microtitre plate format of the assay, could detect the presence of mutations 
that existed at lower frequencies, and that may have been missed by previous 
techniques and by sequencing analysis. 
This technique utilises the nested polymerase chain reaction (see section 2.3.3), where 
the secondary reaction incorporated a biotinylated primer to tag the DNA template for 
subsequent solid phase analysis. After binding of the template to streptavidin-coated 
solid matrix, the DNA duplex is denatured to produce the single stranded template. 
The solid matrix, in the form of the microtitre plate, allowed easy manipulation of the 
template in subsequent steps. The assay itself involves an incorporation of a single S 35 
radiolabelled nucleotide from an oligonucleotide probe, annealed exactly adjacent to 
the point mutation of interest. After the extension reaction is completed the fragment 
is eluted into liquid scintillant for counting. From the scintillation counter results the 
nucleotide sequence at a given position can be determined by the incorporation levels 
of the four labelled nucleotides, from which the proportions of wild type to mutants 
can be calculated. 
7.1.3 Dynabeads Point Mutation Assay 
In this section a version of the above technique is described which was investigated as 
an initial step for screening large study populations for the presence of ZDV 
associated mutations. As a Topcount microtitre scintillation counter was not available, 
an approach based on procedures routinely carried out within the department was 
adopted (see section 2.5). 
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7.2 Results 
7.2.1 Study group 
Patients were chosen from the IvIRC Molecular Epidemiology Project (see section 
3.2.1.1 and 3.2.1.2). The group for this analysis contained both antiretroviral-naive 
and ZDV-experienced individuals (see Table 7.1 below, antiretroviral therapy shown 
were relevant). 
TABLE 7.1 
IITV-1 Study Group 
Sample Sample Date Therapy Therapy 
Date 
ZDV 1988 
1009 19.01.93 - - 
1037 01.03.93 ZDV 14.02.91 
1051 26.04.93 - - 
1064 20.05.93 ZDV 23.04.93 
1072 08.06.93 - - 
1083 08.07.93 - - 
1086 03.08.93 ZDV 15.10.91 
1087 05.08.93 - - 
1118 03.11.93 ZDV 01.07.93 
1154 19.01.94 - - 
1201 11.02.94 ZDV 07.12.92 
1219 23.02.94 - - 
1317 24.04.94 - - 
7.2.1.1 ZDV Resistant Variant Controls 
P74 *  
This patient was infected with HIV-1 through infected plasma factor VIII, and 
seroconverted in 1984. This patient had been extensively studied within the Centre 
for HTV Research, Edinburgh (Cleland eta!, 1990; Simmonds eta!, 1990; Balfe eta!, 
1990). The patient had initiated ZDV therapy in 1988, terminating therapy in 1990. 
The patient subsequently died in October of 1991. 
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Sequence analysis of the RT coding region ofpoi was carried out on both proviral 
DNA and plasma RNA extracted from samples obtained from 1984 through to 
October 1991. This analysis showed a nucleotide substitution at codon 215, from the 
ACC wild type to the mutant TAC genotype, within the proviral DNA population 56 
weeks after initiation of therapy (present at 22 weeks in the RNA sample at a 
frequency of 25%). This variant was chosen as a known ZDV resistance-carrying 
variant for use in the PMA. 
1037 
Patient 1037 was chosen from the repository for initial work undertaken, including 
limit dilution PCR and automated sequencing (see section 3.2.1.4). This analysis 
showed the presence of the codon 215 nucleotide substitutions associated with 
resistance to ZDV: ACC to TAC (see Table 3.3). 
Treated MEP Repository Patients 
Patients 1064, 1086, 1118, 1201 were chosen from the repository under the criteria 
that they had undergone ZDV therapy (therapy levels from one month, up to two 
years, see Table 3.6). At the time that they were used in the PMA their genotype at 
position 215 was as yet undetermined. 
7.2.1.2 Wild Type Controls 
JJXB2 
The wild type control strain pJiXB2-MCS-ENV, based on the infectious molecular 
clone HXB2-MCS, was used (see section 4.2.1.1). DNA from this clone was 
obtained from Dr R. Walker and E. Harvey (Centre for HIV Research, Edinburgh). 
Nested limit dilution PCR was used to obtain DNA for testing in the PMA, which was 
used in the initial set up of the PMA and in all subsequent assays as the positive 
control. This clone is wild type at codon 215. 
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Untreated MEP Repository Patients 
Patients were chosen from the repository under the criteria that they had never 
undergone any form of antiretroviral therapy. From this search 8 patients were 
chosen: 1009, 1051, 1072, 1083, 1087, 1154, 1219, and 1317 (see Table 3.2). At 
the time that these assays were performed only three of these patients, 1072, 1219 and 
1317, had been sequenced and the nucleotide sequence at codon 215 confirmed as 
wild type. 
7.2.2 Limit Dilution PCR 
Nested PCR was performed on the HXB2 control applying the limit dilution method 
to quantify the proviral DNA present in the neat, unamplified sample. To achieve this 
an initial dilution step generating five different dilutions was carried out and from the 
results of this PCR, 50 reactions at one dilution were undertaken (see chapter 2, 
section 2.3.4). Using the frequency of the negatives and the positives from this PCR 
with 50 tubes, and applying the following formula, one can calculate back to the 
original starting sample, and estimate the DNA concentration in molecules of 
DNA/Ill. 
-in (fo) 
Where (Jo) is the frequency of negatives, for example if there were 10 positive bands 
on the gel, and 40 negatives, (Jo) is equivalent to 40 - 50, or 0.8. Therefore, for this 
example, applying the equation, -In (0.8) = 0.223, which, multiplied by the number of 
samples, that is 50, gives the value of 11 single molecules of DNA in 50g1  of the 
dilution used. Taking account of the dilution factor will give the value in the neat 
sample. 
Using this method, DNA from HXB2 was prepared in a solution of DEPC water at a 
concentration of 1000 copies of DNA per Ill,  for use in all subsequent PMA 
experiments. 
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7.2.3 Calculating the presence of each base 
To calculate what base is present within the sample a formula must be applied to 
remove the ambient background and to correct for the addition of more than one 
base, due to adjacent identical bases at the codon of interest (see Figure 7.1). 
For codon 215 the three bases that can be incorporated are G, A, and T. The C 
count is therefore used as the background and is subtracted from all signals. For 
IHXB2, codon 214 has the sequence CTT, as opposed to TTT observed in many 
patients, the A nucleotide incorporation, and therefore the A signal, must be divided 
by 4 for HXB2 and 5 for patient-derived samples (see Figure 7.1). Table 7.2 gives an 
example of the formula used to obtain the frequency of incorporation of each base at 
codon 215 (see also Appendix IV). 
TABLE 7.2 
Calculating the Frequency of Wild type or Mutant Codons 
Sample 	Base Reading Background 	Aix 	C 	-C % 
1 	G 56,984 27 	 37,320 19,604 100 
A 24,055 6,013 	 -31,306 N/A 
T 7,790 -29 N/A 
As detailed, bases G, A, and T could be incorporated at codon 215 and the readings 
are noted, with the C (reading of 37,320 in this example) acting as the background. 
The 'Background' refers to the value obtained in a vial containing scintillation fluid 
only (and can also be deducted from the base readings). The A reading is divided by 
the appropriate number (4 for HXB2, and 5 for patient samples), then the C 
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FIGURE 7.1 
Point Mutation Assay 
The figure shows the primer sequence used to probe codon 215 in the reverse 
transcriptase region ofpoi, A. The nucleotides that would anneal to the specific wild 
type or mutant sequences during the PMA are shown in bold in figure B, and in figure 
C. Figure C shows the wild type HXB2 sequence, where codon 214 has a C at 
position one of the codon, shown in italics. The underlined sequences shown 
represent the primer. 
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215 Probe 5' CTG ATG TTT TTT GTC TGG TGT G 3' 
lfl 
215 
Wild Type 	 TTT ACC ACA CCA 
GG TGT GGT 
Zidovudine mutant 215 Codons 
215 
Phenylalanine 	 TTT TTC ACA CCA 
AAA AAG TOT GGT 
215 
Tyrosine 	 TTT TAC ACA CCA 
TG TGT GOT 
C 
215 
Wild Type, pBXB2 	CFT ACC ACA CCA 
GO TGT GOT 




CrT TTC ACA CCA 
AA AAG TGT GOT 
215 
Tyrosine 	 Cr1 TAC ACA CCA 
TG TGT GOT 
background is removed from all. The frequency of each nucleotide incorporation is 
then calculated using the figures obtained for '-C', and expressed as a percentage. 
In this example only HXB2 was present, and the result therefore should show 100% 
G, the complement to the second nucleotide position of the wild type codon 215, 
ACC (see Figure 7.1). If the sample contained a mutant codon 215, then the signal 
for A or T would increase, corresponding to the codons TIC,  or  TAC  at 215, 
respectively. 
7.2.4 Titration of 215 Probe 
A concentration of 2.5pM of 215 probe/primer was used in published point mutation 
assays (PMA). These experiments however used the probe in a microtitre format, 
with counting using the Topcount computer based system. The optimum 
concentration suitable for the dynabeads method applied herein was obtained by 
carrying out several experiments titrating the concentration of the probe, in the 
presence of the HXB2 positive control. 
Three concentrations of the 215 probe were initially tested in the dynabeads assay, 
from 2.5RM, 1.0p.M, to 0.25tM. Each concentration was tested in triplicate with the 
wild type control pHXB2. The results of this can be seen in Appendix IV, experiment 
1. The 2.5iM p215 probe showed a 93% G, and 7% A signal, with nothing for the 
T. The large G signal corresponds to the wild type sequence expected. The 1 .Op.M 
probe concentration gave 87%, 70%, and 100% wild type G signal for the three 
tested, with smaller signals detected for T (13%- 22%), and A (8%). For the 
0.25RM sample, values of 89% and 100% were obtained, with smaller signals for A 
(10%), and T (1%). The 1.0I.LM was used in all subsequent experiments. 
7.2.5 Presence of Dynabeads 
As the assay was performed on beads, the effect that these may have on the read out 
was determined by carrying out an experiment in parallel, with one of the experiments 
adopting a final sodium hydroxide elution step, where the radiolabelled DNA would 
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be removed from the beads and added directly to the liquid scintillant (as in the 
experiment above). In the other experiment the DNA/dynabeads mix would be added 
directly to the scintillant (see Appendix IV, experiment 2). 
The results of the PMA carried out with the final elution step showed 100% and 67% 
for the G, wild type signal, with similar results for the parallel experiment where the 
dynabeads were not removed, with signals corresponding to 92% and 79% for G. 
From these results it was decided that the end NaOH elution step did not significantly 
affect the read out, and was not required for future experiments. 
7.2.6 Concentration of Radiolabel 
The 35 S- dNTPs were stored at a stock 1:10 dilution in water of NEN Dupont 1000-
1500 Ci/mmol (section 2.5.4). This was the recommended concentration for use in 
the microtitre format assay (Kaye et al, 1992). To reduce costs, a further dilution of 
the radiolabel was tested with the pHXB2 wild type control, in parallel with the 
standard 1/10 dilution. When tested in triplicate, the dynabeads PMA carried out with 
the 1/10 dilution of 35S gave similar results to that performed with a 1/30 dilution, 
with 87,90, and 93% for the wild type G signal for the 1/10 standard dilution and 99, 
77,92, and 82% for the G signal for the 1/30 dilution (see Appendix IV, experiment 4, 
5, and 6). The 1/30 dilution was adopted in all subsequent experiments. 
7.2.7 PMA Enzyme 
DNA polymerase I Klenow (Large) Fragment was used throughout the experiments. 
The actual procedure for carrying out the dynabeads point mutation assay is more 
time consuming than the microtitre assay based technique, as each radiolabelled 
nucleotide has to be assayed in a separate tube. The readings obtained for each base 
seemed to alter depending on the order in which the experiment was performed, as all 
tubes with one of the 4 radiolabelled base samples were washed and prepared 
together. To determine whether the enzyme was decreasing in efficiency over time, 
an experiment was carried out using the wild type pHXB2 sample. The enzyme was 
added to the labelling mix which contained the S 35-dNTPs, and the relevant amount 
227 
added to each tube, one for each base. The labelling mix with enzyme was then left at 
room temperature for intervals of 5 minutes, and at each time interval up to 25 
minutes a PMA was performed. 
From the results of this experiment, shown in Figure 7.2 (see also Appendix IV, 
experiment 15), it was clear that the activity of the enzyme clearly deteriorated over 
time, dropping steadily over the 25 minutes period, a variable factor that would have 
to be considered when interpreting the data obtained by this more labour intensive 
dynabeads point mutation assay. 
7.2.8 Frequency of wild type/mutant codon 215 
The results of the PMA performed on the repository patients can be seen in detail in 
Appendix IV, from experiment 4 onwards. 
7.2.8.1 Untreated patients 
Patients within the untreated group tested in the PMA were 1317, 1072, 1219, 1009, 
1051, 1083, 1087, 1154 (see Appendix IV, experiments 7, 8, and 9). The nucleotide 
sequence at codon 215 had been determined by sequence analysis for the patients 
1317, 1072, and 1219. The PMA confirmed this, showing a wild type signal of 99% 
and 100% G, for patients 1072 and 1219, respectively. Patient 1087 showed a 




Incorporation of Radiolabelled Nucleotides By Kienow Enzyme 
The diagram shows the incorporation of each radiolabelled nucleotide by the enzyme Kienow. The enzyme mix was prepared at time zero 
and the experiments carried out at 5 minute time intervals. 
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For patient 1317, a greater frequency was observed for the T base, at 72%, which 
would correspond to the presence of the TAC mutant (ACC wild type), however the 
overall counts for this sample were low with the highest count reaching only 273 (see 
experiment 7). Patients 1051 and 1083 also showed the greatest frequency for a 
mutant base, A, 91% and 81% respectively, corresponding to the TIC ZDV-
associated mutation, but again the overall counts for these samples were low. In 
comparison to the wild type control HXB2, all the patient counts are relatively low. 
The PMA carried out on patients 1009 and 1154 were unsuccessful. 
7.2.8.2 Treated patients 
Patients in this group tested included samples from patient 1064, 1086, 1118, and 
1201. Patient 1064 had undergone ZDV monotherapy for only one month prior to 
sampling, and showed the presence of the wild type G, at a frequency of 100%. 
Patient 1086, had been treated with ZDV for two years, and in the PMA showed the 
presence of the mutant signal, T at a frequency of 60%. This would correspond to 
the presence of the ZDV resistance associated mutation TAC at codon 215 (mutant 
bases underlined). Patients 1118 and 1201 were unsuccessfully tested. 
7.2.8.3 ZDV resistant controls 
p 74 
Several different samples were tested for p74, with both wild type and mutant signals 
occurring. In experiment 9 (Appendix IV), the wild type, G signal was present at a 
frequency of 67%, 68%, 58%, and 71%, whereas in experiment 17 this signal ranged 
from 47-85%. The mutant T signal could also be detected at a frequency of 100%, 
and 78%. These samples were obtained 8 weeks post therapy (A. Cleland, MPhil, 
University of Edinburgh, 1995), and suggest the presence of both wild type and 
mutants in these samples. 
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1037 
Patient 1037 had undergone ZDV therapy for two years prior to sampling, and 
proviral DNA had been sequenced showing the presence of both the wild type ACC, 
and the ZDV resistance associated mutation TAC, at codon 215 (at a frequency of 
57% and 43% respectively). Surprisingly the wild type G signal is detected more 
frequently within the PMA samples, ranging from 100% to 75% (Experiments 4 
onwards, Appendix IV), although in experiment 6 this level drops to 43%, with the 
signals for the mutant A and T bases remaining at a similar level. This elevated 
mutant signal correlates with sequence analysis of 1037 single molecules, where the 
mutant TAC, although not ITC, was detected. 
7.3 Discussion 
The data obtained above §how that the detection of both wild type and mutant 
sequences at codon 215 is possible using this dynabeads point mutation assay. The 
inherent problem with this assay is that it is labour intensive and as such prone to 
laboratory experimental variation, as indicated by the rapid decrease in activity of the 
DNA polymerase enzyme. 
Several samples tested by the PMA were then sequenced by the Sequenase dye 
terminator automated sequencing strategy. This analysis confirmed the results 
obtained by the PMA where the presence of the wild type codon 215 was successfully 
detected in patients 1072 and 1219 and 1087. Mixtures of variants were also 
detectable, illustrated by patient 1037, which had been sequenced and showed the 
presence of both wild type and mutant. The PMA not only detected both the 
expected ACC and mutant TAC, but also showed the presence of a further ZDV 
associated mutation, ITC, represented by the A signal, at a frequency of 24-27% (see 
experiment 6, Appendix IV). This mutation is known to exist at lower frequencies 
than the TAC mutation, and its detection may have been missed by the single 
molecule sequencing. Ideally an automated system for the PMA would offer more 
reproducibly consistent data. 
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Subsequently the antiretroviral naive main study group numbers accessible at that time 
were finalised at 35 patients, and it was decided that the additional linkage 
information that sequence analysis could produce meant that the approach was no 
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8.1 Dynamics of HIV-1 Resistance Development 
8.1.1 Genetic variation in RT region of pol 
HIV- 1 is similar to other RNA single stranded viruses in that its reverse transcriptase 
(RT), does not possess proof-reading activity, and as a result of its error-prone 
replication, a high degree of variation is generated. HIV-1 has also been shown to 
circulate in high titres, at all times in infection, resulting in high viral burden, turnover 
and replication. Consequently, this high rate of replication, coupled with the mutation 
rate, which has been estimated at 3 x iO mutations per nucleotide per replication 
cycle (Mansky and Temin, 1995), leads to a population of viruses that are all distinct 
(Coffin, 1995). 
8.1.2 Selective drug pressure and development of resistance to antiretrovirals 
The first drug licensed for use against HIV-1 was ZDV, and, as discussed earlier, 
within 3 years of its use patients were failing on this therapy. Subsequent analysis 
showed that virus from these individuals was phenotypically resistant to ZDV, and 
genotypic analysis showed the presence of variation at 5 amino acids positions within 
the RT to be responsible for this change in sensitivity (Larder and Kemp, 1989; St. 
Clair eta!, 1991; Kellam eta!, 1992). Comparative sequence analysis showed that 
these mutations were only present in those patients who had undertaken therapy 
(Larder and Kemp, 1989; Larder eta!, 1989). It was also observed that resistance 
developed quicker in those on higher doses of ZDV, suggesting that the drug is 
exerting selective pressure. 
Subsequent sequence analysis on antiretroviral naive individuals has not detected the 
presence of variation at these ZDV resistance-associated positions (except at codon 
70, see section 1.8 (Mohri et a!, 1993), but using the mutation frequencies and viral 
replication values, and the size of the HI-i genome, analysis indicates that in any 
given day it is possible for all single and double point mutations to be generated, 
which includes change at resistance-associated positions (Coffin, 1995). However, no 
such variation was observed, until recently, except where isolates showing variation, 
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like those detailed in this thesis, are the result of infections initiated by drug 'resistant' 
variants of HIV-1. 
8.1.3 Detection of variation at ZDV resistance-associated positions 
Direct sequence analysis of the provirus from two patients, 1390 and 1514, detailed in 
Chapter 3, showed the presence of variation at codons 215 and 41 in RT, both amino 
acid sites associated with the use of ZDV therapy. The change observed at codon 41 
was that previously observed with therapy, CTG and ITG, but at codon 215 an 
unusual amino acid, aspartic acid, 215D (C in 1390, and GAT in 1514), was 
detected. Analysis of single molecules of DNA (see section 3.2.3), also detected the 
presence of the ZDV resistance-associated amino acid tyrosine, 215Y (ThC  for 1390, 
and TAT for 1514). In addition, two other variants were observed at codon 215, 
asparagine (215N, AAC, in 1390 and AAI  in 1514) and cysteine (215C, JC in 
1390), although no wild type variants were detected in either patient at this codon. 
These changes at codon 215 were sustained in subsequent timepoints sampled (see 
Tables 3.3 and 3.4), but in patient 1390, 41L appeared to decline, and single molecule 
analysis of the proviral DNA showed the presence of more wild type genotypes than 
mutant at codon 41. This was not observed in patient 1514, were the mutant codon 
remained predominant. 
This study has detailed the isolation of HIV-1 variants carrying variation at ZDV 
resistance-associated positions 41 and 215. The variation at codon 41 was that 
commonly observed after ZDV therapy, but never previously shown to be detected in 
naive patients, although some believe that statistically, on the basis of base 
substitution levels observed in poi, changes at such resistance-associated positions 
could occur (Najera et a!, 1995). However, at the time of the discovery of these 
isolates, the most interesting observations was not only the detection of variation in 
drug naive patients, but the detection of alternative amino acids at codon 215, which, 
as discussed, has never been detailed in any HTV-1 population. 
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These findings were presented at the Conference on Retroviruses and Opportunistic 
Infections (Washington DC, USA, Jan-Feb 1995), where it became clear that several 
other groups had also observed (but not published) this GAC change at codon 215, 
but were not sure of its significance. The detection of this change has subsequently 
increased in the literature (Goudsmit et al, 1996; Goudsmit et al, 1997; Quigg et al, 
1997; Yerly et al, 1998; Berlusconi et a!, 1998). In addition, recent studies have also 
documented additional changes at codon 215 including serine (Goudsmit et a!, as 
above), and cysteine (Yerly et al, as above). 
Analysis of viral RNA is thought to be more representative of the current circulating 
isolates, with the isolates from the proviral DNA population derived possibly from 
defective provims and not representative of a viable viral population. When this 
population was examined in both patients, although analysis was limited, it showed 
the presence of the aspartic acid (215D), observed in the proviral population. Again, 
additional changes at this codon were observed: asparagine (215N, MC, in 1390 
and AAI  in 1514) and histidine (215H, CAC, in 1390), but no wild type variants were 
detected (see Tables 3.3 and 3.4). 
8.2 Transmission of HIV-1 
8.2.1 Transmission of resistant variants of HIV-1 
As discussed in Chapter 1 (see section 1.8), since 1993 the documented occurrences 
of new infections initiated by resistant variants of HIV-1 has increased. Retrospective 
analysis of many populations, undertaken because of this increased awareness of these 
transmission events, has shown the seroconversion rates by such virus to be 
approximately 10%. The estimated numbers of new infections has been calculated by 
many groups throughout the world: 10% of new infections in Spain, where the ZDV 
resistance-associated change K70-9R was detected in a homosexual male, in addition 
to detection of V106-->I (which had in vitro resistance to ZDV), and the V108-->l 
change (associated with resistance to Nevirapine)(de Oliveira et a!, 1998); 13% of 
new infections in both 1993 and 1997, were caused by ZDV-resistant isolates in 
another Spanish group of patients (75 in total at both timepoints, where resistance 
238 
was detected using the LiPa Assay (Murex))(Rubio et a!, 1998); Data from 
Switzerland on the occurrence of primary infections by ZDV resistant variants also 
estimated that 10% of new infections, in the period 1990 to 1994, were caused by 
ZDV resistant variants (Perrin eta!, 1994); 21%, where 4 of 28 (14%) showed the 
presence of the K70—+R change, and 2 of the 28 (7.1%) showed the presence of the 
double mutants 41L/215D and 70R1215Y, detected by direct automated sequencing 
of PCR derived proviral DNA (Berlusconi et al, 1998). 
In a study by Cunningham eta! (1998), looked for the presence of wild type and 
mutant codons at antiretroviral resistance-associated positions 41, 69, 70, 74, 184, 
214, and 215 (which confer resistance to ZDV, ddl, ddC, and 3TC), using the line 
probe assay, LiPa (Murex, Stuyver eta!, 1997, see section 8.2.3.1 later). They found 
that in 1992, eight patients showed resistance to ZDV, represented by the presence of 
the classical mutations at codons 215, 41, and 70, including double mutants with 
mutations at 70 and 215 (see Figure 1.6). In 1993, four transmissions were detected, 
with isolates carrying double mutations at codons 41 and 215. By 1994 this number 
was three, all with isolates of HIV-1 carrying the 41 change alone, and in 1995 four 
transmissions were detected, three isolates with single mutants (70, 41, or 215 alone), 
and one double mutant (41/215). No mutations were detected in the HIV-1 
population in 1996, and in 1997 only one transmission was documented, by an isolate 
showing the presence of the 70 mutation alone. From this study they have concluded 
that the prevalence of ZDV resistance genotypes in recently infected patients has 
decreased over the years. 
Through the detection of infection by resistant variants of HIV-1, from both recent 
newly infected populations and through retrospective analysis of stored material, the 
picture of such transmission events will become clearer. There is not enough 
published information, and it is too early to suggest that the numbers of such 
transmissions have indeed decreased over recent years, especially with the earlier 
more aggressive nature of antiretroviral therapy adopted today, and in light of the 
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number of new drugs available, to all of which some degree of resistance has been 
detected (Schinazi eta!, 1997). 
8.2.2 Identification of unusual variants of HIV-1 
In addition to the transmission events discussed above, caused by HIV-1 carrying 
known resistance to antiretroviral drugs such as ZDV, several groups have also noted 
the presence of unusual changes at codon 215 in patients recently infected and drug 
naive. In a study by Goudsmit eta! (1996, 1997), resistant isolates with the presence 
of the ZDV resistance-associated mutations CTG and ITG at codon 41, were 
detected. They also observed variation at codon 215, with both the ZDV resistance 
mutation TAC (215Y), and also the aspartic acid amino acid, GAC (2151)), as well as 
detection of the mutation TIC (serine, 215S). 
In a study by Yerly et a! (Yerly eta!, 1998), variation in plasma HIV-1 RNA, at 
codon 215, was detected in 12 patients from a total of 136 new infections analysed. 
From this group, eight patients where followed, and at the start of the study two of 
the patients carried a single change at 215Y, 3 had this in conjunction with 41L, 1 
patient had the less frequently observed change 21517, and 2 had variants with multiple 
mutations, 67N/70R1215Y, and 67N170R1215F/219Q. At baseline all were 
antiretroviral naive, however five of the eight patients followed underwent 
antiretroviral therapy initiated at seroconversion, three on ZDV monotherapy, and one 
on ZDV plus ddl, for a period of approximately 6 months. One patient did not 
receive treatment until 20 months post seroconversion, again ZDV monotherapy for 6 
months. 
The mutations detected were the classical ZDV resistance-associated changes, 
however, when these patients were observed genotypically over a 48 month period, 
the mutations 215D, and 215C (IC, cysteine), were subsequently detected. The 
appearance of the 215D change was shown to occur as early as 6 or 24 months in 
patients who initiated immediate ZDV monotherapy, or not until 40 months in those 
who never received any therapy (although therapy was limited). 
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It appears that the prevalence of recent infections with isolates carrying either the 
known resistance mutations and/or the 'new' variation aspartic acid at codon 215 (or 
the cysteine, observed by Yerly et al, 1998, or the serine observed by Goudsmit et a!, 
1996, and 1997), is increasing. Cunnigham eta! (see section 8.2. 1) stated that 
transmissions with resistant HI\T1 are decreasing. The above data would appear to 
contradict this, with new infections still being detected. It may be the means of 
detection which produces these aberrant results. 
8.2.3 Detecting transmissions of IHIV-1 with variation in drug associated 
codons 
8.2.3.1 	Phenotypic and genotypic monitoring of HIV-1 
With the development of detection assays, that allow detection of mutations 
associated with drug therapy, greater numbers of samples could be rapidly screened. 
Systems such as the point mutations assay (PMA, discussed in Chapter 7), were 
widely used in many clinical trials for the investigation of resistance profiles. 
However, point mutation based systems, such as the PMA and more recently the line 
probe assay developed for clinical diagnosis (LiPa, Stuyver eta!, 1997), are only 
directed at known ZDV resistance-associated variation documented to occur during 
therapy at for example codon 215: ACC (wild type), ThC and UC (mutant). Such 
systems are limited by the fact that they only detect exactly what is being probed. The 
figures obtained by such point mutation based assays could be underestimates or 
falsely representative of the transmission of isolates with some form of variation at 
codon 215: detection of the TAC variant could actually be GAC, and vice versa in 
point mutation based assays. It is clear that the occurrence of this aspartic acid 
change, and indeed other amino acids shown to arise at this position, are increasing, 
confirmed by the numbers documented in the literature (as discussed above), and the 
implications of such detection assays must be addressed. For the line probe assay, 
discovery of a new variant could be added to the system by addition of a newly 
designed probe. However the numbers of variants at codon 215 (ACC, IAC, ITC, 
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AC, GAT, ]C, !CC), make interpretation of such results difficult and always 
subject to discussion. 
8.2.3.2 	Estimation of transmission frequency 
From the study group detailed in this thesis the percentage of transmissions occurring 
by 1-UV-1 isolates carrying some form of variation at resistance associated positions 
was 5.7% (2 from a group of 35 individuals). This group included patients who had 
estimated seroconversion dates between 1990 and 1994, with one transmission 
occurring in 1992 (patient 1390), and the other in 1993 (patient 1514), with no other 
transmission events detected within the study period. Samples from both these 
patients were first obtained in 1994, some 2-3 years post-seroconversion. 
Clarification of the drug naive status was achieved by the clinicians in several follow 
up appointments. 
The genotypic data, and the clinical data at that time strongly indicated that these two 
individuals were infected by a resistant strain/s of HIV-1. In addition to the unusual 
variation at codon 215, the existence of the resistance mutation at codon 41 was 
further clarification of transmission, because, as discussed above, this change is 
associated with ZDV use, which the patients had never been prescribed, and which 
both patients denied having taken. 
The individuals who were the suspected sources of infection for both patient 1390 and 
1514 have died (see Appendix III), in 1994. It is reasonable to suggest therefore, that 
at the time of transmission to patients 1390 and 1514 (in 1992 and 1993 respectively), 
the contact could have been in the later stages of infection and on antiretroviral 
therapy, and therefore could have conceivably developed resistant viral isolates 
(although there are no data available on the 'source' of infection). 
In this study transmission occurred through the homosexual route, although 
transmission of resistant virus by all routes has been documented (see section 1.8). 
The Scottish National AIDS/HW Register is a database of individuals reported to the 
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Scottish Centre for Infection and Environmental Health (SCIEH), who have tested 
positive for Hill-antibody, or who have been diagnosed as having AIDS. SCIEH 
monitors and publishes the numbers of new infections reported, and Table 8.1 below 
shows the numbers of H1V-1 infections between 1989 and 1995 by risk category. 
TABLE 8.1 
lilY Infected persons by exposure category and year of report 
Transmission Category 	 Infections by year of report 
1989 1990 1991 1992 1993 1994 1995 
Sexual Intercourse between men 48 56 64 63 74 	82 71 
Heterosexual 27 41 42 45 41 	39 58 
Injecting drug use 51 34 50 38 56 	27 26 
Other/undetermined 10 9 8 6 6 	7 22 
TOTAL 	 136 140 164 152 177 155 177 
* Taken from HIV infection and AIDS in Scotland annual review to 31 December 
1995, ANSWER, 26 January 1996 
It can be seen that in the years that patients 1390 and 1514 became infected, 63 
(1992), and 74 (1993), cases of infection by the homosexual route were reported in 
Scotland. Using the percentage of new infections caused by resistant variants of HIV-
1 calculated in this study, 5.7%, and the average figure of 10%, we can crudely 
predict that between 3-7 people will have been infected by a resistant variant of 
HIV-1 through homosexual contact in the years 1992 and 1993 (the years patients 
1390 and 1514 where infected). 
8.2.3.3 	Underestimation of transmission frequency? 
As discussed earlier sampling from patients 1390 and 1514 was not carried out until 
at least 1-2 years post-seroconversion, although this ranged from 2 months to 4 years 
in the remainder of the study group. Although other detection systems may produce 
results which as discussed previously, may be difficult to interpret, the analysis used 
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for detection of resistance in this thesis, direct sequence analysis, would detect the 
presence of any mutation (although frequency of the mutant would be a factor in bulk 
sequence analysis). Recent evidence from the study published by Yerly et al (1998), 
suggests that the timescale between infection and sampling may also be a factor in the 
detection of transmission events, and underestimation of such events. 
In the Yerly study, discussed earlier, they followed patients in the early stages of 
infection, and they showed that there was a change in the viral population soon after 
transmission, which varied from the 215Y ZDV resistant variants (early in infection), 
to the 215D variants, and also 215C. The time for the changes in population to 
occur, or be detected, varied in each individual, but no wild type variants were 
detected in the early samples, or indeed 48 months later. 
It seems unlikely therefore that any other transmission events occurred, other than the 
2 documented, within this study group, as only wild type genotypes were observed. 
No change from either ZDV-resistant, or the alternative variants such as 215D, to 
wild type genotypes within a 4 year period after transmission has been shown. In the 
two patients discussed in detail in this study, 1390 and 1514, no wild type sequences 
were detected in either the proviral DNA or RNA populations for codon 215 at any 
time over a 4 year study period in a drug naive environment. 
The estimated transmission of variants that differ from wild type obtained in this 
study, for the HIV-1 population covering Eire, Northern Ireland, north of England 
and Scotland, may be an accurate measure. However, some may have been missed 
because they did not represent a high enough frequency within the viral population, 
where initial screening was of bulk material, which although capable of detecting 
minor variants, is more likely to detect the dominant variants. Therefore, the 
transmission frequency may still be a slight underestimation. 
244 
8.3 Evolution of Resistance in HIV-1 Populations 
8.3.1 Reversion of resistance with cessation of therapy 
The reversion of resistance to antiretroviral therapy in patients whose treatment was 
interrupted, by the change in variation at amino acids encoded by the RT region of pol 
has been investigated (as discussed in section 1.7.7). What these studies showed was 
that the reversion of the classical ZDV resistance mutations at codons 41, 67, 70, 215 
and 219 varied in each individual, and the change was in general, slow, taking up to a 
year. The changes in the mutant to wild type frequencies detected could be the result 
of two mechanisms, the selective outgrowth of the virus most suited to that 
environment, or alternatively, molecular reversion. 
When two variants, produced by site-directed mutagenesis of a wild type clone, were 
grown together in equal proportions in vitro (wild type and the partially resistant 
variant carrying only the 215Y change), the wild type quickly became the dominant 
variant, increasing in frequency by passage 20, which was also reflected by an increase 
in sensitivity obtained by phenotypic assays (Boucher eta!, 1993). This, and 
subsequent studies discussed previously, indicate that the second mechanism, 
outgrowth, is active in such environments, and that the growth advantage of such wild 
type variants (though small), is sufficient to result in replacement of mutant 
populations (carrying the classical ZDV resistance associated mutations), in the drug 
free environment. 
8.3.2 Reversion after transmission of ZDV resistant variants of II1V-1 
The accumulation of mutations in HIV- 1 in the presence of ZDV therapy and/or 
increasing resistance to the drug, has been shown to occur in an ordered and temporal 
fashion (Kellam eta!, 1994). The data now accumulating on the transmission of 
resistant variants indicates that there may also be a pattern in the change in profiles of 
resistant variants after transmission. This is illustrated by the step-wise change from 
215Y> 215C > 215D (Yerly eta!, 1998), or the 215Y> 215D > 215S (Goudsmit et 
a!, 1996, 1997), and also possibly 215Y> 215C > 215D from the patients detailed in 
this thesis (where an initial 215Y population is proposed based on the sequence data 
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detecting such variants in the proviral DNA, and the possibility of the 215C 
intermediate due to its detection in patient 1390). 
When the initial population was 215Y (TAC), no reversion to wild type at codon 215 
was detected in the transmission studies detailed so far, as the only wild type 
genotypes were detected in patients who showed the presence of the 215F variant, 
which appears in the absence of drug to be replaced by wild type virus. Interestingly, 
during limited drug therapy (6 months), these isolates quickly obtained additional 
ZDV-associated mutations, which was not observed when therapy was used in the 
215Y isolates, although again therapy was limited in all (6 months)(Yerly et al, 1998). 
It appears that reversion to wild type is slower when the transmitting population 
contains the 'new' 215 mutations. 
8.3.3 Evolution of the codon 215 in drug free environment 
8.3.3.1 	Viability of the QC change 
To understand better what effect the mutations, such as aspartic acid at codon 215, 
within the viral enzyme have on the virus, recombinant virus was produced, as 
detailed in Chapter 4. These recombinant viruses contained the wild type sequence of 
111EV- 1 from HXB2, but with the RT sequence replaced with patient derived material 
from the proviral DNA. The recovery and production of such virus meant that only 
viable virus would grow, and by direct sequence analysis of the RT region after 
recovery of the new recombinant virus, any additional changes, that may have effected 
the growth of the virus, would have been detected. 
Such virus was easily recoverable from the recombinant viral assay, and the virus 
produced was able to spread by both cell-free, and cell-to-cell contact, which suggests 
that the presence of the GAC change at codon 215 did not have any major effect on 
the growth capacity of the virus. Indeed, such virus was able to produce comparable 
titres in in vitro culture to that of wild type virus. The only isolate that did not grow 
at similar rates was the AAT,  asparagine recombinant from patient 1514. This virus, 
did not produce syncytia in a similar manner to the others, and did not appear to have 
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as great a cytopathic effect, not killing all the cells, but causing some ballooning. This 
culture was monitored by staining and ELISA experiments, as the visual observations 
of syncytia production were not reliable. 
8.3.3.2 	Viral growth kinetics 
In vitro assays studying the growth of these recombinant isolates were undertaken 
(see Chapter 6). The aim of the experiments was to clarify the significance of the 
215D change, and what the fitness of this variant was, especially as it had persisted in 
both patients 1390 and 1514 for a period of up to 4 years. The experiments allowed 
predetermined mixtures of two viruses to be grown in a controlled in vitro cell culture 
system in the absence of drug, allowing the fitness of each isolate to be determined, by 
following the changes in frequency of each. Such experiments allow the effects of 
different mutations within the RT alone to be determined. Any changes in the 
enzyme's ability to function would be due to that particular RT, the genotype of 
which is known, as it is only this gene that differs between each recombinant virus, as 
each is produced from the same wild type parental strain. 
The ability of each virus to replicate and produce infectious progeny and, by 
reflection, the effect of the mutations in the RT enzyme, can be determined by 
removing virus at each passage, and through RT-PCR on cDNA obtained from these 
cultures the frequency of each isolate at different times can be determined by the 
signal from direct sequence analysis (as detailed in Chapter 3). 
As discussed in Chapter 6 only a representative number of samples were tested from 
these viral growth competition assays, but the limited data showed that in the absence 
of drug pressure then wild type virus rapidly replaced the 215D carrying isolates in 
the in vitro system. Direct sequence analysis of the viral RNA population showed 
only the presence of wild type genotypes, independent of the input frequency, which 
had been fixed at between 10, 30, 70 and 90%. However, in three samples from the 
41L/215D against wild type virus assay, the presence of another population at a lower 
frequency was observed. The presence of the aspartic acid change at codon 215 was 
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present, represented by the a smaller peak in the automated sequence data, and was 
detectable in three timepoints over a 2 week period (see Figure 3.3). Interestingly 
multiple peaks were detected in the assay with the higher input of 215D virus, but not 
in any of the assays where the input was at a lower frequency. However, the level of 
the 215D variant decreased to undetectable levels, again being replaced by the wild 
type variants. It appeared that at a higher input frequency it took longer for 
replacement, and longer for the wild type sequence to completely dominate the 
culture. 
The drug sensitivity data (in this thesis) suggest a similar sensitivity to ZDV for both 
the 41M1215 and 41L/215D virus, but the effect of the presence of the mutation at 41 
on the growth kinetics is still not clearly understood. In the absence of drug, the 
presence of the 41L mutation with 215Y imparted a decrease in fitness relative to wild 
type, surprisingly however, 4 1 L alone was less fit than the double mutant in the drug 
free environment. It may be that the acquisition of the 215D onto the 41L 
background generates the fittest virus in the drug free environment, a question that 
could be answered by analysis of later timepoints in the assay competing 41M/215D 
with 41L1215D. 
8.3.3.3 	Phenotypic resistance profiles 
Growth assays gives some indication of the fitness of the aspartic acid variants, and an 
insight into what effect this change would have on the situation in vivo. One crucial 
aspect of viral phenotypic profiles is the drug sensitivity, as tested in established in 
vitro assays, which allow different isolates to be categorised as either sensitive or 
resistant virus. The HeLa plaque reduction assay that was performed by S. Albanil 
(UCSD) on the recombinant virus produced in this study (as detailed in Chapters 4 
and 5) showed that the GAC variation at codon 215 conferred a 2.8 fold increase in 
resistance to ZDV (as detailed in Chapter 5, Table 5.7). Of greater interest was the 
observation that the double mutant, 41L/215D, showed a 2.8 fold increase in 
resistance when compared to the wild type HXB2. These changes are minimal, where 
as the ZDV resistance change 41L alone confers a 4-fold increase in resistance 
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(Kellam eta!, 1992), but is a slight increase above wild type.. It appears that in the 
presence of change at 215, variation at 41 is not important in affecting the function of 
the RT enzyme with respect to phenotypic resistance. The 215D isolate, shows some 
increase in resistance, but is more sensitive to ZDV than the classical ZDV resistance-
associated changes, such as 41L, 215Y. 
The data obtained from the HeLa assay showed the effect of the 215D alone or in 
conjunction with 41L at one time, and although it shows an increase in resistance, it is 
minimal and the virus is all but sensitive, and it is hard to interpret such data as they 
stand alone. Several studies have subsequently confirmed the 'sensitivity' of the 
215D change to ZDV, where its acquisition on a resistant background resulted in a 
decrease in resistance. In the Yerly et a! study (1998), the sensitivity of isolates 
containing the 215D in the presence of other ZDV resistance mutations was detailed. 
In one patient the initial isolate carried the ZDV resistance-associated mutations 
41 L/67D/70K/2 1 SY/2 19K, with an 1050 value of 0.1 8pM (when tested with ZDV in 
the PBMC assay, see section 5.1.3). At 24 months the 215Y mutation had been 
replaced with 215D, and this resulted in an IC50 value of<0.O1IIM. These data 
clearly show that the replacement of the 215Y with 215D results in an increase in 
sensitivity to ZDV. 
Interestingly when there was a change in the 41 codon from mutant to wild type in the 
above background the IC50 value remained at <0.0 1p.M. It appears that the presence 
or absence of the 41L mutation makes no difference to the phenotypic resistance to 
ZDV when 215D is present, similar to the observations in this thesis where the 
presence or absence of mutations at codon 41 did not alter the IC50 value, which still 
conferred an increase in sensitivity to ZDV of 2.8 fold. In vitro fitness assays on 
known ZDV resistant variants (Harrigan et a!, 1998), suggested that an isolate with 
the single 215Y change had an equal fitness to one which also had the 41L mutation 
(i.e. 41L/215Y), although these experiments were not designed for optimal sensitivity. 
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As discussed above, other changes in addition to the aspartic acid, have been 
observed at codon 215. The replacement of the 215Y with 215C (ICC), in a 
41M167D/70K1219K background was shown to also confer sensitivity to ZDV, in a 
similar fashion to that detailed with the 215D replacement (Yerly, as above). The 
215S, ICC change has also been shown to be sensitive to ZDV (Lacey and Larder, 
1994). However, although the sensitivity of the effects of these additional amino 
acids has been determined, the fitness of these, especially in the presence of wild type 
variants is again unclear. Goudsmit showed that the 215S serine change was slightly 
fitter than the 215D change, although both decreased resistance to ZDV in drug 
sensitivity assays at a similar level (Goudsmit et al, 1996). This indicates that several 
aspects of such isolates must be investigated to fully understand what the situation is 
in vivo and the effects of these variants is likely to be. 
8.3.3.4 	Transmission of ZDV-resistant HIV-1 
Several studies have shown that the GAC has a fitness advantage over ZDV resistant 
variants (Goudsmit and Yerly, as discussed above), but none have shown the 
relevance of this change in the presence of wild type virus. In the growth competition 
assays discussed above and in Chapter 6, it is clear that in the presence of wild type 
virus, GAC variants are outgrown, rapidly. This indicates that in a drug free 
environment the wild type virus does have a fitness advantage over the 215D variants, 
even when the wild type is present at a low frequency, as indicated by the above 
where the wild type virus dominated the culture rapidly even when the infection was 
only initiated with 10% of this wild type isolate. 
From these observations, and data from other studies following changes in viral 
populations after transmission of RT variants of HIV-1, it appears that if wild type 
virus was present in vivo (in a drug free environment) then it would rapidly replace 
the 215D variants (although how rapid this would be in vivo is unclear). 
In both patients 1390 and 1514, direct sequence analysis of single molecules of 
proviral DNA from the PBMCs did not detect the presence of any wild type variants 
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at codon 215. Analysis of viral RNA, which is thought to be more representative of 
the current circulating isolates, although limited in numbers and sequences, also did 
not detect wild type variants. The lack of these wild type variants may be the reason 
why the 215D isolates persisted for up to 4 years in these patients. Interestingly no 
wild type variants have been detected in either of the studies discussed on 
transmission of resistant variants (Yerly and Goudsmit, as above), and the only 
reversion to wild type was observed in two patients who had been infected by virus 
with the 215F virus, which appears to follow a different evolutionary pathway. 
In one study (Yerly et.  al, 1998) analysis of the population soon after infection showed 
there was an initial population of 215Y ZDV resistant isolates that was replaced by 
the 215D. In both patients 1390 and 1514 such 215Y variants were detected (see 
Tables 3.3 and 3.4), and it seems likely that these may have dominated in the initial 1-
2 years post-seroconversion, a window which we were unable to analyse in this study 
and where replication without the selective pressure of the drug probably allowed 
replacement of the 215Y with the fitter 215D. 
In the Yerly study the replacement of the 215Y was followed by the transient 
appearance of the 215C change, which was subsequently, in some patients followed 
for the longest periods, to be replaced by the 215D change. Inpatient 1390, analysis 
of proviral DNA showed the presence of 215C in the first sample, which was not 
observed in the two later samples analysed. Although we can only hypothesise on the 
population between the transmission and first sample analysed, the data in this study, 
along with the observations from other studies, suggest that the same route was 
followed (population may have been predominantly 215Y, which has subsequently 
been replaced by the 215D variants). 
8.3.4 Mutational bias of 111EV-1 RT 
The retroviral RT shows a mutational bias favouring transitions (purine to 
purine/pyrimidine to pyrimidine) over transversions (purine to pyrimidine, and vice 
versa)(Swanstrom, R., 1997; Leitner et al, 1997; Mansky and Temin, 1995), with a 
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preferred G to A change (see section 1.4.1.1). These authors also found that some 
transitions occurred more frequently than others, with a trend from 
G—*A>T-+C>A---G>C--T. This bias has been shown in HLV-1 during therapy with 
the nucleoside 3TC, and the appearance of mutations at codon 184 in the RT (Keulen 
et a!, 1997). In patients treated with 3 TC the pattern of emergence of resistance was 
from the wild type 184 Met (ATG), followed by the appearance of 184 lie (ATA), 
which is subsequently replaced by 184 Val (TG). The 184 Val mutant has been 
shown to have a greater fitness than the 184 He (Back eta!, 1996), explaining the 
outgrowth of this variant, but the reason for the initial outgrowth of the 184 lie was 
unclear. Using a technique for isolation of minor variants present at a lower 
frequency, without in vitro selective pressures, the limit dilution technique was 
applied, and through this analysis an additional variant at codon 184, Thr (AG), was 
also detected (Keulen et a!, 1997). 
Genotypic analysis of these 184 variants showed a significant bias toward transitions 
over transversions, and significantly higher frequencies of the G—A transition 
mutations, which would lead to 1 8411e, than the A-3G transitions, that would lead to 
184Val. These data suggest that the relative frequencies of the virus pool, pretherapy, 
are determined by the mutational bias of the RT enzyme, and that subsequent 
selection is based on the relative fitness of the variants, indicated by the subsequent 
outgrowth of the 1 84 Va! variant under the selective pressure of drug therapy. They 
hypothesised that variants obtained by transversions, are selected only if they then 
exhibit an increased fitness over variants that can be more easily generated through 
transitions. 
In the study by Yerly eta! (1998), an initial population with the ZDV resistance 
mutation ThC at 215, was followed by the transient appearance of ThC, with 
eventual replacement by the aspartic acid 215D, GAC variants. The change from 
TAC to TGC is through a transitional mutation at the second nucleotide position of 
the amino acid, a change shown to be favoured by the RT of HIV-1, a similar 
situation to that seen in 184. This variant is however replaced by AC, which could 
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be produced through a double mutation from wild type, through a transition at the 
first and second position and a transversion at the second (ACC to Q4C)  or through a 
transversion at the first nucleotide position from the ZDV resistance associated 
mutations (LAC to GAC). Therefore in a similar manner to that discussed for the 
3TC variant 184Va1, the variant with the more difficult evolutionary path becomes 
dominant because it appears to be fitter in the drug naive/drug limited environment (in 
the apparent absence of wild type sequences). Again it may be that through 
mutational bias of the RT the intermediate was present in the viral pool, but selection 
of the fitter variant in the absence of drug allowed the GAC variant to dominate. 
In the patients discussed in this thesis, five amino acid 215 variants were detected: 
ThC (Y), GAT/AC (D), AAI (N), !QC (C), and CAC (H) (see Chapter 3). 
Through the RT mutational bias, changes such as the H and C can be explained, 
produced through mutation from the Y (see diagram 8.1 below, wild type ACC 
highlighted in italics/bold). 
The flow diagram in Figure 8.1 shows the mutational pathway from one amino acid to 
another, and shows that through point mutations (transition, or transversion (show as 
blue broken line)), all the variants observed could be generated in the virus pool at the 
time of/soon after transmission. The predominance of the GAC variants therefore is 
likely due to the increased fitness of this variant in the drug free environment. Of 
particular interest is the positioning of the asparagine, AAC/N in the middle of the 
flow diagram. This amino acid was found in patient 1514, and as discussed in 
Chapters 4 and 5 (sections 4.2.4 and 5.2.2), isolation of this recombinant was difficult, 
and cultures could only be monitored by production of p24Ag, as the cytopathic 
effects normally observed with the HXB2 background did not present. This variant 
may be the intermediate from wild type at codon 215, to IAC/Y, in the presence of 
ZDV therapy (highlighted in red broken line, see diagram 8.1). The time scale for 
appearance of most of the ZDV resistance associated mutations is generally greater 
than that observed for other nucleoside antiretroviral drugs (NRTIs, such as 3TC, 
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FIGURE 8.1 
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GAC/D 
where resistance can be detected within 2 weeks of therapy). We have shown in this 
laboratory that this isolate is more difficult to culture, and this may be the reason why 
it has never been detected in vivo, and why the detection of the resistance codon 
215Y may take longer, due to this slower growing intermediate. Also, the detection 
of the less frequently observed change at codon 215, phenylalanine, flC/F, may be 
explained by the mutational bias discussed above, requiring a transversion from the 
second nucleotide position, from 'A' to 'T' (TAC-4TIC). 
To investigate the idea of the slower growing AAC intermediate further, more 
stringent growth kinetic experiments over a greater time scale would have to be 
performed to allow a greater understanding of this asparagine isolate. The env gene 
of this variant was not sequenced, and this would have to be carried out to clarify that 
the effects observed where due to changes in the RT and not due to mutation within 
the V3 loop, responsible for syncytia formation. 
8.4 Fitness of liv-! Variants With Variation at Drug Associated 
Codons 
Although detection of HIV-1 by genotypic analysis gives an insight into the 
quasispecies that exist within an individual, the above discussions illustrate that the 
effects of mutations cannot be obtained by this analysis alone. Indeed, variants 
detected in the proviral population such as the unusual 215D isolates may be from 
defective provirus, and phenotypic experiments are required to translate the genotypic 
data to understand the effects of such viral isolates in vivo. 
It is clear from the above discussion that several new changes are being detected by 
several groups at the amino acid position 215 in the RT gene. The relevance of such 
variation (resistance) can be monitored by the presence of mutations in the proviral 
DNA or RNA populations. A consequence of such mutations may be the alteration of 
the viral enzyme, RT, which could alter the replicative ability of the virus. 
Antiretroviral therapy and the development of drug resistance offered markers for 
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following changes within viral populations and understanding the changes that take 
place. The use of drugs allowed a greater understanding of the dynamics of HIV-1 
and the data generated on viral generation times and turnover, (Ho eta!, 1995; Wei et 
a!, 1995; Perelson eta!, 1996), a combination of in vivo observations, in vitro assays 
along with the application of mathematical models, combined, allow a greater 
understanding of the complex nature of MV-1 and antiretroviral drug resistance. 
8.4.1 Fitness of IHV-1 with variation at codon 215 
The genotype and phenotype of ZDV resistant variants of HIV-1 have been 
extensively investigated, but it is clear that an increasing number of infections are 
occurring with virus that carries some form of variation at classical antiretroviral 
resistance positions in the RI, but not those previously detailed. 
Recent studies by Harrigan eta!, (1998), looking at the classical ZDV mutations, led 
to the proposal that when two variants of HIV-1 are grown together then, by 
Darwinian competition, the fittest virus would be selected. To determine what was 
the fittest variant, they grew mixtures of viral isolates containing the commonly 
observed ZDV resistance-associated mutations (prepared by site-directed mutagenesis 
of a parental HIV- 1 H34B2 wild type), M41-3L, K70-+R, T215—>Y, and the double 
mutant M41L + T215Y, against wild type virus, and monitored the infection by direct 
sequence analysis of the RT region (in a similar manner to that discussed in Chapter 
6). They followed the frequency of the variants at each culture passage as they 
replicated in cell culture. In the absence of drug the order of relative fitness was: 
Wild Type> K70R>> T215Y = M41L + T215Y > M41L. 
What this information tells us is that the presence of mutations at certain drug 
associated positions renders the virus less fit in the drug free environment in vitro, and 
we can use such information to understand changes in populations of resistant virus in 
vivo. 
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As discussed previously several groups have now shown the existence of the 215D 
change and other changes at this amino acid position, and it is important to acquire 
information of the growth kinetics of such variants by both observational and 
experimental means, to understand, and allow predictions and increase our knowledge 
of this set of variants, in a similar manner to that amassed for the ZDV resistant 
isolates. 
Goudsmit et a! (1996; 1997), discovered resistant isolates of HLV-1 in patients who 
had recently seroconverted, and also observed the 215D, and a serine, 215S 
mutation, TIC (detected by the point mutation assay (see Chapter 7)). Subsequent 
genotypic observations showed that in these patients the TAC variants were being 
replaced by the IIC isolates over time, and, from their data they concluded that in a 
drug free environment the fittest virus was that carrying the ICC change at codon 
215 (where no wild type variants were detected and excluded from this): ICC> 
GAC>TAC 
They applied standard mathematical models on the above data, that allowed the effect 
of selection on one nucleotide position, on the fitness of that population to be 
calculated. Using two different approaches, they looked at the serine ITC change. 
The first model assumed discrete generations of viral replication, and the second 
assumed replication in continuous time, and both were based on the assumption that 
both wild type and mutant variants were present at a defined time zero, which both 
had different fitness. 
From their analysis they concluded that using the first model, the ZDV resistant 
variant was 1% less fit than the TIC mutant, although changing the parameters of the 
equation, such as altering the input ratio (information they did not have), then a value 
of between 1-2.3% was obtained. Using the second model they found a value of 0.4-
0.6%, again dependent on alterations to the input parameters. What this initial analysis 
showed was a minimal fitness gain of the TIC over the rest of the population, of 
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between 0.4-2.3%. They also noted that there was no change in the viral load, which 
may not be expected with such a small fitness difference. 
Subsequent analysis of this TIC mutation, through cloning of plasma derived HIV-1 
RNA, from the individual infected by these resistant variants, and the source of 
infection, over a 20 month period, allowed the evolution of this change to be 
monitored (Goudsmit eta!, 1997). In the previous model they could only estimate 
the frequency of the TIC variant against the rest of the population, because the 
detection assay could not distinguish between TAC and GAC at codon 215 (the PMA 
is based on extension through the 2 r nucleotide position of the codon, which is 'A' 
for both TAC  and  GAC  mutations). Through sequence analysis of the cloned 
material, the changes in the RT could be monitored more accurately. They again 
observed that the dominant variant in the drug free environment after transmission 
was the TIC change, and showed by mathematical modelling that the fitness of this 
variant was only 1% higher than that of the GAC. However, the relative fitness of the 
1AC was found to be 10-25% higher than the ThC resistant variant (Gousdmit et a!, 
1997; data from this thesis (see section 6.2.5)). Such predictions could be useful in 
understanding what changes may occur in other individuals infected by similar strains, 
and the time scales thai would be involved in the frequency changes of each virus from 
the relative fitness values obtained. 
8.4.2 Following frequency changes in viral populations using point mutations 
Several studies have been discussed previously (as above), where the changes in 
frequencies of particular viruses can be followed through direct sequencing and 
detection of mutations in vivo. Several groups mimicked the in vivo situation in vitro, 
carrying out experiments competing two viruses in predetermined mixtures, in a 
continuous cell culture, where the parameters of mathematical models can be 
controlled: such as the input viral ratio, the output ratio, time in culture (in a similar 
manner to that discussed in Chapter 6). To follow such experiments, direct sequence 
analysis has been applied, where the changes in the frequency of a point mutation 
could be followed by the change in peak height observed in the trace data obtained by 
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such analysis (discussed in sections 6.1. 1/2)(Larder et a!, 1993, 1995; Sharma and 
Crumpacker, 1997; Harrigan eta!, 1998). The changes in each variant can be 
calculated as a frequency of the peak height, and therefore a prediction of the relative 
levels of each variant in that population. The data can then used in the equation, 
s = lit In [q(t)p(0) / p(t) q(0)] 
as detailed in Chapter 6 (sections 6.1.3, and 6.2.5). This analysis was applied to the 
competition assays carried out in the study detailed in this thesis, as discussed above 
and in Chapter 6. 
From the relative fitness values obtained in this and the other studies discussed above, 
it appears that the important steps in the evolution of the HIV-1 population after 
transmission, and in a drug free environment, appear to be from wild type to known 
ZDV resistance at codon 215, such as TAC, then the subsequent change to GAC, 
which have both been shown to represent an approximate fitness difference of 10-
30%. This transition to the GAC in the drug free environment in one study was 
shown to occur through an intermediate variant expressing the cysteine, TGC, at 
codon 215 (Yerly eta!, as above). It would be interesting to determine the fitness of 
this variant, where observational data, through sequence analysis, suggests that it is 
more fit in this environment than the ThC, but not as fit as the GAC. However in the 
Goudsmit studies (1997, 1996), the ICC change, was deduced to be 1% fitter than 
the GAC, replacing it slowly in the host. The serine ICC variants, although shown to 
be fitter than the GAC variants, did not dominate the population immediately, instead 
the GAC rapidly replaced the IAC mutant population, followed by a slower 
replacement of the GAC population by the ICC, the speed of replacement an 
indication of the fitness of each variant, as derived through the application of 
mathematical formulas discussed above. 
It is clear from this and other studies that in the drug free environment the order of 
fitness is wild type> ThC>1AC > TAC, or possibly wild type ICC >IcC>AC 
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>IAC. Although elucidation of such patterns is useful in following infection within a 
patient, it is still not clear what the relevance of these variants in the presence of 
antiretroviral therapy will be. Such studies with drug intervention in such individuals 
after transmission are limited, although in the Yerly et al study (1998), limited ZDV 
monotherapy did not seem to alter the transition from resistant to sensitive virus 
through the pathway detailed above. Although, this therapy was sufficient to lead to 
accumulation of additional mutations when the initial amino acid at codon 215 was 
phenylalanine (215F). Harrigan eta! (1998), did investigate the change in the 
population of classical ZDV resistant carrying isolates in the presence of drug, but 
have not looked at the lesser known changes, such as the GAC, discussed in this 
thesis. 
8.5 Conclusions 
In recent years the use of ZDV, as a monotherapy or in combination with other drugs, 
has increased, and in addition, is given earlier in infection. This, compounded by 
other factors such as the high viral turnover, and therefore high population size, 
means that at the time of transmission the viral population of the 'source' could, in all 
probability, be dominated by resistant variants. Now we have this intermediate group 
of isolates, which can be classed as both sensitive and resistant. They hold variation 
at drug-associated positions, but not the changes classically observed. These changes 
do alter the sensitivity of the virus, where some groups have shown a increase in 
sensitivity to within the range classically defined as the 'sensitive' isolates (i.e. <1.0 in 
the HeLa plaque reduction assay), but in this thesis there was an increase in resistance 
above that of wild type, which although only 2.8 fold, the 41L change alone only 
results in a 4-fold increase, not greatly different for that observed for this new 215D 
change. This indicates the difficulty arising now, where the detection of recent 
documented changes at previously well defined amino acids is occurring more 
frequently. 
In this thesis, and in other studies recently published (as discussed above), such 
variants of HIV-1 that carry mutations at drug associated positions have been 
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discussed. Variation at amino acid codon 215 has never been documented in patients 
who have never undergone any therapy. Actually, the changes discussed above, that 
have now been shown to occur at codon 215, have never been documented during 
therapy either, even with the massive amount of literature which has accumulated 
over the past decade of antiretroviral therapy. Although the fact that we have not 
observed them is not conclusive proof that they did not exist, perhaps as a smaller 
pool of the quasispecies, it is interesting that they are only now being documented 
with the onset of combination drug regimes that are being used more aggressively and 
earlier in infection. 
8.5.1 Implications of infection with resistant variants of lilY-i 
The two patients discussed in detail in this thesis, who showed the presence of the 
215D mutation, were, according to in vitro experiments, showing minimal resistance 
to the drug ZDV. Unfortunately there are no data showing what happens to such 
variants in the presence of drug pressure. Limited drug treatment with ZDV 
monotherapy did not show replacement of the 215D variants with resistant isolates, 
but this treatment was of limited duration, and is not sufficient data to suggest that the 
emergence of classical ZDV resistant variants would not arise upon initiation of 
therapy (Yerly et al, 1998). 
Phenotypic and mathematical modelling indicates that in a drug free environment 
could be: 
WT>TCCGAC>TAC 
Combining the data from different studies shows that the GAC is 10-25% fitter than 
the TAC, with the ICC only 1% fitter than the GAC, and the wild type showing a 
30% relative fitness gain over the GAC. From the fitness gains/losses shown by the 
models, and the rapid replacement of the GAC by wild type, or indeed the TAC by 
AC, observed through genotypic analysis of either in vivo or in vitro samples (from 
growth kinetic experiments), it would seem feasible to suggest that the changes 
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observed in the absence of drug may be mimicked in the opposite direction in the 
presence of drug pressure, where variants such as the aspartic acid at 215, would be 
quickly replaced by resistant isolates. 
The 'contacts' may have received only these variants, and in the drug free 
environment, the GAC had the replicative advantage over the classical ZDV-resistant 
variants (such as 215Y). Due to this replicative advantage the 1AC carrying isolate 
has been shown to persist for up to 4 years after infection, and as yet has not been 
shown to revert to wild type or to resistant genotype. 
8.5.2 Individualisation of patient therapy 
For the reason discussed above, it would not be in the best interests of patients 1390 
and 1514, or indeed those identified in other studies, to be prescribed ZDV with the 
data available on these 215D/C/S isolates of lilY-i at present. For this reason, and 
the accumulating data on the initiation of infection with HIV- 1 virus containing 
resistance to antiretroviral drugs, a more individual approach to patient therapy may 
be the most efficient way in managing infection in the clinical environment. 
With the development of the rapid diagnostic techniques for detection of mutations, 
and the ability to follow, with greater accuracy, the viral load of each patient, such 
individualisation of therapy may be a possible goal. Although more extensive analysis, 
such as direct sequencing, is the most accurate technique for detecting the existence 
of mutations that may not be being detected by the point mutation based assays, it is a 
costly and time-consuming procedure, not suitable for the quick results required in the 
clinical setting. 
8.5.3 Eradication of BIV-1 
With the development of the new highly active antiretroviral therapy (HAART), using 
3-5 different drugs in combination, that are maintaining the levels of plasma RNA at 
undetectable levels (<50 copies/ml), the possibility of eradication of I11V- 1 has been 
discussed. Obviously the problem with such a goal is the ability of HIY-1 to 'hide' in 
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reservoirs that are either not replicating (latently infected T-lymphocytes), or are not 
accessible to drug therapy (brain, CNS). For eradication to be feasible, destruction of 
HIV-1 in all areas of the body must be achieved. 
Early studies have shown that patients on HA.ART, with undetectable levels of plasma 
HIV-1 RNA, do still contain virus within the latent T-lymphocyte population that is 
capable of being activated into replication in vitro, a process that may also occur in 
vivo (Wong et a!, 1997; Chun eta!, 1997). These viruses, however, through 
genotypic analysis, have been shown not to contain resistance to antiretrovirals 
(Wong eta!, as above). Some researchers have suggested that to eradicate HIV-1 
these latent reservoirs must be stimulated into production to allow the destruction of 
the proviral population they are harbouring. The fact that such reservoirs do not 
contain resistant virus means that they would still be sensitive to drug therapy, 
although the antiretrovirals today are still only directed at de novo replication and 
prevent production of progeny virions. 
However, as the accounts of infections with drug resistant isolates increases, such as 
those discussed in this thesis, latently infected cells may well contain resistant variants. 
Sequence analysis of the viral population during the symptomatic phase of primary 
infection showed only the presence of mutant variants of lily-i after transmission 
(Yerly eta!, 1998). Even though HAART is, by viral load measurements, successful, 
in these cases the latent pools are likely to hold resistant variants, a point that must be 
clarified in such patients who have been infected by resistant variants and initiated on 
some form of therapy. It is this population that will require the greatest attention over 
the subsequent years where the discussion of eradication will no doubt intensify. If 
such latent reservoirs of resistant variants are stimulated into production, they may 
not be as easily controlled by even the most aggressive of treatments. 
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8.5.4 Conclusion 
In this thesis I have shown the existence of resistant variants of HIV-1 and in addition 
the presence of virus with new changes at codon 215, which could be termed 
resistant, although this resistance is minimal, only conferring a 2.8 fold increase in 
resistance to ZDV. The evidence from this study confirms that of other groups, 
showing that such variants have a fitness advantage over the classically resistant 
variants of HIV-1 in the drug free environment. In this study we have also shown that 
when present, wild type isolates are the fittest in in vitro experiments. However, the 
changes that will occur in the presence of drug pressure have not yet been examined, 
and it is this which in addition to the information gained on these variants of HIV-1 
with changes at amino acid codon 215, will complete our understanding of the 
situation for the patient, where antiretroviral drug intervention is now successful, 
through multi-drug combinations, in maintaining the viral loads at significantly low 
levels over greater periods than previously achieved. The main concern is to fully 
understand the significance of this new set of variants in this situation. 
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APPENDIX I 
PATIENT DATA INFORMATION 
COLLECTION 
Appendix I 
The following shows the patient questionnaire completed by the clinician, 
accompanying each sample. Also included are the two main tables from the Paradox 
4.0 MEP Repository database, showing the information available for selection of 
patients. 
Patient questionnaire 
2 	Patient table 
3 	Data table 
266 
MRC AIDS DIRECTED PROGRAMME - MOLECULAR EPIDEMIOLOGY PRCGR4ME 
Form to accompany each blood sample sent to repository 
Date of sample: 0J01E0 (day, month. year) 




Gate of birth: 
initials: 	 Hospital/Clinic No:  
Sex (1=rnale,2female) 	Li M.E.P. no. of sample:  
4ieave blank) 
Race or ethnic group'escenl 0 (1—White; 2Afncan. specrly; 3—Indian Sub-contfnent; 
	
4=Wesf lndian/Guyanar,-5=Offiei or mixed, specify 	J 
Country of birth [1 t l = UK 2 = Eh.; 3 =Other Eutopean, specify 	:4 Uganda; 
5= Other African, specify 	: 6 other, specify________ 
 Probable transmission route U sexual intercourse between men 
2 = sharing injecting equipment 
3 = transfusion 
4 = contaminated blood product 
5 = sexual interCourco borwoon man and woman 
6 = vertical 
7 other (specify)  
8 = vnkncwn 
Place of infection (U known): Town/City 	Country 
Presumed dale of HIV Infection from behavioural information: 
between EIJtI] and ELJE[J reason:______________________________ 
rnthyr 	 mthyr 
(example: shared injecting equipment between July '85 and May '87 = between 06185 and 05/67) 
Date of last negative HIV ab test (I? performed) 	 [[JELIIEEI 
Date of first positive HIV ab test 	 [LICEIII] 
Date of suspected seroconversion illness (If appllc3ble) IJJ.LE1LLJ 
Was first positive test carried out as part of investigation of an illness which was subsequently judged 
to be I-lW-related ? 0 1`1=Yes, 
is information available br the contact person from whom the virus 	U 
presumably acquired? (1-Yes, ONo) 
U yes, give probable transmission route by wtich contact person originally 
acquired the virus ? (Specify tram 7 options in Question 3) 	 [1] 
Could contact person be invited to participate in this study? (1-Yes, O_-No) U 
Patient has AIDS diagnosis? 	0 	(1- yes, O=Vo) 
Date and details of AIDS diagnosis (if applicable) 
mo_ 
Has patient.. 
ever been on open zidovvdine 7 0 	(1-Yes, O=No 
ever been on open doll ? 	0 (1=Yes, O=No) 
ever been on open ddC? 	U (1=Yes, O=No) 
ever been on other anti-relroviral? [] 	(l=Yes, 0--No) 
ever been in trial of ant]-retmviral? [I (1=Yes, O--No) 
If yes, name trial 1 	date started OJEIJEE] 
name trial 2 	date started EEIIJ]CD  
If yes, date stailed EII][I]{T] 
If yes, date staled []II]EL1II[1 
If yes, date started {I]E[J[] 
If yes, date staled [IIEIE[D 
Trial no.  
Trial no.  
10. 	Does patient have any iliness!symptorns at time sample taken - whether HIV-related or otherwl;e 
(eq cold symptoms, other STtYs)? 0 (1= Yes, O_-No) 
If yes, please specify 
it. 	Most recent C04 lympocyto count (if any) 
F1 I 1 1 1mm3 	Date of count LIJ[JIJ[JJ 
Amount of EDTA 	blood provided mm( 
Amount of clotted blood provided 	[I] ml 
Has a sample from this patient ever previously been sent to the repository? U (i=Yes, O-NO 
Please note. We shall be requesting basic follow-up information on this patient at appmx(mately annual 
intervals. 
Send a copy of this form with the blood sample(s) to: 
Dr Andrew Leigh Brown, Division of Wologicill Sciences, lCAPB Genetics Buudlng, University 01 
Edinburgh, West Mains Road, Edinburgh £119 UN, Scotland. 
PATIENT TABLE 
Patient MEP number MEP# A4* 
Hospital/clinic identification code HOSPCOIDE A4 
Soundex code SOUNDX 
Date of birth DOFBIRTH D 
Patient's initials INIT A4 
Patient's hospital/clinic number HOSP/CLIN# AlO 
Sex MIF M/F Al 
Race or ethnic group RACE Al 
Country of birth COUNTRY Al 
Probable transmission route TRANSROUTE Al 
Is city of infection in U.K? Y/N UKC1TY? Al 
If Yes enter city/town dialling code C1TYINP A6 
If No enter country dialling code COUNTRYINF A7 
Presumed date of HIV infection from 
behavioral information  
DATEINP All 
Reason for date assignment REASON M10 
Date last negative HP! test LASTNEG D 
Date first positive HIV test FIRSTPOS D 
Date of suspected seroconversion illness DATESEROCON D 
Was first positive test part of investigation 
into an illness subsequently judged REV 
related? Y/N  
H1VRELATED Al 
Is information available for the contact person 
from whom virus presumably acquired? Y/N  
CONTtNFO Al 
Probable transmission route for contact person CONTTRANS Al 
Could contact person be invited to participate 
in this study? YIN 
CONTPART Al 
DATA TABLE 
Form/Sample MEP number FORM/SAMPL# A6* 
Patient MEP# MEN A4 
Does a sample accompany this form? Y/N SAMPLY/N Al 
Sample or data date DATADATE D 
Hospital/clinic identification code HOSPCODE - A4 
Patient has Aids diagnosis? Y/N AIDS Al 
Aids diagnosis date A1DSDATE D 
Aids diagnosis details AIDSDETAILS A3 
Patient on open Zidovudine? Y/N AZT Al 
Start date zidovudjne AZTDATE D 
Patient on open ddl? Y/N DDI Al 
Start date open ddE DDIDATE D 
Patient on open ddC? Y/N DDC Al 
Start date open ddC DDCDATE D 
Patient on other anti-retroviral? YIN IANTMET Al 
Start date other andrewoviral ANTIRETDATE D 
Patient on other anti-renxjviral n-ia!? Y/N ANTIRETTRIAL Al 
Trial 1 name TRLICODE A2 
Trial 1 start date TRLIDATE D 
Trial ino: TRLI# 	 JAIO 
Trial 2 name TRL2CQDE A2 
Trial 2 start date TRL2DATE D 
Trial 2no: TRL2# AlO 
Does patient have any illness or 
symptoms at time sample taken Y/N 
S'YMFT Al 
Ifsymptomspleasespecify SPECIPYSYMPT M 
Most recent CD4 count/rnm3 CD4COIJNT N 
CD4 count date CD4DATE D 




The following shows the nucleotide sequences of the reverse transcriptase region of 
pot, aligned against the subtype D HI V-la and/or subtype B ITV-1 HXB2. Below is 
the list of sequences shown. All ZDV resistance associated codons are highlighted in 
bold type: codons 41, 67, 70, 215 and 219 (see Figure 1.6 for nucleotide and amino 
acid changes) 
1 	1037 
2 	Antiretroviral naive study group 
3 	Patient 1390 
4 	Patient 1514 
5 Antiretroviral experienced study group 
6 	Competition Assay Dilutions Sequences 
7 	Competition Assay Dye Terminator Sequences 
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1 
Nucleotide Sequence Alignment of the Reverse Transcriptase Region of poi 
Gene for Zidovudine Treated Patient 1037 












1037.1 1 ------------------------------------------------ GT 
1037.2 1 ------------------------------------------------ GT 
1037.3 1 ---------- - CA.TG.0 .............................. GT 
1037.4 1 -------A.. .CA.TG.0 .. .......... .......... ........ GT 
1037.5 1 ---------- ---------- - A.T ...... .......... ........ GT 
1037.6 1 --... 	 .AG ........................................ GT 
1037.7 1 ---------T .0 ........ .......... .......... ........ GT 
51 61 71 81 91 	100 
I I 	41 I I I I 
Eli 51 AGAAATTTGT ACAGATATGG AAAAGGAAGG AAAAATTTCA AGAATTGGGC 
1037.1 51 ...... C ... ..... A .... .......... G ......... .......... 
1037.2 51 ...... C ... ..... A .... .......... . ......... .......... 
1037.3 51 ......C... G .... AT ... .......... G ......... .......... 
1037.4 51 ......C... G .... AT ... .......... G ......... .......... 
1037.5 51 ......C... G .... AT ... .......... G ......... .A.G ...... 
1037.6 51 ......C... G .... AT ... ......... A G ......... .A.G ...... 
1037.7 51 ...... C... G .... AT ... .......... G ......... .......... 
101 111 121 131 141 	150 
I I I I I 67 	I 
Eli 101 CTGAAAATCC ATACAATACT CCAATATTTG CCATAAAGAA AAAAGACAGT 
1037.1 101 .......... .......... ... G.G .... .......... ......... C 
1037.2 101 .......... ... T ...... ... G.G .... .......... .......... 
1037.3 101 .......... ... T ..... A . 	. 	.G .......................... 
1037.4 101 .......... ... T ...... ... G.G .... .......... G ... A..... 
1037.5 101 .......... ... T ...... ... G ...... .......... .... A..... 
1037.6 101 .......... ... T ...... ... G ...... .......... ... GA..... 
1037.7 101 .......... ... T ...... ... G ...... .......... G ... A..... 
151 161 171 181 191 	200 
I 	70 I 1 I I I 
Eli 151 ACCAAGTGGA GAAAATTAGT AGATTTCAGA GAACTTAATA AGAGAACTCA 
1037.1 151 . 	.T. 	.A..................................... A...... 
1037.2 151 . 	.T. 	.A................. C ...... .......... ... A ... A.. 
1037.3 151 . 	.T. 	.A............................................ 
1037.4 151 . 	.T.GA............................................ 
1037.5 151 . 	.T.GA............................................ 
1037.6 151 . .T.GA............................................ 
1037.7 151 . 	.T.GA............................................ 












1037.1 201 G. .0 ...... .......... .......... A ..... C ... ... T.A. .G. 
1037.2 201 . . .0 ...... .......... .......... A ..... C ... ... T.A...  
1037.3 201 . . .0 ...... .......... .......... A ..... C ... ... T.A. .G. 
1037.4 201 . . .0 ...... .......... .......... A ..... C ... ... T.A. .G. 
1037.5 201 . . .0 ...... .......... .......... A ..... C ... ... T.A. .G. 
1037.6 201 . 	. .0 ...... .......... .......... A ..... C ... ... T.A. .G. 
1037.7 201 .... ....... .......... .......... A ..... C ... ... T.A. .G. 
273 
251 261 271 281 291 	300 














301 311 321 331 341 	350 









1037.1 301 ......... A . . . .A. .0 ..... G ..... T ..A ....... ..C ....... 
1037.2 301 ..T ...... A . .. .A. .0 ..... G ..... T . .A ..... T. ..0 ....... 
1037.3 301 ..T ...... A . . . .A. .0 ..... G ..... T . .A ......... C ...... C 
1037.4 301 ..T ...... A . . . .A. .0 ..... G ..... T . .A ......... C ....... 
1037.5 301 ......... A . . . .A. .0 ..... G ..... T . .A ......... C ....... 
1037.6 301 ........ CA . . . .A. .0 ..... G ..... T . .A ......... C ....... 
1037.7 301 ......... A . . . .A. .0 ..... G ..... T . .A ......... C ....... 


















1037.7 351 ....... A.. .......... .......... .......... .......... 












1037.1 401 .......... ...... A ... ......... T .0 .................. 
1037.2 401 ....... G .. ...... A ... ......... T .0 .................. 
1037.3 401 .......... ...... A ... ......... T .0 ........ .......... 
1037.4 401 .......... ...... A ... ......... T .0 .................. 
1037.5 401 .......... ...... A ... ......... T .0 ........ ... G...... 
1037.6 401 .......... ...... A ... ......... T .0 .................. 
1037.7 401 .......... ...... A ... ......... T .C. .T ............... 












1037.1 451 .....T .... .......... ...... C. .A .................... 
1037.2 451 .....T .... .......... ...... C. .A . .G................. 
1037.3 451 .....T .... ..... G.G.. ...... C. .A . 	.G................. 
1037.4 451 .....T .... ..... G.G.. ...... C. .A . 	.G................. 
1037.5 451 .....T .... .......... ...... C. .A .................... 
1037.6 451 .....T .... ..... G.G.. ...... C. .A . 	.G................. 
1037.7 451 .....T .... ..... G.G.. ...... C. .A . 	.G................. 












1037 .1 501 .......... .......... .......... .......... ..A....... 
1037.2 501 .......... .......... .......... .......... ..A....... 
1037.3 501 .......... .......... .......... .......... ..A....... 
1037.4 501 ......A ... .......... .......... .......... ..A....... 
1037.5 501 .......... .......... .......... .......... ..A....... 
1037.6 501 .......... .......... .......... .......... ..A....... 
1037.7 501 .......... .......... ..... A .... .......... ..A....... 
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551 561 571 581 591 600 
I I I I 	 2151 I 
Eli 551 TAGAGAAATT AAGAGAACAT CTATTGAGGT GGGGATTTAC CAGACCAGAT 
1037.1 551 ..... G. .0. G ... C ....... G.. . .A .............. C ...... C 
1037.2 551 ..... G. .C. G ... C ..... ..G ....... .......... ..C ...... C 
1037.3 551 ..... G. .C. G ... C ....... G... .A .......... TA . .0 ....... 
1037.4 551 ..... G. .C. G ... 0 ....... G.G. .A .......... TA . .0 ...... C 
1037.5 551 ..... G. .0. G ... C ....... G ................... C ...... C 
1037.6 551 ..... G. .0. G ... 0 ....... G.. . .A .......... TA . .0 ....... 
1037.7 551 ..... G. .0. G ... C ....... G.G. .AA ......... TA . .0 ...... C 
601 611 621 631 641 
219 I I I I 
Eli 601 AAAAAACATC AGAAAGAACC CCCATTTCTT TGGATGGGTT AT 
1037.1 601 .......... ....... C.T .AT.CCT.. 
1037.2 601 ........ C . .......... T ..... C ..... 
1037.3 601 .......... .......... T ..... C... 
1037.4 601 .......... ....... C. 
1037.5 601 ....... TAT CAG. .AG.A .T.CA 	. .CG .TTG 
1037.6 601 G ......... .......... T ..... C ..... 
1037.7 601 .......... ....... T T ..... C ..... 
2 
Nucleotide Sequence Alignment of the Reverse Transcriptase Region of the poi 
Gene From Amino Acid Codon 137 to 229 for Repository Study Group 
1 11 21 31 41 	50 
137 I I I I I 
Eli AATGAGACAC CAGGGATTAG ATATCAGTAC AATGTGCTTC CACAGGGATG 
1009.1 .......... .......... .......... ........ G ........... 
1051.1 
1072.1 .......... ....... A ................................ 
1083.1 




1146 .1 .......... .... A ..... .......... ........ G ........... 
1147.1 
1154 .1 .......... .......... ...... A ....................... 
1219 .1 .......... .......... ...... A ....................... 
1249.1 
1294 .1 .......... .......... .......... ....... G............ 
1301.2 
1313 .1 .......... ...... C ... .......... ........ C ........... 
1317 .1 .......... .......... .......... .......... .... A ..... 
1334 .1 .......... .......... .......... ........ A ........... 
1367.1 
1390.1 
1407 .1 .......... .... A ..... G ............................. 
1433 .1 .......... .......... .......... .......... .... A ..... 
1438 .1 .......... .......... G ......... .......... .......... 
1441.1 
1442.1 
1444 .1 .......... ...... C ... .......... ........ C ........... 











1568.1 	.......... 	 .......... 	 .......... 	 .......... 	 .... A 











1009.1 .......... .. A ....... ....... C ...................... 
1051.1 .......... .. A ..................................... 
1072.1 .......... .. A ..................................... 
1083.1 .......... .. A ..................................... 
1087.1 .......... .. A ....... .. ... T ........................ 
1105.1 .......... .. A ..................................... 
1111.1 .......... .. A ....... ....... C ...................... 
1111.2 .......... .. A ....... ....... C ...................... 
1146.1 .......... .. A ....... .... G. .0 T ....... G ........... 
1147.1 .......... .. A ..................................... 
1154.1 .......... .. A ....... .......... .......... ..... G..T. 
1219.1 .......... .. A ....... .......... .......... .. T ....... 
1249.1 .......... .. A ....... ....... C ...................... 
1294.1 .......... .. A ..................................... 
1301.2 .......... .. A ....... ....... C ...................... 
1313 .1 .......... .. A ....... .......... .......... ........ A. 
1317 .1 .......... ..A ....... ..... T ........................ 
1334 .1 .......... ..A ....... ..... T ........................ 
1367.1 .......... ..A ....... .. ..... c.. .......... ..... G.... 
1390 .1 .......... ..A ....... ..... T .... .......... ..T .....T. 
1407.1 .......... .. A ....... ....... C ...................... 
1433 .1 .......... ..A ....... ..... T .... .......... ..A ....... 
1438 .1 .......... ..A ....... ..... T ........................ 
1441.1 ...... T... ..A  ......... ..... C ...................... 
1442.1 .......... .. A ....... ..... GCC ...................... 
1444 .1 .......... ..A ....... .......... .......... ........ A. 
1446 .1 .......... ..A ............ CA ....................... 
1449 .1 .......... ..A ....... .......... .......... ..T ....... 
1488 .1 .......... ..A ....... ..... T.0 ...................... 
1504 .1 .......... ..A ..................................... 
1514 .1 .......... ..A ....... .......... T ................... 
1525 .1 .......... ..A ....... ..... T.0 ...................... 
1531 .1 .......... .. A ....... ..... T.0 ...................... 
1542.1 .......... .. A ....... ....... C ...................... 
1544 .1 .......... .. A ....... ....... C ...................... 
1568 .1 . 	. .G ...... .. A ....... .... GT ........................ 










1009.1 .T ........ .......... ..C. 	.A. 	.K..................... 
1051 .1 .T ........ .......... ..... A ........................ 
1072 .1 .T ........ .......... ..CC .......................... 
1083 .1 .T ........ .......... ..C. .A .... .......... T ......... 
1087 .1 .T ........ .......... ..C. 	.A ........................ 
1105.1 .T ........ .......... ..C. .A .... ....... G ............ 
1111.1 .T ........ .. G ....... ..C. 	.A ........................ 
1111 .2 .T ........ .......... ..C. 	.A ........................ 
1146 .1 .T ........ .......... ..... A ........................ 
276 
1147.1 .T . C. .A . 
1154.1 .T . C. .R . 
1219.1 .T ........ .......... ..C. 	.A ........................ 
1249.1 .T ........ .......... ..C. 	.A ........................ 
1294.1 .T.K ...... ... G ...... .. C. 	.A. 	.0 ..................... 
1301.2 .T ........ .......... ..C. 	.A ........................ 
1313.1 .T ........ .......... ..C. 	.A ........................ 
1317.1 .T ........ .......... ..C. .A .............. T ......... 
1334.1 .T ........ ... G ...... .. C ..... A ..................... 
1367.1 .T ........ .......... ..C. 	.A ........................ 
1390.1 .T ........ .......... ..C. 	.A ........................ 
1407.1 .T ........ GA ........ .. C. 	.A ........................ 
1433.1 .......... .......... .. C. .A .... .......... T ........ C 
1438.1 .T ........ G ......... ..C. .A .... .......... .......... 
1441.1 .T ........ .......... ..C. .A ........... G ............ 
1442.1 .T ........ .......... ..C. 	.A ....................... C 
1444.1 .T ........ .......... ..C. .A .... .......... .......... 
1446.1 .T ........ .......... ..C. .A ........... G ............ 
1449.1 .T ........ .......... ..C. .A. 	.0 ..................... 
1488.1 .T ........ .......... ..... A .... .......... .......... 
1504.1 .T .................... CT .......................... 
1514.1 .T ........ .......... ..C. .A ........ C ............... 
1525.1 .T ........ .......... ..C. .A .... ....... G.. T ......... 
1531.1 .T ........ .......... ..C. .A .... .......... .......... 
1542.1 .T ........ .......... ..... AA ... .......... T ......... 
1544.1 .T ........ .......... ..... A .... .......... T ......... 
1568.1 .T ........ ......... R . 	C. .A. .Y. .......... .......... 












1009 .1 .......... .......... .......... ........ A........... 
1051 .1 . 	.A................................... A........... 
1072 .1 .......... .......... ......... A ..... C. 	.A........... 
1083 .1 .......... .......... .......... ........ A........... 
1087 .1 .......... .......... .......... ........ A........... 
1105 .1 .......... .......... .......... ........ A........... 
1111.1 .......... .......... ........ A. ........ A. T ......... 
1111 .2 .......... .......... ........ A . ........ A. T......... 
1146 .1 .......... .......... ........ A. ........ A........... 
1147 .1 .......... .......... .......... ........ A. T ......... 
1154 .1 .......... .......... .......... ........ A........... 
1219 .1 .......... ..... A .... ........ A. ........ A........... 
1249 .1 .......... .......... ......... R ........ A........... 
1294 .1 .......... ....... T .. ......... A ........ A........... 
1301.2 .......... .......... .......... ........ A ........... 
1313 .1 .......... ....... T .. ........ A . ........ A........... 
1317 .1 .......... .......... .......... ..A ..... A........... 
1334 .1 .......... .......... ......... A . .A.....A........... 
1367 .1 .......... .......... .......... ........ A........... 
1390 .1 C ......... .......... .......... ........ A........... 
1407 .1 .......... .......... ........ A. ........ A........... 
1433 .1 .......... .......... .......... ........ A........... 
1438 .1 .......... .......... .......... ........ A ........... 
1441 .1 .......... .......... .......... ........ A........... 
1442 .1 .......... ....... T .. .......... ........ A........... 
1444 .1 .......... ....... T .. ........ A. ........ A........... 
1446 .1 .......... .... G ..... .......... ........ A........... 
1449 .1 .......... .......... .......... ........ A........... 
1488 .1 .......... .......... .......... ........ A. ........ S. 
1504 .1 .......... .......... .... C ..... ........ A........... 
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1514.1 	 . A . 
1531.1 . A . 
1542.1 	.......... 	 .......... 	 .......... 	 ........ A ........... 
1544.1 ...................................... AG .......... 
1568.1 	...................................... AG .......... 
201 211 221 231 241 250 
I I I I 	215 I 2191 
Eli GAAATTAAGA GAACATCTAT TGAGGTGGGG ATTTACCAGA CCAGATAAAA 
1009.1 .G. .C.G... C ....... G. .......... ........ C . ..... C.... 
1051.1 .G. .C.G... C ..... T.G. .......... ........ C . ..... C.... 
1072.1 .G. .C.G... C ....... G ... ........ G ....... C . ..... C.... 
1083.1 .G.. . .G... C ....... G. .......... ........ C . ..... C.... 
1087.1 .G. .C.G... C.G ..... G. .......... ........ C . ..... C.... 
1105.1 .G. .C.G... C ....... G. .......... ........ C . ..... C.... 
1111.1 .G. .C.G... C ....... G... ....... ...... T.0 . ..... C.... 
1111.2 .G. .C.G... C ....... G ... ........ ...... T.0 . ..... C. .R. 
1146.1 .G. .C.G... C ....... G... ........ ........ C . ..... C.... 
1147.1 .G. .C.G... C.T .....G. . 	. 	.A.............. C . ..... C.... 
1154.1 .G. .C.G ... ........ G. . 	. 	.A.............. C . ..... C. .G. 
1219.1 .G. .C.G... C ....... G. .......... ........ C . ..... C.... 
1249.1 .G. .C.G... C ....... G..... R ..... ........ C . ..... C.... 
1294.1 .G. .C.G... C ........A . 	. 	.A.............. C . ..... C....  
1301.2 .G. .C.G ... ........ G. . 	. 	.R.............. C . ..... C....  
1313.1 AG. .C.G... C .....T.G . 	. 	.A.............. C . ..... C.... 
1317.1 .G. .C.G........... G .A.A ...... ........ C . ..... C.... 
1334.1 .G. .C.G... C ......... ... A ...... ........ C . ..... C.... 
1367.1 .G. .C.G... C ....... G. .......... ... A .... C . ..... C.... 
1390.1 .G. .C.G... C ....... G. .......... .... GA. .0 . ..... C.... 
1407.1 .G. .C.G... C .......G . 	. 	.A...... G. .G. . . .0 . ..... C.... 
1433.1 .G. .C.G... C ....... G. ....... R.. ........ C . ..... C.... 
1438.1 .G. .C.G. .R CR 	.T.G . .......... .. ...... C . ..... C.... 
1441.1 .G. .C.G... C ....... G. .......... G ....... C . ..... C.... 
1442.1 .G. .C.G... C ....... G. .......... ........ C . ..... C.... 
1444.1 AG. .C.G... C .....T.G . 	. 	.A.............. C . ..... C.... 
1446.1 .G. .C.G... C ......... ... A ...... ........ C . ..... C.... 
1449.1 .G. .C.G... C .......G . 	. 	.A.............. CG ..... C.... 
1488.1 .G. .C.G... C ....... G. .......... ........ C . ..... C.... 
1504.1 .G. .C.G... C .......G .M.R ...... ........ C . ..... C.... 
1514.1 .G.GC.G... C ....... G. .......... G ... GAT.0 . ..... C.... 
1525.1 .G. .0 ..... C ....... G. .......... ........ C . ..... C.... 
1531.1 .G. .C.G... C ....... G... ........ ... C .... C . ..... C.... 
1542.1 .G. .C.G... C .......G . . .A...... G.......C . ..... C.... 
1544.1 .G. .C.G... C ....... G. .......... ........ C . ..... C.... 
1568.1 .G. .Y.G..... T ..... G... ........ ... C .... C . ..... C.... 
251 261 271 
I I I 	229 
Eli AACATCAGAA AGAACCCCCA TTTCTTTGG 
1009.1 .......... ...... T... ..0  ...... 
1051.1 .......... ...... T... ..0  ...... 
1072.1 .......... ...... T... ..0  ...... 
1083.1 .......... ...... T... ..0  ...... 
1087.1 .......... ...... T... ..0  ...... 
1105.1 .......... ...... T... ..0  ...... 
1111.1 .......... ...... T... ..0  ...... 
1111.2 .......... G ..... T... ..0  ...... 
1146 .1 .......... ...... T... ..0  ...... 
1147.1 .......... ...... T... ..0  ...... 
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1154.1 . T ... ..0 ...... 
1219.1 . C. 
1249.1 . T ... ..0 ...... 
1294.1 .......... .......... .. C ...... 
1301.2 .......... ...... T... ..0 ...... 
1313.1 .......... .......... .. C ...... 
1317.1 ......... G ...... T ............ 
1334.1 .......... ...... T... ..0 ...... 
1367.1 a ......... ...... T... ..0 ...... 
1390.1 .......... G ..... T... ..0 ...... 
1407.1 .......... ...... T... ..0 ...... 
1433.1 .......... ...... T... ..0 ...... 
1438.1 .......... ...... T... ..0 ...... 
1441.1 .......... ...... T... ..0 ...... 
1442.1 .......... ...... T... ..0 ...... 
1444.1 .......... .......... ..C ...... 
1446.1 .......... .......... ..C ...... 
1449.1 .......... ...... T... ..0 ...... 
1488.1 .......... ...... T... ..0 ...... 
1504.1 .......... ...... T... ..0 ...... 
1514.1 .......... ...... T... ..0 ...... 
1525.1 .......... ...... T... ..0 ...... 
1531.1 .......... ... G. .T ..... C ...... 
1542.1 .......... ...... T... ..0 ...... 
1544.1 .......... ...... T... ..0 ...... 
1568.1 .......... ...... T... ..0 ...... 
3 
Nucleotide Sequence Alignment for Patient 1390 Timepoint 1 Single Molecules 
of Proviral DNA 
1 	 11 	 21 	 31 	 41 	50 
Eli.pol TTAAACAATG GCCATTGACA GAAGAAAAAA TAAAAGCATT AACAGAAATT 
HX.B2.pol 
13901.16 	-- 	................... G........................... 
13901.21 	---------------------- G ....... 	.......... .......... 
13901.23 	---------------------- G ....... 	.......... .......... 
13901.27 ---------- ---------- 	-- G ....... 	.......... .......... 
13901.4 	---------- ---------- 	.. G ....... 	.......... .......... 
13901.5 ...................... G ........................... 
13901.6 	---------- ---------- 	.. G ....... 	.......... .......... 





13 . 1 . seq 
13 .2 . seq 
13. 6 . seq 
13 . 8 . seq 
13 . 10 . se 
13 . 7 . seq 
13. 9 . seq 
13.11.se 
13 .5 . seq 
13901.28 
279 
13901.28 	 - 
51 	 61 	 71 	 81 	 91 	100 
I 411 I I I I 
Eli.pol TGTACAGATA TGGAAAAGGA AGGAAAAATT TCAAGAATTG GGCCTGAAA.A 
HXB2 .pol ........ G ........... ... G ...... .... A ..... .......... 
13901.16 	........ AC ........................................ 
13901.21 	........ AC ........................................ 
13901.23 	........ AC ....... T ................................ 
13901.27 	........ AC ........................................ 
13901.4 ......... AC 	........................................ 
13901.5 ......... AC 	........................................ 
13901.6 ......... AC ........................................ 
13901.11 ........ AC ........................................ 
13901.1 ......... AC ........................................ 
13901.2 ......... AC ........................................ 
13901.18 	---. . . . .AC ........................................ 
13901.3. 	--------AC ........................................ 
13. 1 . seq ---------- ---------- ---------- ---------- ---------- 
13.2.seq --------------------------------------------------
13 . 6 . seq 
13 . 8 . seq 
13 . 10 . se 
13 . 7 . seq 
13 . 9 . seq -------------------------------------------------- 
13 . 11 . se 

















13. 1. seq 
13 .2 . seq 
13. 6. seq 
13.8 . seq 
13.10. se 
13.7 .seq 
13. 9. seq 
13.11. se 






C ......... 	...... G... 
C ......... 	...... G... 
C ......... 	...... G... 
C ......... 	...... G... 
C ......... 	...... G... 
C ......... 	...... G... 
C ......... 	...... G... 
C ......... 	...... G... 
C ......... 	...... G... 
C ......... 	...... G... 
C ......... 	...... G... 
C ......... G ..... G... 
121 	131 	141 	150 
I I 67 	I 701 
TTGCCATAAA GAAAAAAGAC AGTACCAAGT 
T..A. 
G ... 	..... T..A. 
G ... 	..... T..A. 
G ... ..... T..A. 
G ... ..... T..A. 
G ... 	..... T..A. 
G ... 	..... T..A. 
G ... 	..... T..A. 
G ... ..... T..A. 
G ... 	..... T..A. 
G ... 	..... T..A. 
G ... 	..... T..A. 
G ... 	..... T..A. 
280 
151 	161 	171 	181 	191 	200 
Eli.pol GGAGAAAATT AGTAGATTTC AGAGAACTTA ATAAGAGAAC TCAAGATTTC 
HXB2 .pol 	.......... 	.......... 	.......... 	.......... 	...... C... 
13901.16 . . . .G. .G .............. G ....................... C... 
13901.21 	. . . .G ..... 	.......... 	..G ....... 	.......... 	...... C...  
13901.23 .. . .G ..... 	.......... 	..G ....... 	.......... 	...... C... 
13901.27 	. . . .G ..... 	.......... 	..G ....... 	.......... 	...... C... 
13901.4. ....G ..... 	.......... 	..G ....... 	.......... 	...... C... 
13901.5. 	....G ..... 	.......... 	..G ....... 	.......... 	...... C... 
13901.6. ....G ..... 	.......... 	.......... 	.......... 	...... C...  
13901.11 	. . . .G ..... 	.......... 	..G ....... 	.......... 	...... C... 
13901.1. ....G ..... 	.......... 	..G ....... 	.......... 	...... C... 
13901.2. 	....G ..... 	.......... 	..G ....... 	.......... 	...... C... 
13901.18 . . . .G ..... 	.......... 	..G ....... 	.......... 	...... C...  
13901.3. 	....G ..... 	.......... 	..G ....... 	.......... 	...... C... 
13. 1 . seq ---------- ---------- ---------- ---------- ---------- 
13.2.seq ---------- ---------- ---------- ---------- ---------- 
13.6.seq ---------- ---------- ---------- ---------- ---------- 
13.8.seq --------------------------------------------------
13 . 10 . se 
13 .7 . seq ---------- ---------- ---------- ---------- ---------- 
13.9.seq --------------------------------------------------
13 . 11 . se 
13 .5 . seq ---------- ---------- ---------- ---------- ---------- 
13901.28 
13901.28 















T.A. 	..... a.... 
t.A. 	..... a.... 
Eli.pol TGGGAAGTTC AATTAGGAAT ACCGCATCCT 
HXB2.pol 	.......... .......... ... A ..... C 
13901.16 .......... 	.......... 	... A ...... 
13901.21 	.......... 	.......... 	... A ...... 
13901.23 .......... 	.......... 	... A ...... 
13901.27 	.......... 	.......... 	... A ...... 
13901.4 . .......... 	.......... 	... A ...... 
13901.5 . 	.......... 	.......... 	... A ...... 
13901.6 . .......... 	.......... 	... A ...... 
13901.11 	........... 	.......... 	... A ...... 
13901.1 . .......... 	.......... 	... A ...... 
13901.2 . 	.......... 	.......... 	... A ...... 
13901.18 .......... 	.......... 	... A ...... 
13901.3 . 	.......... 	.......... 	... A ...... 
13.1.seq ---------- ---------- C. .A ...... 
13.2.seq ---------- ---------- C. .A ...... 
13. 6 . seq ------------------------------
13 . 8 . seq ------------------------------
13 . 10 . se ------------------------------
13 . 7 . seq ---------- ---------- ---------- 
13.9.seq ------------------------------
13 . 11 . se ------------------------------
13 . 5 . seq ------------------------------
13901.28 ------------------------------
13901.28 ---------- ---------- ---------- 
251 	261 	271 	281 	291 	300 













13901.18 .......... ..... A .... .......... .......... .......... 
13901.3 ................................................... 
13.1.seq .......... .......... .......... C ................... 
13.2.seq 
13. 6. seq --------------------------------------------------
13 . 8. seq ---------- ---------- ---------- ---------- ---------- 
13. 10. se 
13 .7 . seq ---------- ---------- ---------- ---------- ---------- 
13. 9. seq ---------- ---------- ---------- ---------- ---------- 
13. 11. se 
13 .5 . seq ---------- ---------- ---------- ---------- ---------- 
13901.28 
13901.28 
301 	311 	321 	331 	341 	350 
Eli.pol ATGAAGATTT TAGGAAATAT ACCGCCTTTA CCATATCTAG TATAAACAAT 
HXB2.pol ....... C.. C ..... G ..... T. .A .... ..... C .............. 
13901.16 . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG ...... 
13901.21 . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C .... ..CGa ..... 
13901.23 . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C .... ..C ....... 
13901.27 .CA.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG ...... 
13901.4. . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG ...... 
13901.5. . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG ...... 
13901.6. . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG ...... 
13901.11 . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG ...... 
13901.1. . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG ...... 
13901.2. . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG ...... 
13901.18 . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG ...... 
13901.3. . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C .... ..CG ...... 
13.1.seq . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG...... 
13.2.seq . 	A.G. .C.. C ..... G. .0 . .T. .A .... ..... C ...... CG...... 
13. 6. seq 
13 . 8 . seq 
13. 10. se 
13 . 7 . seq 
13. 9. seq 
13. 11. se 
13 .5 . seq 
13901.28 
13901.28 
351 361 371 381 391 	400 

















13. 6. seq 	---------- ---------- ---------- ---------- ---------- 
13.8.seq 
13. 10 . se 
13.7 .seq ---------- ---------- -. CA ...... .......... .......... 
13. 9 . seq --------------------------------------------------
13.11.se 
13 . 5 . seq --------------------------------------------------
13901 .28 
13901.28 
401 	411 	421 	431 	441 	450 
Eli.pol AGGATCACCG GCAATATTCC AAAGTAGCAT 
HXB2.pol 	......... A .................... 
13901.16 ......... A .......... 	..T ....... 
13901.21 	......... A .......... 	..T ....... 
13901.23 ......... A .......... 	..T ....... 
13901.27 	......... A .......... 	..T ....... 
13901.4 . ......... A .......... 	..T ....... 
13901.5 . 	......... A .......... 	..T ....... 
13901.6 . ......... A .......... 	..T ....... 
13901.11 	......... A .......... 	..T ....... 
13901.1 . ......... A .......... 	..T ....... 
13901.2 . 	......... A ........ T ..T ....... 
13901.18 ......... A .......... 	..T ....... 
13901.3 . 	......... A .......... 	..T ....... 
13.1.seq ......... A .......... 	..T ....... 
13.2.seq 	......... A .......... 	..T ....... 
13.6.seq 	.........A .......... 	..T ....... 
13.8.seq ......... A .......... 	..T ....... 
13.10.se 	......... A .......... 	..T ....... 
13.7.seq ......... A .......... 	..T ....... 
13.9.seq 	......... A .......... 	..T ....... 
13.11.se ......... A .......... 	..T ....... 
13.5.seq 	......... A .......... 	..T ....... 
13901.28 ......... A .......... 	..T ....... 
13901.28 	......... A .......... 	..T ....... 
GACAAAA.ATC TTAGAGCCCT 
T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
T ..... T..T. 
451 	461 	471 	481 	491 	500 
Eli.pol TTAGAAAACA AAATCCAGAA ATGGTTATCT ATCAATACAT GGATGATTTG 
HXB2 .pol 	.......... 	......... C . .A ........................... 
13901.16 .......... 	......... C . .A ........................ C.. 
13901.21 	.......... 	......... C . .A ........................ C.. 
13901.23 .......... 	......... C . .A ........................ C.. 
13901.27 	.......... 	......... C . .A ........................ C.. 
13901.4 . .......... 	......... C . .A ........................ C.. 
13901.5 . 	.......... 	......... C . .A ........................ C.. 
13901.6 . .......... 	......... C . .A ........................ C.. 
13901.11 	.......... 	......... C . .A ........................ C.. 
13901.1 . .......... 	......... C . .A ........................ C.. 
13901.2 . 	.......... 	......... C . .A ........................ C.. 
13901.18 .......... 	......... C . .A ........................ C.. 
13901.3 . 	.......... 	......... C . .A ........................ C.. 
13.1.seq .......... 	....... A.0 . .A ........................ C.. 


























































531 	541 	550 
I I I 
CATAGGACAA AAATAGAGAA 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	 ........ G. 
A .... 	........ G. 
551 561 571 	581 591 600 
I I 1215 I 	219 	I 
Eli.pol ATTAAGAGAA CATCTATTGA GGTGGGGATT TACCAGACCA GATAAAAAAC 
HXB2.pol GC.G ... C .. ..... G .... ........ C. 	..... C .... ..C ....... 
13901.16 .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13901.21 .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13901.23 .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13901.27 .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13901.4. .C.G ... C .. ..... G .... .......... 	..A. .0 .... ..C ....... 
13901.5. .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13901.6. .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13901.11 .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13901.1. .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13901.2. .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13901.18 .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13901.3. .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13.1.seq .C.G ... 0 .. ..... G .... .......... 	....C .... ..C ....... 
13.2.seq .C.G ... C .. ..... G .... .......... 	....C.... . .0 ....... 
13.6.seq .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13.8.seq .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13.10.se .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
13.7.seq .C.G ... C .. ..... G .... .......... 	....C .... ..C ....... 
284 
13.9.seq C.G. . .0 . G . C . C. 
13.11.se C.G. ..0 .. ..... G .... 	.......... . GA. .C .... ..c ....... 
13.5.seq .C.G ... C .. ..... G .... 	.......... ..A. .0 .... ..C ....... 
13901.28 .C.G ... C .. ..... G .... 	.......... . GA. .C .... ..C ....... 
13901.28 .C.G ... C .. ..... G .... 	.......... . GA. .C .... ..C ....... 
601 611 	621 631 641 	650 
Eli.pol ATCAGAAAGA ACCCCCATTT CTTTGGATGG GTTATGAACT CCATCCTGAT 
HXB2 .pol 	.......... 	... T ..... C .............................. 
13901.16 ....... G ..... T ..... C .............................. 
13901.21 	....... G ..... T ..... C .............................. 
13901.23 ....... G.. 	... T ..... C .............................. 
13901.27 	....... G.. 	...T  ..... C .............................. 
13901.4 . ....... G.. 	...T  ..... C 	.............................. 
13901.5 . 	....... G.. 	...T ..... C 	.............................. 
13901.6 . ....... G.. 	...T ..... C 	.............................. 
13901.11 	....... G ..... T ..... C ............................... 
13901.1 . ....... G.. 	...T ..... C .............................. 
13901.2 . 	....... G.. 	...T  ..... C .............................. 
13901.18 ....... G ..... T ..... C .............................. 
13901.3 . 	....... G.. 	...T ..... C 	.............................. 
13.1.seq ....... G ..... T ..... C .............................. 
13.2.seq 	....... G.. 	...T  ..... C .............................. 
13.6.seq ....... G.. 	...T  ..... C 	............................... 
13.8.seq 	....... G 
13.10.se ....... . ... 	... T ..... C ........ A. 	.......... 	.......... 
13.7.seq 	....... G ..... T .....C .............................. 
13.9.seq 	....... G.....T .....C .............................. 
13.11.se ....... G.....T .....C 	.............................. 
13.5.seq 	....... G.....T .....C .............................. 
13901.28 ....... G.....T .....C .............................. 
13901.28 	....... G.....T .....C .............................. 
651 	 661 	671 	681 
Eli.pol AAATGGACAG TACAGTCTAT AAAACTGCCA GAAAAG 

























Nucleotide Sequence Alignment of The RT Region of pol for Patient 1514 
1 	 11 	 21 	 31 	 41 	50 
	
15.1 	---------- --- TGTGCTT CCACAGGGAT GGAAAGGATC ACCAGCAATA 
15.2 TTCAGCAGTA CAA ..................................... 
15.3 
15.4 	. . . .TCAGTA CAA ..................................... 
15.5 . . . .TCAGTA CAA ..................................... 
51 	 61 	 71 	 81 	 91 	100 





101 	 111 	 121 	 131 	 141 	150 
15.1 	AGACATAGTT ATCTACCAAT ACATGGATGA TTTGTATGTA GGATCTGACT 
15.2 
15.3 




151 	 161 	 171 	 181 	 191 	200 











211 	 221 	 231 	 241 	250 
I 215 	I 2191 I I 
GGTTTTATAC ACCAGACAAA AAACATCAGA AAGAACCTCC 
G .... 	 .......... 	 .......... 	 .......... 
G .... 	 .......... 	 .......... 	 .......... 
251 	 261 	 271 	 281 	 291 
15.1 	ATTCCTTTGG ATGGGCTATG AACTCCATCC TGATAAATGG ACATCCAG 
15.2 .......... 	 .......... 	 .......... 	 .......... 	 ... GT.CAGC 
15.3 	.......... 	 .......... 	 .......... 	 .......... 	 ... GT 
15.4 .......... 	 .......... 	 .......... 	 .......... 	 ... GT.CAGC 
15.5 	.......... 	 .......... 	 .......... 	 .......... 	 ... GT.CAG 
286 
5 
Nucleotide Sequence Alignment of the RT Region of pol for Antiretroviral 
Experienced Patients 
1 	 11 	21 	31 	41 	50 
I I I 141 I I 
E1±.pol ---------- --- ACAGAAA TTTGTACAGA TATGGAAAAG GAAGGAAPLAP. 
HXB2.pol 	......AGCA TTAG ...... .......... G ......... ..... G.... 











51 	 61 	71 	81 	91 	100 
I I I I I I 
Eli.pol TTTCAAGAAT TGGGCCTGAA AATCCATACA ATACTCCAAT ATTTGCCATA 
HXB2 .pol 	......A ... 	.......... 	.......... 	........ G........... 











101 	111 	121 	131 	141 	150 
I 67 	I 70 	I I I 
E1i.pol AAGAAAAAAG ACAGTACCAA GTGGAGAAAA TTAGTAGATT TCAGAGAACT 
HXB2 .pol 	.......... 	....... T.. A ......... 	.......... 	.......... 
1086 .1 .......... 	....... T.. A ......... 	.......... 	.......... 










151 	161 	171 	181 	191 	200 
Eli.pol TAATAAGAGA ACTCAAGATT TCTGGGAAGT TCAATTAGGA ATACCGCATC 
HXB2 .pol 	.......... 	........ C . 	.......... 	.......... 	..... A.... 
1086 .1 ...... A ... 	........ C . 	.......... 	.......... 	..... A.... 
1271.1 	.......... 	........ C . 	.......... 	.......... 	..... A.... 
287 
1118.1 	 . C . C. .G 	 . A.... 
1153.1 ---------- -------- C 	 . A.... 
1538.1 	------------------C . .......... .......... ..... A.... 






201 	211 	221 	231 	241 	250 
I I I I I I 
Eli.pol CTGCAGGGCT GAAAAAGAAA AAATCAGTAA CAGTACTGGA TGTGGGTGAT 
HXB2.pol 	.0 ...... T. A ....................................... 
1086.1 .0 ...... T ......................................... 
1271.1 	.0 ...... T. A ......... 	.......... 	.......... 	.......... 
1118.1 .0 ........ A ....................................... 
1153.1 	.0 ...... T. A ......... 	........ G. 	.......... 	.......... 
1538.1 .0 ...... T. A ......... 	.......... 	....... A ..... A ...... 
1364.1 	.0 ...... T. A ......... 	.......... 	.......... 	...... G... 
1371.1 -------- T. A ....................................... 




251 	261 	271 	281 	291 	300 
I I I I I I 
Eli.pol GCATATTTTT CAGTTCCCTT AGATGAAGAT TTTAGGAAAT ATACCGCCTT 
HXB2.pol 	.......... 	.......... 	......... C ..0 ..... G ..... T. .A.. 
1086.1 ....................... CA... .0 . .0 .A. .G ..... T. .A.. 
1271.1 	.......... 	....... A .. 	.... A .... A ..0 ..... G ..... T. .A.. 
1118.1 .......... 	.......... 	.... A .... A ..0 ..... G ..... T. .A.. 
1153.1 	.......... 	.......... 	.... A .... C ..... A. .G ..... T. .A.. 
1538.1 .......... 	....... T .. 	.... A .... A ..0 ..... G ..... T. .A.. 
1364.1 	C .... 	.......... 	.... A .... C ..... A .... 	.... T. .A.. 
1371.1 .......... 	.......... 	......... C ..0 ..... G ..... T. .A.. 
1523.1 	.......... 	.......... 	...... G. .A ..0 ..... G ..... T. .A.. 
1121.1 --------------------------------C ..... G ..... T. .A.. 
1064.1 	---------- ---------- --------- C ..0 ..... G ..... T. .A.. 
1447.1 
301 	311 	321 	331 	341 	350 
I I I I I 
Eli.pol TACCATATCT AGTATAAACA ATGAGACACC AGGGATTAGA TATCAGTACA 
HXB2 .pol 	....... C .......................................... 
1086.1 ....... C .. 	.......... 	.......... 	.......... 	..... A.... 
1271.1 	....... C ..... G .................................... 
1118.1 ....... C .. 	.......... 	.......... 	.......... 	.. C ....... 
1153.1 	....... C .. 	.......... 	.......... 	.......... 	..... A.... 
1538.1 ....... C .......................................... 
1364.1 	....... C ..... G .................................... 
1371.1 ....... C .. 	.... C ... T ............................... 
1523.1 	....... C.A . . . .0 ..... 	.......... 	.......... 	..C ....... 
1121.1 ....... C .......................................... 
1064.1 	....... C .. 	.......... 	.......... 	.... G ..... 	.......... 
1447.1 
351 	361 	371 	381 	391 	400 
I I I I I I 
Eli.pol ATGTGCTTCC ACAGGGATGG AAAGGATCAC CGGCAATATT CCAAAGTAGC 
HXB2.pol 
288 







1523.1 .......... .......... .......... .. ........ .... T ..... 
1121.1 ....... G ..... A .......................... T ......... 
1064.1 .......... .......... .......... .. ........ .... T ..... 
1447.1 .......... .......... .......... -- ........ ...... c... 











HXB2.po .......... .......... T ......... .......... .... A ..... 
1086.1 ....... G.. .......... T ...... C .. ......... A .C. .A ..... 
1271.1 .......... .......... T ............................. 
1118.1 .......... .......... T ......... .......... .... A ..... 
1153.1 .......... .... G. .T T ......... .......... .......... 
1538.1 .......... .......... T ......... .......... .... A ..... 
1364.1 .......... .. ........ T ......... .......... .... A ..... 
1371.1 .......... .......... T ......... .......... .... A ..... 
1523.1 .......... ....... A .. .......... ..... ......... A ..... 
1121.1 ........ G. .......... T ......... .......... ....A..... 
1064 .1 .......... .......... T ..... G ... ..... Y .... .... A..... 
1447.1 .......... .......... T ........ G A ......... ....A..... 
451 461 471 481 491 	500 
Eli.pol CTATCAATAC ATGGATGATT TGTATGTAGG ATCTGACTTA GAAATAGGGC 
HXB2.pol 




1538.1 	...... G. .T 	........................................ 
1364.1 
1371.1 	T ......... 	.......... 	.. ........ 	....... c .. 	........ A. 
1523.1 M ......... 	......... C .A ........ 	.......... 	........ A. 
1121.1 	......G ........................................... 
1064.1 
1447 .1 	.......... 	.......... 	... R ...... 	.......... 	..C... 
6 
Nucleotide Sequence alignment of the Reverse Transcriptase Region of poi for 
Competition Assay Dilution Series 
1 	 11 	 21 	 31 	 41 	50 










51 	 61 	 71 	 81 	 91 	100 













101 	111 	121 	131 	141 	150 













151 161 171 181 	191 	200 
I I I I 215 













201 211 221 231 	241 	250 
1219 

































Nucleotide Sequence Alignment of the Reverse Transcriptase Region of the poi 
Gene, for the MD with LD Competition Assay, Passage Number 2. 
A 
1 	 11 	 21 	 31 	 41 	50 
30 I I I 41 I 
89,90:10 AAAATAAAAG CATTAGTAGA AATTTGTACA GAAATGGWI AGGAAGGAAA 
90,70:30 
95,30:70 	.......... 	.......... 	.......... 	... C ................ 
96,10:90 	.......... 	.......... 	.......... 	... C ................ 
51 	 61 	 71 	 81 	 91 	100 
I I I I I 




101 	 111 	 121 	 131 	 141 	150 
67 70 I I 




151 	 161 	 171 	 181 	 191 	200 
I 1 I I I I 





201 	 211 	 221 	 231 	 241 
I I I I I 	111 





1 	 11 	 21 	 31 	 41 	50 
149 I I I 1 I 
89,90:10 CTTCCACAAG GATGGAAAGG ATCACCAGCA ATATTCCAAT GTAGCATGAC 
90,70:30 	........ G. 	.......... 	.......... 	.......... 	.......... 
95,30:70 ........ G. 	.......... 	.......... 	.......... 	.......... 
96,10:90 	........G ......................................... 
51 	 61 	 71 	 81 	 91 	100 
I I I I I 




101 	 111 	 121 	 131 	 141 	150 
I I I I 1 I 
89,90:10 AATACATGGA TGATCTGTAT GTAGGATCTG ACTTAGAAAT AGGGCAGCAT 
90,70:30 
95,30:70 	.......... 	.......... 	.... C ..... 	...... G ... 	.......... 
96,10:90 .......... 	.......... 	.... C ..... 	...... G ... 	.......... 
151 	 161 	 171 	 181 	 191 	200 
I I I I I 215 
89,90:10 AGAACAAAAA TAGAGGAACT GAGACAACAT CTGTTGAGGT GGGGATTTGA 
90,70:30 
95,30:70 	.......... 	..A ....... 	.......... 	.......... 	.......... 
96,10:90 .......... 	..A ....... 	.......... 	.......... 	..A ....... 
201 	 211 	 221 	 231 	 241 	250 
I 219 I I I I 




251 	 261 
I 2351 




Nucleotide Sequence Alignment of the Reverse Transcriptase Region of the poi 
Gene, for the MD with MCS Competition Assay, 30:70 ratio. 
A 
1 	 11 	 21 	 31 	 41 	50 
27 I I I I 41 I 




51 	 61 	 71 	 81 	 91 	100 
I I I I I I 
71.2 	GGAAGGGAAA ATTTCAAAAA TTGGGCCTGA AAATCCATAC AATACTCCAG 
171.4 
271.6 
101 	 111 	 121 	 131 	 141 	150 
I I 67 70 I I 
71.2 	TATTTGCCAT AAAGAGAAAA GA.CAGTACTA_AATGGAGAAA ATTAGTAGAT 
171.4 .......... 	..... A .................................. 
271.6 	.......... 	..... A .... 	.......... 	.......... 	.......... 
151 	 161 	 171 	 181 	 191 	200 
I I I I 
71.2 	TTCAGAGAAC TTAATAAGAG AACTCAAGAC TTCTGGGAAG TTCAATTAGG 
171.4 
271.6 
201 	 211 	 221 	 231 	 241 	250 
I I I I I I 
71.2 	AATACCACAT CCCGCAGGGT TAAAAAAGAA AAAATCAGTA ACAGTACTGG 
171.4 
271.6 
251 	 261 	 271 	 281 	 291 	300 
I I I I I 126 
71.2 	ATGTGGGTGA TGCATATTTT TCAGTTCCCT TAGATGAAGA CTTCAGGAAA 
171.4 .......... 	......... . 	.......... 	C ................... 
271.6 
B 
1 	 11 	 21 	 31 	 41 	50 
149 I I 1 I I 
71.2 	CTTCCACAGG GATGGAA.AGG ATCACCAGCA ATATTCCAAA GTAGCATGAC 
171.4 
271.6 
51 	 61 	 71 	 81 	 91 	100 
I I I I I I 
71.2 	AAAAATCTTA GAGCCTTTTA GAAAACAAAA TCCAGACATA GTTATCTATC 
171.4 
271.6 
101 	 111 	 121 	 131 	 141 	150 
I I I I 
71.2 	AATACATGGA TGATTTGTAT GTAGGATCTG ACTTAGAAAT AGGGCAGCAT 
171.4 
271.6 
151 	 161 	 171 	 181 	 191 	200 
I I I I I 215 
71.2 	AGAACAAAAA TAGAGGAGCT GAGACAACAT CTGTTGAGGT GGGGACTTAC 
171.4 
271.6 
201 	 211 	 221 	 231 	 241 	250 
I 219 I I I I 




251 	 261 
I 1236 
71.2 	ATGAACTCCA TCCT 
171.4 
271.6 
Nucleotide Sequence Alignment of the Reverse Transcriptase Region of the pol 
Gene, for the MD with MCS Competition Assay, 70:30 ratio. 
1 11 21 31 	 41 	50 
4041 I I I I I 
68.2 GAGATGGAAA AGGAAGGGAA AATTTCAPJA ATTGGGCCTG AAAATCCATA 
168.4 
268.6 
51 61 71 81 	 91 	100 
I I I 167 70 I 
68.2 CAATACTCCA GTATTTGCCA TAAAGAA.W AGACAGTACT AAATGGAGAA 
168.4 
268.6 
























201 	 211 	 221 	 231 
I I I 1117 
	




1 	 11 	 21 	 31 	 41 	50 
1161 	 I I I I 
68.2 	CCWtGTAGC ATGACAAAAA TCTTAGAGCC TTTTAGAAA1 CAAAATCCAG 
168.4 
268.6 
51 	 61 	 71 	 81 	 91 	100 
I I I I I I 




101 	 111 	 121 	 131 	 141 	150 
I I I I I 
	
68.2 	GAATAGGGC AGCATAGAAC AAAAATAGAG GAGCTGAGAC AACATCTGTT 
168.4 
268.6 
151 	 161 	 171 	 181 	 191 	200 
I 1215 	I 219 	I I I 








Nucleotide Sequence Alignment of the Reverse Transcriptase Region of the poi 
Gene, for the LD with LY Competition Assay, Passage Number 2. 
A 
1 11 21 31 41 	50 
38 	 41 I I I I 
77, 90:10 TGTACAGAAC_TGGAAAAGGA AGGAAAAATT TCAAGAATTG GGCCTGAAAA 
78,70:30 
51 61 71 81 91 	100 
I I I I 	671 701 
77,90:10 CCCATACAAT ACTCCAGTAT TTGCCATAAA GAAAAGGAC AGTACTAAAT 
78,70:30 








































77,90:10 ATAAGGACTT CACA 
78,70:30 
B 
1 11 21 31 41 	50 
149 I I I I I 
77,90:10 CTTCCACAGG GATGGAAAGG ATCACCAGCA ATATTCCAAT GTAGCATGAC 
295 
78,70:30 
51 	 61 	 71 	 81 	 91 	100 
I I I I I I 
77,90:10 AA.AAATTTTA GATCCTTTTA GAAAACAAAA TCCAGACATA GTTATCTATC 
78,70:30 
101 	 111 	 121 	 131 	 141 	150 
I I 1 I I I 
77,90:10 AATACATGGA TGATCTGTAT GTAGCATCTG ACTTAGGAAT AGGGCAGCAT 
78,70:30 
151 	 161 	 171 	 181 	 191 	200 
I I I I I 215 
77,90:10 AGAACAAAAA TAAAGGAACT GAGACAACAT CTGTTGAGGT GGGGATTTGA 
78,70:30 
201 	 211 	 221 	 231 	 241 	250 
I 219 I I I I 
77,90:10 CACACCAGAC AAAAAACATC AGAAGGAACC TCCATTCCTT TGGATGGGTT 
78,70:30 
251 	 261 
I 1236 
77,90:10 ATGAACTCCA TCCT 
78,70:30 
Nucleotide Sequence Alignment of the Reverse Transcriptase Region of the poi 
Gene, for the LD with MCS Competition Assay, 10:90 ratio. 
A 
1 	 11 	 21 	 31 	 41 	50 
27 I I I I 41 
	
10.1 	ACAGAAGAAA AAATAAAAGC ATTAGTAGAA ATTTGTACAG AGATGGAAAA 
60.2 
260.6 
51 	 61 	 71 	 81 	 91 	100 
I I I I I I 
10.1 	GGAAGGGAAA ATTTCAAAAA TTGGGCCTGA AAATCCATAC AATACTCCAG 
60.2 
260.6 
101 	 111 	 121 	 131 	 141 	150 
I I 67 70 I I 
10.1 	TATTTGCCAT AAAGAAA.AAA GACAGTACTA_AATGGAGAAA ATTAGTAGAT 
60.2 
260.6 
151 	 161 	 171 	 181 	 191 	200 
I I I I I I 
10.1 	TTCAGAGAAC TTAATAAGAG AACTCAAGAC TTCTGGGAAG TTCAATTAGG 
60.2 
260.6 
201 	 211 	 221 	 231 	 241 	250 
296 
I 	 I 	 I 	 I 	 I 	I 
10.1 	AATACCACAT CCCGCAGGGT TAAAAAAGAA AAAATCAGTA ACAGTACTGG 
60.2 
260.6 
251 261 271 
I I I 	119 




1 11 21 31 41 	50 
159 I I I I I 


































151 161 171 181 191 	200 
I I 	215 219 I I 




201 211 221 231 
I I I 1236 




Nucleotide Sequence Alignment of the Reverse Transcriptase Region of the poi 
Gene, for the LD with MCS Competition Assay, 30:70 ratio. 
A 
1 11 21 31 41 	50 
27 I I I I 	41 I 




51 	 61 	 71 	 81 	 91 	100 
I I I I I I 
58.2 	GGAAGGGAAA ATTTCAAAAA TTGGGCCTGA AAATCCATAC AATACTCCAG 
159.4 
259.6 
101 	 111 	 121 	 131 	 141 	150 
I I 67 70 I I 
58.2 	TATTTGCCAT AAAGAAAAAA GACAGTACTA_AATGGAGAAA ATTAGTAGAT 
159.4 
259.6 
151 	 161 	 171 	 181 	 191 	200 
I I I I I I 
58.2 	TTCAGAGAAC TTAATAAGAG APCTCAAGAC TTCTGGGAAG TTCAATTAGG 
159.4 
259.6 
201 	 211 	 221 	 231 	 241 	250 
I I I I I I 
58.2 	AATACCACAT CCCGCAGGGT TAAAAAAGAA AAAATCAGTA ACAGTACTGG 
159.4 
259.6 
251 	 261 	 271 
I I 119 




1 	 11 	 21 	 31 	 41 	50 
159 I I I I I 
159.4 	CCACAGGGAT GGAAAGGATC ACCAGCAATA TTCCAAAGTA GCATGACAAA 
259.6 . . . .CA ............................................ 
51 	 61 	 71 	 81 	 91 	100 
I I I I I I 
159.4 	AATCTTAGAG CCTTTTAGAA AACAAAATCC AGACATAGTT ATCTATCAAT 
259.6 
101 	 111 	 121 	 131 	 141 	150 
I I I I I I 
159.4 	ACATGGATGA TTTGTATGTA GGATCTGACT TAGAAATAGG GCAGCATAGA 
259.6 
151 	 161 	 171 	 181 	 191 	200 
I I I I I 2151 
159.4 	ACAAAAATAG AGGAGCTGAG ACAACATCTG TTGAGGTGGG GACTTACCAC 
259.6 
201 	 211 	 221 	 231 	 241 	250 
I 219 	I I I I I 
159.4 	ACCAGACAAA AAACATCAGA AAGAACCTCC ATTCCTTTGG ATGGGTTATG 
259.6 
251 	 261 
2361 
159.4 	AACTCCATCC T 
259.6 
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Nucleotide Sequence Alignment of the Reverse Transcriptase Region of the poi 
Gene, for the LD with MCS Competition Assay, 70:30 ratio. 
1 	 11 	 21 	 31 	 41 	50 
27 I I I I 41 
	
55.2 	ACAGAAGAAA AAATAAAAGC ATTAGTAGAA ATTTGTACAG AGATGGAMA 
156.4 
256.6 
51 	 61 	 71 	 81 	 91 	100 
I I I I 
55.2 	GGAAGGGAAA ATTTCA.AAAA TTGGGCCTGA AAATCCATAC AATACTCCAG 
156.4 
256.6 
101 	 111 	 121 	 131 	 141 	150 
I I 67 70 I I 
55.2 	TATTTGCCAT AAAGAAAAAA GACAGTACTA_AATGGAGAAA ATTAGTAGAT 
156.4 
256.6 
151 	 161 	 171 	 181 	 191 	200 
I I I I I 
55.2 	TTCAGAGAAC TTAATAAGAG AACTCAAGAC TTCTGGGAAG TTCAATTAGG 
156.4 
256.6 
201 	 211 	 221 	 231 	 241 	250 
I I I I I I 
55.2 	ATACCACAT CCCGCAGGGT TAAAAAAGAA AAAATCAGTA ACAGTACTGG 
156.4 
256.6 
251 	 261 	 271 	 281 	 291 	300 
I I I I I I 
55.2 	ATGTGGGTGA TGCATATTTT TCAGTTCCCT TAGATGAAGA CTTCAGGAAA 
156.4 
256.6 
301 	 311 	 321 
I I I 	119 




1 	 11 	 21 	 31 	 41 	50 
159 I I I I I 
55.2 	GGATCACCAG CAATATTCCA AAGTAGCATG ACAAAAATCT TAGAGCCTTT 
156.4 
259.6 
51 	 61 	 71 	 81 	 91 	100 
I I I I I 




101 	 111 	 121 	 131 	 141 	150 
I I I I I 
	
55.2 	ATGTAGGATC TGACTTAGAA ATAGGGCAGC ATAGAACAAA AATAGAGGAG 
156.4 
259.6 
151 	 161 	 171 	 181 	 191 	200 
I I I 215 1219 I 
55.2 	CTGAGACAAC ATCTGTTGAG GTGGGGACTT ACCACACCAG ACAAAAAACA 
156.4 
259.6 
201 	 211 	 221 	 231 	 241 
I I I I I 	236 
55.2 	TCAGAAAGAA CCTCCATTCC TTTGGATGGG TTATGAACTC CATCCT 
156.4 
259.6 
Nucleotide Sequence Alignment of the Reverse Transcriptase Region of the poi 
Gene, for the LD with MCS Competition Assay, 90:10 ratio. 
A 
1 11 21 31 41 	50 
27 I I I I 	41 I 
3.1 ACAGAAGAAA AATAAAAGC ATTAGTAGAA ATTTGTACAG AGATGGAAAA 
53.2 
153.4 G ................................................. 
253.6 













101 111 121 131 141 	150 
I 67 	 70 I I 
















53.2 .......... .......... ...... a ....................... 
153.4 
253.6 
201 	 211 	 221 	 231 	 241 	250 
I I I I 




251 	 261 	 271 	 281 
300 
I 	 I 	 I 	 120 
3.1 	ATGTGGGTGA TGCATATTTT TCAGTTCCCT TA 
53.2 . . . . r ........................... 
153.4 
253.6 
1 11 21 31 41 	50 
149 I I I I I 


































151 161 171 181 191 	200 
I I I I I 215 




201 211 221 231 241 	250 
219 I I 1 I 
3.1 CACACCAGAC AAAAAACATC AGAAAGAACC TCCATTCCTT TGGATGGGTT 
53.2 ......... T ........................................ 
153.4 ......... T ........................................ 
253.6 ......... T ........................................ 
251 	 261 
I 1236 








The following gives the clinical history of both patients 1390 and 1514, including the 
HP/-i test dates, seroconversion dates, AIDS status, and T-cell lymphocyte counts. 
Figure 1 	Patient 1390 lymphocyte counts 
Figure 2 	Patient 1514 lymphocyte counts 
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Patient 1390 
This patient is a homosexual male, Caucasian, aged 38, who until tested positive for 
HIV-1 was a regular blood donor, despite his sexual risk group. The route of 
transmission was presumed to be homosexual and place of infection was Scotland. 
In August of 1992 he had a visit from a homosexual friend, following which he 
encountered symptoms of acute infection, fevers and weight loss. In September of 
1993 he again donated blood, which was found to be HIV-1 positive. The contact has 
subsequently died, aged 37, in 1994. 
Two additional follow up samples were obtained on 9 May 96 and again on 4 
December 96. On the 28 October 1996 patient 1390 was diagnosed with the AIDS 
defining illness Pneumocystis carinii pneumonia (PCP). The CD4 counts are shown 
in Figure 1. 
Last negative HIV-1 test 	04.92 
First positive HIV-1 test 	 09.93 
Estimated seroconversion date 	08.92 
(estimated by detection of a seroconversion illness) 
304 
FIGURE 1 
Patient 1390 Lymphocyte Counts 
The table shows the lymphocyte counts for patient 1390 over a three year period, 
showing the average CD4 count over the 11 timepoints, and the average CD4:CD8 
ratio. Three samples were obtained from this patient on the 15-06-94, 09-05-96, and 
on 04-12-96 (illustrated by the arrows). 
Opposite page number 305 
Patient 1390 
DATE CD4 COUNT % CD4 %CD8 Ratio 
(mm3) CD4:CD8 
19.11.93 360 20 66 0.3 
22.02.94 480 23 66 0.3 
15.06.94 315 15 64 0.2 
07.09.94 322 14 63 0.2 
17.01.95 304 16 70 0.2 
24.04.95 352 16 63 0.2 
27.07.95 400 16 61 0.2 
12.03.96 527 17 59 0.3 
07.08.96 230 ND ND ND 
29.10.96 60 ND ND ND 
20.11.96 50  ND  ND ND 
-309  0.2 
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This patient is a homosexual male, Caucasian, aged 35. The route of infection was 
presumed to be through homosexual contact in Scotland, although he had 
unprotected sex with a Greek male in 1993. At time of sampling no AIDS diagnosis 
had been given. Contact information was available but subsequently found that the 
Scottish contact had died in September of 1994. 
An additional sample was obtained on 22 May 1996, at which time the patient was 
experiencing weight loss, but no AIDS diagnosis was made. Patient CD4 counts are 
shown in Figure 2. 
For ethical reasons no follow up information can be obtained regarding the deceased 
contacts. It does however seem likely that they were on some form of antiretroviral 
therapy. This would probably have involved ZDV, whether as monotherapy or as 
part of a combination. 
Last negative HIV-1 test 	08.93 
First positive HIV- 1 test 	 01.94 
Estimated seroconversion date 	08.93 
(estimated from behavioural information) 
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FIGURE 2 
Patient 1514 Lymphocyte Counts 
The table show the lymphocyte counts for patient 1514 over a two year period 
showing the average CD4 count over the 11 timepoints, and the average CD4:CD8 
ratio. Two samples were obtained from this patient on 25-10-94 and 22-05-96 
(illustrated by the arrows). 
Opposite page number 307 
Patient 1514 
DATE CD4 COUNT %CD4 %CD8 Ratio 
(mm3) CD4:CD8 
18.01.94 624 34 46 0.7 
19.04.94 891 33 39 0.8 
25.10.94 396 23 39 0.6 
29.11.94 680 34 40 0.85 
07.02.95 569 31 38 0.8 
09.05.95 471 33 38 0.8 
09.08.95 456 32 42 0.8 
18.10.95 810 29 50 0.6 
07.02.96 640 32 51 0.6 
28.02.96 462 30 48 0.6 
22.05.96 378 27 46 0.6 
579 
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POINT MUTATION ASSAY 
SCINTILLATION COUNTS 
Appendix IV 
The following shows the results of the experiments carried out for the point mutation 
assay detailed in Chapter 7. The results show the scintillation counts obtained for the 
17 experiments carried out before the procedure was abandoned. 
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Experiment 1 
PMA of Wild Type Control pHXB2 
Sample Base Reading Background A/4 C -C % 
p215 	No.  
2.5 	1 G 2,432 27 4976 -2544 N/A 
A 16,763 4,190 -785 N/A 
T 1,028 -3948 N/A 
2 G 6,896 27 17,783 -10,887 N/A 
A 27,388 6,847 -10,936 N/A 
T 4,052 -13,731 N/A 
3 G 28,191 27 8,954 19,237 93 
A 42,009 10,502 1,548 7 
T 2,621 -6,333 N/A 
0.1 	1 G 49,937 27 4,789 45,148 87 
A 13,631 3,407 -1,381 N/A 
T 11,287 6,498 13 
2 G 14,075 27 1,492 12,583 70 
A 11,915 2,978 1,486 8 
1 5,292 3,800 22 
3 G 56,984 27 37,320 19,604 100 
A 24,055 6,013 -31,306 N/A 
T 7,790 -29 N/A 
0.25 	1 G 52,905 27 884 52,021 89 
A 27,578 6,895 6,011 10 
T 1,407 523 1 
2 G 68,674 27 11,913 56,761 100 
A 9,655 2,414 -9,499 N/A 
T 10,400 -1,513 N/A 
3 G 26,761 27 41,514 -14,753 N/A 
A 5,196 1,299 -40,215 N/A 
T 10,433 -10,391 N/A 
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Experiment 2 
PAM of Wild Type Control pIIXB2 
Sample Base Reading Background AM C -C 	I % 
p215 No.  
1.Ot 1 G 3,225 17.5 515 2,710 100 
A 2,037 509 -5 N/A 
T 448 -67 N/A 
2 G 14,454 17.5 12,912 1,542 67 
A 5,783 1,445 -11,467 N/A 
T 13,679 767 33 
3* G 520 17.5 340 180 100 
A 75 18 -321 N/A 
T 86 -254 N/A 
1.0# 4 G 54,346 17.5 426 53,920 92 
A 19,483 4,870 4,444 8 
T 5,141 -46,000 N/A 
5 G 41,3944 17.5 693 40,701 79 
A 17,642 4,410 3,718 7 
T 7,604 6,911 14 
6* G 516 17.5 643 -127 N/A 
A 580 145 -498 N/A 
Y 587 -56 N/A 
* Denotes, no enzyme used 
Where a final NaOH denaturation step was performed and the radiolabelled 
fragment removed from the dynabeads and added to the scintallint. 
# Where the dynabeads were not removed by a final NaOH denaturation step, and 
remain in the scintallint. 
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Experiment 3 
PMA with Wild Type Control pIIXB2 
Sample Base Reading Background A/4 C -C % 
p215 No.  
1.0 19 G 19,960 16 460 19,500 81 
A 14,293 3,573 3,113 13 
T 1,875 1,415 6 
2* G 64,270 16 332 63,938 91 
A 21,709 5,427 5,095 7 
T 1,968 1,636 2 
3 t G 285 16 77 208 71 
A 180 45 -32 N/A 
T 164 87 29 
0.75 4# G 24,917 16 464 21,453 83 
A 12,298 3,075 2,611 10 
T 2,380 1,916 7 
5* G 16,185 16 245 15,940 75 
A 11,891 2,973 2,728 13 
T 2,801 2,556 12 
0.5 6# G 12,510 16 339 12,171 72 
A 9,343 2,336 1,997 12 
T 2,974 2,635 16 
7* G 8,859 16 219 8,640 58 
A 14,551 3,638 3,419 23 
T 3,068 2,849 19 
0.25 89 G 29,766 16 322 29,444 80 
A 27,999 7000 6,678 18 
T 1,008 686 2 
9* G 24,899 16 429 24,470 83 
A 10,561 2,640 2,211 8 
T 3,284 2,855 9 
# The radiolabelled DNA is contained in 401.11 Tris Tween 20 
* The radiolabelled DNA is contained in 40j.11 water 
t No enzyme control 
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Experiment 4 
Carried out with 1.ORM P215 
Sample Base Reading 
No.  
Background A/X* C -C 	I 
HXB2 	1 G 9,066 23 1,469 7,597 87 
A 6,907 1,727 258 3 
T 2,354 885 10 
2 G 7,897 23 1,987 5,910 90 
A 8,842 2,211 224 3 
T 2,442 455 7 
3 G 6,580 23 1,758 4,822 93 
A 8,165 2,041 283 6 
T 1,824 66 1 
4# G 1,302 23 771 531 10 
A 856 214 -557 N/A 
T 5,480 4,709 90 
1037 	5 G 10,445 23 2,103 8,342 99 
A 6,883 1,377 -726 N/A 
T 2,149 46 1 
HXB2 	6 G 3,572 23 454 3,118 77 
A 3,047 761 307 8 
T 1,060 606 15 
7 G 14,046 23 690 13,356 92 
A 5,369 1,342 652 4 
T 1,205 515 4 
8 G 4,750 23 686 4,064 82 
A 3,492 873 187 4 
T 1,380 694 14 
1037 	9 G 5,097 23 3,210 1,887 100 
A 782 156 -3,054 N/A 
T 1,072 -2,138 1 N/A 
# Where the wild type control is divided by 4, and the patient 1037, divided by 5 
* No enzyme control 
Samples 1 - 5 carried out with a 1/10 dilution of S 35dNTPs 
Samples 6 - 9 carried out with a 1/30 dilution of S 35dNTPs 
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Experiment 5 
Carried out with 1.Op.M p215 on IIIXB2 
Sample Base ReadinZ s35 	No.  
Background A/4 C -C 
1/10 1 G 24,465 19 305 23,160 92 
A 6,808 1,702 1,397 6 
T 889 584 2 
2 G 27,326 19 213 27,113 87 
A 5,471 1,367 1,154 4 
T 3,313 2,918 9 
3 G 18,728 19 511 18,217 91 
A 9,594 2,398 1,887 9 
T 404 -1,994 N/A 
4 G 9,607 19 100 9,507 91 
A 3,487 871 771 7 
T 238 138 2 
5* G 178 19 570 -392 N/A 
A 236 59 -511 N/A 
T 58 -512 N/A 
1/30 	6 G 10,540 19 122 10,418 90 
A 3,316 829 707 6 
T 641 95 4 
7 G 6,043 19 68 5,975 88 
A 3,234 808 740 11 
T 162 95 1 
8* G 131 19 75 56 18 
A 111 28 -47 N/A 
T 338 263 82 
* No enzyme control 
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Experiment 6 
Carried out with 1.OI.LM p215 and a 1/30 dilution of S 35  
Sample Base Reading Background .A/x* C-C . . 
No  
HXB2 	1 G 23,811 18 85 23,726 89 
A 9,043 2,260 2,175 8 
T 956 871 3 
2 G 17,874 18 74 17,800 86 
A 9,660 2,415 2,341 11 
T 567 493 3 
3 G 21,629 18 61 21,568 83 
A 16,167 4,041 3,980 15 
T 4448 387 2 
4 G 16,318 18 72 16,246 85 
A 10,997 2,749 2,677 14 
T 321 249 1 
1037 	5 G 4,522 18 713 3,809 43 
A 15,354 3,070 2,357 27 
T 3,458 2,745 31 
6 G 4,309 18 167 4,142 44 
A 11,940 2,388 2,221 24 
T 3,221 3,054 1 	33 
* Where the 'A' count is divided by 4 for HXB2 and by 5 for 1037 
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Experiment 7 
Carried out with 1.0iM p215 and a 1/30 dilution of S 35 
HXB2 G 5,827 14 59 5,768 97 
A 622 155 97 1 
1 168 109 2 
G 3,931 14 51 3,880 97 
A 416 104 53 1 
1 118 67 2 
1037 G 4,328 14 64 4,264 80 
A 775 155 91 11 
T 1,067 1,003 19 
1037 G 3,180 14 83 3,097 86 
A 1,012 202 119 4 
T 456 373 10 
1317# G 108 14 29 79 23 
A 235 47 18 5 
T 273 244 72 
1072# G 21,108 14 44 21,064 99 
A 119 23 -21 N/A 
T 115 71 1 
1219w G 245 14 181 64 100 
A 2544 50 -131 N/A 
1 87 -94 N/A 
1009 G 147 14 233 -86 N/A 
A 333 60 -173 N/A 
1 44 -189 N/A 
1051 G 100 14 86 14 9 
A 1,127 225 139 91 
T 45 -41 N/A 
1064 G 244 14 94 150 100 
A 175 32 -62 N/A 
T 37 -57 N/A 
* Where the 'A' count is divided by 4 for HXB2 and by 5 for patient samples 
# Sequenced wild type at codon 215 (bulk sequence). 
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Experiment 8 
Carried out with 1.0ILM p215 and a 1/30 dilution of S 35 
..... 
H3B2 1 G 12,109 21 100 12,009 94 
A 2,738 684 584 5 
T 265 165 1 
2 G 3,935 21 445 3,490 94 
A 3,370 674 229 6 
T 153 -292 N/A 
3 G 10,994 21 98 10,896 90 
A 6,227 1,245 1,147 9 
T 168 70 1 
4 G 29,498 21 123 29,375 97 
A 4,042 808 685 2 
T 280 1157 1 
1037 1 G 9,650 21 125 9,525 86 
A 952 190 65 1 
T 1,586 1,461 13 
2 G 6,416 21 123 6,293 75 
A 3,162 632 509 6 
T 1,720 1,597 19 
1083 G 123 21 88 35 15 
A 1,371 274 186 81 
T 95 7 3 
1086 G 135 21 75 60 39 
A 383 76 1 1 
T 170 95 60 
1087 G 147 21 100 47 100 
A 258 51 -49 N/A 
T 89 -11 N/A 
1118 G 92 21 111 -19 N/A 
A 170 34 -77 N/A 
T 91 -20 N/A 
* Where the 'A' count is divided by 4 for HXB2 and by 5 for patient samples 
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Experiment 9 
Carried out with 1.0ILM p215 and a 1/30 dilution of S 
............ Base Reading Background A/x* C -C 
HXB2 1 G 38,098 18 197 37,901 94 
A 9,184 2,296 2,099 5 
T 256 59 1 
2 G 32,220 18 91 32,129 96 
A 3,096 774 683 2 
T 596 505 2 
3 G 27,466 18 91 27,375 93 
A 5,120 1,280 1,189 4 
T 866 775 3 
4 G 27,992 18 89 27,903 94 
A 6,456 1,614 1,525 5 
T 153 64 1 
p74 1 G 7,805 18 103 7,702 67 
A 5,808 1,162 1,059 9 
T 2,798 2,695 24 
2 G 8,407 18 97 8,310 68 
A 8,666 1,733 1,636 14 
T 2,376 2,282 18 
3 G 6,329 18 285 6,044 58 
A 6,292 1,258 973 10 
T 3,612 3,327 32 
4 G 10,482 18 137 10,345 71 
A 6,110 1,222 1,085 7 
1 3,293 3,156 22 
1154 G 154 18 458 -304 N/A 
A 52 10 -475 N/A 
T 46 -412 N/A 
1201 G 106 18 485 -379 N/A 
A 108 -377 N/A 
T 91 -3944 N/A 
* Where the 'A' count is divided by 4 for HXB2 and by 5 for patient samples 
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Experiment 10 
Carried out with 1.0ILM p215 and a 1/30 dilution of S 35 
Samnie 	Base Reading Background 	A14 	C 	-C 	I ................... -............. .............................. .... ................... ............................................................................................................. ....... ...........  
HXB2 	1 
 
G 19,773 24 117 19,656 74 
A 9,688 2,422 2,305 9 
T 4,607 4,490 17 
2 G 18,843 24 174 18,669 78 
A 10,122 2,530 2,356 10 
T 3,0622 2,888 12 
3 G 12,676 24 103 12,573 86 
A 6,955 1,7738 1,635 11 
T 593 490 3 
4 G 21,708 24 129 21,579 90 
A 9,010 2,252 2,123 9 
T 499 370 1 
5 G 22,484 24 139 22,345 89 
A 11,329 2,832 2,693 11 
T 213 74 - 
6 G 22,166 24 129 22,037 90 
A 7,264 1,816 1,687 7 
T 837 708 3 
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Experiment 11 
Carried out with 1.ORM p215 and a 1/30 dilution of S35 
Sample .Base . dnz 	..cgound .A14.................... C -C ............ 
HXB2 	1 G 12,791 	18 2,830 9,961 100 
A 176 44 -2,786 N/A 
T 431 -2,399 N/A 
2 G 13,786 	18 1,040 12,746 100 
A 206 51 -989 N/A 
T 411 -629 N/A 
3 G 12,676 	18 663 12,013 99 
A 457 114 -549 N/A 
T 826 163 1 
4 G 14,995 	18 1,938 13,057 100 
A 199 49 -1,889 N/A 
T 437 -1,501 N/A 
5 G 13,799 	18 987 12,812 98 
A 358 89 -898 N/A 
T 1,257 270 2 
6 G 10,716 	18 1,326 9,390 100 
A 1,914 478 -848 N/A 
T 362 -964 N/A 
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Experiment 12 
Carried out with 1.0ILM p215 With the Kienow enzyme, and a 1/30 
dilution of S35  
Sample Base Reading Background A14 C -cf 
H3B2 	1 G 11,943 15 2,754 9,189 100 
A 230 57 - N/A 
T 445 - N/A 
2 G 14,239 15 2,208 12,031 100 
A 712 178 - N/A 
T 659 - N/A 
3 G 10,637 15 1,668 8,969 100 
A 232 58 - N/A 
T 320 - N/A 
4 G 6,353 15 1,914 4,439 90 
A 1,509 377 - N/A 
T 2,411 497 10 
5 G 3,997 15 1,333 2,664 100 
A 296 74 - N/A 
T 383 - N/A 
6 G 3,826 15 278 3,548 100 
A 73 18 - N/A 
1 179 - N/A 
321 
Experiment 13 
Carried out with 1.0JJM p215 With the Klenow enzyme, and a 1/30 
dilution of S 
Sample Base Reading Background A/4 C -C 	j % 
HXB2 	1 G 16,968 20 69 16,899 88 
A 9,091 2,272 2,204 12 
T 242 173 - 
2 G 19,596 20 58 19,538 81 
A 18,746 4,686 4,629 19 
T 120 62 - 
3 G 21,536 20 78 21,458 84 
A 16,130 4,033 3,955 16 
T 197 119 - 
4 G 16,465 20 77 16,388 82 
A 14,313 3,579 3,501 18 
T 297 220 - 
5 G 14,204 20 74 14,130 85 
A 9,737 2,434 2,360 14 
T 193 119 1 
6* G 153 20 132 21 2 
A 190 48 -85 N/A 
T 1,197 1,065 98 
* No enzyme control 
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Experiment 14 
Carried out with 1.OlLM p215 With the Kienow enzyme, and a 1/30 
dilution of S 
Sample Base Reading Background 4 C -C 	I % 
1IXB2 	1 G 21,288 20 196 21,092 94 
A 6,101 1,525 1,329 6 
T 258 62 - 
2 G 19,393 20 96 19,297 86 
A 5,524 1,381 1,285 7 
T 2,091 1,995 7 
3 G 23,446 20 181 23,265 90 
A 8,908 2,227 2,046 8 
T 821 640 2 
4 G 17,857 20 206 17,651 92 
A 6,215 1,553 1,347 7 
T 383 177 1 
5 G 13,515 20 520 12,995 98 
A 3,268 817 297 2 
T 471 -49 - 
6* G 78 20 44 34 46 
A 53 13 -31 N/A 
T 74 40 1 	54 
* No enzyme control 
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Experiment 15 
Carried out with 1.0ILM p215 With the Kienow enzyme, and a 1/30 
dilution of S35 
Sample 	Base 0 5 10 15 20 25 
HXB2 A 13,667 11,536 4,659 1,616 2,842 1,025 
G 65,265 48,837 37,760 32,300 16,421 9,120 
C 74 91 139 192 55 74 
T 1,429 1,506 918 1,117 1,011 132 
Where the enzyme was added to the labelling mix, and incubated at the times 
indicated above before being mixed with the template DNA. 
Experiment 16 
Carried out with 1.0lJ.M p215 With the Kienow enzyme, and a 1/30 
dilution of S 
Time 
BXB2 0 20 
Klenow T7 Klenow T7 
dATP 15,259 4,832 8,999 150 
22,310 2,165 8,827 211 
dGTP 62,331 9,380 30,899 759 
43,926 12,017 25,228 533 
dCTP 2644 172 154 117 
253 172 190 122 
dTTP 8,194 1,822 1,388 247 
3,712 2,393 1,657 1,448 
As above, where the enzyme was added to the labelling mix, and incubated at the 
times indicated above before being mixed with the template DNA, however this time 
with two different enzymes, Kienow and T7. 
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Experiment 17 
Carried out with 1.0ILM p215 With the Kienow enzyme, and a 1/30 
dilution of S 
Sample Base Reading Background A/x* C -C 	T % 
HXB2 1 G 42,640 20 265 42,375 68 
A 44,632 11,158 10,893 18 
T 9,409 9,144 14 
2 G 56,853 20 312 56,541 86 
A 33,183 8,295 7,984 12 
T 1,799 1,4487 2 
p74 3 G 14,717 20 366 14,351 85 
(38N) A 6,724 1,345 979 6 
T 2,848 1,503 9 
4 G 17,671 20 718 16,953 47 
A 11,072 2,215 1,496 4 
T 18,626 17,908 49 
p74 5 G 941 20 835 106 - 
(38) A 3,599 720 -115 N/A 
T 22,322 21,487 100 
6 G 2,074 20 1,206 868 22 
A 1,889 378 -828 N/A 
T 4,287 3,081 78 
p74 7 G 754 20 876 -122 N/A 
(40) A 3,314 663 -213 N/A 
T 1,761 885 100 
8 G 773 20 1,622 -849 N/A 
A 4,575 915 -707 N/A 
T 2,660 1,038 1 	100 
* No enzyme control ; 
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